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The ability to elucidate the mechanisms underlying inter-individual responses to 
pharmacotherapy is paramount in personalised medicine research. Considering 
the superorganismic nature of the human host, the influence of gut microbiota and 
its associated metabolic activities on inter-individual responses to 
pharmacotherapy should not be undermined. Tacrine, an Alzheimer’s disease 
drug, exhibits significant inter-individual variability in its pharmacokinetic and 
hepatotoxicity profiles of yet unknown etiology. The unpredictable toxicokinetics 
of tacrine was detrimental to the clinical fate of this drug in light of safer and 
more efficacious alternatives. Here, we found that gut bacteria influences the 
toxicokinetics of tacrine in Lister hooded rats through modulating intestinal β-
glucuronidase activities. Pharmacokinetics demonstrated a 3.3-fold higher 
systemic exposure of tacrine and double Cmax phenomenon in extreme responders 
to tacrine-induced transaminitis, revealing enhanced enterohepatic recirculation of 
deglucuronidated tacrine, not attributable to variation in the host disposition gene 
expression. Metabonomics uncovered metabolites of microbial and co-microbial 
origins that defined tacrine-induced transaminitis. Metagenomics further 
delineated greater deglucuronidation propensities in extreme responders, based on 
differential faecal abundance of bacteria, such as Lactobacillus, 
Enterobacteriaceae, Bacteroides and Blautia, known to possess or modulate β-
glucuronidase activities. Co-administration of oral β-glucuronidase in an 
independent group of tacrine-dosed rats significantly increased susceptibility to 
tacrine-induced transaminitis from 41% to 76%. The results emphasise the roles 
of gut bacteria and its associated β-glucuronidase activities in defining the 
therapeutic outcomes of drugs.   
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 Chapter 1 Introduction 
 Personalised Medicine: Understanding and Managing Inter-1.1
individual Variation to Optimise Therapeutic Outcomes 
Each individual is unique. Our unique age, gender, genetic makeup, nutritional 
state, disease conditions and environmental exposure play an influential role in 
determining our responses to pharmacological therapies. Clinical trials in drug 
development programs, however, are often designed to investigate the efficacy 
and safety of new drug therapies as compared to the controls (e.g. gold standard 
therapy or placebo), and not the mechanisms accounting for the individual 
treatment responses (1). Based on such clinical trials, a recommended treatment 
regimen is derived based on the beneficial risk-benefit profile extrapolated from 
the clinical data gleaned from a selected pool of patients. While such a treatment 
regimen works for majority of the patients in the general framework, large inter-
individual variation in therapeutic outcomes is still a challenge in current clinical 
practices. The inability to predict therapeutic outcomes has wide ranging 
consequences. For the patients, this compromises their health and safety; for the 
pharmaceutical industries, this drives up the drug development cost; for the 
healthcare policy makers, this casts challenges in maintaining the quality and 
affordability of public health (1). The recognition of the importance of 
understanding and managing inter-individual differences to drug response has 
thus spawned the move towards “Personalised Medicine” (1-4). 
While the variation in individual response to therapy is long recognised in the 
medical field, the ability to truly provide customised patient care has been limited 
by technologies that may facilitate this goal. With the emergence and 
development of the ‘omics’ technologies and the determination of the human 
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genome in the recent decades, there has been a shift towards understanding 
disease processes and sourcing for drug therapies using the ‘omics’ technologies 
(5-8). In the move towards personalised medicine, pharmacogenomics is 
becoming increasingly important in predicting responses to pharmacotherapy (9, 
10). United States Food and Drug Administration (FDA) has issued 
recommendations for genotyping of patients prior to treatment using drugs such 
as herceptin, clopidogrel, carbamazepine and irinotecan based on 
pharmacogenomics studies that suggest differential efficacy and toxicity for 
stratified patient cohorts. Nonetheless, it is essential to recognise that 
pharmacogenomics is not all encompassing as it is not able to fully account for 
effects of environmental and disease factors on drug absorption and disposition 
(metabolism, distribution and excretion) not attributed to the variation of host 
(human or animals) genetics (11). As such, a more holistic, integrative and 
complementary approach to study the heterogenous inter-individual drug 
responses should be adopted.  
 The Gut Microbiota and its Influence on Drug Disposition and 1.2
Therapeutic Outcomes  
1.2.1 The Other Genome – The Microbiome 
Lederberg has coined human beings as “Superorganisms” (12). The human body 
is a complex biological system in which the function is dictated by two sets of 
genomes – the genetically inherited human genome and the environmentally 
acquired microbiome. It has been estimated that there are approximately 1012 
parenchymal cells in human (excluding blood cells and neurons) and 1012 bacteria 
on the skin, 1010 in the mouth, and 1014 in the guts (13). Considering the sheer 
proportion of the microbial to human cells that reside on the human body, 
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wherein the microbial cells outnumber the total human cells by a factor of 10, the 
extragenomic influence from the microbiome that coexist on the human body 
should definitely not be undermined in the approach to personalised medicine 
(14). In fact, the microbiome is gaining increasing attention from the scientific 
community in recent years and accumulating evidence indicates its diverse and 
immense impacts on human health, including nutrition, physiology and host 
metabolism (15). Its disturbance (or dysbiosis) has also been linked to 
pathological conditions such as inflammatory bowel diseases (16, 17), diabetes 
(18), obesity (19-21) and autism (22). 
1.2.2 Host Metabotype-Microbiota Interaction in Drug Disposition and 
Therapeutic Outcomes 
The gut microbiota forms an important component of the gastrointestinal 
ecosystem and it is often referred to as an external “organ”. To date, more than 
400 different species of bacteria have been found in the human gastrointestinal 
tract (23, 24). It is notable that the mass of these intestinal bacteria contributes 
about 1.5 kg of the human body weight (25). This is highly comparable to the 
weight of major human organs like the liver (~1.5 kg) and the brain (~1.4 kg) and 
the mass exceeds that of the lung (~0.84 kg), kidneys (~0.27 kg) and the spleen 
(~0.14 kg) (26). Importantly, the gut microbiota is known to play pivotal roles 
within the host by providing functional activities not encoded by the genetically 
inherited host genome. Taking desert woodrats as an example, woodrats living in 
the Mojave desert of the United States of America were found to harbor gut 
microbiota that facilitates their dietary consumption of highly toxic creosote bush 
which invaded their habitat 17,000 years ago (27). The leaves of the creosote bush 
are covered with a phenolic-rich resin that is largely made up of 
nordihydroguaiaretic acid that is known to induce kidney cysts and liver damage 
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in laboratory rodents (28, 29). In a recent study by Kohl et al., the authors 
demonstrated that the distinct gut microbiota communities residing in Mojave 
woodrats compared to the naïve woodrats (that lack ecological and evolutionary 
experience with creosote) confer tolerance within the former population to the 
creosote plant toxins. The Mojave woodrats have higher abundance of microbes 
with genes that facilitate metabolism (e.g. aryl-alcohol dehydroxylation) and 
detoxification of the aromatic toxic compounds (30). This example highlighted 
how microbial adaptation in an ecological and evolutionary context conferred 
competitive advantage to the host by expanding its access to nutrients that are 
otherwise toxic to other competitors not capable of performing microbial 
detoxification (31). 
1.2.2.1 The Liver in Drug Disposition and Therapeutic Outcomes 
To understand drug disposition and therapeutic outcomes, pharmaceutical 
scientists have placed much attention in investigating the role of the host (e.g. 
species, gene expression, genetic polymorphism, disease, gender and age), drug 
and its metabolites (e.g. chemical structure, dosage and frequency of 
administration) and other xeno-compounds (e.g. diet, supplements and other 
concomitant drugs) rather than the gut microbiota (32). The liver being a major 
organ responsible for metabolising xenobiotics including drugs and food has 
received particular attention. It is well recognised that the liver plays a central role 
in biotransformation of drugs and is equipped with a range of metabolising 
enzymes and transporters necessary for its function. Cytochrome P450 (CYP) is a 
major class of drug metabolising enzymes in the liver responsible for Phase I 
functionalisation reactions (e.g. hydroxylation, oxidation, reduction and 
hydrolysis) to introduce polar functional groups to nonpolar molecules (33-35). 
Phase II enzymes (e.g. uridine diphosphate-glucuronosyltransferase (UGTs), 
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sulfotransferases or glutathione-S-transferases) catalyse conjugation reactions 
which add polar moieties such as glucuronic acid, sulfate or glutathione to the 
functional groups (35). These processes facilitate the clearance of the xenobiotics 
via the urinary or biliary route with the aid of transporters or efflux pumps. 
Considering the key roles of the hepatic metabolising enzymes in drug 
disposition, factors such as induction, inhibition or genetic polymorphism which 
leads to alterations in the expression and functional activities of these enzymes, 
may contribute to inter-individual variation in drug disposition and therapeutic 
outcomes (efficacy or toxicity) (36-43). These, however, do not account for all 
forms of heterogeneity in drug disposition and responses among individuals.   
1.2.2.2 Gut Microbiota-Mediated Drug Disposition and Therapeutic 
Outcomes 
In recent years, the interest to elucidate the roles of the gut microbiota on drug 
disposition and therapeutic outcomes has rekindled. The gut microbiota is known 
to possess a diverse range of metabolic activities that is capable of influencing the 
fates of administered drugs and modulate therapeutic outcomes (44-49). Scheline 
has even proposed that the gut microbiota has the metabolic potential at least 
equivalent to the liver (50).  
Mechanistically, the gut microbiota is known to partake in the direct metabolism 
of xenobiotics or indirect interaction with the host enzymatic system (44-49). The 
indirect interaction is facilitated through the production of microbial or 
mammalian-microbial co-metabolites that compete for metabolism of xenobiotics 
or act as signaling molecules that influence the host gene expression. Such 
interactions may complement or oppose the host’s enzymatic action and 
culminate in wide-ranging metabolic and therapeutic consequences.  
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Table 1-1 illustrates a list of drugs where their disposition and therapeutic 
outcomes have been reported to be mediated by the gut microbiota. In the liver, 
the metabolism of xenobiotics comprises mainly oxidative and conjugative 
reactions. On the other hand, the metabolic activities of the gut microbiota include 
reduction, hydrolysis, degradation and synthesis (50-52). It is notable that 
compared to the metabolic activities of the host, the reactions associated with the 
gut microbiota are primarily reductive reactions and hydrolytic cleavage of 
conjugates such as glucuronides and sulfate conjugates that have been biliarily 
secreted into gastrointestinal tract (50-52). Furthermore, the gut microbiota can 
generate metabolites that are otherwise not produced by the host. Nitrazepam, a 
benzodiazepine drug, has been reported to induce teratogenicity (53). Incubation 
of nitrazepam with bacterial suspensions prepared from rat caecal contents led to 
extensive reduction to generate 7-aminonitrazepam, which underwent further 
acetylation in the liver to generate 7-acetylaminonitrazepam. These metabolites 
were reported to cause foetal malformation. Suppression of the nitroreductase 
activity of the gut microbiota by antibiotics prior to administration of nitrazepam 
significantly decreased the urinary and faecal excretion of the two reduced 
metabolites from 30% to 2% and markedly reduced the incidence of 
teratogenicity, underscoring the roles of gut microbiota in nitrazepam-induced 
teratogenicity (53). In view that Phase II conjugation is a means of the host to 
facilitate clearance of drugs, the hydrolytic activity of the gut microbiota to 
deconjugate these Phase II drug metabolites may potentiate the pharmacological 
or toxic effects of drugs by augmenting the systemic exposure of these drugs if 
the aglycones are subjected to enterohepatic recirculation (50-52). The indirect 
action of the gut microbiota on drug metabolism is exemplified by the work of 
Clayton et al. (47) where it was identified that in patients administered with 1 g of 
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acetaminophen, individuals that have high pre-dose urinary levels of p-cresol 
sulfate had low post-dose urinary ratios of acetaminophen sulfate to 
acetaminophen glucuronide. The authors attributed the reduced metabolic 
clearance of acetaminophen sulfate in implicated individuals to the generation of 
higher levels of microbially derived p-cresol that competes with acetaminophen 
for sulfonation in the liver (47). Extrapolating this finding, one may hypothesise 
that the gut microbiota potentially affects the disposition of other drugs in which 
sulfonation is essential. From the above examples, it is clear that the gut 
microbiota possesses great metabolic capability that can augment or reduce the 
metabolic status of the host and produce metabolites of active, inactive or toxic 
properties, some of which are not synthesised endogenously. Such activities 
contribute to variability in drug disposition and therapeutic outcomes. Many 
recent metagenomics studies observed large variation in the gut microbiota 
composition amongst individuals across different age groups and populations, 
further supporting the gut microbiota as a source of inter-individual variation in 
drug disposition and responses (20, 54, 55). Collectively, these findings 
emphasise the importance of the gut microbiota in pharmaceutical research and 




Table 1-1 Examples of drugs whose disposition or therapeutic outcomes are 
mediated by gut microbiota, either directly or indirectly (45, 47, 56-58).  
Reaction Drug 
Bacteria or its 
enzymes 
Consequences of gut microbiota 
metabolism on drug disposition 






Activation of azo-bond 
containing pro-drug to 
sulfanilamide 
Neoprontosil 
Sulfasalazine Activation of azo-bond 
containing pro-drug to 5-
aminosalicylic acid Balsalazide 
Olsalazine 
Nitrazepam Nitroreductase Co-metabolism of nitrazepam 
produces 7-
acetylaminonitrazepam 
responsible for teratogenic 
activity: 
Step 1: Nitroreduction of 
nitrazepam to 7-
aminonitrazepam by gut 
microbiota 
Step 2: 7-aminonitrazepam is 
converted to 7-
acetylaminonitrazepam in the 
liver 
Clonazepam N.R. Nearly complete reduction to 7-
aminoclonazepam 
Misonidazole N.R. Reduction to 1-(2-
aminoimidazol-1-yl)-3-
methoxypropan-2-ol 
Omeprazole N.R. In vitro reduction by gut 
microbiota to omeprazole sulfide 
metabolite. 
However, there was no alteration 
of oral in vivo pharmacokinetics 
as omeprazole is fully absorbed 
before reaching hindgut. 
Sulfinpyrazone N.R. Reduction to sulfinpyrazone 
sulfide metabolite (solely by gut 
microbiota) 






lentum prior to 
1999) 
Reduction to inactive 
metabolites (e.g. dihydrodigoxin 
or dihydrodigoxigenin) by gut 
microbiota reduce therapeutic 
efficacy 
Zonisamide N.R. Reduction to 2-
sulfamoyacetylphenol 






Bacteria or its 
enzymes 
Consequences of gut microbiota 
metabolism on drug disposition 
and therapeutic outcomes 





Therapeutic activity depends on 
its metabolism by intestinal 








A major metabolite of 
sorivudine, (E)-5-(2-
bromovinyl)uracil, generated 
from microbial metabolism of 
the drug was found to inactivate 
a key liver enzyme involved in 
the metabolism of 5-fluorouracil. 
Co-administration of sorivudine 
and 5-fluorouracil resulted in 
drug interactions that led to 
death. 
Deconjugation of 
drugs excreted in 




Hydrolysis of glucuronide 
Indomethacin Hydrolysis of glucuronide of 
indomethacin release the 
aglycone which leads to 
gastrointestinal toxicity  
Morphine Hydrolysis of glucuronide 
Irinotecan Hydrolysis of SN-38 
glucuronide of irinotecan (pro-
drug) release SN-38 in the 




Succinylsulfathiazole N.R. Activation of pro-drug to 
sulfathiazole 
Dehydroxylation L-Dopa N.R. Alteration of L-dopa 
pharmacokinetics by gut 





N.R. Acetylation to form acetylated  
5-aminosalicylic acid 
Deacetylation Phenacetin N.R. Formation of p-phenetidin from 
deacetylation reaction is 





Ranitidine N.R. Susceptible to N-oxide bond 
cleavage by gut bacteria 
Nizatidine N.R. Susceptible to N-oxide bond 
cleavage by gut bacteria 
Proteolysis Insulin N.R. Susceptible to proteolysis 




Bacteria or its 
enzymes 
Consequences of gut microbiota 
metabolism on drug disposition 
and therapeutic outcomes 




Isosorbide dinitrate N.R. Generate isomeric mononitrates 
and isosorbide 
Amine formation 
and hydrolysis of 
amide linkage 
Chloramphenicol N.R. Metabolised to metabolites such 
as p-aminophenyl-2-amino-1,3-
propanediol. 
Aplasia of the marrow, the most 
serious complication of 
chloramphenicol, has been 
proposed to be due to the 








Generate levametabol-I, II and 
III metabolites 
Isoxazole scission Risperidone N.R. Scission of the isoxazole in the 
benzisoxazole ring system of 
risperidone is a major metabolic 
pathway contributed by the gut 
microbiota 
N-demethylation Methamphetamine N.R. Converted to amphetamine by 
gut microbiota. 
May be inconsequential to man 
since the parent drug is quite 






Phase II drug 
clearance  
Acetaminophen Bacteria like 
Clostridium 
difficile is a p-
cresol 
producer 
High pre-dose levels of 
microbial metabolite p-cresol 
compete for clearance by hepatic 
sulfotransferase and diminish the 
host’s metabolic capacity for 





hepatic uptake of 
drug 
Simvastatin Bacteria like 
Lactobacillus 
is involved in 
production of 
coprostanol 
Microbially derived secondary 
bile acids may compete with 
simvastatin for hepatic uptake by 
SLCO1B1 transporters, thereby 
affecting the pharmacokinetics 
and pharmacodynamics of 
simvastatin, and increasing the 
risk of myopathy.  




1.2.2.3 Elucidating the Underlying Mechanisms for Gut Microbiota-
Mediated Drug Disposition and Therapeutic Outcomes: A Need (Not 
Want) 
Despite the vast metabolic potential of the gut microbiota, it has been estimated 
that only about thirty or so marketed drugs were identified as substrates of the gut 
bacteria to date (45). One explanation is the rapid and complete absorption of 
most orally administered drugs in the upper gastrointestinal tract, hence 
minimising their direct exposure to the intestinal bacteria (45). However, it is 
clear that the interaction with the gut microbiota may take place via other means, 
such as with biliary excreted metabolites of drugs which may not even be 
administered orally (e.g. glucuronidated metabolites of irinotecan and morphine). 
Additionally, using competitive sulfonation of acetaminophen as an example, 
Clayton et al. suggested a new mechanism in which the gut microbiota may 
mediate drug disposition and therapeutic outcomes which is brought about 
through the generation of microbial metabolites or co-metabolites (47). This mode 
of interaction completely bypasses the need for direct contact between the drug 
and gut microbiota, yet enabling the gut microbiota to exert a remote influence on 
the fate of drug disposition by effecting changes on the metabolic phenotype 
which in turn modulates the host’s physiology and enzymatic activities. In light of 
the extensive influence of the gut microbiota on the global metabolic phenotype 
(59, 60), it is believed that this work sets a new direction to investigate the 
pervasive influence of gut microbiota on the pharmacokinetic characteristics of 
other drugs. Digoxin, a cardiac drug for treatment of heart failure and arrhythmia, 
is known to possess narrow therapeutic index and requires therapeutic drug 
monitoring. It has been long known that digoxin can be inactivated by the gut 
microbiota into dihydrodigoxin and dihydrodigoxigenin and Eggerthella lenta has 
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been identified to be capable of its reduction (61, 62). 10% of the population is 
known to harbor these enteric bacteria that metabolise more than 40% of the 
orally ingested dose to inactive metabolites prior to its absorption (63). 
Coadministration of antibiotics erythromycin and tetracycline which eradicate the 
gut bacteria has been reported to decrease microbial metabolism of digoxin (64). 
However, not all patients harboring high abundance of Eggerthella lenta will 
reduce digoxin (62). This has remained a mystery since 1983 until a recent 
discovery by Haiser et al. who mechanistically elucidated the concerted influence 
of colonisation by distinct digoxin-reducing strains of Eggerthella lenta, 
microbial interaction and host diet (arginine) on the pharmacokinetics of digoxin 
(48). Digoxin’s case study further emphasised the need to scrutinise the genetic 
and metabolic functions represented by the microbial communities to derive a 
more refined understanding of the microbiota’s influences in the area of 
pharmaceutical research. 
We suggest that the relatively few examples related to microbial xenobiotic 
metabolism may be a reflection of our humble level of knowledge. Definitely, 
more studies that will help unveil the underlying mechanisms of the gut 
microbiota in drug disposition, efficacy and toxicity are necessary. Such 
mechanistic understanding will in turn aid the characterisation of drugs that are 
susceptible to the metabolic influence of gut microbiota and provide therapeutic 
insights for the management of pharmacotherapy (44, 56, 65-70).   
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 Modern Approaches to Study the Effects of Host-Microbiota 1.3
Interaction on Drug Disposition and Therapeutic Outcomes 
The poor understanding of the effects of host-gut microbiota interaction might be 
largely contributed by the lack of systematic scientific techniques and approaches 
to elucidate their complex interaction. Fortunately, this situation has greatly 
improved with scientific advancement in analytical sciences, molecular biology 
and bioinformatics. The following section highlights the techniques that greatly 
support the endeavor of systems biology-based investigation of host-gut 
microbiota interaction in pharmaceutical research. 
1.3.1 Metabonomics: Mining the Metabolome to Study Host-Gut Microbiota 
Interaction in Pharmaceutical Research 
There is now an increasing awareness of the symbiotic relationship between the 
host and gut microbiota and their combinatorial metabolic capacities. The global 
metabolic phenotype (metabotype) is a culmination of both host systems biology 
and gut microbiota biology (60, 71-76). Even though the gut microbiota resides in 
the intestines, the vena portae and lymphatic system facilitate its interaction with 
the host through the transportation of metabolites via the enterohepatic circulation 
system. As these metabotypes are reflected within the host metabolomes in 
biological matrices (e.g. plasma, urine and faeces), it renders the metabolome an 
important source for elucidating the interaction between the host and gut 
microbiota. Metabonomics is an attractive platform which provides access to this 
wealth of information embedded within the metabolome and facilitates valuable 
insights into the shared responsibility between the host and gut microbiota in 
modulating therapeutic outcomes (77-81). The birth of metabonomics dates back 
to the mid-1980s (77). Through the use of powerful analytical instruments such as 
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nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS), 
we are able to identify and quantify the small metabolites (<1500 Da) present 
within the metabolome and obtain evidence of the complex interactions between 
the host and the gut microbiota (59, 73, 82, 83).  
1.3.1.1 The Metabonomics Workflow and its Applications 
The typical metabonomics workflow is illustrated in Figure 1-1A. Figure 1-1B 
further illustrates the various processes involved in a metabonomics study using 
gas chromatography time-of-flight mass spectrometry (GC/TOFMS) as the 
analytical platform. In brief, the workflow starts with the research question which 
will determine the experimental design and the choice of matrix. As many 
metabonomic investigations are clinically translational in nature, urine and blood 
samples are analysed most frequently due to the ease of obtaining these samples 
(84). Being integrative biofluids, the urinary and blood metabolic profiles are 
known to reflect variation owing to the host, drug, environment (e.g. diet, stress 
and lifestyle) and gut microbiota. The samples are then prepared according to the 
type of bio-matrices being analysed and the instrument used for performing data 
acquisition. For example, urine is known to contain high concentration of urea 
which will impose chromatographic interference. Hence, incubation with urease is 
performed to remove this interference during sample preparation (83, 85). For 
samples that will be subjected to GC/TOFMS analysis, they are typically 
subjected to derivatisation such that the analytes are sufficiently volatile and 
thermally stable for GC/TOFMS analysis (86). Due to the great chemical 
diversity of the metabolites present within the metabolome, no single analytical 
technique is able to capture the full set of metabolites. As such, various analytical 
techniques such as NMR, GC/MS and liquid chromatography-mass spectrometry 
(LC/MS) are often used complementarily to broaden the metabolic coverage and 
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resolve the metabolites completely in complex biological matrices. This approach 
has been adopted to profile the metabolomes of human urine, blood and 
cerebrospinal fluid and the findings are made available in databases like the 
Human Metabolome Database (HMDB) (87-91). Due to the complexity of 
biological samples, metabonomic investigations typically generate a plethora of 
data in which meaningful interpretation is made possible by proper preprocessing 
of the data to workable formats for further downstream analysis with statistical 
tools (84, 85, 92, 93). This approach has been applied to identify marker 
metabolites implicated in diseases mechanisms related to gastroenterological 
diseases (94), central nervous disorders (95), cancers (96-100) and kidney 
diseases (101). Metabonomics has also been employed in preclinical toxicological 
screening and its usefulness has been comprehensively evaluated by the 
Consortium for Metabonomic Toxicology (COMET) which comprises scientists 







Figure 1-1 (A) A typical metabonomics workflow and (B) flow diagram of 
various processes typically involved in GC/TOFMS-based metabonomics.  
1.3.1.2 Metabonomics Revealed Extensive Influence of Host-Gut Microbiota 
Interaction on Drug Disposition 
More recently, metabonomics has been used to understand the interaction 
between the host and gut microbiota. Through the use of different experimental 
designs such as antibiotic-perturbed rodents (60, 71), germfree versus 
conventional rodents (72, 73) or through gut microbiota colonisation of axenic 
mice (74, 75), metabonomic analysis of the bio-matrices (e.g. urine, plasma, 
faecal extracts, intestines, liver and kidney) revealed extensive gut microbiota 
modulation of the host systemic metabolism. For instance, alteration of gut 
microbial communities has led to perturbation of marker metabolites such as short 
chain fatty acids, amino acids, primary and secondary bile acids, tryptophan and 
carbohydrate metabolism. The alterations of such metabolites (e.g. bile acids) as a 
results of combinatorial activities of the host and gut microbiota suggested broad 
metabolic implications on drug metabolism. In a study by Toda et al., the authors 
determined the effects of the intestinal microbiota on CYP expression by 
A    B 
17 
 
comparing the specific pathogen-free (SPF) and germfree mice (106). SPF mice 
are free of specific infectious microorganisms and parasites but are otherwise 
normally colonised with an undefined microbiota. They observed a higher mRNA 
expression of a majority of CYPs in the livers of SPF mice. Using a mouse 
CYP3A substrate, triazolam, the authors demonstrated a higher metabolic activity 
of liver microsomes extracted from the SPF mice compared with germfree mice, 
corroborating with the higher CYP3A expression in the SPF mice. Nuclear 
receptors like aryl hydrocarbon receptor (AhR), constitutive androstane receptor 
(CAR), farnesoid X receptor (FXR) and pregnane X receptor (PXR) which 
modulate the expressions of the CYPs were also highly expressed in the livers of 
these SPF mice than germfree mice. Interestingly, cholesterol-derived metabolites 
such as bile acids (e.g. lithocholic acid), steroid hormones and bilirubin have been 
proposed to function as activators of liver nuclear receptors and the levels of these 
metabolites were known to be mediated by microbial metabolism (107, 108). As 
such, this study together with other similar works demonstrated that the gut 
microbiota can meditate Phase I metabolism by the liver through influencing 
nuclear receptor and CYP expressions via microbial metabolism of substrates like 
bile acids (74, 106, 109). In addition, the metabolic processes of the enteric 
bacteria are also known to impose a huge burden on the Phase II metabolic 
processes of the host. Using a broad untargeted MS-based profiling approach, 
metabonomic analysis by Wikoff et al. revealed large effects of gut microbiota in 
the metabolic profiles of the mouse serum (73). Compared to the germfree mice, 
conventional mice were observed to have exclusive presence of numerous 
sulfated, glycine-conjugated and glucuronide adducts. For example, indoxyl 
sulfate was identified exclusively in the serum of conventional mice. This 
metabolite is formed as a result of the Phase II sulfonation of the bacterial 
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metabolite indole, which is derived from the enzymatic conversion of tryptophan 
by bacterial tryptophanase (73). Apart from the indole derivatives, numerous 
metabolites apparently resulting from Phase II processing of microbial 
metabolites (e.g. hippuric acid, p-cresol sulfate, phenylacetylglycine) suggested a 
broad, drug-like Phase II metabolic response of the host to the microbial 
metabolites (73). This metabolic burden by microbial metabolites is not trivial as 
many drugs are rendered more polar for clearance by Phase II metabolism by the 
liver. This is illustrated by the competition for Phase II metabolism between 
acetaminophen and p-cresol as reported by Clayton et al. (47). This provides an 
actual example that demonstrates that microbial metabolites may disturb the 
detoxification process for drugs and culminate in wide ranging toxicological 
consequences. From these studies, it is clear that the complex interaction between 
the host and gut microbiota plays a pertinent role in influencing the metabolic 
phenotype, which in turn underpins the varied metabolic capabilities between 
individuals with different gut microbiota compositions.  
1.3.2 Culture-based and Culture-independent Techniques for Studying the 
Gut Microbiota   
The ability to characterise the microbial composition and to identify the 
implicated gut microbes plays a major part towards expanding our understanding 
of their involvement in pharmacology. The initial work on the gut microbiota 
since the 1970s relies on culture-based techniques (110). Through the use of 
selective growth media and conditions, more than 400 to 500 bacterial species 
have been identified in the human gut. The following section will first describe 
the application of culture-based techniques which have traditionally been used to 
study microbial metabolism in pharmaceutical research followed by the more 
modern culture-independent approaches to study the gut microbiota. 
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1.3.2.1 Culture-based Techniques in the Study of Microbial Metabolism in 
Pharmaceutical Research 
The majority of gut bacteria resides in the colon and it is a major site for 
microbial metabolism of many endogenous and exogenous compounds (45, 110). 
However, the anatomical location of the human colon poses a barrier for direct 
examination of the functional activities of the microbiota. As such, in vitro 
determination of drug metabolism using culture-based techniques has a particular 
place in pharmaceutical research as it circumvents the challenge of invasive 
procedures, ethical drawbacks, cost and laborious nature associated with in vivo 
investigation (45). In this regards, static batch culture is an example of an in vitro 
method that has been frequently employed for elucidating microbial metabolism 
of drugs (45, 111). Such cultures attempt to closely simulate the colonic 
environment by placing specific strains of bacteria, caecal or intestinal contents 
(of animals) or faeces (of animal or human) into a suitable medium. Care is also 
taken in the maintenance of factors such as anaerobic condition and pH. Drug is 
added to such cultures and samples are taken intermittently to quantify the 
amount of drug and its metabolites. It is notable that for majority of the drugs 
listed in Table 1-1, static batch culture technique has been applied to establish the 
involvement of gut microbiota in their metabolism (45). 
However, some key limitations exist with the use of culture-based techniques. 
Inherent to the nature of bacteria cultivation technique, this method provides an 
incomplete view of the phylogenetic diversity of gut microbial community as 
some bacteria remain uncultivable (110). To date, less than 30% of gut bacteria 
species have been cultured (112). The symbiotic relationship of gut microbiota 
species such that the survival of an organism depends on the metabolic activity of 
another and the fastidious growth conditions adds to the difficulties in 
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characterising and reproducing appropriate growth environment for these bacteria 
(113-115). Such constraints impede culture efforts and render difficulties in 
creating an environment that supports the growth of all intestinal or faecal 
bacteria to mimic the actual colonic environment to study microbial metabolism 
of drugs. Furthermore, culture-based techniques have the problem of being over 
simplistic as they do not consider other dynamic processes that occur in intact 
physiological conditions such as metabolic exchange and interaction between the 
host and gut microbial community and absorption of fermented products (45).   
Owing to these limitations, in vivo studies are conducted often complementarily 
with in vitro studies, to obtain deeper insights that are otherwise not obtainable 
from in vitro culture-based investigations alone. Animal studies may involve 
investigating microbial metabolism by comparing bile metabolites with faecal 
metabolites or lower gut metabolites with upper gut metabolites (45). In addition, 
further confirmatory work may be performed by comparing the drug metabolism 
between germfree or antibiotic-treated animals with conventional animals (45). 
For human studies, experimental designs to study bacterial metabolism may 
involve comparison of extended release with immediate release formulation or 
intravenous with oral drug delivery or metabolism in ileostomy patients with 
healthy subjects (45).   
1.3.2.2 Culture-independent Techniques and its Applications 
Since the 1990s, the development of molecular biology gave rise to culture-
independent techniques which revolutionised our knowledge of the gut microbiota 
(112). The application of molecular tools has greatly improved our understanding 
of the microbial community by providing us the ability to analyse the structural 
diversity and potential functional activities of the microbes, even for those that 
cannot be cultured. The following section will introduce two main culture-
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independent approaches to survey the microbiome; one method is based on the 
analysis of the 16S ribosomal ribonucleic acid (rRNA) genes and the other 
method is based on the whole genome of the microbes (110, 112, 116-120).  
Present throughout the cytoplasm of a bacterial cell are 70S ribosomes that are 
made up of two subunits, the 30S and 50S subunits (112). The 30S subunit is 
known to contain the 16S rRNA. The 16S rRNA gene is universally present in 
bacteria and has highly conserved domains flanking nine hypervariable regions 
which possess considerable sequence diversity to be used for distinguishing 
bacteria (118, 121). As such, the 16S rRNA gene has been considered as a 
phylogenetic and evolutionary marker for bacteria identification (118). Majority 
of the culture-independent techniques for the analysis of the gut microbiota are 
based on the analysis of the 16S rRNA genes. Such techniques include 
quantitative polymerase chain reaction (qPCR), denaturing gradient gel 
electrophoresis (DGGE), temperature gradient gel electrophoresis (TGGE), 
terminal restriction fragment length polymorphism (T-RFLP), fluorescence in situ 
hybridisation (FISH), deoxyribonucleic acid (DNA) microarrays and sequencing 
of 16S rRNA amplicons (110, 112, 118). Amongst these techniques, qPCR has 
been widely employed in gut microbiota investigations as the method is fast, 
sensitive, quantitative, enables phylogenetic discrimination and targeted analysis 
of specific bacteria of interest through primer design (110, 112, 122, 123). 
However, it is subjected to inherent bias of PCR-based techniques and does not 
allow identification of unknown bacteria (110, 124, 125). The 16S rRNA gene 
sequencing on the other hand is able to detect unknown bacteria and yields 
information on the proportion of various microbes to allow inference of the 
composition of microbial communities (112). With the development of next-
generation sequencing techniques (e.g. 454 Pyrosequencing®, Illumina® and 
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SOLiDTM), this has led to significant reduction in sequencing cost and time (116), 
making these sequencing techniques more widely adopted in research. In a study 
to examine the long term effects of exogenous microbiota transplantation 
combined with and without an antibiotic pretreatment using rat model, Maichanh 
et al. combined the application of qPCR and 16S rRNA gene sequencing to 
determine the degree to which the gut microbiota can be experimentally 
manipulated (126). qPCR was employed to elucidate the bacterial load present in 
the rat faecal samples and a decrease in bacterial load was confirmed following 
the administration of antibiotics. Using 16S rRNA gene sequencing, Maichanh et 
al. discovered that the exogenous transplant of caecal materials from different 
strains of donor rats led to a change in the faecal bacterial diversity of the 
recipients (without antibiotic pretreatment) to highly resemble the donor samples 
and the effect persist even up to 3 months following a single inoculation. 
Interestingly, pretreatment with antibiotics was not found to facilitate the 
establishment of the exogenous microbiota in the recipient rats. Instead, it 
culminated into a greater reshaping effect, leading to a gut microbiome 
composition that is distant from both the donor and long-term antibiotic treatment 
samples. Although this result is highly counterintuitive to the authors’ original 
hypothesis of antibiotic helping to enhance the reshaping effect of microbiota 
transplantation, the authors suggested that this should be taken into consideration 
in the design of future faecal microbiota transplantation studies (126). Integrated 
approach that combines 16S rRNA gene sequencing with metabonomics has also 
been employed in system biology-based investigations. Using this integrated 
approach, Lu et al. revealed that the environmental toxin, arsenic, significantly 
perturbed the gut microbiome composition of C57BL/6 mice and correlation 
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analysis showed that the abundance of some of these bacteria was highly 
correlated with the altered gut microbiota-related metabolites (127).  
The other culture-independent technique known as whole-genome shotgun 
sequencing involves sequencing the entire genomes of the microbes (112, 117). 
This method involves random fragmentation of microbial DNA, sequencing of 
DNA fragments and reconstruction of overlapping sequence to assemble them 
into a continuous sequence (112). Through whole-genome shotgun sequencing of 
the microbiome, microbial genes that encode for metabolic functions can be 
identified, providing insights into the potential functional activities by the 
microbes. Whole-genome shotgun sequencing provides information on both 
genetic diversity and functions of the gut microbiota while 16S rRNA gene 
sequencing gives only information of genetic diversity. However, this comes at a 
higher cost and is computationally more intensive. Other drawbacks include the 
requirement for large amount of DNA for analysis unless genome amplification is 





 Tacrine: A Hepatotoxic Probe With Undefined Etiology Behind Its 1.4
Variable Toxicokinetics 
1.4.1 Tacrine and the Variable Toxicological Responses to This Drug 
Tacrine is a centrally acting acetylcholinesterase inhibitor and it was the first drug 
marketed for the treatment of Alzheimer’s disease. However, tacrine was 
discontinued by FDA due to cases of hepatotoxicity and the emergence of safer 
and more efficacious alternatives such as Aricept (Donepezil). Tacrine is known 
to induce hepatocellular injury that is characterised by elevation in 
aminotransferase but not bilirubin or alkaline phosphatase levels (128). In a 
clinical trial involving 2446 Alzheimer’s disease patients receiving a daily dose of 
40-160 mg tacrine, 49%, 25% and 2% of the patients developed elevation of 
alanine aminotransferase (ALT) level higher, three times higher and twenty times 
higher than the upper limit of normal (ULN), respectively (128). Although most 
patients were asymptomatic, a subset of the patients was highly susceptible to the 
hepatotoxicant. These patients developed jaundice and/or hepatocellular necrosis 
as confirmed by liver biopsy (128-131). Despite the prominent increase in liver 
function enzymes and histopathological changes suggestive of serious liver 
injury, some patients with previous ALT elevation were able to resume their long-
term therapy upon rechallenge with tacrine.  
Although the incidences of transaminitis were prevalent clinically, earlier 
preclinical studies in rats, mice and dogs showed no clear evidence of such 
hepatotoxic effects of tacrine (132). Subsequent studies in rodents, however, 
demonstrated tacrine-induced transaminitis (133-135). This phenomenon suggests 
an inter-individual and inter-species variation in the susceptibility to tacrine-
induced transaminitis.  
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1.4.2 Absorption, Distribution, Metabolism and Excretion of Tacrine 
1.4.2.1 Clinical Pharmacokinetics of Tacrine 
Apart from the hepatotoxic potential of tacrine, the clinical application of tacrine 
was also confounded by the large inter-individual variation in its pharmacokinetic 
disposition (136-141). The clinical pharmacokinetic profile of tacrine is 
summarised in Table 1-2. The lipophilic nature of tacrine (Figure 1-2) renders it 
to be rapidly (time to maximum plasma concentration, Tmax of 0.5 to 3 h) and well 
absorbed after oral administration. However, this drug exhibits low and variable 
bioavailability, potentially due to extensive first-pass metabolism as evident by 
the presence of metabolites in the plasma soon after oral administration. Tacrine 
has a wide volume of distribution and high concentration of the drug has been 
found in the kidneys, liver, adrenal gland and brain tissue using animal models 
(142). Tacrine is extensively metabolised by the hepatic CYP1A2 enzymes to 
form hydroxylated metabolites such as 1-hydroxytacrine, 2-hydroxytacrine, 4-
hydroxytacrine and 7-hydroxytacrine (Figure 1-2). These hydroxylated 
metabolites undergo further glucuronidation by UGTs and are rendered polar for 
excretion (Figure 1-2). Large inter-individual differences were observed in the 
exposure to tacrine. Lou et al. observed that the systemic exposure, as indicated 
by the area under the plasma concentration-time curve, varied from 41.1 to 102.4 
µg×h/L when a group of four elderly patients were administered the same oral 
dose of 50 mg tacrine (138). Urine is the primary route of excretion of tacrine and 
its metabolites. In humans, 54% of a single oral dose of 40 mg radioactive 14C 





Table 1-2 Clinical pharmacokinetics of tacrine (136-139, 141).  
Clinical pharmacokinetics 
Absorption 
 Rapid absorption and well absorbed  
 Peak plasma concentration (Cmax) achieved within 0.5 to 3 h 
 Low and variable oral bioavailability ranging from 17 to 37% 
Distribution  Large volume of distribution 
Metabolism 
 Phase I metabolism: Hydroxylation by hepatic CYP1A2 
o Metabolites: 1-hydroxytacrine, 2-hydroxytacrine, 4-
hydroxytacrine and 7-hydroxtacrine 
 Phase II metabolism: Glucuronidation by UGTs 
 Elimination half-life of 1.3 to 7 h  









































1.4.2.2 Kinetic Disposition Profile of Tacrine In Relation to Manifestation of 
Hepatotoxicity 
Variation in the pharmacokinetics of tacrine may possibly affect both the 
therapeutic outcomes and occurrence of adverse effects in patients (136-141). 
Toxicokinetics has been defined as the generation of kinetic data to study and 
correlate the systemic exposure of the ‘perpetrator’ drug (145, 146). Such 
toxicokinetic studies are performed in order to enhance the interpretation of 
toxicological findings. In a placebo-controlled, double-blind crossover clinical 
trial conducted on 66 patients (140), the authors highlighted the predictive value 
of blood concentrations of tacrine and its metabolites in assessing the risk of 
adverse effects compared to dose alone. Although a slightly higher serum tacrine 
concentration in patients with abnormal liver function tests were observed 
compared to patients without abnormality (14 ng/mL vs 12 ng/mL), statistical 
difference between the groups was not achieved. Nevertheless, it was noted that 
the blood concentration of tacrine was exceptionally high (85 and 96 ng/mL) in 
two subjects manifesting transaminitis and other symptomatic adverse effects 
(140). The ratio of tacrine concentration to metabolite concentration was further 
found to be significantly higher in those patients exhibiting transaminitis 
compared to patients without liver abnormality (0.52 vs 0.41, P<0.05). 
Consequently, Ford et al. suggested that this ratio may be a crude indicator of the 
metabolic capability of the liver for tacrine. In which, a high ratio is suggestive of 
reduced metabolism and is associated with an increased propensity toward 
development of adverse effects including hepatotoxicity (140).  
There appears to be an apparently poor relationship between dose and the 
incidence of tacrine toxicity. In a parallel study in which 77 patients were 
randomised to receive 20 mg/day tacrine and 76 patients to receive 40 mg/day for 
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a period of 12 weeks, the incidence of transaminitis was similar in the two groups 
(128). 23% and 18% of the patients developed elevation of ALT more than 3 
times ULN in each of the respective groups. This finding is consistent with that 
reported by Ford et al.in which a similar incidence of hepatotoxicity occurred at 
all dose levels from 50 to 150 mg and they found no ‘safe dose’ below which 
adverse effects to tacrine were absent (140).  
Altogether, the preceding literatures highlight the highly variable toxicokinetic 
profiles of tacrine in the history of its clinical application. While these studies 
were unable to determine the underlying etiology of tacrine-induced transaminitis, 
it is important to recognise the association of the disposition kinetics with tacrine-
induced transaminitis. These early studies illuminate the potential of combining 
toxicokinetic studies with other studies to elucidate the mechanisms of tacrine-
induced transaminitis.  
1.4.2.3 Kinetic Disposition of Tacrine in Animal Models 
Pool et al. performed an inter-species comparison of the metabolic disposition of 
tacrine in rats, dogs and human (143). Similar to the pharmacokinetics in human, 
tacrine was well absorbed in the animal models, with urinary excretion being the 
predominant route of drug elimination. 1-Hydroxytacrine, 2-hydroxytacrine and 
4-hydroxytacrine metabolites were detected in all species. Marked species 
differences however exist in the quantitative amounts of metabolites compared to 
humans (143, 147-149). The rat is the most commonly utilised animal model for 
determining the potential toxicity of drugs (150). However, Pool et al. suggested 
that the human urinary metabolic profiles, whereby no single major metabolites 
were observed, were more similar to that in dogs than in rats (143). Several polar 
metabolites (e.g. dihydroxylated tacrine) made up ~26% of dose after 10 and 40 
mg doses in human and the combined amount of the monohydroxylated 
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metabolites and tacrine accounted for less than 7% of dose excreted in urine. In 
contrast, monohydroxylated metabolites (1-hydroxytacrine, 2-hydroxytacrine and 
4-hydroxytacrine) and tacrine accounted for ~60% of the dose in urine following 
a single 2 mg/kg dose of tacrine in rats. In rats given a single oral dose of 20 
mg/kg of tacrine, ~60% of the dose was also found in urine collected over 48 h 
and ~15% of the dose was Phase II conjugates (147). Interestingly, this urinary 
excretion study indicates the formation of tacrine-N-glucuronide although no 
earlier studies have confirmed its presence (Figure 1-2). 
1.4.3 Tacrine-induced Hepatotoxicity and the Mechanisms of Toxicity  
Current literatures are divided in the postulated mechanisms of tacrine-induced 
transaminitis; some suggest the existence of a toxic tacrine metabolite (144, 151, 
152), while others propose that tacrine itself can induce hepatocellular damage 
(133, 153-157).  
1.4.3.1 A Reactive Quinone Methide? 
In the former hypothesis, tacrine is proposed to undergo a two-step bioactivation 
involving an initial step of 7-hydroxylation by hepatic CYP1A2, followed by a 
subsequent two electron oxidation to form a reactive quinone methide (Figure 
1-3) (144, 151, 152). In vitro incubation of radioactive labeled tacrine with human 
and rat liver microsomes revealed a similar metabolic profile whereby there was 
extensive metabolism of tacrine to 1-hydroxytacrine with minor quantities of 2-
hydroxytacrine, 4-hydroxytacrine and 7-hydroxytacrine in both species. Poor 
recovery of the radioactivity in the post-incubation mixture indicated an 
irreversible binding of protein reactive metabolites with the microsomal proteins. 
Co-incubation of thiol-containing agents like glutathione in reaction mixture was 
able to inhibit the degree of protein binding without affecting the extent of 
metabolism, supporting the formation of an electrophilic reactive metabolites 
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from tacrine metabolism (144, 151, 152). Species differences however was 
observed in which a 3-fold lower degree of protein binding was observed in rat 
liver microsomes compared to human liver microsomes (144). The lower 
bioactivation of tacrine in rat derived from these in vitro studies has hence led to 
doubts about the suitability of this model to investigate hepatotoxicity induced by 
tacrine. However, it is pertinent to note that no studies to date were able to trap 
and detect the putative 7-hydroxytacrine-derived quinone methide adducts using 
trapping agent like glutathione. As such, prudent interpretation of the results is 
essential, especially in view of the variable inter-individual and inter-strain 

























Figure 1-3 Proposed mechanism for bioactivation of tacrine (144, 151). 
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Conflicting views prevailed regarding the involvement of CYP1A2 and the effect 
of oxidative stress on tacrine-induced hepatotoxicity based on studies using 
different cell lines. Meng et al. attributed this controversy to the differential 
expression levels of CYP1A2 in the cell lines and primary hepatocytes selected in 
each study design (157). Using gel entrapment culture of rat hepatocytes which 
retained the in vivo-like morphology and metabolic activities in standard cell 
culture conditions, the authors detected greater sensitivity to tacrine-induced 
toxicity compared to hepatocytes cultured as monolayer culture. The maintenance 
of CYP1A2 metabolic activity in these cells coupled with evidences of reduction 
of tacrine-mediated toxicity by addition of CYP1A2 inhibitor like fluvoxamine to 
the gel entrapped hepatocytes reinforced the close relationship of CYP1A2 with 
tacrine toxicity (157). They further demonstrated that addition of glycyrrhetinic 
acid, a free radical scavenger and glutathione inducer, protected the cells from 
tacrine-mediated cytotoxicity. The findings highlighted the implication of 
oxidative stress in tacrine-induced toxicity (157).  
1.4.3.2 Tacrine: A Direct Hepatotoxicant? 
Some studies proposed the parent drug, tacrine, to be a direct hepatotoxin. In vitro 
studies suggested several mechanisms through which tacrine leads to hepatic 
dysfunction: Fariss et al. proposed that tacrine adversely affects protein synthesis, 
ribosomal structure and function in rat hepatocytes (153); Berson et al. 
demonstrated that tacrine exerts a protonphoric effect in mitochondria which 
impairs energy production in rat and human cells (154); Mansouri et al. further 
confirmed the occurrence of tacrine in mitochondria and its ability to inhibit 
mitochondria DNA replication, leading to depletion of mitochondria DNA, 
necrosis and apoptosis of hepatocytes (156). The cytotoxic effect of tacrine was 
further demonstrated in rat hepatocytes and in human hepatoma cell line (HepG2) 
 33 
 
where the parent drug was observed to be more cytotoxic compared to its 
monohydroxylated and dihydroxylated metabolites (155).  
Rat species has been suggested to be less vulnerable to tacrine-induced 
hepatotoxicity due to lower degree of bioactivation of tacrine as suggested by the 
results of in vitro studies (144, 151, 152). However, the theory has been dispelled 
by Stachlewitz et al. and Ma et al. who studied the hepatotoxicity of tacrine in 
Sprague-Dawley rats (133, 134). Stachlewitz et al. suggested that tacrine induces 
hepatotoxicity through modulating the sympathetic nervous system, thereby 
leading to hypoxia-reoxygenation injury (133). In the study, tacrine was found to 
increase the sympathetic activity in the liver, leading to vasoconstriction which 
diminished blood flow to the liver and induced tissue hypoxia. The subsequent 
metabolism of tacrine by hepatic CYP1A2 reversed the stimulation of the 
sympathetic hepatic nerve. However, this restoration of hepatic blood flow in turn 
resulted in production of free radicals which brought about reperfusion injury to 
the hypoxic hepatic tissues. The hypothesis proposed by Stachlewitz et al. 
interestingly reconciled with the findings by other independent research groups 
that supported the implications of CYP1A2, oxidative stress and direct toxicity of 
tacrine underlying the mechanism for tacrine-induced hepatotoxicity. In addition, 
the direct hepatotoxic nature of tacrine corroborated with the findings by Ford et 
al. where higher ratios of tacrine concentration to metabolite concentration (lower 
metabolic capability of liver for tacrine) are associated with higher propensity 
toward tacrine-induced hepatotoxicity (140). 
1.4.3.3 Host-Gut Microbiota Interaction in the Variable Toxicokinetics of 
Tacrine  
While many in vivo (133, 134, 156) and in vitro (144, 151-155, 157) studies were 
conducted to elucidate the mechanisms of tacrine-induced hepatotoxicity, these 
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studies were unable to account for the variable toxicological susceptibility to 
tacrine-induced transaminitis. In particular, little is known with regards to the 
contribution of host-gut microbiota interaction on the highly variable 
toxicokinetics of tacrine despite our understanding of the substantial metabolic 
potential of the extragenomic influence from the gut microbiota.  
In a preliminary in-house study, we dosed a small group of Lister hooded (LH) 
rats with a single oral gavage of tacrine at 20 mg/kg body weight (n=7) while the 
control arm received 1% methylcellulose vehicle (n=5) (Figure 1-4A). Severe 
transaminitis was observed in three of the tacrine-dosed rats (ALT>2× and 
aspartate aminotransferase (AST)>3× mean of controls) while the other four 
tacrine-dosed rats showed no obvious elevations of plasma liver injury markers 
(Figure 1-4B and C). The former group was classified as responders while the 
latter as non-responders. GC/TOFMS-based metabonomic analysis of the urinary 
metabolomes of the LH rats at 0–8 h following tacrine administration revealed a 
drift in the urinary metabolic profiles of the tacrine-dosed rats from the control 
group (Figure 1-4D). Interestingly, we observed that the urinary metabotypes of 
the three responders clustered distinctly from the control group and non-
responders at the 24–48 h period where transaminitis was most prominent (Figure 
1-4E). Figure 1-4F illustrated a list of transaminitis-related marker metabolites 
differentiating the responders from non-responders. Among the list, many marker 
metabolites (e.g. hippuric acid, glutaric acid and 5-hydroxyindole) were of 
microbial or co-metabolic origin. These preliminary findings suggest that the gut 
microbiota may play a role in determining the susceptibility of LH rats to tacrine-
induced transaminitis. However, further studies are warranted to elucidate the 





Figure 1-4 Experimental design and results for preliminary in-house study. (A) 
Study design, plasma (B) ALT and (C) AST levels of LH rats in the control group 
(n=5), responder group (n=3) and non-responder group (n=4). Principle 
component analysis (PCA) scores plots of the urinary metabolome of LH rats at 
the (D) 0–8 h and (E) 24–48 h time periods.  (F) Transaminitis-related urinary 
marker metabolites identified at the 24–48 h time periods with variable 
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 Research Objectives and Significance 1.5
1.5.1 Research Question and Objectives 
Despite the huge metabolic potential of the gut microbiota, the gut microbiota is 
known to mediate the disposition and therapeutic outcomes of a 
disproportionately low number of drugs compared to those subjected to the 
metabolic influence of the liver. This suggests the limited knowledge of the 
metabolic influence of the gut microbiota in drug research. Based on our 
preliminary in-house study on tacrine, the findings suggested that the complex 
interplay between the host and gut microbiota is possibly significant in explaining 
the variable toxicokinetic profile of tacrine. However, the effect of this host-gut 
microbiota interaction on tacrine toxicokinetic profile has not been thoroughly 
investigated. As such, the overarching aim of this thesis is to elucidate the 
contribution of the host-gut microbiota interaction on the toxicokinetics of tacrine. 
To study this intricate relationship, a holistic investigation that combines clinical 
chemistry, pharmacokinetics, metabonomics, computational bioinformatics, 
metagenomics and genetic analysis was performed. The specific objectives of the 
thesis are as follow: 
1) Establish LH rats as an animal model that manifests variable susceptibility 
to tacrine-induced transaminitis.  
2) Determine the pharmacokinetic profiles of tacrine-dosed LH rats. 
3) Profile the messenger ribonucleic acid (mRNA) expression of disposition-
related genes in the livers of tacrine-dosed LH rats. 
4) Screen urinary and faecal metabolomes of LH rats for transaminitis-




5) Profile the gut microbiome in LH rat faeces. 
6) Elucidate the mechanism of inter-individual susceptibility to tacrine-
induced transaminitis by modifying the intestinal β-glucuronidase 
activities. 
1.5.2 Thesis Outline 
An overview of the methodological framework adopted in this thesis is 
summarised in Figure 1-5. 
 
Figure 1-5 Overview of methodological framework to characterise host-gut 
microbiota interaction. Central to the thesis is the unknown etiology behind the 
variable toxicokinetics of tacrine. An integrated strategy was adopted to study the 
intricate relationship between the drug (tacrine), host (LH rats) and gut microbiota 
on the variable toxicokinetics of tacrine and this will be covered by the various 





In Chapter 2, we performed an in vivo toxicity study by administering a single 
oral dose of tacrine to LH rats. Plasma liver injury markers (ALT and AST) were 
measured and the pharmacokinetic profiles of tacrine and metabolites in the rats 
were determined. Chapter 3 investigates the contribution of the host on the 
variable response to tacrine-induced transaminitis. Using qPCR, the mRNA 
expressions of disposition-related genes in the livers of LH rats were profiled. In 
Chapter 4, GC/TOFMS-based metabonomics was used to examine the urinary and 
faecal metabolomes and screen marker metabolites of host, gut microbial or co-
metabolic origins that were predictive of the toxicity phenotypes of tacrine-dosed 
rats. In Chapter 5, we elucidated the plausible roles of the gut microbiota on 
tacrine-induced transaminitis by analysing the gut microbiome using targeted 
qPCR and 16S metagenomics analysis.  
Based on our findings from Chapter 2 to 5, a separate in vivo study on LH rats 
was performed as detailed in Chapter 6 to mechanistically elucidate the 
underlying etiology of variable toxicokinetics of tacrine. In this mechanistic 
study, the intestinal β-glucuronidase activities of a group of tacrine-dosed LH rats 
were modified with oral β-glucuronidase enzymes. The toxicological 
susceptibility of this group of rats was compared with that of tacrine-dosed LH 
rats not supplemented with oral β-glucuronidase. 
1.5.3 Scope  
Tacrine was previously used in the treatment of Alzheimer’s disease but has now 
been withdrawn from the market. It is not the aim of this thesis to restore the 
clinical application of tacrine. Instead, the focus of the thesis is to study and 
understand how host-gut microbiota interaction contributes to variation in inter-
individual responses to pharmacotherapy, specifically through its impact on the 
toxicokinetics of our hepatotoxic probe – tacrine.  
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Many host factors (e.g. genetic polymorphism, organ functions and age) affect 
drug metabolism and toxicity. The liver is a major organ in the body responsible 
for the disposition and detoxification of many drugs. We acknowledge that many 
other aspects of the host may influence drug disposition and toxicity. For the 
investigation of the contribution of the host on the variable toxicokinetics of 
tacrine, this report is however confined to assessing the expression of disposition-
related genes in the livers of LH rats.  
1.5.4 Significance of Project 
The symbiotic relationship between the host and gut microbiota is crucial for our 
understanding of inter-individual responses to pharmacotherapy. Even though 
much of the host-gut microbiota relationship remains to be elucidated, the 
currently held opinions of the gut microbiota based on existing literatures 
suggested that it possesses significant capability for xenobiotic metabolism. If 
animals hosting diversified gut microbiota profiles react differently in terms of 
drug disposition, this could give rise to potential variation in therapeutic 
responses in preclinical studies. However, the elucidation of host-gut microbiota 
interaction has not been incorporated into the existing drug discovery framework. 
Current drug discovery and development programs reveal inter-laboratory, inter-
species and inter-individual variation with respect to drug disposition, 
pharmacology and toxicity. If the mammalian host-gut microbiota interaction is a 
silent phenotype that plays a vital role in drug disposition, it may account for 
idiosyncratic toxicity or differential efficacy related to some therapeutic agents. 
As such, elucidating the role of the inter-relationship between the gut microbiota 
and the host is relevant and pertinent to help streamline and improve the 
pharmaceutical development process.   
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Interethnic and inter-individual variations in gut microbiota exist due to 
differences in the genetic makeup, health status, diet and environmental factors in 
human. The ability to identify the relevant gut microbiota and its xenobiotic-




 Chapter 2 Toxicokinetics in Tacrine-dosed Lister hooded 
Rats 
 Chapter Summary 2.1
Background: Understanding the underlying causes for variation in therapeutic 
efficacy and toxicity is paramount for the clinical management of patients. 
Tacrine, an Alzheimer’s disease drug, is withdrawn due to its high prevalence of 
hepatotoxicity and the emergence of safer and more efficacious alternatives. 
Large inter-individual variability in tacrine disposition and susceptibility to 
tacrine-induced transaminitis were observed clinically and preclinically (132-
141). However, the mechanisms associated with such variability are unknown; 
particularly the contribution of the host-gut microbiome interaction has not been 
investigated. 
Objectives: This chapter aims to first establish if LH rat is a suitable animal 
model to investigate the variable susceptibility to tacrine-induced transaminitis. 
Next, we aim to characterise the plasma and faecal pharmacokinetic profiles of 
tacrine-dosed rats to facilitate the elucidation of the mechanism(s) accounting for 
the variable toxicokinetic of tacrine.  
Methodology: An acute oral dose of tacrine (20 mg/kg) was administered to male 
LH rats (n=28) that were monitored over 7 days. Clinical chemistry 
measurements were performed to assess tacrine-induced transaminitis. Liquid 
chromatography tandem mass spectrometry (LC/MS/MS) was used to determine 
the in vivo plasma and faecal pharmacokinetic profiles of tacrine-dosed rats. In 
addition, tacrine-N-glucuronide was synthesised in vitro using LH rat liver 
microsomes to confirm its identity in vivo using LC/MS/MS. 
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Results and Discussion: LH rats were found to be a suitable model for our 
investigation as they recapitulated transaminitis similar to humans. Based on the 
severity of transaminitis, rats were stratified as extreme responder, moderate 
responder, mild responder or non-responder. Large inter-individual variations in 
the plasma pharmacokinetic profiles were observed where 3.3-fold higher 
systemic exposure of tacrine and double Cmax phenomenon in extreme responders, 
suggestive of enhanced enterohepatic recirculation of deglucuronidated tacrine, 
were noted. Tacrine has been proposed to be a direct hepatotoxin. We postulated 
that the enhanced enterohepatic recirculation of the hepatotoxic tacrine 
exacerbated the toxicity in the extreme responders. In addition, we demonstrated a 
vastly different faecal excretion patterns between the extreme responders and non-
responders, with the percentage conjugation of tacrine as well as the total faecal 
amount of tacrine (free and conjugated form), being significantly higher in the 
extreme responders. This is consistent with our postulation of extensive 
enterohepatic recirculation in this group. 
Conclusion: LH rat is a suitable model to investigate tacrine-induced 
transaminitis. Findings from our toxicokinetic studies suggest the implication of 
enterohepatic recirculation, a physiological process influenced jointly by the host 
and the gut microbiota, in the variable toxicokinetics of tacrine. The 
deconjugation of tacrine-N-glucuronides during enterohepatic recycling shed 




 Chapter Introduction 2.2
Significant inter-individual variation in the toxicokinetic profile of tacrine is well 
documented in both clinical and preclinical studies (132-141). The unpredictable 
disposition kinetics of tacrine and the variable toxicological susceptibility to 
tacrine-induced hepatotoxicity were detrimental to the clinical fate of this drug. 
Tacrine has now been replaced by other more effective and safer therapeutic 
alternatives such as Donepezil and Memantine. Indeed, understanding the 
underlying causes for variation in therapeutic efficacy and toxicity is of utmost 
importance for the clinical management of patients and realising the goal of 
personalised medicine. As tacrine was withdrawn from the market due to its 
variable efficacy and unfavorable hepatotoxicity profile, it presents itself as a 
valuable candidate for the investigation of inter-individual variation in terms of 
drug-induced hepatotoxicity.   
Due to its withdrawal, preclinical studies are necessary to investigate the variable 
toxicokinetics of tacrine. While rat is a widely used animal model in preclinical 
studies (150), some authors cautioned that rats make poor models for the 
investigation of tacrine-induced hepatotoxicity based on in vitro studies that 
suggest rats are less active in the bioactivation of tacrine (144, 151, 152) and the 
absence of clear hepatotoxicity in some rat studies (132). Nevertheless, 
Stachlewitz et al. and Ma et al. were able to induce hepatotoxicity in rats using 
tacrine (133, 134). Collectively, the discrepancies observed in these preclinical 
studies underscore the underlying variation in the disposition and toxicity profile 
of tacrine. The selection of a suitable rat model is fundamental to the study of 
tacrine-induced hepatotoxicity and the contribution of the host-gut microbiota 
interaction on the toxicokinetics of tacrine. In this chapter, we first aim to 
establish if LH rats is a suitable animal model that manifests the variable 
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susceptibility to tacrine-induced transaminitis. With this foundation, we next 
determine the pharmacokinetics of tacrine in these LH rats considering the value 
of toxicokinetic analysis as described in the previous chapter in Section 1.4.2.2. 
 Materials and Methods 2.3
2.3.1 Materials 
Tacrine hydrochloride, 1% methylcellulose (MC), β-glucuronidase (from 
Escherichia coli), uridine diphosphoglucuronic acid (UDPGA), alamethicin, 
potassium phosphate dibasic (ACS grade) and phosphate buffered saline (PBS) 
were obtained from Sigma-Aldrich (St Louis, MO, USA). ALT and AST kits 
were purchased from Roche Diagnostics (Basel, Switzerland). Phenacetin was 
purchased from Fluka (Buchs, Switzerland). 1-Hydroxytacrine maleate was 
purchased from Enzo Life Sciences Inc. (Farmingdale, NY, USA). Formic acid 
was from BDH (Poole, UK). HPLC-grade acetonitrile (ACN) was purchased from 
Tedia Company Inc. (Fairfield, OH, USA). Sodium phosphate dibasic (ACS 
grade) and potassium phosphate monobasic (ACS grade) were purchased from JT 
Baker Chemical Co. (Phillipsburg, NJ, USA). Sodium hydroxide was obtained 
from Merck (Darmstadt, Germany). HPLC-grade ethyl acetate, methanol and 
absolute ethanol were obtained from Fisher Scientific (Leicestershire, UK). Water 
was purified using a Milli-Q water purification system (Millipore, Bedford, MA, 
USA). LH rat liver microsomes were isolated in-house. All other reagents used 
were of analytical grades. 
2.3.2 Animal Study and Sample Collection 
2.3.2.1 Animals 
Animal experiments were conducted in compliance with the GSK Policy on the 
Care, Welfare and Treatment of Laboratory Animals, the guidelines of the 
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Institutional Animal Care and Use Committee (IACUC) (Protocol number: 
080342 and T29/10) at GSK and NUS and the National Advisory Committee for 
Laboratory Animal Care and Research. 40 male LH rats (2-3 months old; 
weighing 237-373 g; Harlan, UK) were acclimatised for 1 week and then housed 
individually in clear metabolic cages for 2 days before treatment. Rats were 
maintained in a controlled environment (12 h light/dark cycle; 20 ± 1°C; relative 
humidity of 45 ± 5%) with free access to feeds (Teklad Irradiated Global 14% 
Protein Maintenance Diet, 2914, Harlan Laboratories) and water.  
2.3.2.2 Dosing 
In the treatment group, twenty-eight rats received by oral gavage a single dose of 
20 mg/kg body weight of tacrine, dissolved in 1% MC, at a volume of 10 mL/kg. 
This dose was chosen to induce liver injury without causing death based on our 
in-house preliminary study and literature review (132-134). The remaining twelve 
rats in the control group were orally dosed with vehicle (1% MC, at a volume of 
10 mL/kg). All rats were housed individually back to their metabolic cages after 
treatment.  
2.3.2.3 Plasma Collection 
Each rat had an indwelling cannula implanted in its right jugular vein 3 days 
before the treatment. Each rat was fitted with vascular access harness (Instech 
Solomon, PA, USA) consisting of a self-sealing port from which serial blood 
sampling was facilitated and allowing for free movement within its cage. 
Approximately 200 to 300 μL of blood samples were collected in heparinised 
tubes via the jugular vein cannula before dosing and at 0.5, 1, 2, 4, 8, 24, 28, 32, 
48 and 176 h post-dosing. Plasma samples were prepared by centrifugation of the 
blood samples (to separate from red blood cells) at approximately 10,500 g for 10 
min at 4°C. All samples were stored at –80°C prior to analysis. 
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2.3.2.4 Urine and Faeces Collection 
Urine was collected into tubes attached to the metabolic cages that were kept 
frozen in dry ice to minimise degradation of the metabolites. Pre-dose (–24 to 0 
h), 0–8 h, 8–24 h, 24–48 h and 72–96 h urine samples were collected separately 
for each rat. The urine samples were stored at –80°C prior to analysis. Voided 
faeces were collected at 20 ± 1°C in tubes attached to the metabolic cages at the 
same time periods as the collection of urine. Faeces were stored at –80°C prior to 
analysis. 
2.3.2.5 Liver Collection  
At the end of the study, all the rats were sacrificed by decapitation. The livers 
were collected immediately after sacrifice. Cardiac perfusion with 50 mL of cold 
PBS (a cut was made in the right atrium and a 50 mL syringe with 19G needle 
was inserted into the left ventricle) or till the liver becomes pale in color was 
performed prior to the removal of the liver. All samples were snap frozen with dry 
ice upon collection and stored at –80°C until further analysis. 
The animal study and sample collection is summarised in Figure 2-1. 
 
Figure 2-1 Animal study and time period of sample collection.  
2.3.3 Clinical Chemistry Measurement and Toxicity Phenotyping  
AST and ALT were measured in heparinised plasma using a Cobas C111 analyser 
(Roche Diagnostics, Basel, Switzerland) at 0 h (pre-tacrine dose) and at 4, 8, 24, 
28, 32, 48 and 176 h (post-tacrine dose). Tacrine-dosed rats with AST more than 
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3 times the mean AST of controls from 0–176 h were classified as responders to 
tacrine-induced transaminitis, while those rats not meeting this criterion were 
classified as non-responders. The responders were further arbitrarily classified as 
extreme responders (AST elevation ≥3 measurements), moderate responders 
(AST elevation over 2 measurements) or mild responders (AST elevation over 1 
measurement) based on their graded transaminitis responses.    
Statistical differences of the AST and ALT levels from the pre-dose levels were 
analysed using Friedman test with Dunn’s post hoc test using Prism 6.01 
(Graphpad Inc., San Diego, CA, USA). Statistical significance was established 
when P<0.05. 
2.3.4 In vivo Pharmacokinetic Profiling of Tacrine and Hydroxytacrine 
Metabolites in Rat Plasma 
2.3.4.1 Plasma Sample Preparation Procedures 
To 40 μL of each plasma sample, 50 μL of 0.5 M sodium hydroxide, 10 μL of 
water and 10 μL of 200 ng/mL of phenacetin (internal standard, IS) were added. 
1250 μL of ethyl acetate was added to the mixture and the mixture was shaken for 
30 min. The mixture was then centrifuged at 16,500 g for 15 min at 4°C for 
separation of the organic and aqueous phases. 1100 μL of the organic phase (top) 
was transferred to a clean microtube and evaporated to dryness under a stream of 
nitrogen at 40°C for about 30 min using a Turbovap LV (Caliper Life Sciences, 
Hopkinton, MA, USA). The residue was reconstituted with 50 μL of 8% ACN in 
water, shaken for 5 min and centrifuged at 16,500 g for 5 min at 4°C. 40 μL of 
each supernatant was transferred to a HPLC vial and 3 μL was injected for 
LC/MS/MS analysis. Samples with analyte concentration above the upper limit of 
quantification were re-analysed after dilution with 8% ACN with water so that the 




LC/MS/MS analysis was performed using an Agilent 1290 Infinity ultra-high 
pressure liquid chromatography (UHPLC) interfaced with an Agilent 6430 triple 
quadruple mass spectrometer (Agilent Technologies, Santa Clara, CA, USA). The 
UHPLC and MS systems were controlled by the Agilent MassHunter Workstation 
Software (version B.03.01, Agilent Technologies). Multiple reaction monitoring 
(MRM) experiments were performed using positive electrospray ionisation (ESI) 
mode. The dwell time used for all MRM experiments was 20 msec. The source-
dependent MS parameters such as gas temperature, gas flow, nebulizer gas and 
capillary voltage were set at 350°C, 12 L/min, 40 psi and 3500 V, respectively. 
The compound-dependent MS parameters for the analytes are shown in Table 2-1.  
Table 2-1 Optimised compound-dependent MS parameters using Agilent 6430 
triple quadruple MS. 






Tacrine 199.1  171.1 136 33 
1-Hydroxytacrine 215.1  197.1 110 12 
Phenacetin 180  110 104 20 
  
All chromatographic separations were performed using an ACQUITY UPLC 
BEH C18 1.7 μm 50 х 2.1 mm i.d. column (Waters, Milford, MA, USA). The 
column and autosampler temperatures were maintained at 45°C and 6°C, 
respectively. The mobile phase flow rate was 0.6 mL/min. Mobile phase consisted 
of 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile 
(solvent B). The optimized elution conditions were: gradient of 8.0–80.0% 
solvent B (0–1.40 min), gradient of 80.0–95.0% solvent B (1.40–1.45 min), 
isocratic at 95.0% solvent B (1.45–1.90 min), gradient of 95.0–8.0% solvent B 
(1.90–1.95 min) and isocratic at 8.0% solvent B (1.95–2.50 min). The injection 
volume was 3 μL. The analysis time for each sample was 2.5 min. 
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Chromatographic peak integration was performed using the Agilent MassHunter 
Workstation software (Agilent Technologies).  
2.3.4.3 Method Validation for LC/MS/MS Quantitation of Tacrine in Plasma 
Calibration Standards and Spiked Quality Control Standards  
Stock solutions. Stock solutions of 1 mg/mL of tacrine, 1-hydroxytacrine and 
phenacetin (IS) were prepared separately. Tacrine and 1-hydroxytacrine were 
dissolved in Milli-Q water and phenacetin was prepared in ethanol. The stock 
solutions were used to prepare the working solutions of tacrine and 1-
hydroxytacrine mixture by serial dilution with water.  
Calibration standards. A calibration curve consisting of total blank (without IS), 
blank (with IS) and 9 calibration standards comprising 0.50, 1, 2, 5, 10, 100, 200, 
300 and 400 ng/mL of tacrine and 1-hydroxytacrine spiked in LH rat plasma were 
prepared in triplicates. To prepare calibration standards, blank plasma (40 μL) 
were spiked with 50 μL of 0.5 M sodium hydroxide, 10 μL of working solution 
mixture of tacrine and 1-hydroxytacrine at appropriate concentrations, and 10 μL 
of 200 ng/mL IS (water was added in place of IS for total blank) and followed by 
sample extraction procedure detailed above.   
Quality controls (QC). Spiked QC standards were prepared using LH rat plasma 
for validation of precision or accuracy of the assay. The concentrations of the low, 
medium and high QCs were 3, 150 and 350 ng/mL, respectively. The QCs were 
prepared in triplicates on each of day 1, 3 and 4 of sample preparation.  
Method Validation  
Specificity. Chromatographic interference from endogenous compounds was 
determined by comparing chromatograms of blank rat plasma, plasma spiked with 
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tacrine, 1-hydroxytacrine and phenacetin, and plasma samples obtained from 
tacrine-dosed rats.  
Sensitivity. The lower limit of quantification (LLOQ) was determined when 
assessing the linear range of the calibration standards. LLOQ was defined as the 
lowest concentration yielding a precision (coefficient of variation, CV) of 20%, 
accuracy within 20% of theoretical value, and signal to noise (S/N) ratio of at 
least 5. 
Linearity of calibration curve. Calibration curves were obtained by plotting the 
peak area ratios of each analyte to the IS versus the theoretical concentrations of 
the spiked analytes in plasma. The linearity of the calibration curves were 
determined by linear regression analysis and evaluated using 1/χ as a weighing 
factor.  
Precision and accuracy. Assay precision and accuracy were evaluated using the 
spiked QCs at low, medium and high concentrations. Intra-day precision was 
examined by analysing nine replicates at each of the three concentrations and 
calculating the %CV for the analysis. Accuracy was calculated by comparing the 
mean concentration to the nominal concentrations and expressed in percentage. 
Inter-day precision was not necessary and hence not performed because sample 
analysis was performed on a single day. Precision with %CV within 20% and 
accuracy 100 ± 20% of nominal concentrations were considered acceptable in our 
analysis.  
Recovery. The recoveries of tacrine, 1-hydroxytacrine and IS from plasma were 
assessed by adding known amounts to blank rat plasma to yield concentrations at 
3, 150 and 350 ng/mL (using the spiked QCs). Extraction efficiencies of the 
analytes were calculated by comparing the peak areas from spiked plasma after 
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extraction with peak areas from equivalent quantities of unextracted authentic 
standards in the mobile phase that represent 100% recovery.   
Autosampler stability. Processed calibration samples were kept at 4–6°C 
(temperature of autosampler) after their first injection at the start of sample 
analysis. These samples were then re-injected 24 h later to determine the stability 
of the analytes over the anticipated run time of 24 h for the batch by comparing 
concentrations with the original calibration standards. A relative stability of 100 ± 
15% was considered acceptable.  
2.3.4.4 Pharmacokinetic Analysis 
The developed and validated LC/MS/MS method was applied for the 
measurement of tacrine and hydroxytacrine metabolites in the plasma collected 
from the tacrine-dosed rats (n=28) and control rats (n=2). Plasma samples 
collected at pre-dose (0 h), 0.5, 1, 2, 4, 8 and 24 h after treatment were selected 
for analysis based on the consideration of the half-life of tacrine.  
1-Hydroxytacrine was reported to elute closely with 2-hydroxytacrine and 4-
hydroxytacrine (143, 144, 149). In this study, complete chromatographic 
separation of these positional isomers was not effected as expected. Thus, the 
peak at the retention time of 1-hydroxytacrine standard was quantified 
collectively as ‘OH-THA’ to include all the 3 positional isomers. Pharmacokinetic 
analysis was performed using Phoenix WinNonlin® 6.0 software (Tripos, L.P.) 
using non-compartmental analysis. The calculated pharmacokinetic parameters 
included Cmax, Tmax, plasma clearance (CL), volume of distribution (Vd), terminal 
half-life (T1/2), area under the plasma concentration-time curve (AUC0-t) with t 
being 24 h or time of last quantifiable concentration and AUC0-∞ for AUC 
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extrapolated to infinity. AUCs were calculated using linear up log down 
trapezoidal rule. 
2.3.5 Pharmacokinetic Profiling of Faecal Excretion of Tacrine and 
Metabolites 
2.3.5.1 Faecal Sample Preparation Procedure  
20 mg of faeces weighed in microtubes were homogenised for 1 min with 200 µL 
of cold 0.2 M sodium phosphate buffer (pH 6.8) containing 130 ng/mL of 
phenacetin (IS). The samples were then sonicated on ice for 10 min and 
centrifuged at 9,000 g for 5 min at 4˚C before aliquoting 50 µL of the supernatant 
into each of two new microtubes (aliquots 1 and 2). Aliquot 1 was extracted 
immediately to determine the free tacrine and OH-THA levels while aliquot 2 was 
subjected to β-glucuronidase hydrolysis to enable determination of total 
(conjugated and unconjugated) tacrine and OH-THA present in the faecal extract. 
To aliquot 1, 100 µL of 0.2 M phosphate buffer was added while to aliquot 2, 100 
µL of β-glucuronidase (3000 units/mL) dissolved in phosphate buffer was added 
and the mixture incubated at 37˚C for 10 h. To both aliquots, 50 µL of 4 M 
sodium hydroxide was added and the samples were briefly vortex-mixed before 
adding 1.3 mL ethyl acetate for extraction. The tubes were mixed on a LabQuip 
shaker for 10 min and centrifuged at 16,000 g for 15 min at 4˚C for the separation 
of the organic and aqueous phase. 1150 µL of the organic phase was then 
transferred to a clean 1.5 mL microtube and evaporated to dryness under a 
nitrogen stream at 25˚C, using a TurboVap LV.  The residue was reconstituted in 
650 µL of mobile phase (8% ACN) and mixed on a shaker for 5 min. 40 μL of the 





LC/MS/MS analysis was performed using an Agilent 1290 Infinity UHPLC 
system interfaced with an AB Sciex Qtrap® 5500 hybrid linear ion-trap 
quadrupole mass spectrometer equipped with a TurboIonSpray source (QTRAP 
5500, Applied Biosystems, Foster City, CA). Tandem mass spectrometry was 
operated in the ESI +ve mode. MS source conditions were: ionspray voltage, 
4500 V; temperature, 600°C; curtain gas 25 psi; ion source gas 1, 40 psi; and ion 
source gas 2, 40 psi. The dwell time used for all MRM experiments was 75 msec. 
The optimised compound-dependent MS parameters for the analytes are as shown 
in Table 2-2.   
Table 2-2 Optimised compound-dependent MS parameters using AB Sciex 
















Tacrine 199.1  171.1 39 7 103 15 
1-Hydroxytacrine 215.1  197.1 40 7 100 12 
Phenacetin 180  110 27 8 99 7 
 
All chromatographic separations were performed using a Waters Acquity UPLC 
BEH C18 column (1.7 μm, 50 mm × 2.1 mm i.d). The LC method is identical to 
the method detailed earlier. 1 µL injection volume was used for all analysis. The 
needle of the autosampler was flushed with HPLC-grade methanol for 20 sec 
post-injection to prevent carry-over effect. Chromatographic peak integration was 
performed using the Analyst version 1.5.2. 
2.3.5.3 Method Validation for LC/MS/MS Quantitation of Tacrine in Faeces 
Calibration standards. A calibration curve consisting of total blank (without IS), 
blank (with IS) and 7 calibration standards at concentrations of 80, 300, 600, 900, 
1400, 1800 and 2200 ng/mL for 1-hydroxytacrine and 40, 150, 300, 450, 700, 900 
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and 1100 ng/mL for tacrine spiked in LH rat faeces were prepared in triplicates. 
To prepare the calibration standards, 20 mg of pooled blank faeces were spiked 
with 200 µL of working solutions containing 130 ng/mL IS, and tacrine and 1-
hydroxytacrine at the appropriate concentrations. The calibrants were then 
extracted by sample preparation procedures described earlier. Quantitative 
analysis of the calibration standards was derived with reference to the IS using 
peak area ratio (analyte/IS). 
QC. Spiked QC standards were prepared using LH rat faeces for validation of 
assay accuracy. The concentrations of the low, medium and high QCs were 240, 
1000 and 1600 ng/mL for 1-hydroxytacrine and 120, 500 and 800 ng/mL for 
tacrine, respectively. 
Recovery. Standards were prepared in triplicates by mixing known amounts of 1-
hydroxytacrine, tacrine and phenacetin with the mobile phase. Recovery was 
evaluated at 240, 1000 and 1600 ng/mL for 1-hydroxytacrine and 120, 500 and 
800 ng/mL for tacrine. To determine absolute recovery of the analytes, analyte 
peak area of the QC samples after extraction was compared with the peak area 
obtained from direct injection of equivalent quantities of pure standard in the 
mobile phase.   
Validation criteria for specificity, linearity, precision and accuracy were similar to 
those described in Section 2.3.4.3. 
2.3.5.4 Quantitation and Data Analysis 
Tacrine and OH-THA (1-hydroxytacrine, 2-hydroxytacrine and 4-hydroxytacrine) 
were quantitated using LC/MS/MS in the faeces of 4 extreme responder rats (T8, 
T10, T12 and T14) and 6 non-responder rats (T1, T2, T11, T16, T18 and T27) 
collected over the time periods of 0–8 h and 8–24 h.  
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The amount of tacrine and OH-THA (nmol) was normalised against the dose (mg) 
administered to each LH rat. The percentage conjugation of OH-THA and tacrine 
were calculated using the equation below, where ‘Total’ refers to the summation 
of free unconjugated and conjugated analyte, and ‘Free’ refers to the free 
unconjugated analyte.  
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑐𝑜𝑛𝑗𝑢𝑔𝑎𝑡𝑖𝑜𝑛 =  
𝑇𝑜𝑡𝑎𝑙 − 𝐹𝑟𝑒𝑒
𝑇𝑜𝑡𝑎𝑙
 × 100% 
Mann-Whitney U test was used to compare the dose-normalised amount of tacrine 
and OH-THA (nmol/mg dose) excreted over the different time periods as well as 
the percentage conjugation of tacrine and OH-THA between the extreme 
responders and non-responders. Statistical differences were established with 
P<0.05. 
The percentage of total OH-THA excreted over 24 h was calculated using the 
equation below. 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑇𝑜𝑡𝑎𝑙 𝑂𝐻 − 𝑇𝐻𝐴 𝑒𝑥𝑐𝑟𝑒𝑡𝑒𝑑 𝑜𝑣𝑒𝑟 24 ℎ
=  
𝑇𝑜𝑡𝑎𝑙 𝑂𝐻 − 𝑇𝐻𝐴 𝑒𝑥𝑐𝑟𝑒𝑡𝑒𝑑 𝑜𝑣𝑒𝑟 24 ℎ (𝑛𝑚𝑜𝑙) × 100%
𝑇𝑜𝑡𝑎𝑙 𝑂𝐻 − 𝑇𝐻𝐴 𝑒𝑥𝑐𝑟𝑒𝑡𝑒𝑑 𝑜𝑣𝑒𝑟 24 ℎ (𝑛𝑚𝑜𝑙) + 𝑇𝑜𝑡𝑎𝑙 𝑇𝐻𝐴 𝑒𝑥𝑐𝑟𝑒𝑡𝑒𝑑 𝑜𝑣𝑒𝑟 24 ℎ (𝑛𝑚𝑜𝑙)
 
 
2.3.6 Biosynthesis and Identification of Tacrine-N-glucuronide Formation in 
LH rats 
2.3.6.1 Biosynthesis of Tacrine-N-glucuronide using LH Rat Liver 
Microsomes 
To confirm the in vivo production of tacrine-N-glucuronide in LH rats, this 
metabolite was biosynthesised in the following manner. LH rat liver microsomes 
(8.4 mg protein/mL), alamethicin (125 µg/mL), magnesium chloride (1 mM), 
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tacrine (3 mM) and 0.1 M potassium phosphate buffer (pH 7) in the final 
incubation mixture were pre-incubated at 37˚C for 3 min. To initiate the reaction, 
UDPGA was added to give a final incubation concentration and volume of 7.5 
mM and 500 µL respectively. Blank incubation experiments were performed 
without UDPGA. The reaction was quenched with 500 µL of ice-cold acetonitrile 
after 60 min of incubation. The mixture was centrifuged at 16,000 g for 15 min to 
pellet the precipitated protein (Microfuge 22R Centrifuge, Beckman Coulter, 
Fullerton, CA, USA). The supernatant was transferred to a clean microtube and 
dried down under a nitrogen stream at 25˚C and reconstituted in milli-Q water for 
LC/MS/MS analysis.  
2.3.6.2 LC/MS/MS Identification of Synthesised Tacrine-N-glucuronide.  
LC/MS/MS analysis was performed using the instrumentation as described in 
Section 2.3.5.2. Scanning experiments which included neutral loss (NL of 176 
Da) and enhanced product ion (EPI using precursor ion of m/z 375) at two 
collision energies (35 and 45 eV) were performed to identify the synthesised 




2.4.1 Clinical Chemistry Measurement and Toxicity Phenotyping 
Based on the measurement of the liver injury enzymes (ALT and AST), we 
observed that the LH rats exhibited differential susceptibility to tacrine-induced 
transaminitis as supported by the spectrum of aminotransferase elevation (Figure 
2-2). Compared to the elevation of ALT in the rats of the tacrine-dosed group, the 
elevation of AST is much more pronounced. Nevertheless, closer investigation of 
the clinical chemistry results revealed that rats displaying elevation of AST also 
consistently displayed an elevation of their ALT (Figure S1). Since both ALT and 
AST are markers of hepatotoxicity, AST was selected as a marker to differentiate 
the toxicity phenotypes of the tacrine-dosed rats in view that AST shows a clearer 
separation of the rats with respect to their degree of transaminitis than ALT.    
 
Figure 2-2 Plasma (A) ALT and (B) AST levels of each LH rat in the control 
(n=12) and treatment group (n=28). 
The classification of the rats according to their degree and duration of AST 
elevations are as summarised in Figure 2-3. Ten of the 28 tacrine-dosed rats were 
found to display AST elevation more than 3 times the mean AST of the controls 
and they were further classified as extreme, moderate or mild responders. Sixteen 
rats were designated as non-responders as their AST fell below the stated criteria. 
A        B 
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Two tacrine-dosed rats died before the end of the study due to unknown causes 
and they were excluded from the classification.  
 
Figure 2-3 Classification of the toxicological responses of the 28 tacrine-dosed 
LH rats based on their degree and duration of AST elevations. *2 tacrine-dosed 
rats were excluded for analysis due to death prior to the end of study.   
 
As illustrated in Figure 2-4, following the administration of the single oral dose of 
tacrine at 0 h, transaminitis began to develop in the responders at the time period 
of 0–8 h (P<0.0001 of 8 h AST vs. pre-dose, Friedman test with Dunn’s post hoc 
test). The 8–24 h time period corresponded to the peak of transaminitis in the 
responders wherein their aminotransferase levels are statistically higher compared 
to their pre-dose levels (P<0.05 of 24 h ALT; P<0.0001 of 24 h AST, Friedman 
test with Dunn’s post hoc test). After 24 h, the responders began their recovery 
from transaminitis. For the non-responders, their aminotransferase levels 




Figure 2-4 Plasma (A) ALT and (B) AST levels of LH rats in the control group 
(n=12), non-responder group (n=16) and responder group (n=10). Statistical 
analysis established by comparing with pre-dose levels using Friedman test with 
Dunn’s post hoc test, with *P<0.05, ***P<0.001 and ****P<0.0001. Data 
represent means ± standard deviation (SD). 
 
2.4.2 In vivo Pharmacokinetic Profiling of Tacrine and Hydroxytacrine 
Metabolites in Rat Plasma 
2.4.2.1 Method Validation 
Tacrine was well separated from 1-hydroxytacrine and IS in the spiked blank 
plasma and no chromatographic interference from endogenous compounds were 
observed in blank rat plasma (Figure S2). The retention time for tacrine and 1-
hydroxytacrine were 0.73 and 0.57 min, respectively. The LLOQs for tacrine and 
1-hydroxytacrine were 1.0 and 0.5 ng/mL, respectively. Good linearities of 
r2=0.99 were achieved for the calibration curves of both analytes. The intra-day 
precision and accuracy of the analytical method for tacrine and 1-hydroxytacrine 
are shown in Table S1. For all QC samples spiked with 3, 150 and 350 ng/mL 
tacrine and 1-hydroxytacrine, the %CV for intra-day precision were below 17% 
and 13.5%, respectively. For tacrine spiked QC samples, 59% of QC samples are 
within 20% of their respective nominal concentration. For 1-hydroxtacrine spike 
QC samples, 85% of QC samples are within 20% of their respective nominal 
concentration. The mean extraction recovery for tacrine and 1-hydroxytacrine 
A        B 
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ranged from 65.2 to 82.8% and 78.8 to 86.8%, respectively (Table S1). The 
recovery of IS was 51.1 ± 5.1%. Tacrine and 1-hydroxytacrine were found to be 
stable for at least 24 h when stored at 4-6°C in autosampler as there was less than 
1% variation in the gradients of the calibration curves obtained at the start of the 
analysis compared with that obtained after 24 h of storage.    
2.4.2.2 In vivo Plasma Pharmacokinetic Profiles of Tacrine-dosed Rats  
Tacrine 
Large inter-individual variation was observed in the pharmacokinetic profile of 
tacrine-dosed rats similar to that reported in literature (136). The plasma tacrine 
concentration-time profile and the corresponding pharmacokinetic parameters of 
the tacrine-dosed rats are shown in Figure 2-5 and Table 2-3, respectively. 
Pharmacokinetic analysis showed that following oral administration of tacrine, 
the drug was rapidly absorbed with Tmax within 0.5 to 2 h. Cmax varied from 136.3 
to 809.3 ng/mL. Interestingly, several rats were found to exhibit ‘double Cmax’ 
profile whereby a second peak was observed after the initial peak in plasma 
tacrine concentration. This double Cmax profile was most prominent in 3 rats, 
which coincidentally were classified as extreme responders (Figure 2-5B). Apart 
from one of the rats that died before study completion, 4 other rats (T18, T20, 
T21 and T26) that displayed this phenomenon have a smaller second Cmax. 
Despite the same acute oral dose of 20 mg/kg, AUC0-∞ (an estimation of total drug 
exposure) varied from 754.1 to 7732.2 h×ng/mL and CL of tacrine ranged from 
884.6 to 6816.0 mL/h. An adult rat has a blood volume of about 50 mL/kg (158). 
Tacrine appeared to have wide tissue distribution as Vd ranged from 3321.1 to 





Figure 2-5 Plasma tacrine concentration-time profile following an acute oral dose 
of 20 mg/kg of tacrine in the (A) four responder groups and the (B) four rats in 
the extreme responder group (EXT).  
Data represent means ± SD for Figure 2-5A. n=16 for non-responders (NOR), n=3 for mild 
responders (MIL), n=3 for moderate responders (MDR) and n=4 for EXT. 
 
When the pharmacokinetic parameters were analysed with respect to the toxicity 
phenotypes, the extreme responders were found to have the highest Cmax of tacrine 
(Cmax=638±184 ng/mL), largest AUC0-∞ (AUC0-∞ =5494±1714 h×ng/mL) and 
lowest CL (CL=1272±337 mL/h) compared to all other responder groups (Table 
2-3 and Figure 2-6). The higher systemic exposure to tacrine in the extreme 
responders, as characterised by AUC ~3.3-fold higher and CL ~3-fold lower than 
the non-responders, may well be linked to their double Cmax pharmacokinetic 
profile, that is suggestive of secondary absorption. As we surveyed across the 
pharmacokinetic parameters from non-responders to extreme responders (Figure 
2-6B and C), trends of increasing AUC0-∞ and decreasing CL were observed. 
However, lowest Vd were observed in the moderate and extreme responders 
(Figure 2-5). Vd is calculated from the ratio of CL to first order rate constant 
associated with the terminal portion of the plasma concentration-time curve. We 
suggest caution to be taken in the interpretation of the Vd results as the few 
sampling points at the terminal portion of the pharmacokinetic plots might affect 
the accuracy of the estimation of first order rate constant, T1/2 and the Vd results.
Pronounced 
double Cmax 






























Vd Ave Vd SD Vd 
  h ng/mL h ng/mL ng/mL ng/mL h h×ng/mL % h×ng/mL h×ng/mL mL/h mL/h mL/h mL mL mL 
T08 1 429.5 
  
638.1 183.6 






T10 1 583.5 4.0 809.3 7.1 7732.2 9.5 884.6 9066.2 
T12 1 444.5 4.0 774.2 2.1 5925.9 0.1 1107.0 3321.1 
T14 1 277.8 8.0 539.5 2.4 4318.3 0.4 1477.4 5027.1 
T22 0.5 265.8 
  270.1 5.8 





9184.1 3267.0 T23 1 276.7 
  
1.9 2373.9 0.0 2940.3 7862.5 
T26 1 264.4 4.0 267.7 1.4 1913.0 0.0 3387.3 6785.0 
T06 1 320.8     
332.7 55.8 





21537.6 7355.4 T09 1 393.5 
  
4.4 1403.7 2.1 4431.1 28081.6 
T24 1 283.8     4.0 1546.2 26.5 3997.0 22954.4 
T01 0.5 301.9 
  
292.7 120.7 






T02 0.5 326.2 
  
3.1 826.8 0.5 5999.0 26822.7 
T03 1 502.2 
  
3.1 1343.7 0.4 3825.4 17057.6 
T04 1 473.8 
  
2.8 1390.9 0.3 3292.8 13403.4 
T07 2 479.8 
  
3.5 1734.8 0.6 2640.0 13457.1 
T11 2 287.5 
  
4.4 2438.6 1.3 2460.4 15685.1 
T13 1 400.2 
  
3.0 2487.0 0.2 2734.2 11903.6 
T15 0.5 277.1 
  
4.5 1160.1 2.4 4637.6 29978.7 
T16 1 236.2 
  
5.6 1231.9 3.4 3945.3 32020.6 
T17 1 271.3 
  
6.0 1766.5 3.6 3022.9 26128.6 
T18 0.5 171.1 8.0 108.2 3.6 1218.9 2.1 3823.1 19851.9 
T19 0.5 173.5 
  
5.2 1120.9 4.0 4656.9 34754.0 
T20 0.5 167.4 8.0 55.7 3.7 754.1 1.1 6816.0 36661.0 
†T21 1 152.3 8.0 85.1 38.6 5333.4 66.8 933.7 52060.0 
T27 1 136.3 
  
14.0 2940.3 22.8 2231.0 45059.7 
T28 1 327.0 
  
8.3 3501.5 9.0 1982.0 23638.9 
‡T25 1 445.1 8.0 647.7                           
‡T05 1 383.2         1.5 925.9 2.3     5853.5     12274.9     
† T21 was excluded from the calculation of average AUC0-∞, CL and Vd as the AUC is inaccurate since %AUC extrapolated is 66.8%.  



















Figure 2-6 In vivo tacrine plasma pharmacokinetic parameters according to 
responders and non-responder phenotypes. (A) Cmax, (B) AUC0-∞, (C) CL and (D) 
Vd. 
Each bar represents mean ± SD. Statistical analysis established using Kruskal-Wallis test, with 
*P<0.05 and **P<0.01 compared to NOR. n=4 for EXT, n=3 for MDR, n=3 for MIL and 
n=16 for NOR (except for Figure 2-6B, C and D where n=15 for NOR as T21 was excluded 
due to an inaccurate AUC as its %AUC extrapolated is 66.8%). 
 
Hydroxytacrine Metabolites 
1-Hydroxytacrine, 2-hydroxytacrine and 4-hydroxytacrine are monohydroxylated 
metabolites of tacrine. These positional isomers closely co-elute and are difficult 
to be fully resolved chromatographically (143, 144, 149). Using our LC/MS/MS 
method, baseline separation of the monohydroxylated tacrine metabolites was not 
achieved (Figure S2). As no commercial standards are available for 2-
hydroxytacrine and 4-hydroxytacrine, collective semi-quantitation of these three 
metabolites as ‘OH-THA’ was performed through summation of their integrated 
peak areas. The plasma OH-THA metabolites concentration-time profiles and the 
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pharmacokinetic parameters of OH-THA metabolites are shown in Figure 2-7 and 
Table 2-4, respectively. The appearance of OH-THA metabolites soon after the 
absorption of tacrine, with Tmax generally achieved within 0.5 to 2 h, is indicative 
of the rapid metabolism of tacrine.      
For OH-THA metabolites, Cmax values were generally similar across all the 
groups (Table 2-4). The mean AUC0-t for extreme responders was found to be 
significantly higher compared to the non-responders (P<0.05, Kruskal-Wallis 
test). AUC0-t was used for OH-THA instead of AUC0-∞ because not all tacrine 
were converted to hydroxtacrine metabolites and cleared from the circulation by 
24 h.  
 
Figure 2-7 Plasma OH-THA concentration-time profile following an acute oral 
dose of 20 mg/kg of tacrine in the four responder groups.  






Table 2-4 Pharmacokinetic parameters of OH-THA metabolites in tacrine-dosed rats. 
Subjects Tmax Cmax 2nd Tmax 2nd Cmax Ave Cmax SD Cmax T1/2 t AUC0-t Ave AUC0-t SD AUC0-t 
  h ng/mL h ng/mL ng/mL ng/mL h h h×ng/mL h×ng/mL h×ng/mL 
T08 1 179.4 
  
181.8 26.2 
13.6 24 1651.0 
1853.1* 281.7 
T10 1 187.4 4 169.2 15.3 24 2131.0 
T12 1 179.5 4 212.0 5.0 24 2057.1 
T14 1 148.4 
  
7.6 24 1573.3 
T22 2 119.0 
  
120.1 4.7 
5.2 24 1666.3 
1429.1 205.5 T23 1 115.9 
  
4.1 24 1306.4 
T26 1 125.3 
  
2.7 24 1314.5 
T06 1 184.1 
  
174.1 40.0 
3.6 24 1026.1 
1136.6 156.2 
T09 1 208.2 
  
10.5 24 1247.1 
†T24 1 130.1 
  
5.3 8 680.6 
  
T01 1 164.6 
  
152.5 45.3 
6.3 24 1046.1 
1242.7 265.5 
T02 1 146.4 
  
5.3 24 750.1 
T03 1 221.0 
  
5.2 24 1072.4 
T04 1 217.0 
  
3.8 24 944.9 
T07 1 230.0 
  
5.1 24 1302.9 
T11 2 152.0 
  
3.7 24 1660.3 
T13 1 167.5 
  
4.7 24 1368.0 
T15 0.5 174.2 
  
8.9 24 1228.8 
T16 1 150.2 
  
5.8 24 1322.6 
T17 1 138.4 
  
5.3 24 1318.0 
T18 1 126.6 8 77.7 12.6 24 1387.5 
T19 0.5 115.4 
  
9.2 24 1209.9 
T20 0.5 117.1 
  
6.0 24 847.2 
T21 1 88.2 
  
17.4 24 1373.7 
T27 1 79.2 
  
10.9 24 1304.3 
T28 1 120.5 
  
6.6 24 1745.7 
‡T25 1 147.1 8 136.4 
   
8 872.5 
  
‡T05 1 182.5 
    
2.8 8 604.5 
  
† T24 was excluded from the calculation of average and SD of AUC0-t, as its time of last quantifiable concentration was 8 h instead of 24 h. 
‡ T05 and T25 were excluded from the calculation of average Cmax, AUC0-∞, CL and Vd as they died before completion of the study. 


















2.4.3 Faecal Excretion of Tacrine and Metabolites in LH Rats 
2.4.3.1 Method Validation 
Baseline chromatographic separation of tacrine, 1-hydroxytacrine and phenacetin 
in the spiked faeces was observed. No chromatographic interference from 
endogenous compounds was confirmed using the blank rat faeces. The standard 
curves of peak area ratio (analyte/IS) against concentration for tacrine and 1-
hydroxytacrine showed good linearity (r2>0.99) over their respective 
concentration ranges (Figure S3). Precision and accuracy of the analytical method 
for tacrine and 1-hydroxytacrine are shown in Table S2. The CV for intra-day 
precision of the tacrine and 1-hydroxytacrine spiked QC samples were well below 
10%. 89% of the tacrine spiked QC samples were within 15% of their respective 
nominal concentration and 78% of the 1-hydroxytacrine spiked QC samples were 
within 15% of their respective nominal concentration. The mean extraction 
recovery of tacrine and 1-hydroxytacrine ranged from 3.41 to 4.18% and 8.99 to 
9.46%, respectively (Table S2). The multiple steps in the sample preparation 
procedure, comprising of aliquoting and sample dilution, contributed extensively 
to this poor recovery. Despite the poor extraction efficiency, the extent of 
recovery of tacrine and 1-hydroxytacrine was consistent across the low, medium 
and high concentration levels, all with CV well below 10%. The mean recovery of 
the IS in spiked faeces was 16.3% (CV of 3.63%).  
2.4.3.2 Faecal Excretion of Tacrine and Metabolites in Extreme Responders 
and Non-responders 
Our results demonstrated that the administered tacrine was excreted primarily in 
the faeces as free or conjugated OH-THA. The total OH-THA (free OH-THA and 
OH-THA glucuronides) constituted 72.4 ± 11.4% of all excreted tacrine and 
metabolites detected in the faeces of the 10 LH rats selected for analysis. The 
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cumulative excretion of free tacrine (parent drug) and total tacrine (free tacrine 
and tacrine-N-glucuronide) and its metabolites (free OH-THA and OH-THA 
glucuronides) quantitated by LC/MS/MS at the time periods of 0–8 h, 8–24 h and 
0–24 h post-dose, segregated based on the toxicity phenotypes of the rats, are 
summarised in Table 2-5.  
No significant differences were observed in the excretion of OH-THA between 
the extreme responders and non-responders (Figure 2-8). However, it is clear that 
the mean amount of total tacrine excreted by the extreme responders over 24 h 
was significantly higher than that of the non-responders (127.4 ± 69.9 nmol/mg 
dose vs 40.4 ± 17.8 nmol/mg dose, P<0.05; Mann-Whitney U test) (Figure 2-8). 
The percentages of OH-THA and tacrine that were conjugated in faeces collected 
over 0–24 h post-dose are shown in Figure 2-9. Of the total tacrine excreted in the 
faeces of the extreme responders, 58.8 ± 10.0% were in the glucuronidated form. 
This is in strike contrast with the non-responders where we detected a 
significantly lower proportion of tacrine-N-glucuronide (15.6 ± 3.4%) (P<0.05; 
Mann-Whitney U test). The percentage conjugation of OH-THA was similar 
between the two responder groups (4.9 ± 3.8% vs 7.9 ± 6.8%, P> 0.05; Mann-






Table 2-5 Amount of tacrine and metabolites (nmol/mg dose) excreted in the faeces following a single oral dose of 20 mg/kg tacrine. 
Time (h) 
NOR (n=6) EXT (n=4) 
OH-THA Tacrine OH-THA Tacrine 
Free Total* Free Total* Free Total* Free Total* 
0 – 8 21.1 ± 10.4 22.4 ± 11.1 6.5 ± 3.0 8.5 ± 4.8 30.0 ± 23.8 36.8 ± 32.2 11.6 ± 4.78 35.4 ± 31.2 
8 – 24 141.6 ± 86.5 150.8 ± 98.0 27.7 ± 15.0 31.9 ± 17.9 140.1 ± 58.9 146.6 ± 56.3 38.7 ± 25.6 92.0 ± 80.3 
0 – 24 162.7 ± 91.1 173.2 ± 102.9 34.2 ± 15.4 40.4 ± 17.8 170.1 ± 47.5 183.4 ± 41.7 50.3 ± 25.4 127.4 ± 69.9 
Data represent mean ± SD. 







Figure 2-8 Dose-normalised amount of total OH-THA and tacrine (nmol/mg 
dose) quantitated in the faeces of NOR (n=6) and EXT (n=4) collected 0–24 h 
post-dose. Data represented as mean ± SD. Statistical analysis established using 
Mann-Whitney U test, *P<0.05. 
 
Figure 2-9 Percentage conjugation of OH-THA and tacrine (%) in the faeces of 
NOR (n=6) and EXT (n=4) collected 0–24 h post-dose. Data represented as mean 
± SD. Statistical analysis established using Mann-Whitney U test, *P<0.05.  
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2.4.4 In vitro Biosynthesis and Identification of Tacrine-N-glucuronide  
NL and EPI scanning experiments were employed to confirm the biosynthesis of 
tacrine-N-glucuronide. The NL scan of 176 Da in the positive mode yielded a 
parent [M+H]+ ion at m/z 375, corresponding to the m/z of tacrine-N-glucuronide. 
Its absence in the negative control sample without UDPGA addition further 
confirmed that this mass peak corresponded to tacrine-N-glucuronide. The EPI 
(MS/MS) mass spectrum obtained at collision energy of 35 eV showed a 
diagnostic loss of the glucuronyl moiety (176 Da) to form the tacrine product ion 
at m/z 199 (Figure 2-10A). At a higher collision energy of 45 eV, the tacrine ion 
further fragmented to give its characteristic daughter ions at m/z 144 and 171 with 
a consequent drop in the ion intensity of tacrine at m/z 199 (Figure 2-10B) (159). 
These distinct product ions, along with neutral loss of the glucuronyl moiety, 

















Figure 2-10 MS/MS spectra of tacrine-N-glucuronide from EPI scan at collision 
energy of (A) 35 eV and (B) 45 eV. 
 
  
 +EPI (375.00) CE (35): 0.471 min from Sample 7 (THA-Nglu_EPI_CE35_8-20-95_+ve) of sample.wiff (Turbo Spray) Max. 3.2e4 cps.

































 +EPI (375.00) CE (45): 0.476 min from Sample 9 (THA-Nglu_EPI_CE45_8-20-95_+ve) of sample.wiff (Turbo Spray) Max. 1.5e4 cps.















































































































2.5.1 LH Rats: A Suitable Model for Investigating Tacrine-induced 
Transaminitis 
The hallmark of tacrine-induced hepatotoxicity is characterised by the variable 
susceptibility and extent of transaminitis in subjects who consumed the drug (128-
134). Though histopathology is the gold standard to confirm hepatotoxicity, it is 
not commonly performed clinically to provide definitive assessment of drug-
induced liver injury in all patients due to the invasive nature of the procedure. 
Instead, biochemistry assays which measure indicators of hepatic injury like ALT, 
AST, alkaline phosphatase and total bilirubin form the cornerstone for diagnosis 
of hepatotoxicity although limitations exist with respect to their sensitivity and 
organ specificity (160). Tacrine is known to induce hepatocellular injury and the 
International Committee for International Harmonization of Clinical Pathology 
Testing recommended the measurement of aminotransferase enzymes, ALT and 
AST, for hepatocellular injury assessment (160-162). Compared to AST, ALT is 
considered a more specific and sensitive indicator of hepatic injury and the 
magnitude of ALT increase usually exceeds that of AST partly due to longer half-
life of ALT and the larger proportion of AST that is mitochondria bound (162). 
Nevertheless, AST measurement is performed routinely to complement ALT in 
both clinical and preclinical studies to detect hepatocellular injury and its 
elevation provides useful indication of mitochondrial and cytoplasmic injury 
(160). 
Our study demonstrated the suitability of LH rats as a model to investigate 
tacrine-induced transaminitis. The clinical chemistry results revealed a spectrum 
of aminotransferase elevations in LH rats following tacrine’s insult, consistent 
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with the hallmark of tacrine-induced hepatotoxicity. The more pronounced 
elevation of AST compared to ALT may be related to the adverse impact of 
tacrine on the mitochondria (154, 156), wherein AST is a valuable indicator of 
mitochondrial injury (160). Including the two tacrine-dosed LH rats that died, 
AST elevation exceeded the stipulated threshold of 3 times mean of the control in 
43% of the tacrine-dosed LH, recapitulating the transaminitis profile in humans. 
From our study, it is clear that despite given the same dose of tacrine, the rats 
displayed differential susceptibility to tacrine-induced transaminitis. This is in 
alignment with the clinical observation of a poor dose-toxicity relationship for 
tacrine (128, 140). Such atypical response of the rats might explain the failure to 
detect hepatotoxicity during early preclinical studies (132). Considering the 
distinct differences in toxicological susceptibility to tacrine-induced transaminitis, 
we stratified the rats according to their toxicity phenotypes to facilitate the 
investigation of the underlying mechanisms.   
2.5.2 In vivo Toxicokinetic Analysis of Tacrine and Hydroxytacrine in 
Plasma of Tacrine-dosed LH Rats 
Large variation in the pharmacokinetic profile of tacrine has been reported in the 
literature. Several of the proposed mechanisms for tacrine’s hepatotoxicity 
support an association of the drug disposition kinetics with tacrine-induced 
transaminitis (133, 140). It is noteworthy that despite the controlled nature of our 
in vivo preclinical study in LH rats compared to clinical studies, large inter-
individual variation in kinetic disposition of tacrine still prevailed. A salient 
observation in our toxicokinetics profiling of tacrine-dosed rats was the 
occurrence of ‘double Cmax’ in the plasma concentration-time profiles. Double or 
multiple peaking phenomenon in pharmacokinetic disposition has been reported 
in literature (163) but this phenomenon was not previously documented for 
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tacrine’s disposition. This might be attributed to the infrequent occurrence of the 
double Cmax profile in tacrine-dosed rats and the relatively small sample size 
typically used in in vivo studies.  
Based on previous pharmacokinetic studies, it was found that the occurrence of 
multiple Cmax peaks can be caused by factors such as enterohepatic recycling, 
gastric emptying, site-specific absorption, or sustained-release formulation (163, 
164). While the exact mechanism for double Cmax in tacrine’s disposition could 
not be determined at this stage, it is clear that its occurrence contributed greatly 
toward tacrine-induced transaminitis, evident from its contribution towards the 
larger AUC and lower CL especially prominent in the extreme responders. As 
tacrine is reported to be well and rapidly absorbed and the same formulation of 
tacrine is given to all rats, the double Cmax profile is unlikely be due to 
formulation and site-specific absorption issues. Instead, we hypothesise that the 
double Cmax profile is an outcome of the differential enterohepatic recycling of 
tacrine in the systemic circulation. Several studies have suggested the direct 
hepatotoxic nature of tacrine parent drug (133, 134, 153-157). Our findings 
strengthened this stand as we observed a strong correlation of higher systemic 
tacrine exposure with increase susceptibility to tacrine-induced transaminitis. For 
example, the extreme responders possessed the highest Cmax, largest AUC and 
lowest CL of tacrine. Ford et al. illustrated the value of measuring blood 
concentration of tacrine and metabolites for prediction of drug toxicity and our 
results were in concordance (140). We postulate that the enhanced enterohepatic 
recirculation of tacrine exacerbated its direct toxicity effect in the extreme 
responders. No studies to date, however, have reported the enterohepatic 




CYP1A2 is a major hepatic enzyme involved in the Phase I functionalisation of 
tacrine and it has been reported to metabolise tacrine to stable, protein reactive 
and cytotoxic metabolites (143, 144, 151, 152). 1-Hydroxytacrine is a major 
metabolite while 2-hydroxytacrine, 4-hydroxytacrine and 7-hydroxytacrine are 
trace metabolites (143, 144, 149). These metabolites may then undergo Phase II 
conjugation reaction whereby the hydroxylated metabolites are made more polar 
for excretion by forming glucuronide conjugates (143). In this study, 
hydroxytacrine metabolites were formed soon after the oral administration and 
absorption of tacrine.  
7-Hydroxytacrine has been proposed to be an important metabolite that may be 
further bioactivated to form reactive quinone methide capable of conjugating with 
hepatic proteins to induce tissue damage (151). However, in vitro studies 
comparing rat and human liver microsomes found an apparent lack of 7-
hydroxytacrine in rat microsomes and suggested tacrine undergoes significantly 
lower bioactivation to reactive metabolites in rats (143, 144, 151). Similarly, 7-
hydroxytacrine was not observed in our toxicokinetics studies. Despite the 
absence or low abundance of 7-hydroxytacrine metabolites such that it is below 
limit of detection in our assay, transaminitis was still induced in 43% of the 
tacrine-dosed rats. Given this observation, it could be concluded that tacrine plays 
the pivotal role in inducing transaminitis compared to 7-hydroxytacrine. 
2.5.3 Metabolite Excretion Patterns in Faeces of Extreme and Non-
responders 
Based on our in vivo plasma profiling of tacrine, extreme responders were found 
to display a distinct secondary Cmax in the plasma tacrine concentration-time 
profile that is characteristic of enterohepatic recirculation of the parent drug 
(Figure 2-5). Studies have suggested a minimal molecular weight threshold for 
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biliary secretion to occur and drug conjugates generally need to be at least 200-
325 Da in the case of rats (164, 165). Even though enterohepatic recirculation of 
tacrine has not been reported, the molecular weights of the glucuronide 
conjugates are above the molecular weight threshold, making them plausible 
substrates for biliary excretion. The occurrence of the secondary Cmax peak 
between 4 to 8 h post-dose for tacrine is in agreement with other compounds 
which undergo enterohepatic recirculation such as resveratrol (166), morphine 
(167) and phenolphthalein (168). This further lends support to our postulation of 
enterohepatic recirculation of tacrine.  
The polar physicochemical structures of glucuronide conjugates hinder their 
intestinal absorption and intestinal β-glucuronidase are prerequisite to liberate 
tacrine for enterohepatic recirculation (163, 164). Bacteria are reported to be the 
main contributor of the intestinal source of this enzyme (169, 170) and we 
hypothesise the extreme responders may have a higher enzymatic capacity to 
deconjugate tacrine-N-glucuronide as compared to the other toxicity phenotypes. 
As the extent of enterohepatic recirculation can implicate faecal excretion of the 
free and glucuronidated drug (171-173), analysis of the metabolite excretion 
patterns provide a platform for comparison between the extreme responders from 
non-responders. To our knowledge, faecal metabolite excretion patterns of tacrine 
have not been reported in literature. As the standards of tacrine and 
hydroxytacrine glucuronides are unavailable commercially, our study adopted the 
indirect quantitation of conjugates by comparing the amount of free unconjugated 
tacrine or hydroxytacrine in the faeces before and after hydrolysis treatment.  
Most studies reported the urinary excretion profiles of tacrine and metabolites 
(143, 147, 148) but our study is the first faecal conjugate analysis conducted on 
tacrine-dosed rats. If there is a difference in extent of enterohepatic recirculation 
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in the tacrine-dosed rats, we would expect an associated difference in the 
proportion of glucuronidated metabolites detected in the faecal samples. Our 
findings revealed a vastly different faecal excretion patterns between the extreme 
responder and non-responders, with the percentage conjugation of tacrine as well 
as the total faecal amount of tacrine (free and conjugated form), being 
significantly higher in the extreme responders. The differences in the observed 
faecal metabolite excretion patterns further confirmed the extensive enterohepatic 
recirculation of tacrine in the extreme responders. A schematic of our postulation 
is depicted in Figure 2-11. We postulate that a more efficient hydrolysis of 
tacrine-N-glucuronides by intestinal bacterial β-glucuronidase in the extreme 
responders resulted in the increased systemic exposure to tacrine and higher 
plasma residence time, evident from the higher tacrine AUC in the extreme 
responders. The extensive enterohepatic recirculation consequently resulted in the 
faecal accumulation of tacrine and tacrine-N-glucuronides to 3-fold of that found 
in the non-responders (Table 2-5). The presence of free tacrine in faeces was the 
result of the hydrolysis of tacrine-N-glucuronide in the intestine and the observed 
higher free tacrine in the extreme responders further supports our postulation. The 
lipophilic structure of tacrine which enables efficient intestinal reabsorption has 
possibly resulted in the lower faecal accumulation of free tacrine than its 
hydrophilic glucuronide counterpart, hence accounting for the higher percentage 


















Figure 2-11 Postulated enterohepatic recirculation of tacrine. 
Legend- BGE: -glucuronidase enzyme; kaTG: Absorption rate constant of tacrine-N-
glucuronide; kaT: Absorption rate constant of tacrine. We postulate that the intestinal bacterial 
β-glucuronidase in the extreme responder group was able to hydrolyse tacrine-N-glucuronides 
more efficiently, facilitating the deconjugation and reabsorption of a higher amount of tacrine 
back into the systemic circulation. Coupled to potential mechanism-based inactivation of the 
CYP enzymes (174) during hepatic first-pass, the decreased hepatic clearance and increased 
intestinal reabsorption of deconjugated tacrine, collectively account for the higher secondary 
Cmax as observed in the plasma tacrine concentration-time profile of extreme responders 
(Figure 2-5B).  
 
Our results demonstrated for the first time the significant occurrence of tacrine-N-
glucuronide in faecal excretion (Figure 2-9). For example, tacrine-N-glucuronide 
accounted for ~60% of the total tacrine in faeces of the extreme responders, which 
was much higher than the 2% conjugated tacrine as reported by Hsu et al. in rat 
urine (147). Our novel results characterised a distinct excretion pattern of tacrine 
metabolites between the faecal and urinary routes. Although tacrine-N-
glucuronide has been shown to be present indirectly (147), its excretion into the 
urine was reported to be low and hence little emphasis has been given to it thus 
























is central to our hypothesis of the involvement of enterohepatic recirculation in 
tacrine-induced transaminitis.   
A total metabolite excretion analysis investigating both the urinary and faecal 
route would have been most ideal to draw differences in the excretion pathways 
between the extreme and non-responder groups. However, this approach cannot 
be realised as total urine volume was not accounted for in the original study 
design. Nevertheless, our faecal analysis yielded novel and interesting data which 
shed insights on the possible involvement of gut microbiota in tacrine-induced 
transaminitis.  
 Chapter Conclusion 2.6
LH rats are validated as suitable animal model to study the variable susceptibility 
to tacrine-induced transaminitis. In our toxicokinetic studies, we have identified a 
prominent double Cmax profile and its strong association with the in vivo 
toxicokinetics profile of extreme responders. We postulate that this double Cmax 
profile is the result of augmented enterohepatic recirculation of tacrine in the 
extreme responders, leading to higher systemic exposure and lower clearance of 
the parent drug. Crucial differences in the faecal excretion patterns, which include a 
higher dose-normalised tacrine-N-glucuronides and higher percentage conjugation of 
tacrine in the extreme responders, further support this postulation. In summary, the 





 Chapter 3 Profiling mRNA Expression of Disposition-Related 
Genes in the Livers of Tacrine-dosed Lister hooded 
Rats 
 Chapter Summary 3.1
Background: Drug toxicity can be caused by various factors related to the drug, 
environment and host. Host factors play an important role and most are complex 
and unmodifiable. The liver is a major organ involved in the detoxification 
process and it houses many enzymes, transporters and nuclear receptors that are 
implicated in drug disposition and toxicity. Large inter-individual variation was 
observed in the toxicokinetics of the LH rats in Chapter 2 but the contribution of 
the host factors to this outcome is unclear.  
Objective: This chapter aims to profile the mRNA expressions of the disposition-
related genes in the livers of LH rats to determine the contribution of the host to 
susceptibility to tacrine-induced transaminitis. 
Methodology: Literature review was performed to identify uptake and efflux 
transporters, Phase I and II metabolising enzymes, biliary excretion transporters 
and nuclear receptors that are relevant to the pharmacokinetics of tacrine. Primers 
were designed and validated for profiling the mRNA expression of these 
disposition-related genes in the livers of the LH rats. RNA was isolated and 
purified from livers of the LH rats and the complementary deoxyribonucleic acid 
(cDNA), obtained by reverse transcription of isolated mRNA, was profiled and 
normalised against reference genes using qPCR. 
Results and Discussion: A panel of 17 genes was identified to be related to the 
disposition of tacrine. β-Actin and glyceraldehyde 3-phosphate dehydrogenase 
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were selected as the reference genes. The mRNA expression of the panel of 17 
genes was found to be similar between the tacrine-dosed rats (n=26) and vehicle-
dosed rats (n=12) and between the responders (n=10) and non-responders (n=16) 
except for the down-regulation of CYP2D1/5, MRP2 and MDR1A in the mild 
responders and CYP1A2 in the moderate responders (P<0.05, randomisation test 
and bootstrapping techniques by REST 2009). However, the mRNA expressions 
of these 4 genes were not consistently lower across the toxicity phenotypes.  
Conclusion: We conclude that there was no association between the mRNA 
expression levels of the disposition-related genes in LH rats and their differential 
responses to tacrine-induced transaminitis. Our finding is significant as it 
suggested the influence of extra-host factors on the inter-individual variations in 
tacrine pharmacokinetics and tacrine-induced transaminitis.   
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 Chapter Introduction 3.2
The liver is a major organ responsible for the disposition of many drugs, 
including tacrine. Disposition of a drug involves its distribution, metabolism and 
excretion. Orally administered drugs are absorbed in the gastrointestinal tract and 
transported to the liver via the venous portal system where the hepatocytes 
participate in the uptake, biotransformation and clearance of the drug. The liver 
expresses many enzymes and transporters that partake in the disposition of drugs. 
To synthesise these enzymes and transporters, active transcription of genomic 
DNA into mRNA is required. These mRNA transcripts subsequently undergo 
translation to synthesize proteins. In other words, mRNA profiling of constitutive 
gene expression serves as a potential strategy to investigate the enzymatic and 
transporter functions in the liver, based on the broad assumption that all or at least 
most of the translated proteins are functional.  
In Chapter 2, we observed large inter-individual variation in the pharmacokinetics 
of tacrine in the treatment group. These pharmacokinetic parameters were 
associated with the susceptibility of the LH rats to tacrine-induced transaminitis. 
Variability in the expression and regulation of drug metabolising enzymes and 
transporters in the liver are important determinants for differences in therapeutic 
response. Considering the influential role of the liver on drug disposition, this 
chapter aims to profile the mRNA expressions of the disposition-related genes in 
the livers of LH rats using qPCR to determine the contribution of the host on the 




 Materials and Methods 3.3
3.3.1 Materials 
β-mercaptoethanol was obtained from Sigma-Aldrich (St Louis, MO, USA). 
QIAshredder and RNeasy Mini Kit were obtained from Qiagen (Valencia, CA, 
USA). Absolute ethanol was obtained from Merck (Darmstadt, Germany). 
Ambion® DEPC-treated water and DNA-free™ DNase Treatment & Removal 
Reagents were obtained from Life Technologies (Huntingdon, UK). iScript™ 
cDNA Synthesis Kit, SsoFast™ Evagreen® Supermix and EZ Load™ 100 bp 
Molecular Ruler were obtained from Bio-Rad Laboratories (Hercules, CA, USA). 
SeaKem® LE Agarose was obtained from Cambrex Bio Science (Rockland, ME, 
USA). 10× Tris-Acetate-EDTA (TAE) buffer, pH 8.0, Ultra Pure Grade was 
obtained from Vivantis Technologies (Oceanside, CA, USA). GeneRuler Ultra 
Low Range DNA Ladder (0.1 µg/µL) and 6× DNA Loading Dye were obtained 
from Thermo Scientific (Wilmington, DE, USA). All other reagents used were of 
analytical grades. 
3.3.2 Genes of Interest and Reference Genes Selection 
3.3.2.1 Genes of Interest 
Genes of interests were selected based on the fulfillment of three criteria namely 
(1) possible involvement of the gene in tacrine disposition, (2) presence of gene in 
human liver and (3) presence of gene or functionally equivalent gene in rat liver. 
These genes included drug transporters, enzymes involved in drug metabolism 
and the nuclear receptors regulating their expression. 
3.3.2.2 Reference Genes  
Four candidate reference genes were selected from a list of reference genes in rat 
model for hepatotoxicity (175). qPCR was performed on 8 randomly selected 
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samples comprising 5 tacrine-dosed rats and 3 vehicle-dosed rats, to identify the 
best combination of reference genes to be used. The combination of genes with 
the least M value (recommended to be less than 0.5), calculated using geNorm 
algorithm (176) in Bio-Rad CFX Manager, was chosen to be the reference genes. 
The M value indicates the expression stability and is calculated based on the 
average pairwise variation between all studied genes (175, 176). High M values 
indicate high gene expression variability and low expression stability.  
3.3.2.3 Primer Design and Validation 
Design of primers was conducted using PrimerBlast and OligoCalc software. The 
resultant primers were synthesised by 1st BASE Pte Ltd (Singapore). Each primer 
pair was tested and optimized by qPCR with a separate LH rat's cDNA using 
CFX96 real time PCR system (Bio-Rad Laboratories; Hercules, CA, USA).  
Primer specificity was validated in silico using National Center for Biotechnology 
Information (NCBI) Basic Local Alignment Search Tool (BLAST) program and 
through the observation of a single peak in melt curve from qPCR. Additional 
validation includes gel electrophoresis using a 4% agarose gel run in 1× TAE 
buffer, prepared from 10 times dilution of 10× TAE buffer, pH 8.0, Ultra Pure 
Grade, at 100 V for 2 h to check for correct product amplicon size for each set of 
primers and the absence of primer dimers in the corresponding no template 
control (NTC). Absence of primer dimers was also confirmed by checking the 
melting profile. Primers were selected if they passed the above validation criteria 
adapted from MIQE guideline (177) and if there was adequate cDNA 





3.3.3 mRNA Profiling 
The mRNA expressions of the target and reference genes were determined in the 
LH rat livers collected 176 h post-tacrine dose.   
3.3.3.1 Extraction and Purification of RNA 
Approximately 10 mg of tissue were excised from each liver sample for RNA 
isolation. Each sample was disrupted by using a motorised pestle and 
homogenised using QIAshredder homogeniser. Total RNA isolation was 
performed on the samples using RNeasy Mini Kit. Procedures of extraction were 
performed according to manufacturer's protocol for purification of total RNA 
from animal tissues (178). The concentration and purity of the mRNA were 
determined spectrophotometrically using Nanodrop 1000 Spectrophotometer 
(Thermo Scientific; Wilmington, DE, USA). Isolated RNA samples were kept at 
–80°C.  
3.3.3.2 DNase Treatment 
The isolated RNA samples were treated with DNA-free™ DNase Treatment & 
Removal Reagents to eliminate any genomic remnants which may interfere with 
subsequent gene expression analysis. The concentration and purity of the mRNA 
were determined spectrophotometrically using Nanodrop 1000 
Spectrophotometer. The integrity of the isolated mRNA was assessed by gel 
electrophoresis using a 1.5% agarose gel run in 1× TAE buffer, prepared from 10 
times dilution of 10× TAE buffer, pH 8.0, Ultra Pure Grade, at 140 V for 1 h. The 
results from gel electrophoresis were viewed using Molecular Imager Gel Doc 
XR+ with Image Lab Software (Bio-Rad Laboratories; Hercules, CA, USA). The 
criteria for proceeding to cDNA synthesis included the presence of two sharp 
rRNA bands (formed by 28S and 18S rRNA), ratio of 28S rRNA band to 18S 
rRNA band intensity of 2:1 and the absence of RNA debris.  
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3.3.3.3 cDNA Synthesis 
cDNA was prepared from 2 µg of total RNA by using iScript™ cDNA Synthesis 
Kit according to the manufacturer's protocol. 5× iScript Reaction Mix, iScript 
reverse transcriptase and nuclease free water in the kit were added followed by 
incubation for 5 minutes at 25 °C in Bio-Rad MyCycler™ thermal cycler (Bio-Rad 
Laboratories; Hercules, CA, USA). Further incubation for 30 min at 42°C was 
conducted to allow for reverse transcription. The reaction was terminated by 
increasing the temperature to 85°C for 5 min to inactivate the enzyme. Negative 
control without addition of reverse transcriptase was prepared for test sample T1 
(tacrine-dosed rat 1).  
3.3.3.4 qPCR 
Separate mastermix containing primers was prepared for each gene using 
SsoFast™ Evagreen® Supermix according to manufacturer's protocol. Each 
mastermix will contain a final concentration of 500 nM of forward and reverse 
primers, SsoFast™ Evagreen® Supermix and Ambion® DEPC-treated water. 4 µL 
of the cDNA sample was used for each rat liver. 16 µL of the prepared mastermix 
was added to the cDNA sample to make up 20 µL of reaction mixture on 96-well 
plate. The reactions were conducted in triplicates. qPCR was conducted using 
CFX96 real time PCR system. Reaction mixtures were incubated at 95°C for 30 
seconds to activate the Sso7d-fusion polymerase, a DNA polymerase. The 
amplification cycle was set at 95°C for 5 sec to allow for denaturation of the 
strands and subsequently at 60°C for 5 sec for primers annealing and DNA 
extension. The cycle was repeated for another 39 times. The reaction mixtures 
were further incubated at increasing temperature from 65 to 95°C in 0.5°C 




3.3.3.5 Relative Gene Expression Analysis  
The data obtained from qPCR were obtained as average Cq values, and ∆Cq are 
obtained by normalising against the endogenous reference genes. 
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 ∆𝐶𝑞𝑜𝑓 𝑡𝑎𝑟𝑔𝑒𝑡 𝑔𝑒𝑛𝑒
=
∑(𝐶𝑞 𝑜𝑓 𝑡𝑎𝑟𝑔𝑒𝑡 𝑔𝑒𝑛𝑒 − 𝐺𝑒𝑜𝑚𝑒𝑡𝑟𝑖𝑐 𝑚𝑒𝑎𝑛 𝑜𝑓 𝐶𝑞𝑜𝑓 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑔𝑒𝑛𝑒𝑠)
𝑁𝑜. 𝑜𝑓 𝑟𝑎𝑡𝑠 𝑖𝑛 𝑔𝑟𝑜𝑢𝑝
    
The transcript differences between two groups under comparison were measured 
as expression ratio using the following equation where: 
𝐸𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑟𝑎𝑡𝑖𝑜
=  2−(𝐴𝑣𝑒𝑟𝑎𝑔𝑒 ∆𝐶𝑞𝑜𝑓 𝑡𝑎𝑟𝑔𝑒𝑡 𝑔𝑒𝑛𝑒 𝑖𝑛 𝑔𝑟𝑜𝑢𝑝 1−𝐴𝑣𝑒𝑟𝑎𝑔𝑒 ∆𝐶𝑞𝑜𝑓 𝑡𝑎𝑟𝑔𝑒𝑡 𝑔𝑒𝑛𝑒 𝑖𝑛 𝑔𝑟𝑜𝑢𝑝 2) 
Statistical analysis of the relative mRNA expression was performed using the 
Qiagen Relative Expression Software Tool (REST 2009). qPCR reaction 
efficiency was set at 1.0 (assuming 100%). Amplification efficiency, representing 
the fold change in quantity per amplification cycle, is equal to 2 when PCR 
efficiency is assumed 100%. Relative expression of genes of interest were 
normalised against the expression of reference genes (179). REST 2009 uses 
simple statistical randomisation test and bootstrapping techniques to calculate 






3.4.1 Selection of Tacrine Disposition-Related Genes  
Genes of interest were selected based on their possible involvement in the 
metabolism and transport of tacrine and their regulation, and their presence in 
both human and rat livers. The selected genes of interest and their corresponding 
functions in tacrine disposition are described below and summarised in Table 3-1. 
3.4.1.1 Hepatic Uptake and Efflux 
Organic cation transporter type 1 (OCT1), OCT type 2 (OCT2), OCT novel type 
1 (OCTN1), OCT novel type 2 (OCTN2), Multidrug resistance-associated 
protein type 3 (MRP3). Since tacrine is a cationic drug, its transport into the liver 
may be mediated by cationic transporters. To date, five different transport systems 
for organic cations have been identified in rats (OCT1, OCT2, OCT3, OCTN1 
and OCTN2) (180). Tacrine is a reported substrate for OCT2 and OCTN2 which 
facilitate the transport of tacrine across the blood-brain barrier in rat (181). These 
two transporters are also found in both the human and rat liver, although OCT2 is 
most predominantly expressed in the rat kidney and have a low presence in the 
liver (180, 182-184).  OCT1 and OCTN1 can also be found in both human and rat 
liver and they may also be possible transporters of tacrine (180, 182, 184). OCT3 
was not selected as our gene of interest as it was found to be expressed in 
abundance in the placenta but was undetectable or very lowly expressed in the rat 
liver (180, 185).   
MRP3 is found on the hepatic basolateral membrane and is involved in the efflux 
transport of glucuronidated conjugates such as morphine-3-glucuronide and 
bilirubin glucuronides (186). Since tacrine undergoes glucuronidation in the body, 
MRP3 may be involved in the transport of tacrine metabolites (136). MRP3 is 
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expressed in both human and rat livers and its expression can be highly inducible 
during cholestasis and in the absence of functional MRP2 (186). As MRP3 
transports glucuronidated conjugates from the liver into the blood, induction of 
MRP3 in the liver can limit the extent of enterohepatic recirculation of 
glucuronidated drugs, leading to shorter drug exposure. As demonstrated by Slitt 
et al., they observed an increase in the plasma concentration and urinary excretion 
of acetaminophen glucuronides in rats pre-treated with chemicals like trans-
stilbene oxide which induce MRP3 (187). Under normal conditions in the 
controls, acetaminophen glucuronides was predominantly excreted into the bile 
(77% biliary excreted and 23% urinary excreted). However, less than 32% 
acetaminophen glucuronides was biliary excreted and more than 68% was 
excreted into the urine for the inducer-pretreated rats (187). This suggested the 
importance of MRP3 in determining the route of drug excretion.  
3.4.1.2 Metabolism (Phase I) 
CYP1A2 and CYP2D1. As discussed in Chapter 1, CYP1A2 is the major enzyme 
involved in the Phase I metabolism of tacrine (188, 189). Rat CYP2D1 is a 
homologue of human CYP2D6, where human CYP2D6 plays a minor role in the 
Phase I metabolism of tacrine (143, 144, 189-191).  
3.4.1.3 Metabolism (Phase II) 
UGT 1A1, UGT 1A6 and UGT 2B1. UGTs are the enzymes involved in 
glucuronide conjugation reactions. Tacrine and its hydroxylated metabolites are 
known to undergo glucuronidation, a Phase II metabolism, to form glucuronidated 
conjugates that are more water soluble for urinary and biliary excretion (192). As 
the inter-individual variability of UGT expression in livers plays a pertinent role 
in drug pharmacokinetics, efficacy and toxicity, it is important profile their 
expression (193). There is no data on which specific UGTs were involved in 
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tacrine conjugation. Based on sequence similarity, UGTs have been divided into 
UGT1 and UGT2 families (193). UGT 1A1 and UGT 1A6 were chosen as they 
are the major UGT1A family genes in both rat and human liver (193-198). Other 
than UGT1A, the other families of UGTs include the UGT2B family which may 
possibly be involved in the glucuronidation of tacrine as well. Rat UGT 2B1 was 
chosen as it is the homologue of human UGT 2B7, which is an important enzyme 
in the UGT2B family responsible for the conjugation of a wide range of drugs 
such as morphine and gemfibrozil (194, 195, 199, 200).  
Glutathione-S-transferase (GST) M1 and GST T1. One of the hypotheses 
suggested that tacrine is metabolised by CYP1A2 to form reactive quinone 
methide which may be responsible for hepatic damage (144, 151, 152). However, 
no studies to date were able to detect these proposed reactive metabolites 
definitively. Glutathione is an important nucleophile in the bodily system which is 
involved in cellular detoxication of electrophilic metabolites and prevents the 
binding of reactive metabolites to cellular protein or DNA. GSTs are enzymes 
involved in the enzymatic conjugation with glutathione (201). GST M1 and GST 
T1 are known to be polymorphically expressed in the liver and they have received 
particular attention as their double-null variants were associated with higher risk 
of drug-induced liver injury for drugs like troglitazone and carbamazepine (202-
205). Some studies observed that the gene expression levels of GST M1 and GST 
T1 were consistently down-regulated in subjects carrying one and/or two 
deletions of the genes variants. (206, 207). While it still remains debatable the 
association of the polymorphically expressed GST M1 and GST T1 null genotype 
with susceptibility to tacrine-induced hepatotoxicity, the expression of GST M1 




3.4.1.4 Biliary Excretion 
Multidrug resistance protein type 1 (MDR1), MRP2, MDR3 and bile salt export 
pump (BSEP). MDR1 is found along the bile canalicular membrane and is 
involved in the transport of various cationic drugs (208). As tacrine has a 
potential to form protonated cations, MDR1 might be a possible transporter of 
tacrine. In rats, there are two MDR1 genes (MDR1A and MDR1B) capable of 
xenobiotic transport (209). MRP2 is found on the bile canalicular membrane and 
is involved in the transport of conjugates such as glucuronide and glutathione 
conjugates (208, 210). Since tacrine undergoes conjugation reactions in the liver, 
MRP2 might be involved in the transport of tacrine metabolites (136). MDR3 in 
involved in the biliary excretion of a number of drugs like digoxin and paclitaxel 
(211). However, findings from Alfirevic et al. suggested that tacrine is not a 
substrate and inhibitor of MDR3 (212). As we suggest the implication of 
enterohepatic recirculation on the susceptibility to tacrine-induced transaminitis 
(Chapter 2), the expression of MDR3 and BSEP were profiled considering their 
involvement in the transport of bile salts (208). 
3.4.1.5 Expression Regulation 
Constitutive androstane receptor (CAR) and aryl hydrocarbon receptor (AhR). 
Both CAR and AhR are nuclear receptors regulating the expression of various 
metabolising enzymes and transporters in the liver for tacrine. CAR regulates the 
expression of UGT1A1 and UGT1A6 (213-215). There are conflicting reports on 
the involvement of CAR for regulation of MRP3 (216, 217). AhR regulates the 
expression of CYP1A2 and UGT1A6 (215, 218).   
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Table 3-1 Genes of interest and their potential roles in the tacrine’s disposition 
 
3.4.2 Selection of reference genes  
The 4 selected candidate reference genes were: 
β-Actin, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), hypoxanthine-
guanine phosphoribosyltransferase 1 (HPRT1) and  β2 microglobulin (B2m). β-
Actin and GAPDH are traditional reference genes used widely in many gene 
expression studies (175). Additionally, Lardizabal et al. demonstrated that HPRT1 
and B2m were relatively stable to be used in rat hepatotoxicity studies (175).  
The expression stabilities of the different combinations of the four candidate 
reference genes were determined and their respective M values are presented in 
Table 3-2. β-actin and GAPDH were selected as the combinational reference 




Role in tacrine’s disposition 
Hepatic uptake 
and efflux 
OCT1 Possibly involved in the transportation of 
positively charged tacrine into and out of liver OCT2 
OCTN1 
OCTN2 
MRP3 Possibly involved as the export pump of tacrine 
conjugates back into the bloodstream 
Metabolism 
(Phase I) 
CYP1A2 Major metabolising enzyme of tacrine 
CYP2D1 Minor metabolising enzyme of tacrine 
Metabolism 
(Phase II) 
UGT1A1 Glucuronidation of tacrine metabolites 
UGT1A6 
UGT2B1 
GST M1 Possibly involved in the glutathione conjugation 
of the reactive metabolites of tacrine GST T1 
Biliary 
excretion 
BSEP Possibly involved in the biliary transport system 





AhR Involved in the regulation of expression of various 
CYPs and UGTs, especially CYP1A2 CAR 
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value of 0.298. This highest expression stability is suitable for normalisation of 
other gene expression.  








3.4.3 Primer Design 
The primer nucleotide sequences used in the study and their respective amplicon 
length are summarised in Table 3-3. Insufficient amplification (Cq>40) with qPCR 
was observed for OCT2 with respect to the liver samples. As such, OCT2 was 
excluded from the study.  
Candidate reference gene combination M value 
β-actin and GAPDH 0.298 
β-actin and B2m 0.5962 
β-actin and HPRT1 0.6546 
β-actin, GAPDH and B2m 0.5548 
β-actin, GAPDH and HPRT1 0.5950 
β-actin, B2m and HPRT1 0.5486 
β-actin, GAPDH, B2m and HPRT1 0.5910 
GAPDH and B2m 0.7703 
GAPDH and HPRT1 0.8323 
GAPDH, B2m and HPRT1 0.6658 
B2m and HPRT1 0.3948 
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Table 3-3 PCR primer sequences for tacrine disposition-related genes and 
reference genes in LH rat livers and their respective amplicon length. 
Function Gene Accession code 
Primer Sequence (5' to 3') 







OCT1 NM_012697.1 F TTGTTTGGGGTTTTGGGCCTG 163 
R ACTTGCCTGTTTGGACCTGA 
OCTN1 NM_022270.1 F GTCCCCCTGTGGTGGTTTAT 181 
R TGAAGACTTTCTGCTGCTTCAA 
OCTN2 NM_019269.1 F GATGCTCAGGGTCAAAGGAATA 112 
R AGGGTGTTAGAAGGCTGTGC 
















NM_012683.2 F GGTTCCAATGGTGATGATG 166 
R GATGTTCTCCTTGTAACTCTTG 
UGT2B1 NM_173295.1 F TTCCACACCCATTCTTACCTAAT 190 
R GCAAGAGCAGAAGCAACTAC 
GST M1 NM_017014.1 F TCTGCACTGTGGTTCTCT 152 
R AGGTTGTGTTAAGGTGTCAAT 





BSEP NM_031760.1 F TTGTCCACCATCCAGAAC 151 
R GTCTCCAGTCAGGTCAAC 
MDR1A NM_133401.1 F AGTAGAGACACGTGAGGTCG 165 
R AATCTGTCCAGCCAACCTGC 




Function Gene Accession code 
Primer Sequence (5' to 3') 




MDR3 NM_012690.2 F CACGGACCTTACAGGAATT 98 
R AAGCAGCCAGCATAAGAA 




CAR NM_001270839.1 F TCCACTTCCACAAAACCCTGAA 95 
R TAACCCCAGGCCAGGAGAGAA 




β-actin NM_031144.2 F GGTGTGATGGTGGGTATG 103 
R CAATGCCGTGTTCAATGG 
GAPDH NM_017008.3 F GATGGTGAAGGTCGGTGTGA 175 
R GACTGTGCCGTTGAACTTGC 
* In silico BLAST specificity analysis shows primers of CYP2D1 to be specific to both 
CYP2D1 and CYP2D5, thus gene is represented as CYP2D1/5  
** In silico BLAST specificity analysis shows primers of UGT 1A1 and UGT1A6 to be 
unspecific and binds to all UGT1A enzymes, thus gene is represented as UGT1A 
 
3.4.4 Validation of mRNA Integrity and Primers 
The integrity of each mRNA sample isolated from the livers of tacrine-dosed and 
vehicle-dosed rats after DNA digestion was intact as seen from the presence of 
two sharp ribosomal RNA bands formed by 28S and 18S rRNA in the ratio of 2:1 
and the absence of RNA debris (Figure S4). 
Melt curve analysis confirmed the specificity of the primers as revealed by the 
occurrence of a single peak for each set of primer (except for CYP2D1/5 and 
UGT1A as explained above). Gel electrophoresis was used to validate the 
primers. Only primers with a prominent band at the correct approximate amplicon 
length were used in this study. Results of gel electrophoresis are shown in Figure 
S5. All primers in Table 3-3 were found to be optimal with the correct 
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approximate amplicon length, Cq value of approximately 10 to 30 and absence of 
primer dimers. 
3.4.5 Relative Gene Expression Analysis of the Genes of Interest 
No significant difference were found in the mRNA expression levels of the panel 
of 17 genes between the tacrine-dosed rats (n=26) and vehicle-dosed rats (n=12). 
This suggested that the genes were similarly expressed in the livers of these two 
groups of rats. A comparison of the mRNA expression between the tacrine-dosed 
responders (n=10) with the non-responders (n=16) also revealed no statistical 
differences in the expression levels of these genes.  
The relative gene expression profile of each of the toxicity phenotypes was 
compared with that of the non-responders as shown in Figure 3-1. There were no 
statistical differences in the mRNA expression between the mild responders (n=3) 
and non-responders (n=16) for all the genes of interest except for CYP2D1/5, 
MRP2 and MDR1A which were found to be down-regulated in the mild 
responders (P<0.05, randomisation test and bootstrapping techniques by REST 
2009). mRNA expression of the panel of 17 genes were similar when the 
moderate responders (n=3) and non-responders (n=16) were compared except for 
CYP1A2 which showed a lower expression in the moderate responders (P<0.05, 
randomisation test and bootstrapping techniques by REST 2009). No statistical 
differences in the mRNA expression for all genes were observed between the 




Figure 3-1 Box-and-whisker plots of mRNA expression ratio of (A) uptake 
transporters/efflux pumps, (B) Phase I and II metabolising enzymes, (C) biliary 
excretion transporters and (D) nuclear receptors of the mild responders (MIL, 
n=3), moderate responders (MDR, n=3) and extreme responders (EXT, n=4) 
compared to the non-responders (NOR, n=16).  
The boxes represent the interquartile range (IQR) between the first and third quartiles while 
the horizontal line within the boxes represents the median. Whiskers represent the lowest and 
highest values within 1.5 times the IQR from the first and third quartiles respectively. Outliers 
are presented as dots outside the whiskers. Statistical analysis established by randomisation 
test and bootstrapping techniques by REST 2009, *P<0.05. 
  








The liver is a major metabolic organ and its drug metabolising enzymes, 
transporters and nuclear receptors play key roles in determining the disposition 
kinetics of many drugs. For instance, CYP1A2 mRNA expression has been found 
to vary up to 40-fold and this wide individual variation is clinically important as 
CYP1A2 contributes to the metabolism of many drugs such as olanzapine, 
theophylline and clozapine which have narrow therapeutic window (219-221). As 
the differences in the toxicokinetic profiles of tacrine observed in Chapter 2 may 
be attributed to the variation in the expression of disposition-related genes 
inherent to the host, we compiled a list of hepatic transporters, enzymes and 
nuclear receptors that are potentially involved in the transport, metabolism or 
regulation of tacrine. Currently, little information is available on the complete list 
of genes pertaining to the disposition of tacrine in the liver. As such, the genes of 
interests were identified based on our knowledge of the physiochemical structure 
of tacrine, its metabolism pathway and the specificity of potential enzymes or 
transporters for tacrine and its metabolites.  
In this study, LH rat livers collected at the termination of the study (176 h post 
administration of tacrine) were used for mRNA expression profiling. While it 
might be interesting to capture the gene expression profile during the period of 
transaminitis (e.g. 8 and 24 h) to assess the potential effect of tacrine on the 
mRNA expression levels of the candidate genes, our longitudinal study design did 
not permit sacrificing some of the rats midway of the study or performing liver 
biopsy. Nevertheless, based on the microarray study conducted by Carr et al. 
where they gave a comparable single intraperitoneal dose of 40 mg/kg tacrine to 
male Sprague-Dawley rat, none of our genes of interest listed in Table 3-3 were 
found to be dysregulated at 6 h and 24 h following the administration of tacrine 
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(135). However, no information was available for OCTN1 and CAR as they were 
not found within the microarray. Based on this key study by Carr et al. and the 
lack of literature which reported tacrine as an inducer of our target genes (135, 
222), an assumption was made that the mRNA expression profiled in this study 
from the terminal livers were representative of the constitutive and non-induced 
states. This assumption was further supported by (1) the single oral dose of 
tacrine, (2) tacrine’s short elimination half-life of 1.3 to 7 h and (3) the livers were 
collected for mRNA profiling only at 176 h following administration of tacrine 
when the rats have recovered from transaminitis.      
In analysing the gene expression, we observed similar expression of the 17 genes 
of interest when we compared tacrine-dosed rats against vehicle-dosed rats and 
responders against non-responders. This finding may be a reflection of the genetic 
homogeneity of the LH rats as well as the tight dietary and environmental control 
of our in vivo which might otherwise influence gene expression (219, 220, 223, 
224). To further elucidate the association between relative expression of 
disposition-related genes and susceptibility to tacrine-induced transaminitis, we 
compared the mRNA expression of each toxicity phenotypes with the non-
responders. While the expression of CYP2D1/5, MRP2 and MDR1A were 
statistically lower in the mild responders and CYP1A2 lower in the moderate 
responders compared to the non-responders, these differences in mRNA 
expression were clearly not conserved across the toxicity phenotypes. 
Collectively, our findings suggested a relatively homogenous comparable 
constitutive expression of mRNA among all the tacrine-dosed rats.  
Beyond the scope of this thesis, it is to be noted however that genetic expression 
may not necessary correlate with the functional activities of the proteins. Genetic 
polymorphism, such as single nucleotide polymorphism, may alter protein activity 
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and affect drug disposition and response (225). For instance, depending on the 
location and type of genetic variation, majority of CYP1A2 polymorphisms have 
been shown to decrease enzymatic activity while some genetic variants were 
associated with high inducibility and increased enzymatic activity (220, 226, 
227). In this regards, it is noteworthy to mention the work by Alfirevic et al. 
where they investigated whether the single nucleotide polymorphisms in 19 
candidate genes were associated with tacrine-induced hepatotoxicity in 69 
Caucasian patients (212). Amongst the 19 candidate genes studied, 6 genes 
(OCT1, CYP1A2, MDR1, MDR3, BSEP and AhR) were common with our genes 
of interest. It is notable that none of the polymorphisms of the 19 genes were 
significantly associated with tacrine-induced transaminitis in the patients (212).  
 Chapter Conclusion 3.6
In conclusion, there was no association between the mRNA expression levels of 
the disposition-related genes in the LH rats with their differential responses to 
tacrine-induced transaminitis. Integrating the findings in this study with other 
related genetic studies, the lack of host genetic biomarker predictive of 
susceptibility to tacrine-induced transaminitis suggested that host genetic factor 
alone is not sufficient to account for the idiosyncrasy associated with tacrine-




 Chapter 4 GC/TOFMS-based Metabonomic Investigation of 
Tacrine-induced Transaminitis 
 Chapter Summary 4.1
Background: The gut microbiota, possessing a diverse range of metabolic 
activities, is capable of influencing drug disposition directly and indirectly. The 
indirect effect is facilitated via host-gut microbiota interaction where bidirectional 
flow and exchange of metabolites between the host and gut microbiota metabolic 
pathways cause perturbations to drug disposition. While this mechanism has been 
shown to account for a number of pharmacological and toxicological 
idiosyncrasies, the host-gut microbiota interaction has not been well studied 
owing to its complexity. Tacrine is a drug that induces hepatotoxicity but it is 
unclear what underlies the inter-individual variation in tacrine-induced 
transaminitis. 
Objective: In this chapter, we aim to investigate the potential role of host-gut 
microbiota interaction in tacrine-induced transaminitis by screening the urinary 
and faecal metabolomes of LH rats for transaminitis-related marker metabolites.  
Methodology: Global GC/TOFMS-based metabonomics was used to screen the 
urinary and faecal metabolomes of LH rats for transaminitis-related marker 
metabolites. 
Results and Discussion: Principal component analysis (PCA) of the urinary and 
faecal metabolomes revealed a similar pre-dose metabolomes among all rats. At 
the peak of transaminitis (8–24 h), urinary and faecal metabolome analysis 
revealed distinct clustering of the rats exhibiting toxic phenotypes, especially the 
extreme responders from the non-responders. A closer analyses of the extreme 
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responders revealed a metabolic trajectory that followed the progression and 
resolution of transaminitis (Urine: R2X=0.605 and Q2(cum)=0.503, Faeces: 
R2X=0.538 and Q2(cum)=0.312, PCA) over the period of –24 to 96 h. At the 
period of highest transaminase elevation (8–24 h), we found 43 unique urinary 
marker metabolites and 62 unique faecal metabolites associated with tacrine-
induced transaminitis (variable importance in the projection (VIP) values>1 
and/or P<0.05, |r|>0.6). A decrease in urinary levels of citric acid cycle and 
oxidative phosphorylation intermediates suggested an impairment of energy 
metabolism associated with mitochondrial dysfunction in tacrine-induced 
hepatotoxicity. Elevated faecal bile acids in extreme responders further suggested 
novel mechanisms underlying tacrine-induced hepatotoxicity. In addition, a 
majority of the transaminitis-related marker metabolites are co-metabolites, 
nutrients or fermentation products whose abundance are related with the 
composition and metabolic activities of gut microbiota. 
Conclusion: Considering findings gleaned from preceding chapters, our 
metabonomic findings suggest a perturbation of gut microbiota or its associated 
microbial metabolic activity in rats exhibiting tacrine-induced transaminitis. This 
study illuminated a significant potential involvement of host-gut microbiome 
interaction in the variable toxicokinetics of tacrine.    
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 Chapter Introduction 4.2
The variation in therapeutic responses is attributed to several factors such as inter-
individual differences in drug disposition, polymorphism of drug-disposition 
genes, heterogeneity in diseases, gender, age, diet and concurrent drug 
administration. In addition to these factors, another often neglected factor, the gut 
microbiota is receiving increasing attention in recent years with regards to its 
potential in modulating drug response (32). The gut microbiota is able to exert 
direct influence on the biotransformation of drugs (45, 228) and modulate host 
metabolic capacity indirectly via generation of interfering co-metabolites derived 
from both the host and gut microbiota (47, 229) as detailed in Chapter 1. The 
technical difficulty in performing a holistic analysis of these metabolites impeded 
our understanding of the latter mechanism until the advancement of 
metabonomics in recent years which facilitates such investigation. Metabonomics 
has shown particular promise in furthering our understanding of disease 
conditions and mechanisms underlying drug-induced toxicity (57, 79, 96, 97, 101, 
230, 231). Through global metabolic profiling, microbial metabolites like p-cresol 
had been reported to compete with analgesic paracetamol for sulfotransferase 
active sites, an enzyme responsible for phase II sulfonation of paracetamol (47). 
Such findings underscored the ability of metabonomics to discover new 
biomarkers of drug-induced toxicity that in turn may shed lights on the roles of 
gut microbiota in mediating therapeutic responses (59, 73, 109).  
Several mechanisms such as formation of reactive metabolites (144, 151, 152) 
and direct hepatotoxic effect of tacrine via induction of mitochondrial dysfunction 
(154, 156) have been proposed to explain tacrine hepatotoxicity. However we are 
unclear about the contribution of host-gut microbiota interaction in determining 
the variable susceptibility of a given biological system to tacrine-induced 
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transaminitis. In this chapter, we aim to investigate the potential role of host-gut 
microbiota interaction in tacrine-induced transaminitis by screening the urinary 
and faecal metabolomes of LH rats for transaminitis-related marker metabolites 
using global GC/TOFMS-based metabonomics.    
 Materials and Methods 4.3
4.3.1 Materials 
Diclofenac sodium salt, indomethacin, urease Type III from Jack beans, alkane 
standard mixture (C10 to C40), methyl octanoic (C8), methyl dodecanoic (C12), 
methyl tetradecanoic (C14), methyl hexadecanoic (C16), methyl octadecanoic 
(C18), methyl arachidate (C20) and methyl behenate (C22) were obtained from 
Sigma-Aldrich (St Louis, MO, USA). Methyl decanoic (C10) was obtained from 
Alfa Aesar (Ward Hill, MA, USA). Methyl tetracosanoic (C24) and methyl 
hexacosanoic (C26), methyl octacosanoate (C28) and myristic-d27 acid were 
obtained from Santa Cruz (CA, USA). MSTFA (N-methyl-N-
(trimethylsilyl)trifluoroacetamide) with 1% TMCS (trimethylchlorosilane) and  
MOX (2% methoxamine hydrochloride pyridine) were purchased from Thermo 
Scientific (Rockford, IL, USA). Toluene was obtained from JT Baker 
(Phillipsburg, NJ, USA). Hexane was obtained from Fisher Scientific 
(Leicestershire, UK).  
4.3.2 Sample Preparation and Derivatisation 
Pre-dose (–24 to 0 h), 0–8 h, 8–24 h, 24–48 h and 72–96 h urine and faecal 
samples were prepared for GC/TOFMS-based metabonomics.  
4.3.2.1 Urine Samples 
Urine samples were thawed at room temperature (25 ± 3°C). 150 units of urease 
enzyme was added to 200 µL of rat urine and incubated at 37°C for 1 h to remove 
 105 
 
excess urea. 1.2 mL methanol was then added to the mixture to precipitate urease 
and other proteins and this was followed by the addition of 10 μL of IS mixture 
comprising 0.5 mg/mL diclofenac and indomethacin. The mixture was vortex-
mixed at high speed for 5 min and centrifuged at 14,000 g at 24°C for 10 min. 1 
mL of supernatant was collected and evaporated to dryness under a gentle stream 
of nitrogen gas at 50°C using a TurboVap LV.  
4.3.2.2 Faecal Samples 
Faecal samples were cut and homogenized under dry ice, and subsequently 
lyophilised. The lyophilised samples (80 mg) were extracted with 1 mL 
methanol/water (80:20), containing 25 µL each of 10 mg/mL diclofenac, 
indomethacin, myristic-d27 acid as IS. Samples were ultrasonicated in ice for 30 
min and vortex-mixed for 2 min. After centrifugation at 18,000 g at 4°C for 15 
min, 0.5 mL of supernatant was collected and evaporated to dryness at 50°C 
under a gentle stream of nitrogen gas using TurboVap LV.  
4.3.2.3 Derivatisation Procedures 
100 µL of toluene (kept anhydrous with sodium sulphate) was added to the dry 
residue, vortex-mixed for 1 min and evaporated to dryness to eliminate any trace 
of water. 50 µL of MOX was added to the dried extract. The mixture was vortex-
mixed vigorously for 30 sec and incubated for 1.5 h (urine) or 2 h (faeces) at 60°C 
for methoximation. Subsequently, the sample was derivatised by adding 100 µL 
of MSTFA with 1% TCMS and incubated at 60°C for 1 h (urine) or 45 min 
(faeces) to form the trimethylsilyl (TMS) derivatives. After incubation, 100 µL of 
supernatant was transferred into a vial for GC/TOFMS analysis. 
QC samples were prepared in the above manner using either pooled urine or 
faeces of control rats. To mitigate the impact of analytical drift on intensity and 
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retention time, samples were randomised for sample preparation and one QC 
sample of the corresponding matrix type was prepared along every ten to fourteen 
samples.  
4.3.3 GC/TOFMS Analysis 
Analysis was performed using a Pegasus GC/TOFMS instrument (LECO 
Corporation, St. Joseph, MI, USA) equipped with an Agilent 7890 gas 
chromatograph. 1 µL of derivatised sample was injected into a DB-1 capillary 
column (21.5 m × 250 µm (i.d.) × 0.25 µm; Agilent J&W Scientific, Folsom, CA) 
at a split ratio of 1:10 (urine) or 1:15 (faeces) and solvent delay time of ~190 sec. 
Helium gas, at constant flow of 1.5 mL/min, was used as the carrier gas. The 
injector temperature was maintained at 220°C and the front inlet purge flow rate 
was 3 mL/min. The initial GC oven temperature was held at 70°C for 0.2 min, 
raised to 270°C at a rate of 10°C/min (held for 5 min), and to 310°C at a rate of 
40°C/min, where the temperature was maintained for 10 min. The mass 
spectrometer was operated in an electron impact mode at a detector voltage of 
1800 V (urine) or 1600 V (faeces) and electron energy of -70 eV. Mass spectra of 
m/z 40 to 950 were collected at the acquisition rate of 20 spectra/sec. The transfer 
line and ion source temperature were set at 280°C and 250°C respectively. 
The derivatised samples were re-randomised for GC/TOFMS analysis such that 
the analysis sequence was different from the order of sample preparation to 
minimise systematic bias. One QC sample was analysed along every ten to twenty 
samples. Alkane standard mixture (n-alkane; C10 to C40) was injected periodically 
into the system during analysis to detect retention time (Rt) shift. A mixture of n-
fatty acid methyl esters (n-FAME; C8 to C28) was analysed at the end of the whole 
analysis. Subsequently, one chromatogram of n-alkane and n-FAME mixture was 
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used as references for computation of retention index (RI) for metabolite 
identification in the later stage.  
4.3.4 Data Analysis 
4.3.4.1 Data Preprocessing 
Processing of the raw spectral data obtained from GC/TOFMS was based on and 
modified from the Calibration feature in ChromaTOF software (Version 4.41, 
LECO Corporation) as described by Chan et al (85). ChromaTOF software was 
utilised to perform baseline correction, smoothing, peak finding, noise reduction, 
peak area integration, library matching, and retention index computation. Baseline 
offset was set at 0.5 and data point to be averaged for smoothing was set at 
automatic. All metabolite peaks in a representative QC that met these criteria: 
peak width of 2.8 s, number of apexing mass of 3 and S/N ratio of 300, were used 
to generate the reference table. The QC analysed within the middle of the 
analytical batch was selected to build the reference table to facilitate the 
correction of metabolites with significant signal and Rt drifts. Once the reference 
table was generated, it was imported into the calibration feature of ChromaTOF 
for data alignment and peak table generation (85). Eight peaks from early, 
intermediate and late Rt were identified as retention references (RFs) for 
determination and correction of Rt drifts. Peaks from other samples were then 
identified against this table with match threshold of 600 (850 for RFs) and Rt 
deviation of 2.5 sec (8 sec for RFs). Peak areas were calculated and the accuracy 
of peak area integration was manually verified. Asymmetrical peaks, peaks with 
serious co-elution and peaks subjected to interference in the urea region (for urine 
samples) were removed. Upon completion, all the peak area values were exported 
to Microsoft Excel. Data preprocessing of the faecal samples followed a similar 
workflow and parameters were optimised accordingly. 
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For the urine samples, total area normalisation was performed whereby the 
integrated peak area was normalised against the sum of the peak areas within each 
sample chromatogram using custom scripts developed within Microsoft Excel 
2007. A first phase of normalisation was applied to circumvent the time-related 
signal intensity drift in instrumental performance over the long GC/TOFMS 
analysis and the normalised peak area variation (%CV) for all peaks in QC 
samples were calculated. After removing peaks with poor repeatability (CV more 
than 30% in the QCs) (84), total area normalization was performed on the raw 
peak areas of the remaining peaks. The resulting data matrix, comprising peak 
index (Rt-m/z pair), sample names (observations) and normalised peak areas of 
metabolites (variables), was exported to SIMCA-P+ (version 12.0, Umetrics AB, 
Umeå, Sweden) for multivariate data analysis. For the faecal samples, IS 
normalisation was performed by dividing the peak area of metabolites in a sample 
by the peak area of myristic-d27 acid of that sample. Subsequent metabolite peak 
areas presented are relative metabolite peak areas to myristic-d27 acid. Only 
metabolites with normalised peak areas of CV below 30% in QCs were used in 
subsequent analyses.  
Six randomly selected control rats, six non-responders and ten responders that 
exhibited tacrine-induced transaminitis were selected for data analysis.  
4.3.4.2 Statistical Data Analysis 
Mean centering and unit variance scaling were performed prior to multivariate 
data analysis in SIMCA-P+. PCA and partial least square discrimination analysis 
(PLS-DA) were performed on the GC/TOFMS data of the treatment and control 
group at selected time point. Unsupervised PCA was used to detect outliers and 
visualise grouping trends. Supervised PLS-DA was then applied using toxicity 
response as classifier. Based on the PLS-DA model, potential marker metabolites 
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that are responsible for the separation of the extreme responders from the non-
responders class were identified using the VIP values. VIP values reflect the 
importance of the metabolites in distinguishing the classes. Metabolites with VIP 
values greater than 1 were considered as putative marker metabolites. The PLS-
DA models were validated and checked for overfitting by performing 100 
permutation tests. 
Univariate data analysis was performed to verify the statistical significance of 
marker metabolites that differentiate the extreme responders from non-responders 
using Welch’s t-test at P<0.05. The fold changes of the marker metabolites were 
calculated by taking the ratio of the average metabolite level in the extreme 
responders to the non-responders. Metabolite peak areas in the tacrine-dosed rat 
samples were correlated with the AST and ALT levels using Pearson’s 
correlation. Good correlation of metabolites with transaminitis levels was 
determined by |r|>0.6. 
4.3.4.3 Metabolite Identification 
Metabolites were identified by matching mass spectra (MS) against in-house 
libraries, National Institute of Standards and Technology (NIST) standard mass 
spectral database in NIST MS search 2.0 (NIST, Gaithersburg, MD), Golm 
Metabolome Database (GMB) and the Fiehn Metabolomics library (forward or 
reverse match criteria of >600) and RI values against the above databases and 
HMDB database. 
HMDB, Kyoto Encyclopaedia of Genes and Genomes (KEGG) databases and 
literatures were reviewed for association of the putative marker metabolites with 




4.4.1 Validation of GC/TOFMS Methods 
Due to the extensive sample preparation and long analysis time associated with 
our large-scale studies, pooled QCs were incorporated into the analyses to 
monitor the performance of our methods. As the pooled QCs are identical 
biological samples, we would expect the QCs to be closely clustered in the PCA 
scores plot. PCA analysis of our urine and faecal datasets revealed tight clustering 
of the QCs which were analysed at regular intervals throughout the analysis 
amongst the LH rat samples, supporting the validity of our methods (Figure 4-1).  
 
Figure 4-1 PCA scores plots of (A) urinary and (B) faecal metabolic profiles of 
QCs ( ) and LH rats ( ).   
 
4.4.2 Effect of Tacrine Administration on Rat Urine and Faecal 
Metabolomes 
PCA of urine and faecal samples acquired prior to tacrine administration and 
post-dosing revealed some notable alterations in the rat metabolomes. Prior to 
administration of tacrine (–24 to 0 h), all the rats appeared to be closely clustered 
within the 95% Hotelling’s T2 confidence eclipse (Figure 4-2A and D), except for 
A            B 




three outliers (T11, T22 and V01) of faecal origin (Figure 4-2D). The latter two 
samples were subsequently traced to derivatisation errors. 0–8 h was the period 
where transaminitis began to develop in the responders. The PCA scores plot 
from urine collected in this period revealed a distinct clustering of the tacrine-
dosed rats (indicated by triangles) from vehicle-dosed controls (indicated by 
green dots), indicative of metabolic changes following administration of tacrine 
(Figure 4-2B). Additionally, extreme, moderate and mild responders seemed to 
cluster separately from the non-responders during this period with the exception 
of a non-responder (T11) which were found within the cluster of responders. A 
similar findings were observed for the faecal metabolomes of the LH rats (Figure 
4-2E). At the peak of transaminitis (8–24 h), the extreme responders were found 
to form a distinct cluster from the rest of the rats (Figure 4-2C and F). The faecal 
metabolome of one extreme responder (T08) however did not cluster with the 
other three responders (Figure 4-2F). From 24 h onwards, the urine and faecal 
metabolomes of the rats began to converge. This clustering trend corroborated 
with the rats’ recovery from transaminitis. 
4.4.3 Recovery Trajectory of Extreme Responders 
Figure 4-3 shows the overall clustering pattern of the non-responders and extreme 
responders at different time periods. While the non-responders did not show much 
metabolic variation throughout the study period, the extreme responders displayed 
a unique metabolic trajectory. Prior to the administration of tacrine, non-
responders and extreme responders were closely clustered. The extreme 
responders shifted away from the non-responders 0–8 h post-administration of 
tacrine and continued to drift further away at 8–24 h. After 24 h post-dose, the 





















Figure 4-2 PCA scores plots of urinary metabolic profiles of LH rats at (A) –24 to 0 h (pre-dose), (B) 0–8 h and (C) 8–24 h and faecal metabolic 
profiles at (D) –24 to 0 h, (E) 0–8 h and (F) 8–24 h. Each point denotes an individual rat. Extreme responders (EXT) are represented by ( ), moderate 
responders (MDR) by ( ), mild responders (MIL) by ( ), non-responders (NOR) by ( ) and vehicle-dosed controls by ( ).    













Figure 4-3 PCA scores plots of the (A) urine and (B) faecal metabolomes of the 
EXT ( ) and NOR (  ) profiled at all time periods (–24 to 96 h). EXT are further 
color coded such that blue represents –24 to 0 h, gold represents 0–8 h, red 























4.4.4 Transaminitis-related Marker Metabolites  
As the 8–24 h time period corresponded to the peak of transaminitis, we 
compared the metabolomes of the extreme responders with that of the non-
responders to screen for transaminitis-related metabolites. A distinct separation of 
the extreme responders and non-responders was observed in the PCA and PLS-
DA scores plots generated from the urine and faecal metabolomes (Figure 4-4A to 
D). The faecal metabolome of rat T08 (extreme responder) was excluded from the 
PCA and PLS-DA analysis in Figure 4-4C and D as it was shown to be a outlier 
with metabolic profile inconsistent with the other extreme responders.  
While the extreme responders were clearly separated from the non-responders 
based on their urinary metabolomes by PLS-DA (Figure 4-4B), the model did not 
pass validation as a small number of Q2 values obtained after class permutation 
were found to be higher than the original Q2 of 0.829 (Figure 4-4E). However, the 
PLS-DA model in Figure 4-4F passed validation as the original R2 and Q2 values 
(far right) were higher than those obtained in the randomly permutated models. 
This suggested minimal overfitting and chance correlation. Nevertheless, marker 
metabolites with VIP>1 that were responsible for distinguishing the extreme 
responders from non-responders were obtained from both PLS-DA models for 
further investigation. To minimise the possibility of these marker metabolites 
arising due to chance correlation, Welch’s t-test was performed. 95 metabolites 
from the urinary metabolome and 41 metabolites from the faecal metabolome 
were found to be statistically significant (P<0.05) with VIP>1. In addition, a 
complementary Pearson’s correlation analysis was calculated for all metabolites 
based on their normalised peak areas in relation to the aminotransferase levels at 8 
and 24 h to shortlist metabolites highly correlated with transaminitis (|r|>0.6). The 
levels of 82 urinary metabolites and 134 faecal metabolites were found to 
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correlate strongly (|r|>0.6) with the aminotransferase levels at the 8–24 h post-
dose period. Some of these metabolites identified through Pearson’s correlation 
overlapped with the list of metabolites screened using PLS-DA and Welch’s t-
test. The urinary and faecal marker metabolites (all with VIP>1) identified based 
on these combinatorial analyses are provided in Table 4-1 and Table 4-2, with 
information of their VIP scores, P values, correlation coefficient (r) and their fold 
change (with respect to non-responders). It is notable that the overall 
identification rates of marker metabolites in our experiment (matched based on 
MS and/or RI) is 43.5%. Excluding metabolites with the same identities, there are 




Figure 4-4 PCA and PLS-DA scores plots of the 8–24 h (A, B) urinary and (C, 
D) faecal metabolomes of EXT ( ) and NOR ( ). Model validation plots of the 
corresponding (E) urinary and (F) faecal PLS-DA models generated in (B) and 
(D). Rat T08 was excluded from the analysis in (C), (D) and (F) as it was an 






























Table 4-1 Urinary transaminitis-related marker metabolites identified 8–24 h post-tacrine administration. 
No. Postulated metabolite identity RI 
Similarity 
index 












Marker metabolites with VIP>1, P<0.05, ІrІ>0.6 
1 o-Hydroxyphenylacetic acid 1560 601/800 1.72 1.16E-02 0.77 0.89 5.13 Annotated with in-house standards (MS and RI) 
2 Fumaric acid 1345 771/835 1.59 4.45E-04 -0.62 -0.79 -1.98 Annotated with in-house standards (MS and RI) 
3 Mesaconic acid 1397 734/820 1.59 1.43E-03 -0.61 -0.64 -2.81 Annotated with in-house standards (MS and RI) 
4 Nicotinamide 1444 729/845 1.59 2.60E-02 0.79 0.89 3.08 
Annotated with GMD (MS) and in-house 
standards (RI) 
5 Glyceric acid 1344 929/968 1.58 1.06E-03 -0.49 -0.65 -2.56 Annotated with in-house standards (MS and RI) 
6 2-Hydroxyglutaric acid 1584 900/939 1.56 9.56E-04 -0.66 -0.74 -3.06 Annotated with in-house standards (MS and RI) 
7 Malic acid 1501 904/917 1.55 2.60E-03 -0.61 -0.62 -2.64 Annotated with in-house standards (MS and RI) 
8 Succinic acid 1308 757/793 1.55 7.01E-04 -0.65 -0.78 -3.17 
Annotated with GMD (MS) and in-house 
standards (RI) 
9 Indoleacetic acid 1938 698/793 1.54 8.26E-04 -0.51 -0.68 -2.90 Annotated with in-house standards (MS and RI) 
10 Glutaric acid 1396 888/934 1.52 1.51E-03 -0.56 -0.72 -3.39 Annotated with in-house standards (MS and RI) 
11 Xylose 1702 854/886 1.52 1.88E-02 0.72 0.72 1.62 Annotated with in-house standards (MS and RI) 
12 N-Acetylserine 1498 629/874 1.46 3.98E-03 -0.60 -0.67 -2.18 Annotated with GMD (MS and RI) 
13 2-Hydroxypyridine 1023 832/928 1.44 4.95E-02 0.54 0.69 1.89 Annotated with GMD (MS and RI) 
14 2-Ketoglutaric acid 1570 772/835 1.43 5.01E-03 -0.60 -0.67 -3.44 Annotated with in-house standards (MS and RI) 
15 3-Hydroxymethylglutarate 1615 839/917 1.39 5.03E-03 -0.54 -0.67 -2.26 Annotated with in-house standards (MS and RI) 
16 L-Serine 1375 900/943 1.39 9.12E-03 0.60 0.68 1.49 Annotated with in-house standards (MS and RI) 
17 Gluconic lactone 1914 717/729 1.38 6.10E-03 -0.60 -0.69 -1.66 Annotated with in-house standards (MS and RI) 
18 Tricarballylic acid 1737 774/802 1.35 8.31E-03 -0.50 -0.66 -3.39 Annotated with NIST (MS match only) 







No. Postulated metabolite identity RI 
Similarity 
index 












20 Citric acid 1849 858/863 1.30 1.58E-02 -0.47 -0.61 -4.30 Annotated with in-house standards (MS and RI) 
21 2-Ketoadipic acid 1653 871/928 1.26 1.70E-02 -0.51 -0.61 -6.43 Annotated with in-house standards (MS and RI) 
Marker metabolites with VIP>1, P<0.05 
22 Cadaverine 1868 787/814 1.67 9.07E-03   1.97 Annotated with GMD (MS and RI) 
23 Methylsuccinic acid 1323 851/868 1.48 9.88E-03   -1.63 Annotated with NIST (MS and RI) 
24 Dihydroferulic acid 1883 607/671 1.45 8.46E-03   -1.92 Annotated with NIST (MS and RI) 
25 2-Hydroxyadipic acid 2 2221 718/774 1.32 1.46E-02   -1.99 Annotated with NIST (MS match only) 
26 3,4-Dihydroxybutanoic acid 1449 822/837 1.26 1.57E-02   -1.43 Annotated with NIST (MS and RI) 
27 N-Acetylmethionine 1523 660/672 1.23 4.98E-02   -1.35 Annotated with NIST (MS match only) 
28 Ribonic acid 1823 763/798 1.22 4.23E-02   -1.49 Annotated with NIST (MS and RI) 
29 Pimelic acid 1595 871/893 1.20 3.41E-02   -1.93 Annotated with NIST (MS and RI) 
30 Aconitic acid 1749 859/918 1.18 3.93E-02   -1.53 Annotated with NIST (MS and RI) 
31 Azelaic acid 1790 782/801 1.17 3.11E-02   -1.73 Annotated with NIST (MS and RI) 
32 
Ribonolactone or  
Arabinonic acid lactone 
1644 778/814 1.17 3.87E-02   -1.68 Annotated with NIST (MS match only) 
33 4-Hydroxycinnamic acid 1928 648/712 1.16 3.85E-02   -2.12 Annotated with GMD (MS) and NIST (RI) 
Marker metabolites with VIP>1 and ІrІ>0.6 
34 4-Deoxythreonic acid 1370 808/828 1.46 5.12E-02 0.62 0.79 3.60 Annotated with NIST (MS and RI) 
35 Arabitol 1766 670/737 1.35 8.53E-02 0.59 0.63 1.44 Annotated with in-house standards (MS and RI) 
36 β-Alanine 1439 838/870 1.32 1.21E-01 0.78 0.70 1.58 Annotated with Fiehn (MS match only) 
37 Phenylacetylglycine 1837 789/841 1.32 9.64E-02 0.72 0.80 2.45 Annotated with Fiehn (MS match only) 
38 Creatinine 1559 837/887 1.30 1.21E-01 0.81 0.87 4.53 Annotated with Fiehn (MS) and NIST (RI) 







No. Postulated metabolite identity RI 
Similarity 
index 












40 Urea 1225 814/819 1.22 5.05E-02 0.65 0.76 1.54 Annotated with NIST (MS and RI) 
41 Glycerol-3-phosphate 1787 747/821 1.21 1.29E-01 0.71 0.82 1.55 Annotated with GMD (MS) and NIST (RI) 
42 3-Methylcrotonyl glycine 1535 684/769 1.18 1.47E-01 0.64 0.72 1.53 Annotated with NIST (MS and RI) 
43 Myo-Inositol 2157 948/948 1.18 1.38E-01 0.53 0.71 1.68 Annotated with in-house standards (MS and RI) 







Table 4-2 Faecal transaminitis-related marker metabolites identified 8–24 h post-tacrine administration. 
No. Postulated metabolite identity RI 
Similarity 
index 


















Marker metabolites with VIP>1, P<0.05, ІrІ>0.6 
1 Fructose 2 1937 934/951 1.64 1.49E-02   0.84 0.88 5.30 Annotated with in-house standards (MS and RI) 
2 Fructose 1 1928 945/947 1.61 2.51E-02   0.84 0.88 4.45 Annotated with in-house standards (MS and RI) 
3 L-Glutamic acid 2 1630 798/818 1.54 9.29E-03   0.52 0.62 2.92 Annotated with in-house standards (MS and RI) 
4 N-Acetyl-D-mannosamine 2118 830/835 1.53 1.89E-02   0.68 0.73 7.71 Annotated with Fiehn (MS match only) 
5 L-Alanine 1100 923/943 1.50 2.30E-02   0.61 0.71 4.31 Annotated with NIST (MS and RI) 
6 Sebacic acid 1887 855/883 1.47 2.23E-02   0.71 0.78 2.08 Annotated with NIST (MS and RI) 
7 Docosanoic acid 2633 618/729 1.45 2.71E-02   0.65 0.68 2.10 Annotated with NIST (MS and RI) 
8 Pentadecanoic acid 1944 814/867 1.45 1.82E-02   0.68 0.76 1.96 Annotated with NIST (MS and RI) 
9 Suberic acid 1691 655/666 1.34 4.29E-02   0.61 0.70 1.55 Annotated with NIST (MS and RI) 
10 2-Deoxy-D-ribitol 1638 817/825 1.32 1.86E-02   0.75 0.73 1.70 Annotated with NIST (MS match only) 
11 Azelaic acid 1789 832/857 1.31 4.32E-02   0.58 0.66 1.68 Annotated with NIST (MS and RI) 
12 Butane-1,3-diol 1461 794/870 1.19 9.82E-03   -0.45 -0.64 -1.53 Annotated with NIST (MS match only) 
13 Lactamide 1142 840/876 1.14 3.01E-02   -0.65 -0.61 -2.05 Annotated with NIST (MS match only) 
14 Butane-2,3-diol 1047 911/922 1.11 2.04E-02   -0.57 -0.65 -6.25 Annotated with NIST (MS match only) 
Marker metabolites with VIP>1, P<0.05 
15 Tetradecanoic acid 1845 712/855 1.22 9.76E-03     -2.77 Annotated with NIST (MS and RI) 
16 Maltotriose 1 3448 804/816 1.19 1.07E-02     -6.59 Annotated with NIST (MS match only) 
17 Maltotriose 2 3457 737/746 1.16 1.27E-02     -5.78 Annotated with NIST (MS match only) 
18 Mannitol 1 1998 920/922 1.16 1.54E-02     2.79 Annotated with NIST (MS and RI) 
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20 β-Hydroxybutyric acid 1159 917/930 1.13 2.84E-02     -3.20 Annotated with NIST (MS and RI) 
Marker metabolites with VIP>1 and ІrІ>0.6 
21 Phosphoric acid 1276 879/889 1.48 5.97E-02   0.59 0.70 2.28 Annotated with Fiehn (MS) and NIST (RI) 
22 L-Isoleucine 1304 893/894 1.44 9.22E-02   0.59 0.69 10.93 Annotated with NIST (MS and RI) 
23 2-Methylsuccinic acid 1322 889/893 1.42 1.06E-01   0.75 0.82 1.66 Annotated with NIST (MS and RI) 
24 Heptadecanoic acid 2141 745/787 1.40 5.06E-02   0.54 0.68 1.84 Annotated with NIST (MS and RI) 
25 L-Tyrosine 2 1950 713/728 1.40 1.05E-01   0.60 0.71 4.73 Annotated with GMD (MS) and NIST (RI) 
26 Threonine 1405 939/941 1.39 1.06E-01   0.57 0.67 4.61 
Annotated with in-house standards (MS) and 
GMD (RI) 
27 Chenodeoxycholic acid 1 3267 617/743 1.39 1.06E-01   0.58 0.69 3.57 Annotated with NIST (MS match only) 
28 L-Valine 1224 927/928 1.38 1.25E-01   0.60 0.71 13.73 Annotated with NIST (MS and RI) 
29 Mannitol 2 2005 883/898 1.38 1.18E-01   0.57 0.70 3.23 Annotated with in-house standards (MS and RI) 
30 L-Tryptophan 2218 612/671 1.37 1.03E-01   0.63 0.75 2.93 Annotated with NIST (MS) and HMDB (RI) 
31 Glutaric acid 1396 948/950 1.37 8.94E-02   0.61 0.65 1.49 Annotated with in-house standards (MS and RI) 
32 Linoleic acid 2220 764/794 1.37 1.24E-01   0.72 0.82 2.76 Annotated with NIST (MS and RI) 
33 L-Serine 1254 866/870 1.37 1.24E-01   0.54 0.63 4.94 Annotated with NIST (MS and RI) 
34 Ribitol 1780 704/784 1.36 8.16E-02 0.45 0.62 0.70 0.75 1.62 Annotated with in-house standards (MS and RI) 
35 Hydrocaffeic acid 1949 704/723 1.36 8.08E-02   0.55 0.68 2.44 Annotated with GMD (MS) and NIST (RI) 
36 L-Phenylalanine 1626 848/879 1.35 1.41E-01   0.59 0.71 10.16 Annotated with NIST (MS) and GMD (RI) 
37 Mannose 2 1953 927/941 1.35 1.31E-01   0.69 0.66 5.72 Annotated with in-house standards (MS and RI) 
38 Myo-Inositol 2157 953/954 1.34 1.14E-01   0.61 0.73 3.89 Annotated with in-house standards (MS and RI) 
39 L-Methionine 2 1518 868/869 1.34 1.32E-01   0.56 0.68 3.71 Annotated with Fiehn (MS) and NIST (RI) 
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41 4-Hydroxyphenylethanol 1568 612/632 1.33 1.28E-01   0.76 0.81 3.21 Annotated with GMD (MS) and NIST (RI) 
42 L-Lysine 1951 785/805 1.33 1.31E-01   0.53 0.64 2.97 Annotated with GMD (MS match only) 
43 Chenodeoxycholic acid 2 3303 733/854 1.33 1.36E-01   0.61 0.75 4.81 Annotated with GMD (MS match only) 
44 2-Aminobutyric acid 1176 836/896 1.32 1.56E-01   0.53 0.63 30.62 Annotated with NIST (MS and RI) 
45 L-Glutamic acid 1 1524 858/865 1.31 1.63E-01   0.56 0.67 12.83 Annotated with Fiehn (MS) and HMDB (RI) 
46 L-Leucine 1281 888/891 1.31 1.64E-01   0.52 0.63 10.94 
Annotated with in-house standards (MS) and 
GMD (RI) 
47 3-Deoxyhexitol 1877 742/802 1.30 9.50E-02   0.60 0.62 2.49 Annotated with NIST (MS match only) 
48 Oleic acid 2219 865/885 1.30 1.41E-01   0.55 0.62 2.45 Annotated with NIST (MS and RI) 
49 L-Tyrosine 1 1873 684/736 1.29 1.76E-01   0.54 0.65 56.08 Annotated with GMD (MS and RI) 
50 3-Hydroxypyridine 1114 830/850 1.29 1.45E-01   0.65 0.63 1.77 Annotated with Fiehn (MS) and GMD (RI) 
51 Pyruvic acid 1030 812/824 1.28 1.73E-01   0.52 0.65 4.98 Annotated with Fiehn (MS) and HMDB (RI) 
52 L-Methionine 1 1386 803/823 1.28 1.70E-01   0.57 0.70 3.57 Annotated with Fiehn (MS match only) 
53 5-Aminovaleric acid 1640 897/899 1.27 1.82E-01   0.55 0.67 17.51 Annotated with Fiehn (MS) and HMDB (RI) 
54 6-Deoxy-D-glucose 2 1782 787/824 1.27 1.78E-01   0.60 0.72 5.00 Annotated with Fiehn (MS match only) 
55 2-Hydroxy-3-methylvaleric acid 1247 876/933 1.27 1.82E-01   0.60 0.72 17.15 Annotated with NIST (MS and RI) 
56 Lithocholic acid 3248 810/845 1.27 1.69E-01   0.68 0.80 2.81 Annotated with NIST (MS match only) 




2716 726/746 1.25 1.42E-01   0.57 0.67 3.04 Annotated with NIST (MS and RI) 
59 β-Alanine 1439 885/886 1.25 1.93E-01   0.57 0.69 5.60 Annotated with Fiehn (MS) and HMDB (RI) 
60 N-Butylamine 1112 827/847 1.24 1.78E-01   0.60 0.74 2.06 Annotated with NIST (MS match only) 
61 4-Hydroxybutyric acid 1234 918/922 1.22 5.42E-02 0.28 0.68   1.43 Annotated with NIST (MS and RI) 
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1166 742/871 1.20 2.04E-01   0.58 0.70 9.59 Annotated with NIST (MS match only) 
65 Indoleacetic acid 1938 633/642 1.19 2.05E-01   0.66 0.55 1.39 Annotated with Fiehn (MS) and NIST (RI) 
66 Mannose 1 1943 777/785 1.19 2.53E-01   0.70 0.65 6.15 Annotated with in-house standards (MS and RI) 
67 Tyramine 1926 833/842 1.16 2.37E-01   0.59 0.72 19.26 Annotated with Fiehn (MS) and HMDB (RI) 
68 Linolenic acid 2206 851/887 1.09 2.90E-01   0.65 0.60 3.52 Annotated with NIST (MS and RI) 
69 Arachidonic acid 2355 882/918 1.09 2.25E-01   0.48 0.64 1.89 Annotated with NIST (MS and RI) 
70 Melibiose 2869 814/843 1.09 3.67E-01   0.65 0.60 1.99 Annotated with Fiehn (MS) and HMDB (RI) 
71 Cholesterol 3161 837/840 1.06 2.72E-01   0.49 0.63 2.38 Annotated with NIST (MS and RI) 
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56% of the urinary marker metabolites and 45% of the faecal marker metabolites 
were of co-metabolic origin (Figure 4-5) (60, 71-73, 229). The classification of 
the remaining metabolites into microbial, endogenous and dietary origins is as 
shown in Figure 4-5.  
 
Figure 4-5 Origins of the (A) urinary and (B) faecal marker metabolites.  
The marker metabolites were classified as co-metabolites by comparison with the list of 
reported co-metabolites identified in literature (60, 71-73, 229). The remaining metabolites 
(categorised as ‘Others’) were classified to be of microbial, endogenous and/or dietary origin 
using the HMDB database and each metabolite may be from more than one origin. Value in 
brackets refers to number of metabolites.  
 
These identified marker metabolites were subsequently examined for their 
associated metabolic pathways and potential mechanistic relationship with 
tacrine-induced transaminitis. Table 4-3 and Table S3 illustrate the pathways 
listed in KEGG database in which 3 or more of these markers metabolites are 
found to be associated.   
A         B 
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Table 4-3 Exemplary metabolic pathways listed in KEGG database in which 3 or 
more urinary or faecal marker metabolites are found to be associated. 


















C00022 Pyruvate Faeces  4.98 
C00188 L-Threonine Faeces  4.61 
C00041 L-Alanine Faeces  4.31 
C00047 L-Lysine Faeces  2.97 
C00025 L-Glutamate Faeces  2.92 
C00989 4-Hydroxybutanoic acid Faeces  1.43 
C00642 4-Hydroxyphenylacetate Faeces  1.40 
C05852 2-Hydroxyphenylacetate Urine 5.13  
C00086 Urea Urine 1.54  
C00417 Cis-Aconitate Urine -1.53  
C00198 D-Glucono-1,5-lactone Urine -1.66  
C00122 Fumarate Urine -1.98  
C00258 D-Glycerate Urine -2.56  
C00149 (S)-Malate Urine -2.64  
C00026 2-Oxoglutarate Urine -3.44  
C00158 Citrate Urine -4.30  
C00322 2-Oxoadipate Urine -6.43  
C00042 Succinate Urine & Faeces -3.17 15.37 
C00065 L-Serine Urine & Faeces 1.49 4.94 




C00183 L-Valine Faeces  13.73 
C00123 L-Leucine Faeces  10.94 
C00407 L-Isoleucine Faeces  10.93 
C00079 L-Phenylalanine Faeces  10.16 
C00159 D-Mannose Faeces  5.72 
C00188 L-Threonine Faeces  4.61 
C00041 L-Alanine Faeces  4.31 
C00047 L-Lysine Faeces  2.97 
C00025 L-Glutamate Faeces  2.92 
C00392 Mannitol Faeces  2.79 
C00009 Orthophosphate Faeces  2.28 
C05402 Melibiose Faeces  1.99 
C01835 Maltotriose Faeces  0.15 
C00181 D-Xylose Urine 1.62  
C00093 Glycerol 3-phosphate Urine 1.55  
C00086 Urea Urine 1.54  
C00065 L-Serine Urine & Faeces 1.49 4.94 
C00137 Myo-Inositol Urine & Faeces 1.68 3.89 
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and absorption (15) 
C00483 Tyramine Faeces  19.26 
C00183 L-Valine Faeces  13.73 
C00123 L-Leucine Faeces  10.94 
C00407 L-Isoleucine Faeces  10.93 
C00079 L-Phenylalanine Faeces  10.16 
C00082 L-Tyrosine Faeces  4.73 
C00188 L-Threonine Faeces  4.61 
C00041 L-Alanine Faeces  4.31 
C00073 L-Methionine Faeces  3.71 
C00047 L-Lysine Faeces  2.97 
C00078 L-Tryptophan Faeces  2.93 
C00025 L-Glutamate Faeces  2.92 
C01672 Cadaverine Urine 1.97  
C00099 Beta-Alanine Urine & Faeces 1.58 5.60 




C00079 L-Phenylalanine Faeces  10.16 
C00022 Pyruvate Faeces  4.98 
C00082 L-Tyrosine Faeces  4.73 
C05332 Phenethylamine Faeces  4.34 
C00642 4-Hydroxyphenylacetate Faeces  1.40 
C05852 2-Hydroxyphenylacetate Urine 5.13  
C05598 Phenylacetylglycine Urine 2.45  
C00122 Fumarate Urine -1.98  
C00811 4-Coumarate Urine -2.12  




C00483 Tyramine Faeces  19.26 
C00022 Pyruvate Faeces  4.98 
C00082 L-Tyrosine Faeces  4.73 
C06044 4-Hydroxyphenylethanol Faeces  3.21 
C10447 3,4-
Dihydroxyphenylpropanoate 
Faeces  2.44 
C00642 4-Hydroxyphenylacetate Faeces  1.40 
C00122 Fumarate Urine -1.98  




C00022 Pyruvate Faeces  4.98 
C00417 Cis-Aconitate Urine -1.53  
C00122 Fumarate Urine -1.98  
C00149 (S)-Malate Urine -2.64  
C00026 2-Oxoglutarate Urine -3.44  
C00158 Citrate Urine -4.30  
C00042 Succinate Urine & Faeces -3.17 15.37 
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C06427 Linolenic acid Faeces  3.52 
C01595 Linoleate Faeces  2.76 
C00712 (9Z)-Octadecenoic acid Faeces  2.45 
C08281 Docosanoic acid Faeces  2.10 
C01530 Octadecanoic acid Faeces  1.93 
C00219 Arachidonate Faeces   1.89 
ko04976  
Bile secretion (4) 
C02528 Chenodeoxycholate Faeces  3.57 
C03990 Lithocholic acid Faeces  2.81 
C00187 Cholesterol Faeces  2.38 




C00078 L-Tryptophan Faeces  2.93 
C00322 2-Oxoadipate Urine -6.43  




C00712 (9Z)-Octadecenoic acid Faeces  2.45 
C01530 Octadecanoic acid Faeces  1.93 




C00009 Orthophosphate Faeces  2.28 
C00122 Fumarate Urine -1.98  




In this study, global metabonomics was used to investigate the role of host-gut 
microbiota interaction in tacrine-induced transaminitis through profiling the 
metabolites present within the urine and faecal matrices. Urine is frequently 
analysed in metabonomic investigation as it is non-volume-restricted and offers 
the valuable possibilities of monitoring time-related metabolic perturbation (82, 
85). Being an integrative biofluid, the urinary metabolic profiles enable scientists 
to capture information related to drug-induced toxicity as well as the 
combinatorial metabolic activity of the host and gut microbiota. Faecal matter 
was also analysed as the intimate association of this biological matrix with gut 
microbiota made it a valuable matrix to elucidate potential marker metabolites 
related with host-gut microbiota association. 
In metabonomics, quality control and data validation are highly important to 
ensure the accuracy and reliability of the data. This is especially pertinent for 
large scale studies involving multiple samples as described in this chapter. In this 
aspect, we incorporated QCs and IS to detect and correct for sample derivatisation 
variation and instrument drift which might arise inevitably due to the laborious 
sample preparation procedures and long analysis period. The results of our 
validation revealed low analytical variation and fueled our confidence that 
variations observed in the study were of biological origin. 
4.1.1 Metabonomics Revealed Unique Metabotypes associated with Tacrine-
induced Transaminitis 
Our data revealed that tacrine administration resulted in significant and dynamic 
changes in the rat metabolomes. Using PCA, the huge amount of information 
pertaining to the abundance of metabolites that characterise a single urine or 
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faecal sample was reduced to a single data point on the PCA scores plot. The 
proximity of each of these points reflects the degree of similarity in metabolomes 
among the rats. As shown in the PCA results, the basal urine and faecal 
metabolomes of all rats were similar prior to tacrine administration. Upon 
treatment with tacrine, the metabolomes of the responder groups (especially the 
extreme responders) were found to deviate from the non-responders and vehicle-
dosed rats. In addition, there was a time-dependent clustering of the metabolomes 
of extreme responders when compared to the non-responders. Further 
investigation of this clustering pattern unfolded its associated relationship with 
transaminase levels, whereby the peak transaminase elevations occurred at the 
same time when extreme responders demonstrated the greatest metabolome 
differences with non-responders, and the fall to normal transaminase levels 
occurred when there was a corresponding reduction in metabolome differences. 
As extreme responders were compared to the non-responders instead of vehicle-
dosed rats, confounding possibilities due to drug administration were removed. 
Hence, our observed metabolic trajectory of extreme responders strongly 
suggested that the metabolome differences between extreme responders and non-
responders were associated with tacrine-induced transaminitis and that the 
metabolic trajectory follows the recovery from transient liver injury.  
Subsequently, PLS-DA analyses of the extreme responders and non-responders at 
8–24 h were performed to screen for transaminitis-related marker metabolites. 
While both the PCA and PLS-DA scores plots revealed characteristic urinary 
metabolome distinguishing the extreme responders and non-responder at 8–24 h, 
the PLS-DA model failed the validation criteria. We believed that this might be 
attributed to the small number of rats in each toxicity phenotype and the complex 
nature of the in vivo study that was subjected to inherent physiological variability. 
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Considering the majority of the R2 and Q2 values of the permutated models were 
still below the original R2 and Q2 of the model and the good clustering trend 
observed between the extreme responders and non-responders in PCA scores 
plots, we proceeded to investigate the differentiating urinary marker metabolites 
derived from this PLS-DA model with caution. For the faecal dataset, one 
extreme responder (T08) was removed from both the PCA and PLS-DA analyses 
of the 8–24 h time period as experimental records pointed to a likelihood of 
sample derivatisation error. Good performance statistics (R2X=0.462, R2Y=0.988 
and Q2 (cum)=0.725) were achieved for this PLS-DA model. Combinatorial 
analyses with t-test and Pearson’s correlation were performed to consolidate a list 
of related marker metabolites strongly associated with tacrine-induced 
transaminitis. 
4.1.2 Transaminitis-related Marker Metabolites    
One of the proposed mechanisms behind tacrine-induced hepatotoxicity is the 
induction of mitochondria dysfunction by tacrine (154, 156). Citrate acid cycle 
and oxidative phosphorylation are important metabolic pathways involved in the 
generation of energy in the form of adenosine triphosphate. In eukaryotic cells, 
these metabolic processes occur within the mitochondria. Our study is the first 
metabonomics investigation which revealed an overall depletion in citrate acid 
cycle and oxidative phosphorylation intermediates such as citrate, cis-aconitate, 2-
oxoglutarate, succinate, fumarate and malate in the urine of extreme responders 
associated with tacrine-induced transaminitis. This finding is consistent with the 
earlier mechanistic studies which demonstrated the adverse impact of tacrine on 
the hepatic mitochondria. The perturbation of these key pathways may contribute 
towards impairment of energy generation characterised by the decline in 
generation of adenosine triphosphate observed in previous reports (154, 156). Our 
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work emphasised the ability of metabonomics to detect metabolic perturbation 
associated with mitochondria impairment (232-234), an important mechanism in 
drug-induced liver injury.   
In addition, we uncovered a higher excretion of cholesterol, chenodeoxycholic 
acid and lithocholic acid in the faeces of extreme responders. Chenodeoxycholic 
acid is one of the two bile acids formed from cholesterol in the liver and they are 
excreted through the bile canaliculi into the intestine. Lithocholic acid is a 
hydrophobic secondary bile acid that is formed in the intestines by bacterial 7α-
dehydroxylation of chenodeoxycholic acid (235). Members of the Bacteroides, 
Clostridium and Eubacterium genera are known to possess 7α-dehydroxylation 
activity (236, 237). Typically, about 90-95% of the bile acids secreted in bile are 
reabsorbed in the distal ileum back to the liver via a process named enterohepatic 
recirculation (238). The identification of these bile acids as marker metabolites 
distinguishing the toxicity phenotypes suggested the disturbances in bile acid 
metabolism (239) and involvement of enterohepatic recirculation in tacrine-
induced hepatotoxicity, corroborating with our findings in Chapter 2.   
4.1.3 Implication of Gut Microbiota in Tacrine-induced Hepatotoxicity  
It is noteworthy that 49.5% of the overall transaminitis-related marker metabolites 
identified are of co-metabolic origin (60, 71-73, 229) and several of the remaining 
markers are of microbial origin. This finding shed important insights on the 
implication of the gut microbiota in accounting for the susceptibility of the LH 
rats to tacrine-induced transaminitis. Given the pervasive metabolic influence of 
the gut microbiota on the global metabolic phenotype (60, 71-73, 229), this 
metabolic signature that distinguished the toxicity phenotypes suggested a 
structural divergence in the gut microbiota community between the extreme 
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responders and the non-responders and a differential functional metabolic activity 
between their gut microbiota following administration of tacrine.  
A majority of the faecal marker metabolites associated with the toxic phenotypes 
are amino acids (e.g. isoleucine, threonine and phenylalanine), fatty acids (e.g. 
linolenic acid, docosanoic acid and arachidonic acid) and saccharides (e.g. 
melibiose, N-acetyl-D-mannosamine). They are mainly derived from the rat feeds 
or from metabolism of proteins, lipids or carbohydrates in the diet. Not only do 
these metabolites serve as important nutrients and precursors for the metabolic 
activities of the rats, they are essential sources of carbon and energy for the gut 
microbiota. Many of these nutritional marker metabolites are also substrates of 
transporters such as fatty acid transport proteins (240) and ABC transporters 
which facilitate uptake of nutrients into prokaryotic cells (241, 242). The 
accumulation of these marker metabolites in the faecal matter further lend support 
to our speculation of a difference in microflora species colonising the gut of rats 
experiencing transaminitis from the non-responders. We postulate that as the 
nutritional requirement of different bacteria differs, this might hence contribute to 
variation in nutrient uptake and subsequently, the difference was reflected in the 
amount of nutrients excreted into the faeces. For example, lactic acid bacteria 
such as Lactobacillus are unable to synthesise many amino acids such as 
isoleucine and threonine, thereby their growth would mandate the use of amino 
acids from the diet (243). As such, they possess several peptidases to catabolise 
proteins to generate these metabolically important amino acids and amino acid 
transporters to import them intracellularly (244-246). While bacteria species like 
Escherichia coli are able to assimilate amino acids from the external environment, 
they are also capable of synthesising all the twenty amino acids (247). Therefore, 
their requirement of dietary amino acids might be lower. We postulate the 
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accumulation of amino acids in faeces of rats which experienced transaminitis 
might be attributed to them harbouring more bacteria species such as Escherichia 
coli with lower dietary amino acid requirement than bacteria such as lactic acid 
bacteria which utilise more amino acids. This is consistent with studies that 
observed perturbation of faecal amino acid levels when the gut microbiota was 
altered using antibiotics (60, 71).  
While our hypothesis appears to be logical and coherent, we cannot discount other 
factors that might influence the levels of faecal amino acids such as intestinal 
absorption of amino acids, gut microbial metabolism of amino acids into keto-
acids or extraction processes that release amino acids from gut microbes (71, 247, 
248). All these factors contribute towards the complexity in interpreting the 
amino acids levels in the faecal metabolomes. Indeed, our investigation identified 
elevated levels of metabolites like phenethylamine, p-hydroxyphenylacetic acid 
and indoleacetic acid in the faeces of extreme responders compared to non-
responders which are major fermentation products of phenylalanine, tyrosine and 
tryptophan respectively. Several Clostridium and Bacteroides species (e.g. 
Clostridium bartlettii, Bacteroides thetaiotaomicron, Bacteroides eggerthii, 
Bacteroides ovatus, Bacteroides fragilis and Parabacteroides distasonis) were 
reported to be responsible for the metabolism of these aromatic amino acids 
(249). Interestingly, we observed a corresponding 2.5-fold higher urinary 
excretion of phenylacetylglycine in the extreme responders. Phenylacetylglycine 
is a glycine conjugate of phenylacetic acid which is formed from the metabolism 
of phenylalanine (73, 249, 250). Elevated urinary phenylacetylglycine has been 
associated with variability in gut microbiota and is a potential marker metabolite 
for drug-induced phospholipidosis (231, 251). The high urinary 
phenylacetylglycine in extreme responders corroborated with report that 
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demonstrated tacrine-induced phospholipidosis in rat hepatocytes (154). In 
addition, the concordance of a higher extent of phenylalanine metabolism in the 
gastrointestinal tract of the extreme responders with an increase Phase II glycine 
conjugation of the metabolite generated by the gut microbiota to form 
phenylacetylglycine in the liver further underscored the influential role of gut 
microbiota on the metabolic capability of the host and the significant interaction 
between the host and gut microbiota (73).   
Several long chain fatty acids such as oleic acid, stearic acid (octadecanoic acid) 
and linoleic acid were found to be in higher abundance in the faeces of the 
extreme responders. These fatty acids were reported to possess either bactericidal 
or bacteriostatic activities through several mechanisms such as interfering with 
energy production or impeding uptake of nutrients like amino acids into the cell 
(252-254). Considerable variation exists with regards to the susceptibility of 
gram-positive and gram-negative bacteria to these long chain fatty acids. Gram-
negative bacteria such as Escherichia coli generally have higher resistance to the 
toxic effects of long chain fatty acids compared to the former group. This is 
attributed to the presence of a lipopolysaccharide layer in the cell envelope which 
prevents fatty acids accumulation at the cytoplasmic membrane at inhibitory 
concentrations (255) and their ability to oxidise these fatty acids (256). The 
detection of elevated levels of these fatty acids as marker metabolites in rats 
highly susceptible to tacrine-induced transaminitis suggests the likelihood of a 
different gut microbial community in these rats owing to the biological properties 
of these fatty acids. 
Different bacteria possess different metabolic capabilities and they could affect 
drug disposition and toxicity either directly or indirectly via interaction with the 
host. Our study indirectly points to a disturbance in gut bacterial species during 
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transaminitis based on marked differences in the levels of transaminitis-related 
marker metabolites such as co-metabolites, nutritional sources or fermentation 
products whose abundances are subjected to the composition and metabolic 
activities of gut microbiota. However, further studies are required to confirm our 
postulation of a perturbed gut microbiota in the responder rats and elucidate the 
mechanism of the interaction between the host and gut microbiota in tacrine-
induced transaminitis.  
 Chapter Conclusion 4.2
Global GC/TOFMS metabonomic profiling of the urinary and faecal 
metabolomes of tacrine-dosed LH rats revealed transaminitis-related marker 
metabolites connected with mitochondrial dysfunction induced by tacrine. In 
addition, the distinct abundance of faecal bile acids in extreme responders 
suggested novel mechanisms such as the involvement of bile acid metabolism or 
enterohepatic recirculation in tacrine-induced hepatotoxicity. Collectively, many 
transaminitis-related marker metabolites point to the possibility of gut microbiota 
perturbation associated with the variable susceptibility to tacrine-induced 
transaminitis. Integrating these findings together with the toxicokinetics profiles 
of extreme responders in Chapter 2 and disposition-related gene expression study 
in Chapter 3, our work in the current chapter raised an exciting possibility of the 
perturbation of gut microbiota or its associated microbial metabolic activity in rats 
exhibiting tacrine-induced transaminitis.  
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 Chapter 5 The Gut Microbiome: Implications in Tacrine-
induced Transaminitis 
 Chapter Summary 5.1
Background: Dysbiosis in the human gut microbiome has been associated with 
several pathological diseases as well as unusual metabolic responses to drugs. 
Tacrine, an Alzheimer’s disease drug, exhibits significant inter-individual 
variability in its pharmacokinetic and hepatotoxicity profiles of yet unknown 
etiology. Clinically, tacrine induced elevation in AST and ALT in about 50% of 
patients. Our study conducted on LH rats recapitulated transaminitis similar to 
humans. Longitudinal time-based pharmacokinetic, toxicology and genomic 
studies demonstrated a 3.3-fold higher systemic exposure of tacrine and double 
Cmax phenomenon in extreme responders, revealing enhanced enterohepatic 
recirculation of deglucuronidated tacrine, not attributable to variation in the host 
disposition gene expression (Chapter 2 and 3). Metabonomics uncovered 
metabolites of microbial and co-microbial origins and further underscored the 
roles of gut microbiota in tacrine-induced transaminitis (Chapter 4).  
Objective: This chapter aims to profile the gut microbiome to find plausible 
association to tacrine-induced transaminitis.  
Methodology: Targeted gut microbiome profiling was performed using qPCR to 
profile target bacterial groups, namely Clostridium coccoides-Eubacterium 
rectale, Clostridium leptum, Enterobacteriaceae, Bacteroides-Prevotella-
Porphyromonadaceae, Lactobacillus and Erysipelotrichaceae in the pre-dose 
(−24 to 0 h) and post-dose (8–24 h) faecal samples of these LH rats. A paired-end 
(2×250bp) 16S rRNA gene sequencing of the V3-4 region of the gut microbiome 
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of LH rat faecal samples was performed to determine microbiome perturbation 
associated with tacrine-induced transaminitis.  
Results and Discussion: qPCR analyses of target bacterial groups revealed no 
statistical difference in the intrinsic (–24 to 0 h) and post-dose (8–24 h) gut 
microbiome among all tacrine-dosed rats. However, a noticeable elevation in the 
Enterobacteriaceae cell counts was observed in the extreme responders 8–24 h 
following tacrine’s administration compared to the non-responders. Ratio analysis 
of pre-dose Enterobactericeae:Lactobacillus (E/L) revealed an association of 
higher E/L ratio with severe transaminitis. For example, at the 8–24 h time period 
corresponding to the peak of transaminitis, we observed a significantly higher E/L 
ratio in extreme responders vs. non-responders (P<0.05, Kruskal-Wallis test with 
Dunn’s post hoc test). 16S metagenomics also uncovered an enrichment of β-
glucuronidase-producing bacterial genera such as Bacteroides and Blautia in 
extreme responders compared to non-responders at the same period (P<0.05, 
Mann-Whitney U test). Lactobacillus, reported to inhibit bacterial β-
glucuronidase activity and associated with hepatoprotection, was found to be 
lower in abundance in the extreme responders than non-responders throughout the 
study (P<0.05 at 0–8 h, Mann-Whitney U test).  
Conclusion: Our findings delineated greater deglucuronidation propensities in 
extreme responders based on differential faecal abundance of bacteria known to 
possess or modulate β-glucuronidase activities. Together with the evidences 
reported in the earlier chapters, we conclude that inter-individual variation of gut 





 Chapter Introduction 5.2
Enterohepatic recirculation is a common mechanism leading to double or multiple 
peaking in pharmacokinetic profiles (163). We postulated that the glucuronidated 
metabolites of tacrine can be secreted into the intestine via biliary secretion, 
where it can be deconjugated by bacteria and be reabsorbed as tacrine via 
enterohepatic recirculation (Chapter 2), thereby accounting for the double Cmax 
profile observed. The increased exposure of tacrine in the liver may have resulted 
in transaminitis. However, studies from previous chapters only provided indirect 
evidences of the contribution of the gut microbiota on tacrine-induced 
transaminitis, and the direct association of gut microbial communities to 
transaminitis has not been established. 
To bridge this knowledge gap, this chapter aims to elucidate the plausible roles of 
gut microbiota in tacrine-induced transaminitis by profiling the gut microbiome in 
LH rat faeces. To address this objective, we first characterised the gut 
microbiome composition of pre-dosed LH rats to facilitate comparison with the 
post-dosed profiles. Secondly, we compared the inter-species variation in gut 
microbiome composition between LH rats and humans to understand the clinical 
translatability of the findings. Thirdly, gut microbiota perturbation associated with 
transaminitis was studied to gain insight into the probable bacterial taxa 
responsible for tacrine-induced hepatotoxicity. These gut microbiome were 
studied using targeted qPCR and 16S rRNA gene sequencing.    
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 Materials and Methods 5.3
5.3.1 Materials 
The following kits and reagents were used in the study: QIAamp DNA Stool 
Minikit (Qiagen, CA, USA); Quant-iT™ PicoGreen® dsDNA Reagent 
(Invitrogen, CA, USA); KAPA HiFi Hotstart Readymix (Kapa Biosystems, MA, 
USA); Agencourt® AMPure® XP (Beckman Coulter Genomics, CA, USA); 
Nextera® XT DNA Sample Prep Kit (Illumina, San Diego, CA, USA); Nextera® 
XT Index Kit (Illumina, San Diego, CA, USA); MiSeq Reagent v2 500 cycles Kit 
(Illumina, San Diego, CA, USA); RNAlater-ICE (Ambion, Carlsbad, CA, USA); 
Tris-EDTA buffer (TE buffer) (pH 8.0) (Tiagen, Beijing, China); RNase-free 
water (Life Technologies, Gaithersburg, MD); E.Z.N.A. Plasmid mini-kit I 
(Omega Bio-tek, Doraville, GA, USA). Escherichia coli ATCC 11775 and 
Lactobacillus delbrueckii ATCC 9649 were obtained from ATCC (Rockville, 
MD, USA). XL1-blue competent Escherichia coli cells were obtained from 
Stratagene (La Jolla, CA, USA). 425–600 µM acid-washed glass beads and 
ethidium bromide were purchased from Sigma-Aldrich (Sigma, St. Louis, MO, 
USA). 10× DNA loading dye, Gene Ruler 100 bp DNA Ladder and Maxima 
SYBR Green/ROX qPCR Master Mix (2×) were obtained from Thermo Scientific 
(Pittsburgh, PA, USA). Luria-Bertani (LB) broth was obtained from BD (Sparks, 
MD, USA), nutrient agar/broth from Oxoid (Basingstoke, Hampshire, England) 
and MRS broth from Merck (Darmstadt, Germany). SeaKem ® LE Agarose was 
obtained from Cambrex Bio Science (Rockland, ME, USA).   
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5.3.2 Faecal Preparation, DNA Isolation and Quantification 
84 LH rat faecal samples collected from the four toxicity phenotypes at –24 to 0 
h, 0–8 h, 8–24 h, 72–96 h (Table S4) and 24 faecal samples collected from the 
controls at time periods of –24 to 0 h and 8–24 h, were used for DNA isolation. 
All faecal sample preparations were performed on dry ice. Any food debris 
adhering to the faecal pellets were removed using forceps. Pellets were chilled at 
−80°C for 15 min, pounded with a pestle and mortar until loose powder was 
formed and further mixed with a spatula. A 100 mg aliquot of the faecal sample 
was weighed and added into 1 mL of RNAlater-ICE pre-chilled to −80°C and 
kept at −20°C until further use. 
Microbial DNA was isolated using the QIAamp DNA Stool Minikit by following 
a modified Stool Pathogen Detection protocol to maximise DNA extraction. The 
RNAlater-ICE supernatant was decanted from the 100 mg faecal aliquot 
following centrifugation at 20,000 g for 3 min at 25˚C. Faecal samples were 
homogenised with a handheld motorised pestle with 1.4 mL of stool lysis buffer, 
which was added in two volumes to prevent spillage. To increase extraction yield, 
400 µL of supernatant was used instead of 200 µL, with a corresponding doubling 
of the required volumes of proteinase K, lysis buffer and ethanol. The lysate was 
then completely applied to the QIAamp spin column in two steps, with each step 
subjecting half of the lysate to centrifugation at 20,000 g for 1 min and removal of 
filtrate after centrifugation. DNA was then eluted with 200 µL of elution buffer 
by centrifugation at 20,000 g for 1 min. 
Isolated DNA was checked for purity using Nanodrop 2000 (Nanodrop 
Technologies, Wilmingtom, DE, USA) to assess 260/280 and 260/230 values. 
Concentration of double-stranded DNA (dsDNA) was quantified using Quant-iT 
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PicoGreen kit (257). Each sample was diluted to 50 ng/µL and 5 ng/µL with 
RNase-free water. 
5.3.3 Targeted Gut microbiome Profiling using qPCR 
5.3.3.1 Selection of Target Bacterial Groups 
The predominant bacteria present in the rat gut microbiome were identified 
through literature review. Clostridium coccoides and Clostridium leptum are 
abundant in both rat and human gut microbiome and Enterobacteriaceae, 
Porphyromonadaceae, Lactobacillus and Turicibacter are abundant in the rat gut 
microbiome (118, 126, 258-260). These 6 target bacterial groups were selected 
for gut microbiome profiling.   
5.3.3.2 Bacterial Reference Strains  
The bacterial reference strains used as positive controls and as DNA calibrators 
for their respective target bacterial groups are as summarised in Table 5-1. Two 
sources, either plasmid or genomic DNA, were used for calibration depending on 
the reference species. Plasmid DNA was used for bacteria that are difficult to 
obtain or culture. 
Table 5-1 Reference species, strain, target bacterial group and sources of DNA 
for calibration.  










ATCC 27766 Clostridium leptum 
subgroup 
Plasmid 
Escherichia coli ATCC 11775 Enterobacteriaceae Genomic 





ATCC 9649 Lactobacillus Genomic 
Turicibacter 
sanguinis 
MOL361 Erysipelotrichaceae Plasmid 
ATCC refers to American Type Culture Collection and DSM is an abbreviation associated 
with German Collection of Microorganisms and Cell Cultures. 
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5.3.3.3 Culture Conditions of Escherichia coli and Lactobacillus delbrueckii 
Escherichia coli was cultured in nutrient agar/broth at 37˚C for 24 h under aerobic 
condition. Lactobacillus delbrueckii was cultivated in MRS broth at 37˚C for 48 h 
in an aerobic incubator with 5% carbon dioxide. Serial 10-fold dilutions of the 
cultures were prepared and 100 µL of each dilution were plated in triplicates and 
incubated subsequently under the above conditions. Cultural counts in colony 
forming units (CFU) were determined in triplicate.  
5.3.3.4 Extraction and Purification of Genomic DNA from Bacterial Cultures  
Following determination of CFU, broth suspensions of the respective reference 
bacteria were centrifuged to obtain cell pellets, followed by cell lysis using Tris-
sodium deocedyl sulphate solution and mechanical disruption using 425-600 µM 
acid-washed glass beads and Mini Bead-Beater 8 (Biospec, Bartlesville, OK, 
USA). Proteins and cell debris were separated from DNA using chloroform-
isoamyl alcohol-ethanol (80:4:16) extraction. The extracted DNA in the 
supernatant was subsequently precipitated and purified using 3 M sodium acetate 
(pH 5.2), isopropanol and 70% ethanol. DNA was then vacuum dried and re-
suspended in 0.2 mL TE buffer (pH 8.0). The concentration of the extracted DNA 
was determined by NanoVue Spectrometry (GE Healthcare, Munich, Germany). 
5.3.3.5 Plasmid DNA Preparation and Bacterial Transformation 
For bacterial reference strains in which plasmid DNA are used, plasmid DNA 
(IDT, Coralville, IA, USA) was re-suspended in 40 µL of 1× TE solution, 
incubated at room temperature (25 ± 1˚C) for 30 min and then diluted 1000 times 
to form the working dilution for transformation. 1 µL of diluted plasmid was 
added to 50 µL of XL1-blue competent Escherichia coli cells, incubated for 30 
min on ice and then placed in a 42°C water bath for 45 sec for heat shock before 
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immediately returning to ice for 2 min. The mixture was then added to 250 µL of 
LB broth and incubated at 37°C in a shaking incubator for 1 h. 50 µL of the cells 
were spread on LB agar plates containing ampicillin at a concentration of 0.2 
mg/mL in duplicates. The agar plates were placed inverted and were incubated at 
37°C for 16 h before a single colony was picked and inoculated in 3 mL LB broth 
containing 6 µL 100 mg/mL ampicillin. The cells were further incubated at 37°C 
for 16 h on a shaking incubator.  
5.3.3.6 Extraction of Plasmid DNA  
Following incubation, the entire volume of bacterial suspension was used for 
DNA extraction. The bacterial suspension was first centrifuged for 5 min at 
20,000 g and the supernatant was decanted. DNA extraction from the cell pellets 
was performed using the E.Z.N.A. Plasmid mini-kit I and Plasmid Mini Spin 
Protocol. The purified plasmid DNA was eluted with 100 µL of 10 mM Tris-HCl 
buffer (pH 8.5). The concentration of extracted DNA was determined by 
NanoDrop 2000 spectrophotometer and the plasmid copy number was determined 
using the online calculator developed by the URI Genomics and Sequencing 
Center (261).  
5.3.3.7 16S rRNA Gene-targeted Primers and Bacterial targets 
The primer sequences used for profiling the bacterial targets were derived from 
the literature or by design in this study (Table 5-2). All primers were synthesised 
commercially by 1st BASE Ptd Ltd (Singapore). The corresponding target 
bacterial species within each target group profiled by the primers are listed in 
Table S5. The primer pair for the target bacterial group Erysipelotrichaceae was 
designed by obtaining 16S rDNA gene sequences from GenBank of member 
bacterial species Turicibacter sanguinis (MOL361) and Allobaculum 
stercoricanis (DSM13633). A multiple alignment of the sequences was 
 144 
 
constructed with the NCBI Align Sequences Nucleotide BLAST tool and the 
potential primer target sites for family-specific detection were identified. 
Specificity of the primer pair was verified in silico by a BLAST search of 
GenBank and absence of self-complementarity was verified using OligoCalc 
(262). Design of 16S rDNA-targeted primers specific for Porphyromonadaceae 
was attempted. However aligned segments of conserved DNA sequences were not 
specific for Porphyromonadaceae but included bacterial strains from the 
Prevotella and Bacteroides genus. Hence reported primers targeting Bacteroides-
Prevotella-Porphyromonadaceae were used (123).  
Table 5-2 16S rDNA targeted primers for each target bacterial group and the 




Primer Sequence (5’ to 3’) Ref. 
Clostridium coccoides-


















































5.3.3.8 Optimisation of Annealing Temperature and Primer Validation 
The annealing temperatures of primers for each target bacterial group are listed in 
Table S6. The annealing temperature of the primer pair for Erysipelotrichaceae 
was optimised using gradient PCR (Tgradient Thermocycler; Biometra, 
Gottingen, Germany). Thermocycler PCR conditions were:  initial denaturation 
step at 95°C for 5 min, followed by 35 cycles of denaturation at 95°C for 30 sec, 
primer annealing at 58 to 70°C for 30 sec and then elongation at 72°C for 30 sec. 
This is followed by a final extension step at 72°C for 5 min. 
Primer specificity was confirmed through melt curve analysis and gel 
electrophoresis. Observation of a single peak in melt curve following qPCR 
amplification was used to validate specificity of the primers. Slow heating at an 
incremental temperature from 60˚C to 95˚C with continuous fluorescence 
collection were performed to obtain the melt curves. The PCR products were 
subjected to gel electrophoresis at 100 V for 45 min using 1% agarose stained 
with 0.8% of 10 mg/mL ethidium bromide, loaded with 10× DNA loading dye, 
and run alongside with Gene Ruler 100 bp DNA Ladder. The gel was then 
visualised using GeneFlash (Syngene Bioimaging, Federick, MD, USA). A pair 
of specific primers will give a product showing a single band of correct amplicon 
size on the gel. In addition, gel bands for Bacteroides-Prevotella-
Porphyromonadaceae assay were sequenced subsequently using the Sanger 






5.3.3.9 Quantitation of Target Bacterial DNA in PCR Standards and Faecal 
Samples by qPCR  
qPCR amplification and detection were performed using ABI 7500 Fast Real-
Time PCR systems (Applied Biosystems, Foster City, CA, USA). The group-
specific 16S targeted primers and optimised cycling conditions for qPCR are 
summarised in Table 5-2 and Table S6, respectively. All the target bacterial 
groups were profiled except for Erysipelotrichaceae family which fell below 
detection limit in faecal samples (Table S6).      
Each 96-well plate comprised (1) bacterial reference standards, of either genomic 
or plasmid DNA origin, in 5 to 7 serial 10-fold dilutions for calibration of a 
standard curve, and (2) DNA extracted from the faecal samples. All PCR 
experiments for each dilution of the bacterial reference standard and faecal 
sample were performed in triplicate. In each reaction, the reaction mixture 
composed of 2 µL of DNA (a total of 100 ng DNA for faecal samples; various 
dilutions of template DNA of reference standards), 10 µL of Maxima SYBR 
Green/ROX qPCR Master Mix (2×), 0.4 µL of 10 µM of each forward and 
reverse primers, and the remaining volume topped up to 20 µL using nuclease 
free water. For construction of standard curve, serial dilutions of reference 
species’ DNA corresponding to approximately 2.9 to 5.8 × 106 cells or plasmid 
copy number of 108 to 1010 copies were used. The 96-well plate setup was 
automated using the QIAgility PCR workstation (Qiagen, Courtaboeuf, France).  
5.3.3.10 Data Analysis 
Based on the qPCR results, the average target bacterial counts or copy number for 
plasmid DNA in the faecal samples were computed using the standard calibration 
curve generated from the bacterial reference standards. The bacterial counts or 
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copy numbers were normalised to counts or copy number per g of faeces (wet 
weight) used for DNA extraction. Change in bacterial cell counts or copy 
numbers were obtained by comparing post-dose (8–24 h) to pre-dose (–24 to 0 h) 
levels.  
Kruskal-Wallis test followed by Dunn’s multiple comparison post hoc test was 
used for statistical comparison between all toxicity phenotypes from the non-
responders using Prism 6.01 (Graphpad Inc., San Diego, CA, USA). Significant 
differences of all tests were established at P<0.05.  
5.3.4 Microbiome Analysis using 16S rRNA Gene Sequencing  
5.3.4.1 PCR Amplification, Amplicon Purification and Library 
Normalisation 
PCR amplification of V3–V4 region was performed, using the following primer 
pair (265): 
Forward (5’to 3’): 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG 
Reverse (5’ to 3’): 
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC 
2 µL of input DNA (5 ng/µL) and 1.5 µL of each primers (10 µM) were added to 
25 µL of 2×KAPA HiFi Hotstart Readymix, and then made up to 50 µL with 
RNase-free water. Thermocycling conditions were set at 95°C for 1 min, 55°C for 
1 min, then 72°C for 1 min for 25 cycles, followed by a final extension at 72°C 
for 5 min. Amplified products were then purified using Agencourt AMPure XP. 
Following the protocol in Nextera XT DNA Sample Preparation kit, purified 
amplicons were subjected to a limited cycle PCR for the addition of index and 
sequencing adaptors. The PCR products were then purified using Agencourt 
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AMPure XP. Bead-based library normalisation was subsequently performed to 
ensure equal representation of each sample, before samples were pooled to form 
the pooled amplicon library (PAL). To avoid over-loading of DNA into 
sequencer, concentration of DNA in PAL was first determined via quantitative 
PCR. PAL was then diluted to 8–12 pM to obtain the diluted amplicon library 
(DAL). An internal control, PhiX, was added to DAL in the ratio 5:95 by volume, 
and 600 µL of the mixture was loaded into the MiSeq cartridge.  
5.3.4.2 MiSeq Sequencing 
Paired-end 2×250-bp sequencing was performed on the Illumina MiSeq using a 
500-cycles MiSeq Reagent Standard Kit v2 (266). Sequences were demultiplexed 
automatically to generate forward and reverse reads per sample. A total of 
26,166,836 reads were obtained, of which 20,847,932 reads passed the Q30 filter. 
Indexing quality check showed an unusually low read for sample Y18 (Table S4), 
which was omitted in subsequent bioinformatics analysis. 
5.3.4.3 Bioinformatics Quality Control and Analysis 
Samples were recoded for informatics analysis (Table S4). Data processing was 
performed within Ubuntu environment using Oracle VM VirtualBox 4.3.4. Pair-
end overlapping reads were merged to form contigs using FLASH 1.2.7 (267). 
Each contig was then quality filtered to Q30 using split_libraries_fastq.py on 
QIIME 1.7.0 (268). Chimera sequences were detected using USEARCH 6.1 (269) 
and removed. Open-reference operational taxonomic unit (OTU) pick was then 
performed at 97% OTU similarity with USEARCH 6.1 (269) referenced against 
Greengenes (Aug 2013 release) (270), using QIIME’s 
pick_open_reference_otus.py workflow script on default settings. This workflow 
script classified sequences using the RDP classifier (271) at ≥80% confidence, 
aligned them using PyNAST (272), and constructed phylogenetic trees using 
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FastTree2 (273). The result was an OTU table, which was used for subsequent 
downstream analysis. Taxonomic summaries were plotted using 
summarize_taxa_through_plots.py. Alpha (OTU richness in a sample) and beta 
diversity (dissimilarity between bacterial communities of two samples) were also 
calculated using workflow scripts alpha_rarefaction.py and 
beta_diversity_through_plots.py respectively, both at a depth of 10,000 
reads/sample. The beta diversity script calculated UniFrac (274) distances 
(phylogenetic metrics measuring differences between sets of bacterial 
communities) and generated Principal Coordinates Analysis (PCoA) plots based 
on UniFrac distances, which were visualised using KiNG Display Software 2.21 
(275) . 
To compare microbiota between LH rats and humans, demultiplexed fasta files 
were downloaded from three different human studies (55, 276, 277), and recoded 
into Human1, Human2, and Human3. These three studies were recently published 
(2009 – 2012), widely cited and covered human populations from several 
continents. The top twenty samples with the most abundant read were selected 
from each study (Table S7). As each study focused on different regions of the 16S 
rRNA gene, open-reference OTU pick cannot be used to cluster sequences. 
Instead, closed-reference OTU pick was performed via QIIME’s 
pick_closed_reference_otus.py workflow script. Output OTU tables were merged 
with pre-dose LH rat samples. Taxonomic summaries, alpha diversity and beta 
diversity were calculated as described earlier. Limited by abundance of reads on 
human samples, alpha and beta diversity were performed at a depth of 7000 




5.3.4.4 Data Analysis 
Non-parametric multivariate analysis of similarity (ANOSIM), built within 
QIIME, was performed to compare overall microbial communities between 
responder groups at different time periods. This was achieved by comparing 
weighted and unweighted UniFrac distances within responder groups to UniFrac 
distances between responder groups, and significance was assessed using 1000 
permutations. The software package PASW 18.0 (Chicago, IL, USA) was used 
for subsequent statistical analysis. The OTU tables were first filtered of singletons 
(OTUs found only in one sample), and rarefied to 10,000 reads/sample. Non-
parametric Mann–Whitney U test was then applied to detect significant 
differences in gut microbial community between non-responders and extreme 
responders. Spearman’s correlation was performed to compute the correlations 
between fractional bacterial abundance and AST level. Significant differences of 
all tests were established at P<0.05. 
5.3.4.5 Functional Metagenomic Prediction 
While targeted small subunit (e.g. 16S rRNA) gene sequencing can identify 
taxonomic lineage of bacterial communities, whole-genome shotgun can 
complement the picture by providing functional capabilities of the bacterial 
communities themselves. Recent metagenomic studies also favour the presence of 
a core microbiome at a functional level over at a taxonomic level (276, 278-280). 
A prediction algorithm, PICRUSt (281) was hence used to predict functional 
metagenomic information based on 16S input data. Using the OTU table from 
closed-reference OTU pick, PICRUSt first normalised the 16S copy number by 
referencing to a pre-calculated file based on Greengenes database. Metagenome 
prediction was then performed by multiplying the vector of gene counts for each 
OTU by the abundance of that OTU in each sample, and summing across all 
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OTUs. Predictions were sorted into KEGG pathways and Clusters of Orthologous 
Groups (COG). Functional metagenomics summaries were finally plotted via 
summarize_taxa_through_plots.py in QIIME. 
 Results 5.4
5.4.1 Targeted Analysis of Rat Gut Microbiome 
5.4.1.1 Primer Validation 
All the primers obtained from the literature were validated to be specific for their 
respective target bacterial groups based on melt curve and gel electrophoresis 
results. Bacteroides-Prevotella-Porphyromonadaceae assay resulted in two 
distinct melting temperatures between bacterial standards and faecal samples 
(Figure S6A) and gel electrophoresis revealed faecal samples of a slightly larger 
amplicon size compared with the standards (Figure S6B). As such, subsequent 
DNA sequencing was performed and it confirmed that the conserved sequences 
between samples and bacterial standards belonged to bacterial strains within 
Bacteroides-Prevotella-Porphyromonadaceae. Primers designed for 
Erysipelotrichaceae family were able to amplify its bacterial reference standard 
but the assay was not sensitive enough to detect this target bacterial group in 
faecal samples possibly due to its low abundance.  
5.4.1.2 Profile of Gut Microbiome Across Toxicity Phenotypes 
For all the 5 target bacterial groups analysed, no statistical difference was 
observed in their intrinsic (–24 to 0 h) and post-dose (8–24 h) levels between the 
various toxicity phenotypes compared with the non-responders (P>0.05, Kruskal-
Wallis test) (Figure S7 and Figure S8). The relative abundances of the gut 
microbiome of the target bacterial groups across all rats at the two time periods 
are as summarised by the heat maps in Figure 5-1.    
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When the pre-dose and post-dose bacterial cell counts in each target bacterial 
group were compared, a noticeable elevation in the Enterobacteriaceae cell 
counts was observed in the extreme responders following tacrine’s administration 
compared to the non-responders (Figure 5-1 and Figure 5-2A). The levels of 
Lactobacillus however showed a general decline across all LH rats 8–24 h post-
dosing (Figure 5-1 and Figure 5-2B).   
5.4.1.3 Ratio analysis of Enterobacteriaceae:Lactobacillus  
An analysis of the abundance ratio of Enterobacteriaceae:Lactobacillus (E/L) 
revealed an association of higher pre-dose E/L ratio with transaminitis (Figure 
5-3A). For example, the E/L ratio was significantly higher in the extreme 
responders compared to non-responders at the 8–24 h time period which 
corresponded to the peak of transaminitis (P<0.05, Kruskal-Wallis test with 
Dunn’s post hoc test) (Figure 5-3B). Both Enterobacteriaceae and Lactobacillus 
















Figure 5-1 Heat maps of log2 normalised (A) pre-dose (–24 to 0 h) and (B) post-dose (8–24 h) bacterial cell counts or copy number per g of faeces of 
target bacterial groups (rows). Column-wise scaling was performed. Columns are clustered according to groupings of LH rats as indicated by the top 
bars. 
n=12 for controls (VEH, blue bar), n=16 for non-responders (NOR, green bar), n=3 for mild responders (MIL, yellow bar), n=3 for moderate responders (MDR, red bar) and 
n=4 for extreme responders (EXT, black bar). Among the EXT, a decline in abundance of Lactobacillus relative to Enterobacteriaceae from pre-dose to post-dose time 
period was observed as denoted by the change in column Z-score and colour of heat map.          





























Figure 5-2 Box-and-whisker plots of change in (A) Enterobacteriaceae and (B) 
Lactobacillus cell counts per g of faeces by comparing post-dose (8–24 h) from 
pre-dose (–24 to 0 h) bacterial cell counts.    
EXT showed an increase in Enterobacteriaceae but this is not statistically significant 
compared to NOR (P>0.05, Kruskal-Wallis test). n=12 for VEH, n=16 for NOR, n=3 for MIL, 
n=3 for MDR and n=4 for EXT.   
 
 
Figure 5-3 Ratio analysis of (A) pre-dose (–24 to 0 h) and (B) post-dose (8–24 h) 
Enterobacteriaceae:Lactobacillus levels in tacrine-dosed rats. 
Significance (*) was established using Kruskal-Wallis test and Dunn’s post hoc test at P<0.05 
to detect difference from NOR. n=16 for NOR, n=3 for MIL, n=3 for MDR and n=4 for EXT. 
  
A          B 
A          B 
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5.4.2 16S Metagenomics Analysis 
A total of 4,373,680 non-chimeric quality-filtered bacterial 16S rRNA sequences 
were obtained after quality filtering of sequencing run of 84 LH rat faecal DNA 
microbiota samples. The read counts per sample range from 12,211 to 114,768 
(Median: 49,441, Mean: 52,695, SD: 23,335). From the sequences, 18,492 OTUs 
were obtained at 97% sequence similarity via QIIME. 
Alpha rarefaction analysis showed a plateau, indicating that the sampling depth 
from this data set is sufficient, and allowed the estimation of dominant bacterial 
richness (Figure S9). 
5.4.2.1 Basal Gut Microbiome of LH Rats 
The faecal samples of 26 LH rats at pre-dose were selected to characterise the 
basal LH rat microbiome. The three most abundant bacterial phyla were 
Firmicutes (77.1%), Bacteriodetes (18.9%) and Verrucomicrobia (1.2%) (Figure 
5-4A), which represent 97.2% of all phylum-level OTUs. The three most 
abundant bacterial genera were Oscillospira (8.70%), Bacterioides (8.49%) and 
Ruminococcus (7.73%) (Figure 5-4B). They represent 24.9% of all genus-level 
OTUs. Almost all the genera in the gut microbiome of the LH rats expressed large 
variability in their abundance, and there were presence of outliers, especially in 





Figure 5-4 Fractional abundance of bacterial taxa based on sequencing of 16S 
rRNA gene of gut microbiome of the 26 pre-dose LH rat. (A) Phylum fractional 
abundance box plot for all 10 phyla. (B) Genus fractional abundance box plot for 
the 30 most abundant genera. Genera are coloured by their respective phylum in 














A core microbiome refers to a common set of bacteria that is shared across most 
individuals (291). The most stringent definition of an OTU being a member of a 
core microbiome would require its presence within a body site in all rats (100%) 
sampled. Using this definition, 189 OTUs (1.02% of total OTUs from pre-dose 
rats) were found to be shared across all pre-dose LH rats. Lowering the threshold 
would increase the number of shared OTUs linearly (Figure S10), but at the cost 
of compromising the definition of a “core” microbiome. 
Alpha rarefaction analysis using three diversity metrics (chao1, shannon and 
observed species) (Figure S9) showed a qualitatively similar species richness 
between LH rats at pre-dose, suggesting similar number of species between LH 
rats. At a depth of 10,000 reads/sample, pre-dose LH rats are host to an average of 
834 observed species per rat (chao1 estimate=1546). 
PICRUSt predictions of metagenomes were also summarised into bar charts 
(Figure S11 and Figure S12), sorted using both KEGG and COG respectively. 
The prediction gives a clue on the functions of the gut microbiota as a whole. The 
predicted metagenomes revealed largely similar functions between the LH rats at 
pre-dose. KEGG and COG attributed an average of 46.40% and 36.46% of the gut 
metagenome to ‘Metabolism’, which further reinforce the role of the gut as a 
metabolic organ. In both KEGG and COG, the main metabolic function consists 
of ‘Carbohydrate metabolism’ (10.67%) and ‘Carbohydrate transport and 
metabolism’ (10.2%) respectively. 
5.4.2.2 Comparison of Gut Microbiome between Humans and LH Rats 
Taxonomic summaries of microbiota from four different studies (LH rats; 
Human1; Human2; Human3) are presented at phylum (Figure 5-5) and genus 
level (Figure S13). With the exception of Human3, the most abundant phyla 
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present in the LH rats and human individuals are Firmicutes, followed by 
Bacteriodetes, and is coherent with most literature (276, 277, 292, 293). At the 
phylum level, the variation of bacterial phyla in gut microbiome of LH rats is 
relatively small, in contrast to the large variation observed between that of the 
human samples (Figure 5-5). The proportion of Firmicutes alone ranges from 63.8 
– 86.2% in LH rats, compared to a larger range of 46.7 – 97.6% in Human1. 
The number of shared phyla and genera between LH rats and Human1 was also 
summarised in a Venn diagram (Figure 5-6), in order to assess whether both 
habitats host the same group of bacteria regardless of their abundance. 8 of 10 
phyla (80% of total) were found to be common between rats and humans. 
Synergistetes was found to be unique to humans, while Deferribacteres were 
found only in LH rats (Figure 5-6A). When compared at a deeper taxonomic 
classification, 48 of 81 genera (59% of total) were found to be shared between 
rats and humans. 23 genera were found to be unique to humans, and 10 genera 
were found only in LH rats (Figure 5-6B). 
UniFrac measures the phylogenetic distance between samples, and can be used to 
determine whether microbial communities in different samples are significantly 
different. Unweighted Unifrac only takes into consideration differences in 
diversity of bacterial community while weighted Unifrac metric also considers 
OTU abundance on top of differences in diversity of bacterial community. PCoA 
of unweighted Unifrac distance showed a clear host-specific separation between 
human and LH rats (Figure 5-7A). This separation is however obscured when 





Figure 5-5 Taxonomic summaries of microbiota from rats, and humans from 3 
different studies (55, 276, 277), at the phylum level.  
From left to right: LH rats; Turnbaugh et al., 2008 (Human1); Yatsunenko et al., 2012 
(Human2); N. H. W. Group, 2009 (Human3). The 20 most abundant samples were selected 
from each study, from each study’s respective 16S rRNA fasta file, and subsequently recoded 
into Human1, Human2 and Human3 for ease of reference. Taxonomic information in the 









Figure 5-6 Number of gut microbiome taxa shared between LH rats and humans. 
(A) Venn diagram showing number of shared phyla between LH rat and Human1. 
8 phyla (80% of total) were shared between rats and humans. (B) Venn diagram 
showing number of shared genera between LH rat and Human1. 48 genera (59% 
of total) were shared between rats and humans.  
Taxa below 0.0001 were filtered to remove low-abundance bacteria. Human1 was used to 
represent humans as the average sequencing depth used in the study (12,430 reads/sample) 
was most similar to LH rat (47,306 reads/sample) relative to other human studies (Human2: 
766,489 reads/sample, Human3: 10,925 reads/sample) adopted in this paper. 
 
LH rats Human1 Human2 Human3 
A             B  
1       8        1 10       48  23 
80% 59% 
Total=10 Total=81 





Figure 5-7 PCoA plots based on (A) unweighted Unifrac distances, and (B) 
weighted Unifrac distances.  
Each was calculated from 10 rarefied (7000 reads/sample) OTU tables. Unweighted Unifrac 
PCoA only takes into consideration differences in bacterial community. Weighted Unifrac 
PCoA considers OTU abundance on top of differences in bacterial community. The degree of 
variation between 10 jackknifed replicates of PCoA is displayed with confidence ellipsoids 
around each sample.  
5.4.2.3 Comparison of Gut Microbiome between Toxicity Phenotypes 
ANOSIM was performed to compare gut microbiome between four toxicity 
phenotypes (extreme, moderate, mild and non-responders) at four different time 
periods (–24 to 0 h, 0–8 h, 8–24 h, 72–96 h). The analysis generates a value of R 
which was scaled to lie between -1 and +1. R value of zero represents no 
differences among the groups (294). An ANOSIM analysis on unweighted and 
weighted Unifrac distances reveals no significant difference in the gut 
microbiome among all four toxicity phenotypes at P<0.05 (Table 5-3). The results 
indicated a similar global gut microbiome profile among the four responder 
groups despite their phenotypic difference in transaminitis. 
However, a statistical comparison of bacterial OTUs at genus level between 
extreme and non-responders using Mann-Whitney U test revealed significant 
differences in abundance of bacterial OTUs at all four different time periods. 23 
OTUs were found to be significant, of which 8 unidentifiable OTUs and 5 OTUs 
containing an average abundance less than 0.001 (10× of detection limit) were 
A                                         B 
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omitted from subsequent analysis. The remaining 10 OTUs are shown in Table 
5-4. With the exception of Allobaculum, all bacterial genera listed in Table 5-4 
were also found in the human gut. 
The 10 OTUs were found significant at different time periods, with five OTUs 
flagged significant at 8–24 h, the period in which the extreme responders exhibit 
the greatest elevation in AST. Figure 5-8 shows the trend of bacterial abundance 
of Lactobacillus, Bacteroides and Blautia over all four time periods. While most 
OTUs were enriched in extreme responders, OTUs such as Parabacteroides and 
Lactobacillus were enriched in non-responders. Spearman’s correlation was also 
performed, and some OTUs were correlated with AST elevation, including 
Parabacteroides (P=0.0448, r=-0.413) and Butyricimonas (P=2.87×10-5, 
r=0.746).  
Of particular interest were bacteria that were reported to possess β-glucuronidase 
activity or encode the β-glucuronidase gene (282-285, 295-297). Bacteroides and 
Blautia were enriched in extreme responders at 8–24 h post-treatment, while 
Parabacteroides and Lactobacillus were enriched in non-responders at 0–8 h. 
Abundance of Parabacteroides was notably lower than the other three genera 
(Table 5-4), and its contribution to gut β-glucuronidase activity may be limited. 
Interestingly, Lactobacillus was generally found to be in higher abundance in the 
non-responders than the extreme responders. Its abundance was statistically lower 
in the extreme responders at the 0–8 h time period where transaminitis began to 
occur (Figure 5-8A).  
An additional analysis of the Enterobacteriaceae family revealed an elevation in 
the fractional abundance of Enterobacteriaceae following tacrine’s administration 
(Figure 5-8D). Extreme responders clearly have a higher elevation of 
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Enterobacteriaceae than the non-responders and this is consistent with the 
targeted analysis of Enterobacteriaceae reported earlier (Figure 5-2). Taken 
together, these results underscore the implications of β-glucuronidase associated 
gut bacteria with the variable susceptibility to tacrine-induced transaminitis.   
Table 5-3 ANOSIM analysis of Unifrac distances between four toxicity 
phenotypes (EXT, MDR, MIL and NOR).  





R P R P 
–24 to 0 h (Pre-dose) -0.188 0.946 -0.398 0.999 
0–8 h -0.0785 0.745 -0.141 0.893 
8–24 h -0.0339 0.618 0.0347 0.391 
72–96 h 0.0386 0.362 -0.0840 0.772 
Test statistics and corresponding P values are shown. For all comparisons, no significant 







Table 5-4 Significant bacterial OTU differentiating EXT from NOR based on Mann-Whitney U test. Reported excretory products, 























–24 to 0 h Lactococcus 0.0093 0.0027 EXT 0.0293 Yes Lactic acid production (298, 299) 
Oscillospira 0.1405 0.0699 EXT 0.0293 Yes Not well-studied, found to reside in rumen (300) 
0–8 h Lactobacillus 0.0107 0.0329 NOR 0.00952 Yes Lactic acid production (298, 299), and β-
glucuronidase production (285, 286, 295). Reported 
to decrease β-glucuronidase activity (287-290, 301) 
Parabacteroides 0.0023 0.0071 NOR 0.0190 Yes β-glucuronidase production (295),  lower in 
abundance than Blautia and Bacteroides 
8–24 h Allobaculum 0.0018 0.0002 EXT 0.0273 No Short-chain fatty acid (SCFA) production, enriched 
in berberine diet (302, 303) 
Anaerostipes 0.0008 0.0024 NOR 0.0273 Yes Lactate-utilizing, butyric acid producing, indole 
producing (304-306) 
Bacteroides 0.1980 0.1000 EXT 0.0139 Yes β-glucuronidase production (286, 295, 296) 
Blautia 0.0254 0.0046 EXT 0.00206 Yes Short-chain fatty acid (SCFA) production, enriched 
in berberine diet (302). β-glucuronidase production 
(295, 297) 
Butyricimonas 0.0037 0.0018 EXT 0.00619 Yes Butyric acid production (307) 
72–96 h Sutterella 0.0023 0.0050 NOR 0.0190 Yes Linked to autism (308) 
*Significance was assessed using Mann-Whitney U test, performed at P<0.05 
†Presence of bacterial genera in humans was determined using Human1 (Turnbaugh et al., 2008) samples. Genera are considered present when detected 




Figure 5-8 Fractional abundance of (A) Lactobacillus, (B) Bacteroides, (C) 
Blautia and (D) Enterobacteriaceae in EXT and NOR, at four different time 
periods. Statistical analysis established using Mann-Whitney U test, with *P<0.05 
and **P<0.01. No statistical difference in Enterobacteriaceae family was 
observed between EXT and NOR. Data represent mean ± SD. 
A         B 




5.5.1 Microbiome Analysis using Targeted qPCR and 16S rRNA Gene 
Sequencing 
In this study, targeted qPCR and 16S rRNA gene sequencing were applied to 
determine the gut microbiome profile of LH rats. qPCR offers the advantage of 
performing target analysis of selected bacterial groups through the use of 
specially designed and validated 16S rDNA-targeted primers (112, 122, 263). 
However, this method requires a priori knowledge of the composition of the rat 
gut microbial community or preliminary hypothesis to direct the choice of target 
bacterial groups. To our knowledge, the gut microbiome of LH rats has yet to be 
characterised. By using the qPCR approach, we first evaluated the bacterial 
groups which were reported to be predominant in the gut microbiome of other 
strains of rats (118, 126, 258-260).  
Compared with qPCR, 16S metagenomics analysis provides a deeper and more 
comprehensive phylogenetic characterisation of the microbial community (112, 
116). Using the next-generation sequencing technology from Illumina, we were 
able to sequence more reads of shorter read length to detect bacteria that are in 
low abundance (e.g. Allobaculum genus from Erysipelotrichaceae family) and 
detect bacteria that are yet to be identified. Our study represents the first study to 
comprehensively characterise the gut microbiome of LH rats – a rat model often 
used in cognitive studies (309-314). The plateau in the rarefaction curves supports 
the adequacy of our sequencing efforts (Figure S9).   
Three important aspects were considered to ensure accuracy in the 16S rRNA 
sequencing protocol: choice of paired-end sequencing, choice of 16S region, as 
well as choice of database and classifier. Paired-end sequencing was adopted to 
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achieve longer read lengths, and to capitalise on the advantage of sequence check 
when they are overlapping (116, 315). Two 16S regions were also sequenced as 
no single region is able to differentiate all bacteria (116, 316). The V3–V4 region 
was chosen as either region offers the highest species resolution (317), although 
Youssef et al. reported that V3 alone tend to underestimate species richness (318). 
Finally, the Greengenes database with RDP classifier was chosen to generate the 
most accurate and stable results (319), which was also 30 times faster than native 
classifier in Greengenes (319). 
5.5.2 Basal Gut Microbiome of LH Rats 
Using targeted qPCR, large inter-individual variation in the intrinsic levels of gut 
microbiome were observed and there were no statistical difference in the pre-dose 
levels of the panel of target bacterial groups profiled for the rats in different 
groups. Alpha rarefaction analysis of the 16S sequencing results estimates about 
834 observed species (chao1 estimate=1546) in the gut of the LH rats at a 
sampling depth of 10,000 reads/sample, which is higher than the 621 observed 
species (chao1 estimate=1168) in rats reported by Manichanh et al. at a sampling 
depth of 2000 reads/sample (126). However, the difference is likely due to a 
lower sequencing depth adopted by the authors. 
One particular phylum of interest was the Verrucomicrobia. Majority of the reads 
within this phylum are derived from the genus Akkermansia. This genus only held 
one species, Akkermansia muciniphila, and it was found in all LH rats in the 
study. Akkermansia muciniphila was reported to be a mucin-degrading bacterium 
that is inversely correlated with body weight in rodents and humans (320), and 
also reduces the incidence of diabetes in non-obese diabetic mice (321).  
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Looking deeper down to genus level, one could observe a diverse set of genera. 
Few genera occur in high abundance and the microbial community comprised 
mainly of many low-abundance genera which lead to a “long-tail” effect (322) as 
shown in Figure 5-4B. Despite the genetic similarity of LH rats and the rats being 
maintained in a standardised controlled experimental condition, the taxonomic 
composition of the intrinsic gut microbial communities still differ significantly 
among the LH rats. This large inter-individual variation in abundance of gut 
microbiome has also been observed in closely matched monozygotic twins, 
leading to skeptical views of the existence of a ‘core microbiome’ defined by 
shared bacterial lineages (276, 279, 280). Instead, an alternative hypothesis has 
been proposed in support of the definition of a ‘functional’ core microbiome (276, 
279, 280). It appears that although closely-related bacteria tend to have similar 
functions, many genera may occupy the same ecological functional niche despite 
being in a different taxonomic lineage (280). As our metagenomics study focus on 
a universal 16S rRNA marker gene, it cannot directly identify the functional 
contribution of the microbial community. Through the use of PICRUSt, which 
enables prediction of metagenomic functions from 16S rRNA sequencing, we 
observed a largely similar functional role between gut microbiome of LH rats 
(Figure S11 and Figure S12). COG attributed an average of 36.46% of the gut 
metagenome to ‘Metabolism’, which further reinforce the role of the gut as a 
metabolic organ. It should be noted that PICRUSt was validated for human 
microbiome studies. While PICRUSt provides an alternative insight into the 
microbiome, this prediction algorithm should not be seen as a replacement, but as 





5.5.3 Gut Microbiome of LH Rats Compared to Humans 
To bridge the clinical translatability of gut microbiome related findings from rats 
to the human, we investigated and compared the gut microbiome composition of 
LH rats and humans. LH rats and humans share similarities in both the fractional 
abundance (Figure 5-5) and the diversity of phyla (Figure 5-6A). When compared 
at the genus level, 59% of total genera were also found to be shared between rats 
and humans (Figure 5-6B). Although differences in gut microbiome composition 
between these species were observed in the unweighted Unifrac PCoA (Figure 
5-7A), weighted Unifrac PCoA (Figure 5-7B) may be a more truthful depiction of 
microbial communities as abundances of bacteria were factored in. 
Nonetheless, the observed inter-species differences cannot be completely 
disregarded. These differences are likely influenced by multiple factors including 
host genetics and environment (323-325). Genetic factors can influence the 
composition and diversity of gut microbiome (325). Benson and colleagues 
identified 18 host genetic quantitative trait loci (QTL) that show genome-wide 
correlation to relative abundances of specific microbial taxa (323). These QTL 
can affect microbiota composition by controlling individual microbial species or 
groups of taxa, demonstrating the influence of heritable traits on shaping the gut 
microbiota. The genetic difference between rat and human hence help to partially 
explain the inter-species differences in gut microbiome.  Diet is an environmental 
factor known to strongly influence gut microbiome composition (326-328). 
Besides being food for the host, diet also provides nutrition for the gut microbiota. 
In fact, diet was found to shape the gut community (329), which in turn 
influenced the nutritional value of the food ingested. The dietary difference 
between rats and humans is therefore a driving factor for the inter-species 
dissimilarity in gut microbiome. All LH rats in this study were fed with the same 
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diet; but diet was not controlled for the humans involved in the microbiome 
studies. Consequently, the highly controlled environment (e.g. diet and housing) 
in genetically similar LH rats underpinned the intra-species similarity of their 
microbiome relative to that of the humans (Figure 5-5).   
One technical constraint in this comparison study is the variation in sequencing 
depth between the three human studies and our LH rats experiment. Sequencing 
depth has also been found to be a factor resulting in observed differences between 
microbiome. It was found that the resemblance of phyla and genera between 
groups differs dramatically depending on number of reads used for analysis, as 
increasing sequencing depth can uncover more bacteria that the two groups have 
in common (292). Accordingly, Human1 study with average sequencing depth 
closest to our experiment was selected for qualitative comparison with LH rats in 
an attempt to minimise this constraint. Nevertheless, the greater sequencing depth 
of gut microbiome of LH rats in this study could have inevitably introduced 
differences between the rats and humans, by uncovering traces of low-abundance 
bacteria. 
While these differences need to be interpreted prudently, our study yielded 
invaluable insights for translating findings from LH rats to humans. Recent 
studies have also explored the option of transplanting human gut microbiome into 
animal models, and the results have been encouraging (126, 330). Perhaps in the 
near future, gnotobiotic animal models (with fully defined microbial status) that 
are humanised via a gut microbiome transplant may become the model of choice 





5.5.4 Gut Microbiome Perturbation associated with Tacrine-induced 
Transaminitis 
Both PCoA (Figure S14) and ANOSIM analysis (Table 5-3) did not find any 
statistical difference between the overall gut microbiome profile of extreme and 
non-responders. However, a deeper investigation into specific bacterial OTUs at 
the genus level revealed significant differences between extreme and non-
responders via Mann-Whitney U test. Interestingly, Lactobacillus was reported to 
modulate β-glucuronidase activity despite being producers themselves (285, 287-
290, 301), and confer hepatoprotection to the host (331). The augmentation of 
Lactobacillus in the non-responders may have conferred the rats some level of 
hepatoprotection from tacrine-induced toxicity, while the enrichment of β-
glucuronidase candidates like Bacteroides, Blautia and Enterobacteriaceae in the 
extreme responders following the administration of tacrine may have resulted in 
the rats’ susceptibility to tacrine-induced transaminitis. 
In enterohepatic recirculation, endogenous substrates like bile acids and bilirubin 
and conjugated metabolites of drugs like irinotecan and morphine are secreted 
from the liver into the bile, followed by entry into the small intestine, absorption 
by the enterocyte and transport back to the liver (164). The phenomenon has been 
observed in several drugs (163, 164, 166, 295), usually involving the glucuronide 
metabolites, although drug conjugates formed by phenol sulfotransferase and 
cytosolic GST can also undergo enterohepatic recirculation (164). 
Metabolism studies on tacrine revealed that tacrine undergoes extensive Phase I 
metabolism to form hydroxytacrine metabolites (Figure 1-2) (192, 332). The 
hydroxylated metabolites (1-hydroxytacrine, 2-hydroxytacrine, 4-hydroxytacrine 
and 7-hydroxytacrines) accounted for 13.3–70.8% of tacrine incubated in human 
liver microsomes (333). Following which, hydroxytacrine undergo Phase II 
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glucuronidation in the liver (192). Interestingly, our in-house study (Chapter 2) 
observed direct formation of tacrine-N-glucuronide that was secreted into the bile 
and duodenum of LH rats (334). Since gut microbiome of rats are known to 
possess β-glucuronidase activity (45, 286, 335, 336), tacrine-N-glucuronide can 
be hydrolysed by bacterial β-glucuronidase to release tacrine, which can be 
reabsorbed in the intestines and transported back to the liver via the hepatic portal 
vein. Studies have suggested a minimum molecular weight threshold for biliary 
secretion to occur; drug conjugates generally need to be at least 200-325 Da for 
rats and 500 Da for humans (164, 165). At 374 Da, tacrine-N-glucuronide can be 
biliary secreted in rats as observed in this study. Secretion of labelled tacrine into 
the bile and intestine has also been reported, after an intravenous dose of 
radioactive tacrine was given to rats (142). Under the conditions where there was 
a higher abundance of bacteria such as Enterobacteriaceae, Bacteroides and 
Blautia in extreme responders, enterohepatic recirculation of tacrine became 
relatively extensive due to the higher level of intestinal β-glucuronidase. This in 
turn resulted in the greater systemic exposure (AUC) and double Cmax profile of 
tacrine in extreme responders, and the development and exacerbation of 
transaminitis. 
While an association is clear, it is not known whether microbial perturbation on 
the administration of tacrine is a cause or an effect of transaminitis. Given that the 
abundances of key microbial genera (i.e. Bacteroides, Blautia and Lactobacillus) 
were not significantly different between extreme and non-responders at pre-dose, 
the introduction of tacrine could have resulted in the structural divergence of the 
gut microbiota. One postulation is that tacrine increases sympathetic activity in 
the liver leading to vascular constriction and hepatic ischemia (337). When the 
vascular constriction is relieved, the consequent reperfusion disturbs the 
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ecological balance in the gut (338). Xing et al. demonstrated in rats that 
ischemia/reperfusion liver injury leads to disturbance in gut microbiota where 
there is a decrease in Bifidobacteria and Lactobacilli and an increment in 
intestinal Enterobacterium and Enterococcus (338). The apparently higher 
abundance of Lactobacilli level in non-responders might have protected the rats 
against the proliferation of Enterobacteriaceae and other microbes that could 
potentially exacerbate tacrine-induced transaminitis (Figure 5-3 and Figure 5-8). 
 Chapter Conclusion 5.6
Culture-independent qPCR and next-generation sequencing techniques have 
provided interesting insights on the effects of the microbial on tacrine-induced 
transaminitis. With the aid of bioinformatics packages such as QIIME, differences 
and changes in the gut micrbiome can be identified and visualised. In this study, 
Lactobacillus, Enterobacteriaceae, Bacteroides and Blautia were found to be 
potentially involved in the enterohepatic recirculation of tacrine. We propose that 
these bacteria may be implicated in the hydrolysis of glucuronidated metabolites 
of tacrine excreted in the intestines. Our findings delineated greater 
deglucuronidation propensities in extreme responders based on the differential 
faecal abundance of these bacteria known to possess or modulate β-glucuronidase 
activities. The inter-individual variation of such gut microbiome may henceforth 
account for the variation in the toxicokinetics of tacrine. This study illuminated 
the potential influence of gut microbiota on drug disposition and specifically 
highlighted the influence of β-glucuronidase-producing gut microbiota and its 
complement β-glucuronidase activity on toxicological susceptibility to tacrine.  
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 Chapter 6 The Influence of Intestinal β-glucuronidase 
Activity on Susceptibility to Tacrine-induced 
Transaminitis 
 Chapter Summary 6.1
Background: Collectively, findings from the preceding chapters confirmed the 
implication of enterohepatic recirculation on the variable toxicokinetics of tacrine. 
At the hepatic level, we observed no significant differences in the expression of 
disposition-related genes among all rats (Chapter 3). Gut microbiome analysis 
delineated greater deglucuronidation propensities in extreme responders based on 
differential faecal abundance of bacteria known to possess or modulate β-
glucuronidase activity (Chapter 5).  
Objectives: This chapter aims to validate the influence of intestinal β-
glucuronidase activities on the susceptibility of LH rats to tacrine-induced 
transaminitis. 
Methodology: An acute oral dose of tacrine (20 mg/kg) was administered to 
conventional (Group 1, n=17) and β-glucuronidase treated (Group 2, n=17) male 
LH rats. Clinical chemistry measurement and histopathology of livers were used 
to assess tacrine-induced hepatotoxicity. The toxicological susceptibility of β-
glucuronidase treated rats was compared to conventional tacrine-dosed LH rats. In 
vivo pharmacokinetics plasma profiling of the tacrine-dosed rats was performed 
using LC/MS/MS. 
Results and Discussion: Toxicological susceptibility to tacrine-induced 
transaminitis in the conventional LH rats was 41%, similar to the 43% derived 
from the animal study conducted in Chapter 2. Consistent with our earlier 
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confirmation of the association of greater deglucuronidation propensities with the 
occurrence of tacrine-induced transaminitis, enrichment of intestinal β-
glucuronidase significantly increased the toxicological susceptibility to 76% for 
rats in Group 2. Pharmacokinetic parameters (Cmax and AUC0-last) of tacrine were 
significantly higher in the tacrine-dosed LH rats pre-treated with β-glucuronidase 
compared to the conventional rats (P<0.05, Mann-Whitney U test). The 
conversion of rats to ‘responders’ by supplementation with β-glucuronidase 
culminated in the greater overall exposure to tacrine in Group 2. Analysis of Cmax 
and AUC0-last of tacrine revealed comparable pharmacokinetics among the 
responders from the two groups of rats. As pre-treatment of LH rats with β-
glucuronidase did not alter these parameters among the responders from both 
treatment groups, our findings suggested a threshold limit on the enterohepatic 
recirculation kinetics of tacrine.  
Conclusion: Through enrichment of β-glucuronidase in tacrine-dosed LH rats, we 
validated the pertinent role of intestinal β-glucuronidase activity on the 
susceptibility of LH rats to tacrine-induced transaminitis. This in turn confirmed 
the roles of gut microbiota in determining the differential disposition of tacrine 
and its variable therapeutic outcomes. In conclusion, our study underscores the 
importance of studying host-gut microbiota interactions on the enterohepatic 
recirculation of drugs, particularly those drugs with narrow therapeutic window 
and are intensively Phase II conjugated.   
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 Chapter Introduction 6.2
Our findings from the preceding chapters confirmed the implication of 
enterohepatic recirculation in the variable toxicokinetics of tacrine. Metagenomics 
delineated greater deglucuronidation propensities in extreme responders based on 
the differential faecal abundance of β-glucuronidase-associated gut bacteria such 
as Lactobacillus, Bacteroides, Blautia and Enterobacteriaceae (Chapter 5). In this 
chapter, we aim to verify the influence of intestinal β-glucuronidase activities on 
the susceptibility to tacrine-induced transaminitis in an independent group of LH 
rats. We determined the toxicological susceptibility and plasma pharmacokinetic 
profiles of tacrine in rats given an oral dose of β-glucuronidase enzymes to enrich 
their intestinal β-glucuronidase activities. The toxicokinetic profiles of this group 






Animal experiment and study endpoints in this chapter were carried out at the 
WuXi AppTec Co. Ltd. (Waigaoqiao, Shanghai, China)   
6.3.1 Animal Study and Sample Collection 
Forty-six male LH rats (236-293 g; Harlan, UK) were housed individually in clear 
cages following acclimatisation. Rats were maintained with routine animal 
husbandry methods. Water and feeds (Teklad Irradiated Global 18% Protein 
Maintenance Diet 2918, Harlan Laboratories) were available ad libitum on all 
study dates except during the overnight fast before treatment on Day 0.   
The LH rats were divided into two treatment groups as illustrated in Figure 6-1. In 
Group 1 (Figure 6-1A), the rats were first given an oral gavage of vehicle (Tween 
80-distilled water (20:80wt%), at a volume of 0.6 mL/kg) that was used to prepare 
the β-glucuronidase enzymes for Group 2. Five minutes later, seventeen rats 
received by oral gavage a single dose of 20 mg/kg body weight of tacrine, 
dissolved in 1% MC, at a volume of 10 mL/kg and six rats were orally dosed with 
vehicle (1% MC, at a volume of 10 mL/kg). Group 1 mirrored the animal study in 
Chapter 2 and served as a control for the other treatment group. In Group 2, all 
the twenty-three rats were given a single oral dose of 168,400 units/mL of β-
glucuronidase, at dose of 0.6 mL/kg, prior to oral gavage of either tacrine or 1% 




Figure 6-1 Study design to compare the effects of (A) conventional (Group 1) 
and (B) β-glucuronidase treated (Group 2) LH rats on the susceptibility to tacrine-
induced transaminitis.  
 
Approximately 100 to 250 µL of blood samples were collected in EDTA tubes via 
the jugular vein cannula before dosing (0 h) and at 0.5, 1, 2, 4, 8, 16, 24, 28, 32 
and 48 h. Plasma samples were prepared by centrifugation at 3000 g for 15 min at 
4˚C within half an hour of collection. Plasma samples were stored at –80°C prior 
to analysis. 
At the end of the study, rats were sacrificed, portal vein perfusion with saline was 
performed and whole livers were collected from the rats.  
6.3.2 Clinical Chemistry Measurement and Toxicity Phenotyping 
AST, ALT, total bilirubin and direct bilirubin were measured in the plasma 
collected at pre-dose (0 h), 4, 8 16, 24, 28, 32 and 48 h. Tacrine-dosed rats with 








group were classified as responders to tacrine-induced transaminitis, while those 
not meeting this criterion were classified as non-responders.  
6.3.3 Histopathology of Liver  
The livers were fixed in 10% neutral buffered formalin for about 24–48 h 
immediately after collection. The fixed tissue was embedded in paraffin and 
prepared for light microscopy and stained with hematoxylin and eosin.  
6.3.4 In vivo Pharmacokinetic Profiling of Tacrine and Hydroxytacrine 
Metabolites in Rat Plasma 
6.3.4.1 Plasma Sample Preparation Procedures 
An aliquot of 20 µL plasma sample was protein precipitated with 160 µL of IS 
(100 ng/mL labetalol, 100 ng/mL diclofenac and 100 ng/mL tolbutamide in 
acetonitrile). The mixture was vortex-mixed for 1 min and centrifuged at 3220 g 
for 20 min. 20 µL supernatant was then mixed with 180 µL of water with 0.1% 
formic acid, vortex-mixed for 10 min, centrifuged for 10 min at 3220 g at 4°C. 
Calibration curves in the range of 1.00 to 1000 ng/mL and 0.649 to 649 ng/mL 
were prepared for tacrine and hydroxytacrine in LH rat plasma, respectively.  
6.3.4.2 LC/MS/MS 
LC/MS/MS analysis was performed using an ACQUITY UPLC system interfaced 
with API 4000 from AB Sciex. Tandem mass spectrometry was operated in the 
ESI +ve mode. MS source conditions were: ionspray voltage, 5500 V; 
temperature, 550°C; curtain gas 20 psi; ion source gas 1, 60 psi; ion source gas 2, 
60 psi; entrance potential, 10 V and collision cell exit potential, 10 V. The dwell 
time used for all MRM experiments was 30 msec. The optimised compound-
dependent MS parameters for the analytes are as shown in Table 6-1. 
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Table 6-1 Optimised compound-dependent MS parameters using ABI 4000 
LC/MS/MS. 






Tacrine 199.1  171.1 43 80 
1-hydroxytacrine 215.1  197.1 25 30 
Labetalol (IS) 329.2  161.9 34 65 
 
All chromatographic separations were performed using an ACQUITY UPLC 
BEH C18 column (1.7 μm, 50 mm × 2.1 mm i.d). The column and autosampler 
temperatures were maintained at 60°C and 6°C, respectively. The mobile phase 
flow rate was 0.6 mL/min. Mobile phase consisted of 0.025% formic acid and 1 
mM of ammonium acetate in water/acetonitrile (v/v, 95:5) (solvent A) and 
0.025% formic acid and 1 mM of ammonium acetate in acetonitrile/water (v/v, 
95:5) (solvent B). The optimized elution conditions were: gradient of 0–40.0% 
solvent B (0–1.50 min), gradient of 40.0–80.0% solvent B (1.50–1.80 min), 
isocratic at 80.0% solvent B (1.80–2.00 min), gradient of 80.0–0% solvent B 
(2.00–2.01 min) and isocratic at 0% solvent B (2.01–2.50 min). The injection 
volume was 8 μL. The analysis time for each sample was 2.5 min.  
6.3.4.3 Pharmacokinetic Analysis 
The LC/MS/MS method was applied to measure tacrine and hydroxytacrine 
metabolites in the plasma of the tacrine-dosed rats. Plasma samples collected at 
pre-dose (0 h), 0.5, 1, 2, 4, 8, 16, 24 and 32 h after treatment were used for the 
measurements. Pharmacokinetic analysis of the plasma profiles was performed 
using Phoenix WinNonlin® 6.3 software using non-compartmental analysis. 
Pharmacokinetic parameters obtained included Cmax, Tmax, T1/2, AUC0-last and 




6.4.1 Susceptibility of Conventional and β-glucuronidase treated LH rats to 
Tacrine-induced Transaminitis  
Tacrine is known to induce hepatocellular injury and lead to transaminitis. 
Consistent with our findings in Chapter 2, conventional LH rats (Group 1) 
exhibited differential susceptibility to tacrine-induced transaminitis whereby 41% 
of the seventeen tacrine-dosed rats were classified as responders based on 
elevation of AST more than 3 times the average AST of the control rats in the 
group (Figure 6-2A and B and Table 6-2). Using the AST threshold in each of the 
group, we determined the toxicity phenotypes of the β-glucuronidase treated LH 
rats in Group 2 (Figure 6-2C and D). A noticeable increase in susceptibility to 
tacrine-induced transaminitis was observed in the β-glucuronidase treated LH rats 
(Group 2), whereby we observed 76% of rats as responders (Table 6-2) (P<0.05, 
one tailed Fisher’s exact test). The histology of 1% MC-dosed controls and 
tacrine-dosed rats is shown in Figure 6-3. The liver of the control rats were 
normal (Figure 6-3A and B). The occurrences of hepatocellular injury in the 
tacrine-dosed rats were confirmed by the histopathology of liver sections where 
necrosis and fatty changes were observed in the midzonal and pericentral regions 
of the liver lobule as reported in other literature (Figure 6-3C and D) (130, 131, 
133). Total bilirubin and direct bilirubin were also measured but no abnormality 




Figure 6-2 Plasma (A) ALT and (B) AST levels of conventional LH rats in 
Group 1, and (C) ALT and (D) AST levels of β-glucuronidase treated rats in 
Group 2. The respective toxicity phenotypes for tacrine-dosed rats (non-responder 
or responder) were determined by comparison with the AST of the controls in the 
respective groups.  
Data represent mean ± SD. Two control rats were excluded from Group 1 and one control rat 
was excluded from Group 2 as they were found to be outliers. For Group 1, n=4 for control, 
n=10 for non-responders and n=7 for responders. For Group 2, n=5 for control, n=4 for non-
responders and n=13 for responders. 
 
Table 6-2 Percentage of responders in conventional (Group 1) and β-










10 7 41 
Group 2 
(β-glucuronidase treated) 
4 13 76* 
*β-glucuronidase treated LH rats has a significantly higher percentage of rats susceptible to 
tacrine-induced transaminitis (*P<0.05, one tailed Fisher’s exact test). In each group, 
seventeen rats were administered tacrine.  
 
 











Figure 6-3 Liver histology from a representative control rat at (A) 100× power 
and (B) 400× power and responder of tacrine-dosed rat at (C) 100× power and (D) 
400× power. Livers were collected 48 h after single oral administration of 1% MC 
vehicle or 20 mg/kg tacrine. Arrows indicated regions of necrosis and fatty 
changes.  
 
6.4.2 Pharmacokinetics of Conventional and β-glucuronidase treated LH rats  
The kinetic disposition of tacrine was analysed in the two groups of LH rats. 
When the AUC0-last of tacrine were compared across the tacrine-dosed LH rats 
between the two groups, β-glucuronidase treated tacrine-dosed rats in Group 2 
were found to have a significantly higher exposure to tacrine than the 
conventional LH rats in Group 1 (Group 2: 4135 ± 2055 h×ng/mL vs. Group 1: 
2446 ± 1921 h×ng/mL, P<0.05, Mann-Whitney U test). Cmax of tacrine was also 
found to be statistically higher in Group 2 compared to Group 1 (Group 2: 608 ± 
363 ng/mL vs. Group 1: 343 ± 316 ng/mL, P<0.05, Mann-Whitney U test).  
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An analysis of the pharmacokinetics based on the toxicity phenotypes revealed 
that the responders exhibited a differential disposition of tacrine compared to the 
non-responders, in concordance with earlier findings in Chapter 2 (Figure 6-4). 
Consistent among the two groups of rats, the responders were found to have a 
significantly higher Cmax and exposure (AUC0-last) of tacrine compared to the non-
responders (Figure 6-5). These two pharmacokinetic parameters were not 
statistically different between the responders from the two groups of rats. 
 
Figure 6-4 Plasma tacrine concentration-time profile of the non-responders and 
responders following an acute oral dose of 20 mg/kg of tacrine in (A) 
conventional rats (Group 1) and (B) β-glucuronidase treated rats (Group 2). 
 
 
Figure 6-5 In vivo pharmacokinetic parameters of tacrine, (A) Cmax and (B) 
AUC0-last in non-responders and responders.  
Each bar represents mean ± SD. Statistical analysis established using Mann-Whitney U test, 
with *P<0.05, **P<0.01 and ***P<0.001 compared to non-responders. Cmax and AUC0-last 
were not statistically different between the two groups based on Mann-Whitney U test.   
A       B 
A          B 
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The Cmax and AUC0-last of OH-THA metabolites appeared to be slightly higher in 
the responders as compared to the non-responders for both groups of rats (Figure 
6-6). In actual fact, except for Group 1 where we observed a statistically higher 
Cmax in the responders, Cmax and AUC0-last of OH-THA metabolites were similar 
between the responders and non-responders in Group 2 (Figure 6-7).   
 
Figure 6-6 Plasma OH-THA metabolites concentration-time profile of the non-
responders and responders following an acute dose of 20 mg/kg of tacrine in (A) 
conventional rats (Group 1) and (B) β-glucuronidase treated rats (Group 2).  
 
 
Figure 6-7 In vivo pharmacokinetic parameters of OH-THA metabolites, (A) Cmax 
and (B) AUC0-last in non-responders and responders. 
  








The gut microbiota exhibits a wide range of enzymatic activities with profound 
impact on the biotransformation of drugs. In the preceding chapters, we identified 
that intestinal β-glucuronidase activity, primarily derived from bacteria origin 
(169, 170), plays a key role in increasing the susceptibility of LH rats to tacrine-
induced transaminitis by enhancing the enterohepatic recirculation of tacrine 
through deconjugating tacrine-N-glucuronides.  
To confirm our hypothesis, we co-administered oral β-glucuronidase enzymes 
with tacrine in LH rats. The feasibility of enriching intestinal β-glucuronidase 
through supplementation is supported by Eichenbaum et al. who demonstrated 
that intraduodenal administration of β-glucuronidase (34,000-140,000 units/kg) 
with an anticancer compound JNJ-10198409, known to undergo reversible 
glucuronidation and enterohepatic recirculation, successfully facilitated 
enterohepatic recirculation of the parent compound as evident by the significant 
increase in the mean AUC of the parent compound by ~3-fold and Cmax by ~2-
fold in rats (339). In our study, we adopted a similar approach and administered 
an augmented dose of β-glucuronidase to enrich the intestinal β-glucuronidase 
activity of LH rats while avoiding potential loss of enzymatic activity in the rat’s 
stomach. In conventional LH rats dosed with tacrine, we observed consistently 
about 43% (animal study in Chapter 2) and 41% (Group 1 LH rats in this Chapter) 
of rats manifesting tacrine-induced transaminitis. Our results demonstrated that 
co-administration of oral β-glucuronidase with tacrine, significantly increased the 
susceptibility of LH rats to tacrine-induced transaminitis to 76%. Collectively, the 
tacrine-dosed LH rats in the group treated with oral β-glucuronidase have a mean 
AUC of tacrine ~1.7-fold higher than the conventional tacrine-dosed rats not 
administered with β-glucuronidase. This finding is in concordance with our 
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proposed enterohepatic recirculation of tacrine via the intestinal 
deglucuronidation of tacrine-N-glucuronide.  
It is noteworthy to mention that while β-glucuronidase increase the incidence of 
transaminitis, it did not lead to further elevation of tacrine systemic exposure 
(indicated by AUC0-last) in the responders from both Group 1 and Group 2 (Figure 
6-5). Our findings confirmed that the co-administration of β-glucuronidase 
converted ‘non-responders’ to ‘responders’ by increasing their intestinal 
deglucuronidation capacity, leading to elevated systemic exposure to tacrine. 
However, we propose that there may be a limit on the amount of tacrine that is 
available to undergo enterohepatic recirculation in the responders based on the 
dose of tacrine administered and other competing pathways for drug clearance. 
Hence, this might have accounted for the similar Cmax and AUC0-last when we 
compared responders between Group 1 and 2 (Figure 6-5).    
To this end, therapeutic alternatives may be explored if it is deemed necessary to 
inhibit intestinal β-glucuronidase activity. While Lactobacillus is known to 
possess β-glucuronidase activities, dietary supplementation of some strains of 
lactobacillus has been shown to be able to suppress faecal β-glucuronidase 
activities of patients and animal models in multiple studies (287-290). It is 
probable that different strains of lactobacillus may serve different functions (285) 
and this underscores the importance of careful selection of suitable lactobacillus 
strain for inhibition of β-glucuronidase activities. Further, better understanding of 
the dosage, duration of onset of β-glucuronidase suppressing activity as well as 
duration of action of lactobacillus will aid its clinical application. Many other 
studies also explore the use of small molecules to inhibit bacterial β-
glucuronidase (67-69, 340-343). The development of potent and specific bacterial 
β-glucuronidase inhibitors may offer an exciting avenue for modulating 
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therapeutic outcomes. Apart from tacrine, biliary excreted glucuronides of drugs 
like irinotecan and non-steroidal anti-inflammatory drugs like diclofenac are 
known to be cleaved by intestinal β-glucuronidase to release the free aglycone 
that induces gastrointestinal toxicity. Co-administration of β-glucuronidase 
inhibitors has been shown to confer ‘protective’ effect to mitigate their toxicity 
(67-69). It would have been ideal to administer such β-glucuronidase inhibitors in 
our study. However, considering that the earlier studies (67-69) were conducted 
mainly in mouse models and limited pharmacokinetics data is available for the 
inhibitors (58), we did not explore the inhibitors in our in vivo rat studies. This 
highlights the need for further characterisation of such inhibitors to facilitate their 
applications.  
 Chapter Conclusion 6.6
Collectively, in this and the preceding chapters, we confirmed that the intestinal 
β-glucuronidase activity plays an influential role on the susceptibility of LH rats 
to tacrine-induced transaminitis. Through deconjugating tacrine-N-glucuronides, 
the liberation of free tacrine and its subsequent re-absorption contributed to an 
increased systemic exposure of tacrine in the responder rats, thereby resulting in 
tacrine-induced transaminitis. This is confirmed by a statistically higher observed 




 Chapter 7 Conclusions and Future Perspectives 
The ability to elucidate the mechanisms underlying inter-individual responses to 
pharmacotherapy is paramount in personalised medicine research. The gut 
microbiota is known to possess wide-ranging metabolic activities that could 
modulate drug disposition and these activities may lead to inter-individual 
variation in efficacy and toxicity. However, the influence of the gut microbiota in 
drug disposition and therapeutic outcome is not as well studied by the 
pharmaceutical and academic scientists as compared to other factors associated 
with the host, drug and its metabolites (32). Considering the superorganismic 
nature of the human host, the limited understanding of the gut microbiota and its 
associated metabolic activities in personalised medicine may impede efforts for 
better management of inter-individual variation in pharmacotherapeutic 
outcomes. Tacrine, an Alzheimer’s disease drug, exhibits significant inter-
individual variability in its pharmacokinetic and hepatotoxicity profiles of yet 
unknown etiology (128, 140). In this thesis, we investigated the contribution of 
the host-gut microbiota interaction on the variable toxicokinetics of tacrine. 
In Chapter 2, we established that LH rats is a suitable model for our investigation 
as an acute oral dose of 20 mg/kg of tacrine led to differential susceptibility to 
tacrine-induced transaminitis similar to humans. In vivo toxicokinetic profiling of 
tacrine and its metabolites in plasma and faeces led to a new discovery that 
suggests tacrine may undergo enterohepatic recirculation. Furthermore, we 
hypothesised that the enhanced enterohepatic recirculation of hepatotoxic tacrine 
exacerbated the toxicity in the extreme responders. Considering that enterohepatic 
recirculation is a physiological process influenced jointly by the host and the gut 
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microbiota, the information gleaned from Chapter 2 laid the foundation for the 
characterisation of the host and gut microbiota in subsequent chapters.  
The liver is a major metabolic organ involved in drug disposition and 
detoxification processes. In Chapter 3, the mRNA expressions of the disposition-
related genes in the livers of tacrine-dosed LH rats were profiled to determine 
their contribution to tacrine-induced transaminitis. Collectively, the findings in 
this chapter and other related genetic studies revealed a lack of host genetic 
biomarker predictive of susceptibility to tacrine-induced transaminitis.  
In Chapter 4, GC/TOFMS-based metabonomics was employed to screen for 
transaminitis-related marker metabolites in the urine and faeces of the LH rats. 
Marker metabolites connected with mitochondrial dysfunction, a reported 
mechanism for tacrine-induced liver injury, was uncovered. This finding 
substantiated the value of the metabonomics platform in toxicological studies (79, 
102). Many transaminitis-related marker metabolites identified are co-
metabolites, nutrients or fermentation products where their abundances are related 
with the composition and metabolic activities of gut microbiota. Here, our 
metabonomic findings suggest a perturbation of gut microbiota or its associated 
microbial metabolic activity which might account for the augmented 
enterohepatic recirculation of tacrine in the extreme responders as observed in 
Chapter 2. 
To elucidate the roles of the gut microbiota on tacrine-induced transaminitis, we 
profiled the gut microbiome of the LH rat faeces in Chapter 5. qPCR and 16S 
metagenomics delineated greater deglucuronidation propensities in extreme 
responders, based on differential faecal abundance of bacteria such as 
Lactobacillus, Enterobacteriaceae, Bacteroides and Blautia known to possess or 
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modulate β-glucuronidase activities.  Collectively, the findings in Chapters 2 to 5 
highlighted that inter-individual variation of gut microbiome is responsible for the 
variation in the toxicokinetics of tacrine.  
In Chapter 6, we further confirmed that the intestinal β-glucuronidase activity 
plays an influential role on the toxicokinetics of tacrine. Co-administration of oral 
β-glucuronidase in an independent group of tacrine-dosed rats significantly 
increased susceptibility of LH rats to tacrine-induced transaminitis from 41% to 
76%. This is associated with a correspondingly higher exposure of tacrine in the 
group supplemented with oral β-glucuronidase. Taken together with preceding 
chapters, the results emphasise the roles of the gut microbiota and its associated 
β-glucuronidase activities in defining the therapeutic outcomes of drugs.  
Mechanistically, our metabonomic study in Chapter 4 opens avenues for further 
investigation. In this thesis, we elucidated that the gut microbiota can exert direct 
influence over the disposition of tacrine via its β-glucuronidase activities that 
deconjugate biliary excreted tacrine-N-glucuronides in the intestines to liberate 
free tacrine for subsequent re-absorption. The increased systemic exposure of 
hepatotoxic tacrine thereby culminated in tacrine-induced transaminitis in the 
responders. Apart from this direct mechanism, it is worthwhile to explore if the 
gut microbiota can also modulate the disposition of tacrine indirectly. For 
instance, we can screen if the marker metabolites are inhibitors of the hepatic 
CYP1A2 enzymes or competitive substrates of UGTs by co-incubating tacrine 
and the marker metabolites in rat liver microsomes. Further, it will be interesting 
to explore if the faecal marker metabolites exert any influence over the microbial 
β-glucuronidase activity, thereby influencing the toxicokinetics of tacrine.  
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Chapter 5 shed important insights on the microbial communities potentially 
involved in the enterohepatic recirculation of tacrine. While 16S rRNA gene 
sequencing is a useful culture-independent technique for microbiome profiling, it 
has low phylogenetic power at the species level and the problem of poor 
resolution was also observed for some genus (344-346). In this regards, it will be 
of considerable interest to perform whole-genome shotgun sequencing of the LH 
rat gut microbiome which can provide unprecedented phylogenetic resolution to 
discern the closely related bacteria species. Such a study will offer refined 
insights into the specific bacteria species implicated in tacrine-induced 
transaminitis and the potential functional activities encoded by the microbial 
genes. In addition, we may be able to obtain therapeutic insights through 
identifying specific species of Lactobacillus that may confer ‘protective’ effects 
and inhibit the deglucuronidation of tacrine-N-glucuronide.   
On a broader perspective, our study underscores the importance of studying host-
gut microbiota interactions for drugs which are intensively Phase II conjugated 
and subjected to enterohepatic recirculation as their disposition and therapeutic 
outcomes may be similarly influenced by the gut microbiota like tacrine. Table 
7-1 illustrates an exemplified list of drugs and substrates which are subjected to 
enterohepatic recirculation. The effects of host-gut microbiota interactions may be 
particularly pertinent for those drugs with narrow therapeutic window.   
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Table 7-1 Examples of drugs and substrates subjected to enterohepatic 


























































In conclusion, this thesis provided a thorough mechanistic characterisation of the 
inter-individual responses to tacrine-induced transaminitis attributed to both the 
influence of the host and gut microbiota. These insightful findings illuminate the 
powerful application of an integrated strategy that combines clinical chemistry, 
pharmacokinetics, metabonomics, computational bioinformatics, metagenomics 
and genetic analysis in pharmaceutical research. We further envisage that such an 
integrated application will propel the frontier of personalised medicine as the 
ability to identify the relevant gut microbiota and its xenobiotic-modulating 
activity is clinically important to improve therapeutic outcomes of drugs with 







1. J. Woodcock, The Prospects for "Personalized Medicine" in Drug 
Development and Drug Therapy. Clin Pharmacol Ther 81, 164-169 (2007). 
2. L. Mancinelli, M. Cronin, W. Sadee, Pharmacogenomics: the promise of 
personalized medicine. AAPS pharmSci [electronic resource] 2,  (2000). 
3. M. A. Hamburg, F. S. Collins, The Path to Personalized Medicine. New 
England Journal of Medicine 363, 301-304 (2010). 
4. G. S. Ginsburg, J. J. McCarthy, Personalized medicine: revolutionizing drug 
discovery and patient care. Trends in Biotechnology 19, 491-496 (2001). 
5. S. F. Zhou, Y. M. Di, E. Chan, Y. M. Du, V. D. W. Chow, C. C. Xue, X. Lai, 
J. C. Wang, C. G. Li, M. Tian, W. Duan, Clinical pharmacogenetics and 
potential application in personalized medicine. Current Drug Metabolism 9, 
738-784 (2008). 
6. P. Y. Lum, J. M. J. Derry, E. E. Schadt, Integrative genomics and drug 
development. Pharmacogenomics 10, 203-212 (2009). 
7. S. Bates, Progress towards personalized medicine. Drug Discovery Today 15, 
115-120 (2010). 
8. I. S. Chan, G. S. Ginsburg, Personalized Medicine: Progress and Promise. 
Annual Review of Genomics and Human Genetics 12, 217-244 (2011). 
9. M. J. Khoury, E. C. Rich, G. Randhawa, S. M. Teutsch, J. Niederhuber, 
Comparative effectiveness research and genomic medicine: An evolving 
partnership for 21st century medicine. Genetics in Medicine 11, 707-711 
(2009). 
10. S. G. Leckband, J. R. Kelsoe, H. M. Dunnenberger, A. L. George, E. Tran, R. 
Berger, D. J. Muller, M. Whirl-Carrillo, K. E. Caudle, M. Pirmohamed, 
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-
B Genotype and Carbamazepine Dosing. Clin Pharmacol Ther 94, 324-328 
(2013). 
11. D. W. Nebert, L. Jorge-Nebert, E. S. Vesell, Pharmacogenomics and 
"Individualized Drug Therapy": High Expectations and Disappointing 
Achievements. American Journal of PharmacoGenomics 3, 361-370 (2003). 
12. J. Lederberg, Infectious history. Science 288, 287-293 (2000). 
13. K. Todar, in Todar’s online textbook of bacteriology, 
http://textbookofbacteriology.net/. (assessed 22 May 2010). 
14. D. C. Savage, Microbial ecology of the gastrointestinal tract. Annual review 
of microbiology 31, 107-133 (1977). 
15. C. M. Guinane, P. D. Cotter, Role of the gut microbiota in health and chronic 
gastrointestinal disease: understanding a hidden metabolic organ. Therapeutic 
advances in gastroenterology 6, 295-308 (2013). 
16. A. D. Kostic, R. J. Xavier, D. Gevers, The Microbiome in Inflammatory 
Bowel Disease: Current Status and the Future Ahead. Gastroenterology 146, 
1489-1499 (2014). 
17. X. C. Morgan, T. L. Tickle, H. Sokol, D. Gevers, K. L. Devaney, D. V. 
Ward, J. A. Reyes, S. A. Shah, N. LeLeiko, S. B. Snapper, A. Bousvaros, J. 
Korzenik, B. E. Sands, R. J. Xavier, C. Huttenhower, Dysfunction of the 
intestinal microbiome in inflammatory bowel disease and treatment. Genome 
biology 13, R79 (2012). 
18. J. Qin, Y. Li, Z. Cai, S. Li, J. Zhu, F. Zhang, S. Liang, W. Zhang, Y. Guan, 
D. Shen, Y. Peng, D. Zhang, Z. Jie, W. Wu, Y. Qin, W. Xue, J. Li, L. Han, D. 
Lu, P. Wu, Y. Dai, X. Sun, Z. Li, A. Tang, S. Zhong, X. Li, W. Chen, R. Xu, 
M. Wang, Q. Feng, M. Gong, J. Yu, Y. Zhang, M. Zhang, T. Hansen, G. 
Sanchez, J. Raes, G. Falony, S. Okuda, M. Almeida, E. LeChatelier, P. 
Renault, N. Pons, J.-M. Batto, Z. Zhang, H. Chen, R. Yang, W. Zheng, S. Li, 
 194 
 
H. Yang, J. Wang, S. D. Ehrlich, R. Nielsen, O. Pedersen, K. Kristiansen, J. 
Wang, A metagenome-wide association study of gut microbiota in type 2 
diabetes. Nature 490, 55-60 (2012). 
19. P. J. Turnbaugh, R. E. Ley, M. A. Mahowald, V. Magrini, E. R. Mardis, J. I. 
Gordon, An obesity-associated gut microbiome with increased capacity for 
energy harvest. Nature 444, 1027-1031 (2006). 
20. P. J. Turnbaugh, M. Hamady, T. Yatsunenko, B. L. Cantarel, A. Duncan, R. 
E. Ley, M. L. Sogin, W. J. Jones, B. A. Roe, J. P. Affourtit, M. Egholm, B. 
Henrissat, A. C. Heath, R. Knight, J. I. Gordon, A core gut microbiome in 
obese and lean twins. Nature 457, 480-484 (2009). 
21. T. E. Sweeney, J. M. Morton, The human gut microbiome: a review of the 
effect of obesity and surgically induced weight loss. JAMA surgery 148, 563-
569 (2013). 
22. D. W. Kang, J. G. Park, Z. E. Ilhan, G. Wallstrom, J. Labaer, J. B. Adams, R. 
Krajmalnik-Brown, Reduced incidence of Prevotella and other fermenters in 
intestinal microflora of autistic children. PLoS One 8, e68322 (2013). 
23. W. L. Hao, Y. K. Lee, Microflora of the gastrointestinal tract: a review. 
Methods Mol Biol 268, 491-502 (2004). 
24. J. Qin, R. Li, J. Raes, M. Arumugam, K. S. Burgdorf, C. Manichanh, T. 
Nielsen, N. Pons, F. Levenez, T. Yamada, D. R. Mende, J. Li, J. Xu, S. Li, D. 
Li, J. Cao, B. Wang, H. Liang, H. Zheng, Y. Xie, J. Tap, P. Lepage, M. 
Bertalan, J. M. Batto, T. Hansen, D. Le Paslier, A. Linneberg, H. B. Nielsen, 
E. Pelletier, P. Renault, T. Sicheritz-Ponten, K. Turner, H. Zhu, C. Yu, S. Li, 
M. Jian, Y. Zhou, Y. Li, X. Zhang, S. Li, N. Qin, H. Yang, J. Wang, S. 
Brunak, J. Dore, F. Guarner, K. Kristiansen, O. Pedersen, J. Parkhill, J. 
Weissenbach, H. I. T. C. Meta, P. Bork, S. D. Ehrlich, J. Wang, A human gut 
microbial gene catalogue established by metagenomic sequencing. Nature 
464, 59-65 (2010). 
25. P. Toivanen, J. Vaahtovuo, E. Eerola, Influence of major histocompatibility 
complex on bacterial composition of fecal flora. Infection and immunity 69, 
2372-2377 (2001). 
26. D. K. Molina, V. J. DiMaio, Normal organ weights in men: part II-the brain, 
lungs, liver, spleen, and kidneys. The American journal of forensic medicine 
and pathology 33, 368-372 (2012). 
27. W. H. Karasov, Nutritional bottleneck in a herbivore, the desert woodrat 
(Neotoma lepida) Physiol. Zool. 62, 1351-1382 (1989). 
28. J. D. Lambert, D. Zhao, R. O. Meyers, R. K. Kuester, B. N. Timmermann, R. 
T. Dorr, Nordihydroguaiaretic acid: hepatotoxicity and detoxification in the 
mouse. Toxicon : official journal of the International Society on Toxinology 
40, 1701-1708 (2002). 
29. S. Arteaga, A. Andrade-Cetto, R. Cardenas, Larrea tridentata (Creosote 
bush), an abundant plant of Mexican and US-American deserts and its 
metabolite nordihydroguaiaretic acid. Journal of ethnopharmacology 98, 
231-239 (2005). 
30. K. D. Kohl, R. B. Weiss, J. Cox, C. Dale, M. Denise Dearing, Gut microbes 
of mammalian herbivores facilitate intake of plant toxins. Ecology Letters, 
n/a-n/a (2014). 
31. M. D. Dearing, W. J. Foley, S. McLean, The influence of plant secondary 
metabolites on the nutritional ecology of herbivorous terrestrial vertebrates. 
Annual Review of Ecology, Evolution, and Systematics 36, 169-189 (2005). 
32. I. D. Wilson, J. K. Nicholson, The role of gut microbiota in drug response. 
Current Pharmaceutical Design 15, 1519-1523 (2009). 
33. S. A. Wrighton, J. C. Stevens, The Human Hepatic Cytochromes P450 




34. M. Spatzenegger, W. Jaeger, Clinical Importance of Hepatic Cytochrome 
P450 in Drug Metabolism. Drug Metabolism Reviews 27, 397-417 (1995). 
35. T. Iyanagi, Molecular mechanism of phase I and phase II drug-metabolizing 
enzymes: implications for detoxification. International review of cytology 
260, 35-112 (2007). 
36. Y. Ando, H. Saka, M. Ando, T. Sawa, K. Muro, H. Ueoka, A. Yokoyama, S. 
Saitoh, K. Shimokata, Y. Hasegawa, Polymorphisms of UDP-
glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic 
analysis. Cancer research 60, 6921-6926 (2000). 
37. G. M. Shenfield, Genetic polymorphisms, drug metabolism and drug 
concentrations. The Clinical Biochemist Reviews 25, 203 (2004). 
38. D. Tomalik-Scharte, A. Lazar, U. Fuhr, J. Kirchheiner, The clinical role of 
genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J 
8, 4-15 (2007). 
39. M. Ingelman-Sundberg, M. Oscarson, R. A. McLellan, Polymorphic human 
cytochrome P450 enzymes: an opportunity for individualized drug treatment. 
Trends in Pharmacological Sciences 20, 342-349 (1999). 
40. B. Park, N. Kitteringham, M. Pirmohamed, G. Tucker, Relevance of 
induction of human drug‐metabolizing enzymes: pharmacological and 
toxicological implications. British journal of clinical pharmacology 41, 477-
491 (1996). 
41. B. K. Park, A. M. Breckenridge, Clinical implications of enzyme induction 
and enzyme inhibition. Clin Pharmacokinet 6, 1-24 (1981). 
42. Induction and Inhibition of Drug-Metabolising Enzymes in Drug 
Metabolism, C. Ionescu, M. Caira, Eds. (Springer Netherlands, 2005),  chap. 
5, pp. 209-242. 
43. F. P. Guengerich, Cytochrome P450s and other enzymes in drug metabolism 
and toxicity. The AAPS journal 8, E101-111 (2006). 
44. H. J. Haiser, P. J. Turnbaugh, Is it time for a metagenomic basis of 
therapeutics? Science 336, 1253-1255 (2012). 
45. T. Sousa, R. Paterson, V. Moore, A. Carlsson, B. Abrahamsson, A. W. Basit, 
The gastrointestinal microbiota as a site for the biotransformation of drugs. 
International Journal of Pharmaceutics 363, 1-25 (2008). 
46. J. K. Nicholson, E. Holmes, I. D. Wilson, Gut microorganisms, mammalian 
metabolism and personalized health care. Nature Reviews Microbiology 3, 
431-438 (2005). 
47. T. A. Clayton, D. Baker, J. C. Lindon, J. R. Everett, J. K. Nicholson, 
Pharmacometabonomic identification of a significant host-microbiome 
metabolic interaction affecting human drug metabolism. Proceedings of the 
National Academy of Sciences of the United States of America 106, 14728-
14733 (2009). 
48. H. J. Haiser, D. B. Gootenberg, K. Chatman, G. Sirasani, E. P. Balskus, P. J. 
Turnbaugh, Predicting and manipulating cardiac drug inactivation by the 
human gut bacterium Eggerthella lenta. Science 341, 295-298 (2013). 
49. R. R. Scheline, Drug metabolism by intestinal microorganisms. Journal of 
Pharmaceutical Sciences 57, 2021-2037 (1968). 
50. R. R. Scheline, Metabolism of foreign compounds by gastrointestinal 
microorganisms. Pharmacological reviews 25, 451-523 (1973). 
51. I. R. Rowland, Interactions of the gut microflora and the host in toxicology. 
Toxicologic Pathology 16, 147-153 (1988). 
52. P. Goldman, Biochemical pharmacology of the intestinal flora. Annu Rev 
Pharmacol Toxicol 18, 523-539 (1978). 
53. S. Takeno, T. Sakai, Involvement of the intestinal microflora in nitrazepam-
induced teratogenicity in rats and its relationship to nitroreduction. 
Teratology 44, 209-214 (1991). 
 196 
 
54. T. Yatsunenko, F. E. Rey, M. J. Manary, I. Trehan, M. G. Dominguez-Bello, 
M. Contreras, M. Magris, G. Hidalgo, R. N. Baldassano, A. P. Anokhin, A. 
C. Heath, B. Warner, J. Reeder, J. Kuczynski, J. G. Caporaso, C. A. 
Lozupone, C. Lauber, J. C. Clemente, D. Knights, R. Knight, J. I. Gordon, 
Human gut microbiome viewed across age and geography. Nature 486, 222-
227 (2012). 
55. N. H. W. Group, J. Peterson, S. Garges, M. Giovanni, P. McInnes, L. Wang, 
J. A. Schloss, V. Bonazzi, J. E. McEwen, K. A. Wetterstrand, C. Deal, C. C. 
Baker, V. Di Francesco, T. K. Howcroft, R. W. Karp, R. D. Lunsford, C. R. 
Wellington, T. Belachew, M. Wright, C. Giblin, H. David, M. Mills, R. 
Salomon, C. Mullins, B. Akolkar, L. Begg, C. Davis, L. Grandison, M. 
Humble, J. Khalsa, A. R. Little, H. Peavy, C. Pontzer, M. Portnoy, M. H. 
Sayre, P. Starke-Reed, S. Zakhari, J. Read, B. Watson, M. Guyer, The NIH 
Human Microbiome Project. Genome Res 19, 2317-2323 (2009). 
56. H. J. Haiser, P. J. Turnbaugh, Developing a metagenomic view of xenobiotic 
metabolism. Pharmacological research : the official journal of the Italian 
Pharmacological Society 69, 21-31 (2013). 
57. R. Kaddurah-Daouk, R. A. Baillie, H. Zhu, Z.-B. Zeng, M. M. Wiest, U. T. 
Nguyen, K. Wojnoonski, S. M. Watkins, M. Trupp, R. M. Krauss, Enteric 
Microbiome Metabolites Correlate with Response to Simvastatin Treatment. 
PLoS ONE 6, e25482 (2011). 
58. K. S. Saitta, C. Zhang, K. K. Lee, K. Fujimoto, M. R. Redinbo, U. A. 
Boelsterli, Bacterial beta-glucuronidase inhibition protects mice against 
enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of 
action and pharmacokinetics. Xenobiotica 44, 28-35 (2014). 
59. M. Li, B. Wang, M. Zhang, M. Rantalainen, S. Wang, H. Zhou, Y. Zhang, J. 
Shen, X. Pang, H. Wei, Y. Chen, H. Lu, J. Zuo, M. Su, Y. Qiu, W. Jia, C. 
Xiao, L. M. Smith, S. Yang, E. Holmes, H. Tang, G. Zhao, J. K. Nicholson, 
L. Li, L. Zhao, Symbiotic gut microbes modulate human metabolic 
phenotypes. Proceedings of the National Academy of Sciences of the United 
States of America 105, 2117-2122 (2008). 
60. X. Zheng, G. Xie, A. Zhao, L. Zhao, C. Yao, N. H. Chiu, Z. Zhou, Y. Bao, 
W. Jia, J. K. Nicholson, The footprints of gut microbial-mammalian co-
metabolism. J Proteome Res 10, 5512-5522 (2011). 
61. L. W. Robertson, A. Chandrasekaran, R. H. Reuning, J. Hui, B. D. Rawal, 
Reduction of digoxin to 20R-dihydrodigoxin by cultures of Eubacterium 
lentum. Applied and environmental microbiology 51, 1300-1303 (1986). 
62. J. R. Saha, V. P. Butler, Jr., H. C. Neu, J. Lindenbaum, Digoxin-inactivating 
bacteria: identification in human gut flora. Science 220, 325-327 (1983). 
63. H. Li, W. Jia, Cometabolism of microbes and host: implications for drug 
metabolism and drug-induced toxicity. Clin Pharmacol Ther 94, 574-581 
(2013). 
64. J. Lindenbaum, D. G. Rund, V. P. Butler, Jr., D. Tse-Eng, J. R. Saha, 
Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. The 
New England journal of medicine 305, 789-794 (1981). 
65. C. F. Maurice, H. J. Haiser, P. J. Turnbaugh, Xenobiotics shape the 
physiology and gene expression of the active human gut microbiome. Cell 
152, 39-50 (2013). 
66. E. Holmes, J. Kinross, G. R. Gibson, R. Burcelin, W. Jia, S. Pettersson, J. K. 
Nicholson, Therapeutic Modulation of Microbiota-Host Metabolic 
Interactions. Science Translational Medicine 4, 137rv136 (2012). 
67. B. D. Wallace, H. Wang, K. T. Lane, J. E. Scott, J. Orans, J. S. Koo, M. 
Venkatesh, C. Jobin, L.-A. Yeh, S. Mani, M. R. Redinbo, Alleviating Cancer 




68. A. B. Roberts, B. D. Wallace, M. K. Venkatesh, S. Mani, M. R. Redinbo, 
Molecular insights into microbial beta-glucuronidase inhibition to abrogate 
CPT-11 toxicity. Molecular pharmacology 84, 208-217 (2013). 
69. A. LoGuidice, B. D. Wallace, L. Bendel, M. R. Redinbo, U. A. Boelsterli, 
Pharmacologic targeting of bacterial beta-glucuronidase alleviates 
nonsteroidal anti-inflammatory drug-induced enteropathy in mice. The 
Journal of pharmacology and experimental therapeutics 341, 447-454 
(2012). 
70. W. Jia, H. Li, L. Zhao, J. K. Nicholson, Gut microbiota: a potential new 
territory for drug targeting. Nat Rev Drug Discov 7, 123-129 (2008). 
71. Y. Zhao, J. Wu, J. V. Li, N. Y. Zhou, H. Tang, Y. Wang, Gut microbiota 
composition modifies fecal metabolic profiles in mice. J Proteome Res 12, 
2987-2999 (2013). 
72. S. P. Claus, T. M. Tsang, Y. Wang, O. Cloarec, E. Skordi, F. P. Martin, S. 
Rezzi, A. Ross, S. Kochhar, E. Holmes, J. K. Nicholson, Systemic 
multicompartmental effects of the gut microbiome on mouse metabolic 
phenotypes. Mol Syst Biol 4, 219 (2008). 
73. W. R. Wikoff, A. T. Anfora, J. Liu, P. G. Schultz, S. A. Lesley, E. C. Peters, 
G. Siuzdak, Metabolomics analysis reveals large effects of gut microflora on 
mammalian blood metabolites. Proceedings of the National Academy of 
Sciences of the United States of America 106, 3698-3703 (2009). 
74. S. P. Claus, S. L. Ellero, B. Berger, L. Krause, A. Bruttin, J. Molina, A. Paris, 
E. J. Want, I. de Waziers, O. Cloarec, S. E. Richards, Y. Wang, M. E. 
Dumas, A. Ross, S. Rezzi, S. Kochhar, P. Van Bladeren, J. C. Lindon, E. 
Holmes, J. K. Nicholson, Colonization-induced host-gut microbial metabolic 
interaction. mBio 2, e00271-00210 (2011). 
75. F. P. Martin, M. E. Dumas, Y. Wang, C. Legido-Quigley, I. K. Yap, H. Tang, 
S. Zirah, G. M. Murphy, O. Cloarec, J. C. Lindon, N. Sprenger, L. B. Fay, S. 
Kochhar, P. van Bladeren, E. Holmes, J. K. Nicholson, A top-down systems 
biology view of microbiome-mammalian metabolic interactions in a mouse 
model. Mol Syst Biol 3, 112 (2007). 
76. F. P. Martin, N. Sprenger, I. K. Yap, Y. Wang, R. Bibiloni, F. Rochat, S. 
Rezzi, C. Cherbut, S. Kochhar, J. C. Lindon, E. Holmes, J. K. Nicholson, 
Panorganismal gut microbiome-host metabolic crosstalk. J Proteome Res 8, 
2090-2105 (2009). 
77. J. K. Nicholson, J. C. Lindon, E. Holmes, 'Metabonomics': understanding the 
metabolic responses of living systems to pathophysiological stimuli via 
multivariate statistical analysis of biological NMR spectroscopic data. 
Xenobiotica 29, 1181 - 1189 (1999). 
78. J. K. Nicholson, I. D. Wilson, Understanding 'global' systems biology: 
Metabonomics and the continuum of metabolism. Nature Reviews Drug 
Discovery 2, 668-676 (2003). 
79. J. C. Lindon, J. K. Nicholson, E. Holmes, H. Antti, M. E. Bollard, H. Keun, 
O. Beckonert, T. M. Ebbels, M. D. Reily, D. Robertson, G. J. Stevens, P. 
Luke, A. P. Breau, G. H. Cantor, R. H. Bible, U. Niederhauser, H. Senn, G. 
Schlotterbeck, U. G. Sidelmann, S. M. Laursen, A. Tymiak, B. D. Car, L. 
Lehman-McKeeman, J. M. Colet, A. Loukaci, C. Thomas, Contemporary 
issues in toxicology: The role of metabonomics in toxicology and its 
evaluation by the COMET project. Toxicology and Applied Pharmacology 
187, 137-146 (2003). 
80. J. C. Lindon, E. Holmes, J. K. Nicholson, Metabonomics in pharmaceutical R 
& D. FEBS Journal 274, 1140-1151 (2007). 
81. T. A. Clayton, J. C. Lindon, O. Cloarec, H. Antti, C. Charuel, G. Hanton, J. 
P. Provost, J. L. L. Net, D. Baker, R. J. Walley, J. R. Everett, J. K. Nicholson, 
 198 
 
Pharmaco-metabonomic phenotyping and personalized drug treatment. 
Nature 440, 1073-1077 (2006). 
82. L. Y. Yip, E. C. Yong Chan, Chapter 8 - Gas Chromatography/Mass 
Spectrometry-Based Metabonomics in Proteomic and Metabolomic 
Approaches to Biomarker Discovery, H. J. Issaq, T. D. Veenstra, Eds. 
(Academic Press, Boston, 2013), pp. 131-144. 
83. K. K. Pasikanti, P. C. Ho, E. C. Chan, Gas chromatography/mass 
spectrometry in metabolic profiling of biological fluids. J Chromatogr B 
Analyt Technol Biomed Life Sci 871, 202-211 (2008). 
84. W. B. Dunn, D. Broadhurst, P. Begley, E. Zelena, S. Francis-Mcintyre, N. 
Anderson, M. Brown, J. D. Knowles, A. Halsall, J. N. Haselden, A. W. 
Nicholls, I. D. Wilson, D. B. Kell, R. Goodacre, Procedures for large-scale 
metabolic profiling of serum and plasma using gas chromatography and 
liquid chromatography coupled to mass spectrometry. Nature Protocols 6, 
1060-1083 (2011). 
85. E. C. Y. Chan, K. K. Pasikanti, J. K. Nicholson, Global urinary metabolic 
profiling procedures using gas chromatography-mass spectrometry. Nature 
Protocols 6, 1483-1499 (2011). 
86. E. Kaal, H. G. Janssen, Extending the molecular application range of gas 
chromatography. Journal of Chromatography A 1184, 43-60 (2008). 
87. N. Psychogios, D. D. Hau, J. Peng, A. C. Guo, R. Mandal, S. Bouatra, I. 
Sinelnikov, R. Krishnamurthy, R. Eisner, B. Gautam, N. Young, J. Xia, C. 
Knox, E. Dong, P. Huang, Z. Hollander, T. L. Pedersen, S. R. Smith, F. 
Bamforth, R. Greiner, B. McManus, J. W. Newman, T. Goodfriend, D. S. 
Wishart, The human serum metabolome. PLoS One 6, e16957 (2011). 
88. S. Bouatra, F. Aziat, R. Mandal, A. C. Guo, M. R. Wilson, C. Knox, T. C. 
Bjorndahl, R. Krishnamurthy, F. Saleem, P. Liu, Z. T. Dame, J. Poelzer, J. 
Huynh, F. S. Yallou, N. Psychogios, E. Dong, R. Bogumil, C. Roehring, D. 
S. Wishart, The Human Urine Metabolome. PLoS ONE 8, e73076 (2013). 
89. D. S. Wishart, M. J. Lewis, J. A. Morrissey, M. D. Flegel, K. Jeroncic, Y. 
Xiong, D. Cheng, R. Eisner, B. Gautam, D. Tzur, S. Sawhney, F. Bamforth, 
R. Greiner, L. Li, The human cerebrospinal fluid metabolome. J Chromatogr 
B Analyt Technol Biomed Life Sci 871, 164-173 (2008). 
90. R. Mandal, A. C. Guo, K. K. Chaudhary, P. Liu, F. S. Yallou, E. Dong, F. 
Aziat, D. S. Wishart, Multi-platform characterization of the human 
cerebrospinal fluid metabolome: a comprehensive and quantitative update. 
Genome medicine 4, 38 (2012). 
91. D. S. Wishart, T. Jewison, A. C. Guo, M. Wilson, C. Knox, Y. Liu, Y. 
Djoumbou, R. Mandal, F. Aziat, E. Dong, S. Bouatra, I. Sinelnikov, D. 
Arndt, J. Xia, P. Liu, F. Yallou, T. Bjorndahl, R. Perez-Pineiro, R. Eisner, F. 
Allen, V. Neveu, R. Greiner, A. Scalbert, HMDB 3.0—The Human 
Metabolome Database in 2013. Nucleic Acids Research 41, D801-D807 
(2013). 
92. D. S. Wishart, Computational Approaches to Metabolomics in Bioinformatics 
Methods in Clinical Research. (2009), vol. 593, chap. 14, pp. 283-313. 
93. D. P. Enot, B. Haas, K. M. Weinberger, Bioinformatics for Mass 
Spectrometry-Based Metabolomics in Bioinformatics for Omics Data : 
Methods and Protocols. (2011), vol. 719, chap. 16, pp. 351-375. 
94. M. Yoshida, N. Hatano, S. Nishiumi, Y. Irino, Y. Izumi, T. Takenawa, T. 
Azuma, Diagnosis of gastroenterological diseases by metabolome analysis 
using gas chromatography-mass spectrometry. Journal of Gastroenterology 
47, 9-20 (2012). 
95. M. P. Quinones, R. Kaddurah-Daouk, Metabolomics tools for identifying 




96. K. K. Pasikanti, K. Esuvaranathan, P. C. Ho, R. Mahendran, R. Kamaraj, Q. 
H. Wu, E. Chiong, E. C. Y. Chan, Noninvasive urinary metabonomic 
diagnosis of human bladder cancer. Journal of Proteome Research 9, 2988-
2995 (2010). 
97. K. K. Pasikanti, J. Norasmara, S. Cai, R. Mahendran, K. Esuvaranathan, P. C. 
Ho, E. C. Y. Chan, Metabolic footprinting of tumorigenic and 
nontumorigenic uroepithelial cells using two-dimensional gas 
chromatography time-of-flight mass spectrometry. Analytical and 
Bioanalytical Chemistry 398, 1285-1293 (2010). 
98. E. C. Y. Chan, P. K. Koh, M. Mal, P. Y. Cheah, K. W. Eu, A. Backshall, R. 
Cavill, J. K. Nicholson, H. C. Keun, Metabolic profiling of human colorectal 
cancer using high-resolution magic angle spinning nuclear magnetic 
resonance (HR-MAS NMR) spectroscopy and gas chromatography mass 
spectrometry (GC/MS). Journal of Proteome Research 8, 352-361 (2009). 
99. M. Mal, P. K. Koh, P. Y. Cheah, E. C. Y. Chan, Development and validation 
of a gas chromatography/mass spectrometry method for the metabolic 
profiling of human colon tissue. Rapid Communications in Mass 
Spectrometry 23, 487-494 (2009). 
100. M. Mal, P. K. Koh, P. Y. Cheah, E. C. Y. Chan, Metabotyping of human 
colorectal cancer using two-dimensional gas chromatography mass 
spectrometry. Analytical and Bioanalytical Chemistry 403, 483-493 (2012). 
101. R. H. Weiss, K. Kim, Metabolomics in the study of kidney diseases. Nature 
Reviews Nephrology 8, 22-33 (2012). 
102. J. C. Lindon, H. C. Keun, T. M. D. Ebbels, J. M. T. Pearce, E. Holmes, J. K. 
Nicholson, The Consortium for Metabonomic Toxicology (COMET): Aims, 
activities and achievements. Pharmacogenomics 6, 691-699 (2005). 
103. J. R. Zgoda-Pols, S. Chowdhury, M. Wirth, M. V. Milburn, D. C. Alexander, 
K. B. Alton, Metabolomics analysis reveals elevation of 3-indoxyl sulfate in 
plasma and brain during chemically-induced acute kidney injury in mice: 
Investigation of nicotinic acid receptor agonists. Toxicology and Applied 
Pharmacology 255, 48-56 (2011). 
104. T. Ohta, N. Masutomi, N. Tsutsui, T. Sakairi, M. Mitchell, M. V. Milburn, J. 
A. Ryals, K. D. Beebe, L. Guo, Untargeted metabolomic profiling as an 
evaluative tool of fenofibrate-Induced toxicology in fischer 344 male rats. 
Toxicologic Pathology 37, 521-535 (2009). 
105. J. Aa, F. Shao, G. Wang, Q. Huang, W. Zha, B. Yan, T. Zheng, L. Liu, B. 
Cao, J. Shi, M. Li, C. Zhao, X. Wang, Z. Wu, Gas chromatography time-of-
flight mass spectrometry based metabolomic approach to evaluating toxicity 
of triptolide. Metabolomics 7, 217-225 (2011). 
106. T. Toda, N. Saito, N. Ikarashi, K. Ito, M. Yamamoto, A. Ishige, K. Watanabe, 
K. Sugiyama, Intestinal flora induces the expression of Cyp3a in the mouse 
liver. Xenobiotica 39, 323-334 (2009). 
107. T. Li, J. Y. Chiang, Nuclear receptors in bile acid metabolism. Drug Metab 
Rev 45, 145-155 (2013). 
108. P. B. Hylemon, Chapter 12 Metabolism of bile acids in intestinal microflora 
in New Comprehensive Biochemistry, D. Henry, S. Jan, Eds. (Elsevier, 1985), 
vol. Volume 12, pp. 331-343. 
109. B. Bjorkholm, C. M. Bok, A. Lundin, J. Rafter, M. L. Hibberd, S. Pettersson, 
Intestinal microbiota regulate xenobiotic metabolism in the liver. PLoS One 
4, e6958 (2009). 
110. K. M. Tuohy, A. L. McCartney, Molecular Microbial Ecology of the Human 
Gut in Prebiotics: Development & Application. (John Wiley & Sons, Ltd, 
2006), pp. 135-155. 
 200 
 
111. M. Coates, B. Drasar, A. Mallett, I. Rowland, I. Rowland, Methodological 
considerations for the study of bacterial metabolism. Role of the Gut Flora in 
Toxicity and Cancer, 1-21 (1988). 
112. M. H. Fraher, P. W. O'Toole, E. M. Quigley, Techniques used to characterize 
the gut microbiota: a guide for the clinician. Nature reviews. 
Gastroenterology & hepatology 9, 312-322 (2012). 
113. G. V. Doern, Detection of Selected Fastidious Bacteria. Clinical Infectious 
Diseases 30, 166-173 (2000). 
114. H. Miura, M. Horiguchi, T. Matsumoto, Nutritional Interdependence Among 
Rumen Bacteria, Bacteroides amylophilus, Megasphaera elsdenii, and 
Ruminococcus albus. Applied and environmental microbiology 40, 294-300 
(1980). 
115. A. M. Stams, Metabolic interactions between anaerobic bacteria in 
methanogenic environments. Antonie van Leeuwenhoek 66, 271-294 (1994). 
116. J. Kuczynski, C. L. Lauber, W. A. Walters, L. W. Parfrey, J. C. Clemente, D. 
Gevers, R. Knight, Experimental and analytical tools for studying the human 
microbiome. Nat Rev Genet 13, 47-58 (2012). 
117. M. Dave, P. D. Higgins, S. Middha, K. P. Rioux, The human gut 
microbiome: current knowledge, challenges, and future directions. 
Translational research : the journal of laboratory and clinical medicine 160, 
246-257 (2012). 
118. M. Blaut, M. D. Collins, G. W. Welling, J. Dore, J. van Loo, W. de Vos, 
Molecular biological methods for studying the gut microbiota: the EU human 
gut flora project. The British journal of nutrition 87 Suppl 2, S203-211 
(2002). 
119. G. M. Weinstock, Genomic approaches to studying the human microbiota. 
Nature 489, 250-256 (2012). 
120. J. F. Brugere, A. Mihajlovski, M. Missaoui, P. Peyret, Tools for stools: the 
challenge of assessing human intestinal microbiota using molecular 
diagnostics. Expert review of molecular diagnostics 9, 353-365 (2009). 
121. S. Chakravorty, D. Helb, M. Burday, N. Connell, D. Alland, A detailed 
analysis of 16S ribosomal RNA gene segments for the diagnosis of 
pathogenic bacteria. Journal of Microbiological Methods 69, 330-339 (2007). 
122. T. Matsuki, K. Watanabe, J. Fujimoto, Y. Miyamoto, T. Takada, K. 
Matsumoto, H. Oyaizu, R. Tanaka, Development of 16S rRNA-gene-targeted 
group-specific primers for the detection and identification of predominant 
bacteria in human feces. Applied and environmental microbiology 68, 5445-
5451 (2002). 
123. T. Rinttilä, A. Kassinen, E. Malinen, L. Krogius, A. Palva, Development of 
an extensive set of 16S rDNA-targeted primers for quantification of 
pathogenic and indigenous bacteria in faecal samples by real-time PCR. 
Journal of Applied Microbiology 97, 1166-1177 (2004). 
124. M. F. Polz, C. M. Cavanaugh, Bias in template-to-product ratios in 
multitemplate PCR. Applied and environmental microbiology 64, 3724-3730 
(1998). 
125. S. G. Acinas, R. Sarma-Rupavtarm, V. Klepac-Ceraj, M. F. Polz, PCR-
induced sequence artifacts and bias: insights from comparison of two 16S 
rRNA clone libraries constructed from the same sample. Applied and 
environmental microbiology 71, 8966-8969 (2005). 
126. C. Manichanh, J. Reeder, P. Gibert, E. Varela, M. Llopis, M. Antolin, R. 
Guigo, R. Knight, F. Guarner, Reshaping the gut microbiome with bacterial 
transplantation and antibiotic intake. Genome research 20, 1411-1419 (2010). 
127. K. Lu, R. P. Abo, K. A. Schlieper, M. E. Graffam, S. Levine, J. S. Wishnok, 
J. A. Swenberg, S. R. Tannenbaum, J. G. Fox, Arsenic exposure perturbs the 
gut microbiome and its metabolic profile in mice: an integrated 
 201 
 
metagenomics and metabolomics analysis. Environmental health perspectives 
122, 284-291 (2014). 
128. P. B. Watkins, H. J. Zimmerman, M. J. Knapp, S. I. Gracon, K. W. Lewis, 
Hepatotoxic effects of tacrine administration in patients with Alzheimer's 
disease. JAMA 271, 992-998 (1994). 
129. W. G. Blackard Jr, G. K. Sood, D. Ralph Crowe, M. B. Fallon, Tacrine a 
cause of fatal hepatotoxicity? Journal of Clinical Gastroenterology 26, 57-59 
(1998). 
130. D. J. Ames, P. S. Bhathal, B. M. Davies, J. R. E. Fraser, P. R. Gibson, S. 
Roberts, Heterogeneity of adverse hepatic reactions to 
tetrahydroaminoacridine. Australian and New Zealand Journal of Medicine 
20, 193-195 (1990). 
131. P. Hammel, D. Larrey, J. Bernuau, M. Kalafat, E. Freneaux, G. Babany, C. 
Degott, G. Feldmann, D. Pessayre, J. P. Benhamou, Acute hepatitis after 
tetrahydroaminoacridine administration for Alzheimer's disease. J Clin 
Gastroenterol 12, 329-331 (1990). 
132. T. F. Woolf, W. F. Pool, R. M. Walker, D. K. Monteith, Liver reactions to 
tacrine. Handbook of Experimental Pharmacology Drug-Induced 
Hepatotoxicity, 395-410 (1996). 
133. R. F. Stachlewitz, G. E. Arteel, J. A. Raleigh, H. D. Connor, R. P. Mason, R. 
G. Thurman, Development and characterization of a new model of tacrine-
induced hepatotoxicity: Role of the sympathetic nervous system and hypoxia- 
reoxygenation. Journal of Pharmacology and Experimental Therapeutics 
282, 1591-1599 (1997). 
134. X. C. Ma, J. Xin, H. X. Wang, T. Zhang, Z. H. Tu, Acute effects of huperzine 
A and tacrine on rat liver. Acta Pharmacologica Sinica 24, 247-250 (2003). 
135. D. F. Carr, A. Alfirevic, J. D. Tugwood, B. J. Barratt, J. Sherwood, J. Smith, 
M. Pirmohamed, B. Kevin Park, Molecular and genetic association of 
interleukin-6 in tacrine-induced hepatotoxicity. Pharmacogenetics and 
Genomics 17, 961-972 (2007). 
136. S. Madden, V. Spaldin, B. K. Park, Clinical Pharmacokinetics of Tacrine. 
Clinical Pharmacokinetics 28, 449-457 (1995). 
137. M. W. Jann, K. L. Shirley, G. W. Small, Clinical pharmacokinetics and 
pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 41, 719-
739 (2002). 
138. G. Lou, P. R. Montgomery, D. S. Sitar, Bioavailability and pharmacokinetic 
disposition of tacrine in elderly patients with Alzheimer's disease. J 
Psychiatry Neurosci 21, 334-339 (1996). 
139. D. R. Forsyth, G. K. Wilcock, R. A. Morgan, C. A. Truman, J. M. Ford, C. J. 
Roberts, Pharmacokinetics of tacrine hydrochloride in Alzheimer's disease. 
Clin Pharmacol Ther 46, 634-641 (1989). 
140. J. M. Ford, C. A. Truman, G. K. Wilcock, C. J. C. Roberts, Serum 
concentrations of tacrine hydrochloride predict its adverse effects in 
Alzheimer's disease Clin. Pharmacol. Ther. 53, 691-695 (1993). 
141. K. L. Davis, P. Powchick, Tacrine. The Lancet 345, 625-630 (1995). 
142. W. McNally, M. Roth, R. Young, H. Bockbrader, T. Chang, Quantitative 
whole-body autoradiographic determination of tacrine tissue distribution in 
rats following intravenous or oral dose. Pharm Res 6, 924-930 (1989). 
143. W. F. Pool, M. D. Reily, S. M. Bjorge, T. F. Woolf, Metabolic Disposition of 
the Cognition Activator Tacrine in Rats, Dogs, and Humans. Species 
Comparisons. Drug Metab Dispos 25, 590-597 (1997). 
144. T. Woolf, W. Pool, S. Bjorge, T. Chang, O. Goel, C. d. Purchase, M. 
Schroeder, K. Kunze, W. Trager, Bioactivation and irreversible binding of 
the cognition activator tacrine using human and rat liver microsomal 
preparations. Species difference. Drug Metab Dispos 21, 874-882 (1993). 
 202 
 
145. J.-P. H. T. M. Ploemen, H. Kramer, E. I. Krajnc, I. Martin, The Use of 
Toxicokinetic Data in Preclinical Safety Assessment: A Toxicologic 
Pathologist Perspective. Toxicologic Pathology 35, 834-837 (2007). 
146. P. Baldrick, Toxicokinetics in preclinical evaluation. Drug Discovery Today 
8, 127-133 (2003). 
147. R. Hsu, G. Shutske, E. Dileo, S. Chesson, A. Linville, R. Allen, Identification 
of the urinary metabolites of tacrine in the rat. Drug Metab Dispos 18, 779-
783 (1990). 
148. W. Hooper, W. Pool, T. Woolf, J. Gal, Stereoselective hydroxylation of 
tacrine in rats and humans. Drug Metab Dispos 22, 719-724 (1994). 
149. R. S. Hsu, E. M. DiLeo, S. M. Chesson, High-performance liquid 
chromatography for the determination of tacrine and its metabolites in 
plasma. J Chromatogr 530, 170-176 (1990). 
150. B. D. Car, V. M. Eng, N. E. Everds, D. I. Bounous, Chapter 5 - Clinical 
Pathology of the Rat in The Laboratory Rat (Second Edition), M. A. Suckow, 
S. H. Weisbroth, C. L. Franklin, Eds. (Academic Press, Burlington, 2006), 
pp. 127-146. 
151. S. Madden, V. Spaldin, R. N. Hayes, T. F. Woolf, W. F. Pool, B. K. Park, 
Species variation in the bioactivation of tacrine by hepatic microsomes. 
Xenobiotica 25, 103-116 (1995). 
152. S. Madden, T. F. Woolf, W. F. Pool, B. K. Park, An investigation into the 
formation of stable, protein-reactive and cytotoxic metabolites from tacrine in 
vitro. Studies with human and rat liver microsomes. Biochemical 
Pharmacology 46, 13-20 (1993). 
153. M. W. Fariss, S. A. Johnsen, L. P. Walton, V. R. Mumaw, S. D. Ray, 
Tetrahydroaminoacridine-induced ribosomal changes and inhibition of 
protein synthesis in rat hepatocyte suspensions. Hepatology 20, 240-246 
(1994). 
154. A. Berson, S. Renault, P. Letteron, M. A. Robin, B. Fromenty, D. Fau, M. A. 
Le Bot, C. Riche, A. M. Durand-Schneider, G. Feldmann, D. Pessayre, 
Uncoupling of rat and human mitochondria: a possible explanation for 
tacrine-induced liver dysfunction. Gastroenterology 110, 1878-1890 (1996). 
155. C. J. Viau, R. D. Curren, K. Wallace, Cytotoxicity of tacrine and velnacrine 
metabolites in cultured rat, dog and human hepatocytes. Drug Chem Toxicol 
16, 227-239 (1993). 
156. A. Mansouri, D. Haouzi, V. Descatoire, C. Demeilliers, A. Sutton, N. Vadrot, 
B. Fromenty, G. Feldmann, D. Pessayre, A. Berson, Tacrine inhibits 
topoisomerases and DNA synthesis to cause mitochondrial DNA depletion 
and apoptosis in mouse liver. Hepatology 38, 715-725 (2003). 
157. Q. Meng, J. Ru, G. Zhang, C. Shen, S. Schmitmeier, A. Bader, Re-evaluation 
of tacrine hepatotoxicity using gel entrapped hepatocytes. Toxicology Letters 
168, 140-147 (2007). 
158. J. Mark, G. Shayne, The Rat in Animal Models in Toxicology, Second 
Edition. (Informa Healthcare, 2006), pp. 147-276. 
159. L. A. Marques, J. Kool, F. de Kanter, H. Lingeman, W. Niessen, H. Irth, 
Production and on-line acetylcholinesterase bioactivity profiling of chemical 
and biological degradation products of tacrine. Journal of Pharmaceutical 
and Biomedical Analysis 53, 609-616 (2010). 
160. G. O. Evans, Chapter 3- Assessment of Hepatotoxicity in Animal Clinical 
Chemistry. (CRC Press, 2009),  chap. 3, pp. 37-66. 
161. K. Weingand, G. Brown, R. Hall, D. Davies, K. Gossett, D. Neptun, T. 
Waner, T. Matsuzawa, P. Salemink, W. Froelke, J. P. Provost, G. Dal Negro, 
J. Batchelor, M. Nomura, H. Groetsch, A. Boink, J. Kimball, D. Woodman, 
M. York, E. Fabianson-Johnson, M. Lupart, E. Melloni, Harmonization of 
animal clinical pathology testing in toxicity and safety studies. The Joint 
 203 
 
Scientific Committee for International Harmonization of Clinical Pathology 
Testing. Fundamental and applied toxicology : official journal of the Society 
of Toxicology 29, 198-201 (1996). 
162. L. Boone, D. Meyer, P. Cusick, D. Ennulat, A. P. Bolliger, N. Everds, V. 
Meador, G. Elliott, D. Honor, D. Bounous, H. Jordan, Selection and 
interpretation of clinical pathology indicators of hepatic injury in preclinical 
studies. Veterinary clinical pathology / American Society for Veterinary 
Clinical Pathology 34, 182-188 (2005). 
163. N. M. Davies, J. K. Takemoto, D. R. Brocks, J. A. Yanez, Multiple peaking 
phenomena in pharmacokinetic disposition. Clin Pharmacokinet 49, 351-377 
(2010). 
164. M. S. Roberts, B. M. Magnusson, F. J. Burczynski, M. Weiss, Enterohepatic 
circulation: physiological, pharmacokinetic and clinical implications. Clin 
Pharmacokinet 41, 751-790 (2002). 
165. X. Yang, Y. A. Gandhi, D. B. Duignan, M. E. Morris, Prediction of biliary 
excretion in rats and humans using molecular weight and quantitative 
structure-pharmacokinetic relationships. The AAPS journal 11, 511-525 
(2009). 
166. J. F. Marier, P. Vachon, A. Gritsas, J. Zhang, J. P. Moreau, M. P. Ducharme, 
Metabolism and disposition of resveratrol in rats: extent of absorption, 
glucuronidation, and enterohepatic recirculation evidenced by a linked-rat 
model. The Journal of pharmacology and experimental therapeutics 302, 
369-373 (2002). 
167. D. M. Ouellet, G. M. Pollack, Biliary excretion and enterohepatic 
recirculation of morphine-3-glucuronide in rats. Drug Metab Dispos 23, 478-
484 (1995). 
168. W. A. Colburn, P. C. Hirom, R. J. Parker, P. Milburn, A pharmacokinetic 
model for enterohepatic recirculation in the rat: phenolphthalein, a model 
drug. Drug Metab Dispos 7, 100-102 (1979). 
169. T. O. Rod, T. Midtvedt, Origin of intestinal beta-glucuronidase in germfree, 
monocontaminated and conventional rats. Acta pathologica et microbiologica 
Scandinavica. Section B, Microbiology 85, 271-276 (1977). 
170. L. Oleson, M. H. Court, Effect of the beta-glucuronidase inhibitor 
saccharolactone on glucuronidation by human tissue microsomes and 
recombinant UDP-glucuronosyltransferases. The Journal of pharmacy and 
pharmacology 60, 1175-1182 (2008). 
171. M. F. Yancey, D. A. Merritt, J. A. White, S. A. Marsh, C. W. Locuson, 
Distribution, metabolism, and excretion of toceranib phosphate (Palladia, 
SU11654), a novel tyrosine kinase inhibitor, in dogs. Journal of veterinary 
pharmacology and therapeutics 33, 154-161 (2010). 
172. J. E. Patrick, T. Kosoglou, K. L. Stauber, K. B. Alton, S. E. Maxwell, Y. Zhu, 
P. Statkevich, R. Iannucci, S. Chowdhury, M. Affrime, M. N. Cayen, 
Disposition of the selective cholesterol absorption inhibitor ezetimibe in 
healthy male subjects. Drug Metab Dispos 30, 430-437 (2002). 
173. R. J. Parker, P. C. Hirom, P. Millburn, Enterohepatic recycling of 
phenolphthalein, morphine, lysergic acid diethylamide (LSD) and 
diphenylacetic acid in the rat. Hydrolysis of glucuronic acid conjugates in the 
gut lumen. Xenobiotica 10, 689-703 (1980). 
174. J. Z. Peng, R. P. Remmel, R. J. Sawchuk, Inhibition of murine cytochrome 
P4501A by tacrine: in vitro studies. Drug Metab Dispos 32, 805-812 (2004). 
175. M. N. Lardizabal, A. L. Nocito, S. M. Daniele, L. A. Ornella, J. F. Palatnik, 
L. M. Veggi, Reference genes for real-time PCR quantification of 
microRNAs and messenger RNAs in rat models of hepatotoxicity. PloS one 
7, e36323 (2012). 
 204 
 
176. D. Ling, P. M. Salvaterra, Robust RT-qPCR data normalization: validation 
and selection of internal reference genes during post-experimental data 
analysis. PloS one 6, e17762 (2011). 
177. S. A. Bustin, V. Benes, J. A. Garson, J. Hellemans, J. Huggett, M. Kubista, 
R. Mueller, T. Nolan, M. W. Pfaffl, G. L. Shipley, J. Vandesompele, C. T. 
Wittwer, The MIQE guidelines: minimum information for publication of 
quantitative real-time PCR experiments. Clinical chemistry 55, 611-622 
(2009). 
178. QIAGEN, RNeasy® Mini Handbook. 39-44 (September 2010). 
179. QIAGEN, REST 2009 Software User Guide.  (December 2009). 
180. A. L. Slitt, N. J. Cherrington, D. P. Hartley, T. M. Leazer, C. D. Klaassen, 
Tissue distribution and renal developmental changes in rat organic cation 
transporter mRNA levels. Drug Metab Dispos 30, 212-219 (2002). 
181. J. H. Sung, K. H. Yu, J. S. Park, T. Tsuruo, D. D. Kim, C. K. Shim, S. J. 
Chung, Saturable distribution of tacrine into the striatal extracellular fluid of 
the rat: evidence of involvement of multiple organic cation transporters in the 
transport. Drug metabolism and disposition: the biological fate of chemicals 
33, 440-448 (2005). 
182. C. Hilgendorf, G. Ahlin, A. Seithel, P. Artursson, A. L. Ungell, J. Karlsson, 
Expression of thirty-six drug transporter genes in human intestine, liver, 
kidney, and organotypic cell lines. Drug metabolism and disposition: the 
biological fate of chemicals 35, 1333-1340 (2007). 
183. V. Gorboulev, J. C. Ulzheimer, A. Akhoundova, I. Ulzheimer-Teuber, U. 
Karbach, S. Quester, C. Baumann, F. Lang, A. E. Busch, H. Koepsell, 
Cloning and characterization of two human polyspecific organic cation 
transporters. DNA and cell biology 16, 871-881 (1997). 
184. H. Koepsell, Organic cation transporters in intestine, kidney, liver, and brain. 
Annual review of physiology 60, 243-266 (1998). 
185. R. Kekuda, P. D. Prasad, X. Wu, H. Wang, Y.-J. Fei, F. H. Leibach, V. 
Ganapathy, Cloning and Functional Characterization of a Potential-sensitive, 
Polyspecific Organic Cation Transporter (OCT3) Most Abundantly 
Expressed in Placenta. Journal of Biological Chemistry 273, 15971-15979 
(1998). 
186. P. Borst, C. de Wolf, K. van de Wetering, Multidrug resistance-associated 
proteins 3, 4, and 5. Pflugers Archiv : European journal of physiology 453, 
661-673 (2007). 
187. A. L. Slitt, N. J. Cherrington, J. M. Maher, C. D. Klaassen, Induction of 
multidrug resistance protein 3 in rat liver is associated with altered vectorial 
excretion of acetaminophen metabolites. Drug Metabolism and Disposition 
31, 1176-1186 (2003). 
188. L. Azevedo Marques, M. Giera, H. Lingeman, W. M. Niessen, Analysis of 
acetylcholinesterase inhibitors: bioanalysis, degradation and metabolism. 
Biomedical chromatography : BMC 25, 278-299 (2011). 
189. C. W. Goh, C. C. Aw, J. H. Lee, C. P. Chen, E. R. Browne, Pharmacokinetic 
and pharmacodynamic properties of cholinesterase inhibitors donepezil, 
tacrine, and galantamine in aged and young Lister hooded rats. Drug Metab 
Dispos 39, 402-411 (2011). 
190. C. Ioannides, R. S. o. Chemistry, Cytochromes P450: Role in the Metabolism 
and Toxicity of Drugs and Other Xenobiotics.  (RSC Pub., 2008). 
191. R. F. Tyndale, Y. Li, N. Y. Li, E. Messina, S. Miksys, E. M. Sellers, 
Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity 
kinetics for dextromethorphan. Drug Metab Dispos 27, 924-930 (1999). 
192. S. Madden, V. Spaldin, B. K. Park, Clinical pharmacokinetics of tacrine. 
Clinical pharmacokinetics 28, 449-457 (1995). 
 205 
 
193. T. Izukawa, M. Nakajima, R. Fujiwara, H. Yamanaka, T. Fukami, M. 
Takamiya, Y. Aoki, S. Ikushiro, T. Sakaki, T. Yokoi, Quantitative analysis of 
UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in 
human livers. Drug Metab Dispos 37, 1759-1768 (2009). 
194. S. Ohno, S. Nakajin, Determination of mRNA Expression of Human UDP-
Glucuronosyltransferases and Application for Localization in Various Human 
Tissues by Real-Time Reverse Transcriptase-Polymerase Chain Reaction. 
Drug Metabolism and Disposition 37, 32-40 (2009). 
195. M. K. Shelby, N. J. Cherrington, N. R. Vansell, C. D. Klaassen, Tissue 
mRNA expression of the rat UDP-glucuronosyltransferase gene family. Drug 
metabolism and disposition: the biological fate of chemicals 31, 326-333 
(2003). 
196. M. el Mouelhi, S. Beck, K. W. Bock, Stereoselective glucuronidation of (R)- 
and (S)-naproxen by recombinant rat phenol UDP-glucuronosyltransferase 
(UGT1A1) and its human orthologue. Biochemical pharmacology 46, 1298-
1300 (1993). 
197. D. B. Buckley, C. D. Klaassen, Tissue- and gender-specific mRNA 
expression of UDP-glucuronosyltransferases (UGTs) in mice. Drug 
metabolism and disposition: the biological fate of chemicals 35, 121-127 
(2007). 
198. P. I. Mackenzie, K. W. Bock, B. Burchell, C. Guillemette, S. Ikushiro, T. 
Iyanagi, J. O. Miners, I. S. Owens, D. W. Nebert, Nomenclature update for 
the mammalian UDP glycosyltransferase (UGT) gene superfamily. 
Pharmacogenet Genomics 15, 677-685 (2005). 
199. C. S. Mazur, J. F. Kenneke, J. K. Hess-Wilson, J. C. Lipscomb, Differences 
between human and rat intestinal and hepatic bisphenol A glucuronidation 
and the influence of alamethicin on in vitro kinetic measurements. Drug 
metabolism and disposition: the biological fate of chemicals 38, 2232-2238 
(2010). 
200. C. King, W. Tang, J. Ngui, T. Tephly, M. Braun, Characterization of rat and 
human UDP-glucuronosyltransferases responsible for the in vitro 
glucuronidation of diclofenac. Toxicological sciences : an official journal of 
the Society of Toxicology 61, 49-53 (2001). 
201. P. Board, M. Coggan, P. Johnston, V. Ross, T. Suzuki, G. Webb, Genetic 
heterogeneity of the human glutathione transferases: a complex of gene 
families. Pharmacology & therapeutics 48, 357-369 (1990). 
202. R. Okada, Y. Ishizu, R. Endo, A. Lezhava, I. Ieiri, H. Kusuhara, Y. 
Sugiyama, Y. Hayashizaki, Direct and Rapid Genotyping of Glutathione-S-
transferase M1 and T1 from Human Blood Specimens Using the SmartAmp2 
Method. Drug Metabolism and Disposition 38, 1636-1639 (2010). 
203. V. J. Green, M. Pirmohamed, N. R. Kitteringham, M. J. Knapp, B. K. Park, 
Glutathione S-transferase mu genotype (GSTM1*0) in Alzheimer's patients 
with tacrine transaminitis. Br J Clin Pharmacol 39, 411-415 (1995). 
204. T. Simon, L. Becquemont, M. Mary-Krause, I. de Waziers, P. Beaune, C. 
Funck-Brentano, P. Jaillon, Combined glutathione-S-transferase M1 and T1 
genetic polymorphism and tacrine hepatotoxicity. Clin Pharmacol Ther 67, 
432-437 (2000). 
205. M. De Sousa, M. Pirmohamed, N. R. Kitteringham, T. Woolf, B. K. Park, No 
association between tacrine transaminitis and the glutathione transferase theta 
genotype in patients with Alzheimer's disease. Pharmacogenetics 8, 353-355 
(1998). 
206. F. P. Koch, P. W. Kammerer, P. Kammerer, B. Al-Nawas, J. Brieger, 
Influence of class M1 glutathione S-transferase (GST Mu) polymorphism on 
GST M1 gene expression level and tumor size in oral squamous cell 
carcinoma. Oral oncology 46, 128-133 (2010). 
 206 
 
207. M. Rotunno, T. K. Lam, A. Vogt, P. A. Bertazzi, J. H. Lubin, N. E. Caporaso, 
M. T. Landi, GSTM1 and GSTT1 copy numbers and mRNA expression in 
lung cancer. Molecular carcinogenesis 51 Suppl 1, E142-150 (2012). 
208. M. Trauner, J. L. Boyer, Bile salt transporters: molecular characterization, 
function, and regulation. Physiol Rev 83, 633-671 (2003). 
209. J. M. Brady, N. J. Cherrington, D. P. Hartley, S. C. Buist, N. Li, C. D. 
Klaassen, Tissue Distribution and Chemical Induction of Multiple Drug 
Resistance Genes in Rats. Drug Metabolism and Disposition 30, 838-844 
(2002). 
210. D. Keppler, Cholestasis and the Role of Basolateral Efflux Pumps. Z 
Gastroenterol 49, 1553-1557 (2011). 
211. T. Lang, M. Haberl, D. Jung, A. Drescher, R. Schlagenhaufer, A. Keil, E. 
Mornhinweg, B. Stieger, G. A. Kullak-Ublick, R. Kerb, Genetic Variability, 
Haplotype Structures, and Ethnic Diversity of Hepatic Transporters MDR3 
(ABCB4) and Bile Salt Export Pump (ABCB11). Drug Metabolism and 
Disposition 34, 1582-1599 (2006). 
212. A. Alfirevic, T. Mills, D. Carr, B. J. Barratt, A. Jawaid, J. Sherwood, J. C. 
Smith, J. Tugwood, R. Hartkoorn, A. Owen, K. B. Park, M. Pirmohamed, 
Tacrine-induced liver damage: An analysis of 19 candidate genes. 
Pharmacogenetics and Genomics 17, 1091-1100 (2007). 
213. H. Jinno, T. Tanaka-Kagawa, N. Hanioka, S. Ishida, M. Saeki, A. Soyama, 
M. Itoda, T. Nishimura, Y. Saito, S. Ozawa, M. Ando, J. Sawada, 
Identification of novel alternative splice variants of human constitutive 
androstane receptor and characterization of their expression in the liver. 
Molecular pharmacology 65, 496-502 (2004). 
214. J. K. Lamba, V. Lamba, K. Yasuda, Y. S. Lin, M. Assem, E. Thompson, S. 
Strom, E. Schuetz, Expression of constitutive androstane receptor splice 
variants in human tissues and their functional consequences. The Journal of 
pharmacology and experimental therapeutics 311, 811-821 (2004). 
215. M. K. Shelby, C. D. Klaassen, Induction of Rat UDP-
Glucuronosyltransferases in Liver and Duodenum by Microsomal Enzyme 
Inducers That Activate Various Transcriptional Pathways. Drug Metabolism 
and Disposition 34, 1772-1778 (2006). 
216. H. Xiong, K. Yoshinari, K. L. Brouwer, M. Negishi, Role of constitutive 
androstane receptor in the in vivo induction of Mrp3 and CYP2B1/2 by 
phenobarbital. Drug metabolism and disposition: the biological fate of 
chemicals 30, 918-923 (2002). 
217. N. J. Cherrington, A. L. Slitt, J. M. Maher, X. X. Zhang, J. Zhang, W. Huang, 
Y. J. Wan, D. D. Moore, C. D. Klaassen, Induction of multidrug resistance 
protein 3 (mrp3) in vivo is independent of constitutive androstane receptor. 
Drug Metab Dispos 31, 1315-1319 (2003). 
218. D. W. Nebert, A. L. Roe, M. Z. Dieter, W. A. Solis, Y. Yang, T. P. Dalton, 
Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the 
oxidative stress response, cell cycle control, and apoptosis. Biochemical 
pharmacology 59, 65-85 (2000). 
219. V. Perera, A. S. Gross, A. J. McLachlan, Influence of environmental and 
genetic factors on CYP1A2 activity in individuals of South Asian and 
European ancestry. Clin Pharmacol Ther 92, 511-519 (2012). 
220. A. Gunes, M. L. Dahl, Variation in CYP1A2 activity and its clinical 
implications: influence of environmental factors and genetic polymorphisms. 
Pharmacogenomics 9, 625-637 (2008). 
221. H. Schweikl, J. A. Taylor, S. Kitareewan, P. Linko, D. Nagorney, J. A. 
Goldstein, Expression of CYP1A1 and CYP1A2 genes in human liver. 
Pharmacogenetics 3, 239-249 (1993). 
 207 
 
222. M. W. Sinz, T. F. Woolf, Characterization of the induction of rat microsomal 
cytochrome P450 by tacrine. Biochemical Pharmacology 54, 425-427 (1997). 
223. R. Jaenisch, A. Bird, Epigenetic regulation of gene expression: how the 
genome integrates intrinsic and environmental signals. Nature genetics 33 
Suppl, 245-254 (2003). 
224. S. Peterson, Y. Schwarz, S. S. Li, L. Li, I. B. King, C. Chen, D. L. Eaton, J. 
D. Potter, J. W. Lampe, CYP1A2, GSTM1, and GSTT1 Polymorphisms and 
Diet Effects on CYP1A2 Activity in a Crossover Feeding Trial. Cancer 
Epidemiology Biomarkers & Prevention 18, 3118-3125 (2009). 
225. S. F. Zhou, J. P. Liu, B. Chowbay, Polymorphism of human cytochrome 
P450 enzymes and its clinical impact. Drug Metab Rev 41, 89-295 (2009). 
226. Y. Saito, N. Hanioka, K. Maekawa, T. Isobe, Y. Tsuneto, R. Nakamura, A. 
Soyama, S. Ozawa, T. Tanaka-Kagawa, H. Jinno, S. Narimatsu, J. Sawada, 
Functional analysis of three CYP1A2 variants found in a Japanese 
population. Drug Metab Dispos 33, 1905-1910 (2005). 
227. C. Sachse, J. Brockmöller, S. Bauer, I. Roots, Functional significance of a 
C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene 
tested with caffeine. British Journal of Clinical Pharmacology 47, 445-449 
(1999). 
228. R. R. Scheline, The metabolism of drugs and other organic compounds by the 
intestinal microflora. Acta Pharmacol Toxicol 26, 332-342 (1968). 
229. J. K. Nicholson, E. Holmes, J. Kinross, R. Burcelin, G. Gibson, W. Jia, S. 
Pettersson, Host-gut microbiota metabolic interactions. Science 336, 1262-
1267 (2012). 
230. W. G. E. J. Schoonen, C. P. A. M. Kloks, J. P. H. T. M. Ploemen, M. J. Smit, 
P. Zandberg, G. J. Horbach, J. R. Mellema, C. T. van Zuylen, A. C. Tas, J. H. 
J. van Nesselrooij, J. T. W. E. Vogels, Uniform procedure of 1H NMR 
analysis of rat urine and toxicometabonomics Part II: Comparison of NMR 
profiles classification of hepatotoxicity. Toxicological Sciences 98, 286-297 
(2007). 
231. J. C. Park, Y. S. Hong, Y. J. Kim, J. Y. Yang, E. Y. Kim, S. J. Kwack, H. 
Ryu do, G. S. Hwang, B. M. Lee, A metabonomic study on the biochemical 
effects of doxorubicin in rats using (1)H-NMR spectroscopy. Journal of 
toxicology and environmental health. Part A 72, 374-384 (2009). 
232. A. E. M. Vickers, Characterization of Hepatic Mitochondrial Injury Induced 
by Fatty Acid Oxidation Inhibitors. Toxicologic Pathology 37, 78-88 (2009). 
233. S. R. Pieczenik, J. Neustadt, Mitochondrial dysfunction and molecular 
pathways of disease. Experimental and molecular pathology 83, 84-92 
(2007). 
234. K. Sharma, B. Karl, A. V. Mathew, J. A. Gangoiti, C. L. Wassel, R. Saito, M. 
Pu, S. Sharma, Y. H. You, L. Wang, M. Diamond-Stanic, M. T. 
Lindenmeyer, C. Forsblom, W. Wu, J. H. Ix, T. Ideker, J. B. Kopp, S. K. 
Nigam, C. D. Cohen, P. H. Groop, B. A. Barshop, L. Natarajan, W. L. 
Nyhan, R. K. Naviaux, Metabolomics reveals signature of mitochondrial 
dysfunction in diabetic kidney disease. Journal of the American Society of 
Nephrology : JASN 24, 1901-1912 (2013). 
235. B. E. Gustafsson, T. Midtvedt, A. Norman, Isolated fecal microorganisms 
capable of 7α-dehydroxylating bile acids The Journal of Experimental 
Medicine 123, 413-432 (1966). 
236. P. Gérard, Metabolism of Cholesterol and Bile Acids by the Gut Microbiota. 
Pathogens 3, 14-24 (2013). 
237. S. Hirano, N. Masuda, Enhancement of the 7 alpha-dehydroxylase activity of 
a gram-positive intestinal anaerobe by Bacteroides and its significance in the 




238. A. F. Hofmann, Chemistry and enterohepatic circulation of bile acids. 
Hepatology 4, 4s-14s (1984). 
239. A. F. Hofmann, The continuing importance of bile acids in liver and 
intestinal disease. Archives of internal medicine 159, 2647-2658 (1999). 
240. C. C. DiRusso, P. N. Black, Long-chain fatty acid transport in bacteria and 
yeast. Paradigms for defining the mechanism underlying this protein-
mediated process. Molecular and cellular biochemistry 192, 41-52 (1999). 
241. C. F. Higgins, ABC Transporters: From Microorganisms to Man. Annual 
Review of Cell Biology 8, 67-113 (1992). 
242. A. L. Davidson, E. Dassa, C. Orelle, J. Chen, Structure, function, and 
evolution of bacterial ATP-binding cassette systems. Microbiology and 
molecular biology reviews : MMBR 72, 317-364, table of contents (2008). 
243. M. S. Dunn, S. Shankman, M. N. Camien, H. Block, The amino acid 
requirements of twenty-three lactic acid bacteria Journal of Biological 
Chemistry 168, 1-22 (1947). 
244. E. Altermann, W. M. Russell, M. A. Azcarate-Peril, R. Barrangou, B. L. 
Buck, O. McAuliffe, N. Souther, A. Dobson, T. Duong, M. Callanan, S. Lick, 
A. Hamrick, R. Cano, T. R. Klaenhammer, Complete genome sequence of the 
probiotic lactic acid bacterium Lactobacillus acidophilus NCFM. 
Proceedings of the National Academy of Sciences of the United States of 
America 102, 3906-3912 (2005). 
245. E. Pessione, Lactic acid bacteria contribution to gut microbiota complexity: 
lights and shadows. Frontiers in cellular and infection microbiology 2, 86 
(2012). 
246. J. E. Christensen, E. G. Dudley, J. A. Pederson, J. L. Steele, Peptidases and 
amino acid catabolism in lactic acid bacteria. Antonie van Leeuwenhoek 76, 
217-246 (1999). 
247. V. I. Chalova, S. A. Sirsat, C. A. O'Bryan, P. G. Crandall, S. C. Ricke, 
Escherichia coli, an Intestinal Microorganism, as a Biosensor for 
Quantification of Amino Acid Bioavailability. Sensors (Basel, Switzerland) 
9, 7038-7057 (2009). 
248. W. R. Russell, S. H. Duncan, Advanced analytical methodologies to study the 
microbial metabolome of the human gut. TrAC Trends in Analytical 
Chemistry 52, 54-60 (2013). 
249. W. R. Russell, S. H. Duncan, L. Scobbie, G. Duncan, L. Cantlay, A. G. 
Calder, S. E. Anderson, H. J. Flint, Major phenylpropanoid-derived 
metabolites in the human gut can arise from microbial fermentation of 
protein. Molecular nutrition & food research 57, 523-535 (2013). 
250. S. Schneider, M. E. S. Mohamed, G. Fuchs, Anaerobic metabolism of l-
phenylalanine via benzoyl-CoA in the denitrifying bacterium Thauera 
aromatica. Arch Microbiol 168, 310-320 (1997). 
251. J. Delaney, W. A. Neville, A. Swain, A. Miles, M. S. Leonard, C. J. 
Waterfield, Phenylacetylglycine, a putative biomarker of phospholipidosis: 
Its origins and relevance to phospholipid accumulation using amiodarone 
treated rats as a model. Biomarkers 9, 271-290 (2004). 
252. C. Henderson, The effects of fatty acids on pure cultures of rumen bacteria. 
The Journal of Agricultural Science 81, 107-112 (1973). 
253. A. Maczulak, B. Dehority, D. Palmquist, Effects of long-chain fatty acids on 
growth of rumen bacteria. Applied and environmental microbiology 42, 856-
862 (1981). 
254. A. P. Desbois, V. J. Smith, Antibacterial free fatty acids: activities, 
mechanisms of action and biotechnological potential. Applied microbiology 
and biotechnology 85, 1629-1642 (2010). 
 209 
 
255. C. W. Sheu, E. Freese, Lipopolysaccharide Layer Protection of Gram-
Negative Bacteria Against Inhibition by Long-Chain Fatty Acids. Journal of 
Bacteriology 115, 869-875 (1973). 
256. J. Fay, R. Farías, β-Oxidation-mediated resistance ofEscherichia coli to 
inhibition by long-chain fatty acids. Current Microbiology 5, 147-152 (1981). 
257. S. J. Ahn, J. Costa, J. R. Emanuel, PicoGreen quantitation of DNA: effective 
evaluation of samples pre- or post-PCR. Nucleic Acids Res 24, 2623-2625 
(1996). 
258. J. Tomas, P. Langella, C. Cherbuy, The intestinal microbiota in the rat model: 
major breakthroughs from new technologies. Animal health research reviews 
/ Conference of Research Workers in Animal Diseases 13, 54-63 (2012). 
259. S. P. Brooks, M. McAllister, M. Sandoz, M. L. Kalmokoff, Culture-
independent phylogenetic analysis of the faecal flora of the rat. Canadian 
journal of microbiology 49, 589-601 (2003). 
260. A. B. Dalby, D. N. Frank, A. L. St. Amand, A. M. Bendele, N. R. Pace, 
Culture-Independent Analysis of Indomethacin-Induced Alterations in the 
Rat Gastrointestinal Microbiota. Applied and environmental microbiology 72, 
6707-6715 (2006). 
261. A. Staroscik. (URI Genomics & Sequencing Center, 29 January 2004). 
262. K. WA. (Northwestern University, 2007). 
263. T. Matsuki, K. Watanabe, J. Fujimoto, T. Takada, R. Tanaka, Use of 16S 
rRNA gene-targeted group-specific primers for real-time PCR analysis of 
predominant bacteria in human feces. Appl Environ Microbiol 70, 7220-7228 
(2004). 
264. K. Matsuda, H. Tsuji, T. Asahara, Y. Kado, K. Nomoto, Sensitive 
quantitative detection of commensal bacteria by rRNA-targeted reverse 
transcription-PCR. Applied and environmental microbiology 73, 32-39 
(2007). 
265. A. Klindworth, E. Pruesse, T. Schweer, J. Peplies, C. Quast, M. Horn, F. O. 
Glöckner, Evaluation of general 16S ribosomal RNA gene PCR primers for 
classical and next-generation sequencing-based diversity studies. Nucleic 
Acids Research 41, e1 (2013). 
266. J. G. Caporaso, C. L. Lauber, W. A. Walters, D. Berg-Lyons, J. Huntley, N. 
Fierer, S. M. Owens, J. Betley, L. Fraser, M. Bauer, N. Gormley, J. A. 
Gilbert, G. Smith, R. Knight, Ultra-high-throughput microbial community 
analysis on the Illumina HiSeq and MiSeq platforms. The ISME journal 6, 
1621-1624 (2012). 
267. T. Magoc, S. L. Salzberg, FLASH: fast length adjustment of short reads to 
improve genome assemblies. Bioinformatics 27, 2957-2963 (2011). 
268. J. G. Caporaso, J. Kuczynski, J. Stombaugh, K. Bittinger, F. D. Bushman, E. 
K. Costello, N. Fierer, A. G. Pena, J. K. Goodrich, J. I. Gordon, G. A. 
Huttley, S. T. Kelley, D. Knights, J. E. Koenig, R. E. Ley, C. A. Lozupone, 
D. McDonald, B. D. Muegge, M. Pirrung, J. Reeder, J. R. Sevinsky, P. J. 
Turnbaugh, W. A. Walters, J. Widmann, T. Yatsunenko, J. Zaneveld, R. 
Knight, QIIME allows analysis of high-throughput community sequencing 
data. Nature methods 7, 335-336 (2010). 
269. R. C. Edgar, Search and clustering orders of magnitude faster than BLAST. 
Bioinformatics 26, 2460-2461 (2010). 
270. D. McDonald, M. N. Price, J. Goodrich, E. P. Nawrocki, T. Z. DeSantis, A. 
Probst, G. L. Andersen, R. Knight, P. Hugenholtz, An improved Greengenes 
taxonomy with explicit ranks for ecological and evolutionary analyses of 
bacteria and archaea. The ISME journal 6, 610-618 (2012). 
271. Q. Wang, G. M. Garrity, J. M. Tiedje, J. R. Cole, Naive Bayesian classifier 
for rapid assignment of rRNA sequences into the new bacterial taxonomy. 
Applied and environmental microbiology 73, 5261-5267 (2007). 
 210 
 
272. J. G. Caporaso, K. Bittinger, F. D. Bushman, T. Z. DeSantis, G. L. Andersen, 
R. Knight, PyNAST: a flexible tool for aligning sequences to a template 
alignment. Bioinformatics 26, 266-267 (2010). 
273. M. N. Price, P. S. Dehal, A. P. Arkin, FastTree 2--approximately maximum-
likelihood trees for large alignments. PloS one 5, e9490 (2010). 
274. C. Lozupone, R. Knight, UniFrac: a new phylogenetic method for comparing 
microbial communities. Applied and environmental microbiology 71, 8228-
8235 (2005). 
275. V. B. Chen, I. W. Davis, D. C. Richardson, KING (Kinemage, Next 
Generation): a versatile interactive molecular and scientific visualization 
program. Protein science : a publication of the Protein Society 18, 2403-2409 
(2009). 
276. P. J. Turnbaugh, M. Hamady, T. Yatsunenko, B. L. Cantarel, A. Duncan, R. 
E. Ley, M. L. Sogin, W. J. Jones, B. A. Roe, J. P. Affourtit, M. Egholm, B. 
Henrissat, A. C. Heath, R. Knight, J. I. Gordon, A core gut microbiome in 
obese and lean twins. Nature 457, 480-484 (2009). 
277. T. Yatsunenko, F. E. Rey, M. J. Manary, I. Trehan, M. G. Dominguez-Bello, 
M. Contreras, M. Magris, G. Hidalgo, R. N. Baldassano, A. P. Anokhin, A. 
C. Heath, B. Warner, J. Reeder, J. Kuczynski, J. G. Caporaso, C. A. 
Lozupone, C. Lauber, J. C. Clemente, D. Knights, R. Knight, J. I. Gordon, 
Human gut microbiome viewed across age and geography. Nature 486, 222-
227 (2012). 
278. S. R. Gill, M. Pop, R. T. Deboy, P. B. Eckburg, P. J. Turnbaugh, B. S. 
Samuel, J. I. Gordon, D. A. Relman, C. M. Fraser-Liggett, K. E. Nelson, 
Metagenomic analysis of the human distal gut microbiome. Science 312, 
1355-1359 (2006). 
279. A. Shafquat, R. Joice, S. L. Simmons, C. Huttenhower, Functional and 
phylogenetic assembly of microbial communities in the human microbiome. 
Trends in microbiology 22, 261-266 (2014). 
280. M. H. Tschop, P. Hugenholtz, C. L. Karp, Getting to the core of the gut 
microbiome. Nat Biotechnol 27, 344-346 (2009). 
281. M. G. Langille, J. Zaneveld, J. G. Caporaso, D. McDonald, D. Knights, J. A. 
Reyes, J. C. Clemente, D. E. Burkepile, R. L. Vega Thurber, R. Knight, R. G. 
Beiko, C. Huttenhower, Predictive functional profiling of microbial 
communities using 16S rRNA marker gene sequences. Nature biotechnology 
31, 814-821 (2013). 
282. A. M. Stringer, R. J. Gibson, R. M. Logan, J. M. Bowen, A. S. Yeoh, D. M. 
Keefe, Faecal microflora and beta-glucuronidase expression are altered in an 
irinotecan-induced diarrhea model in rats. Cancer biology & therapy 7, 1919-
1925 (2008). 
283. P. C. Feng, P. A. Hartman, Fluorogenic assays for immediate confirmation of 
Escherichia coli. Applied and environmental microbiology 43, 1320-1329 
(1982). 
284. J. W. Leung, Y. L. Liu, P. S. Leung, R. C. Chan, J. F. Inciardi, A. F. Cheng, 
Expression of bacterial beta-glucuronidase in human bile: an in vitro study. 
Gastrointestinal endoscopy 54, 346-350 (2001). 
285. M. Mroczynska, Z. Libudzisz, Beta-glucuronidase and beta-glucosidase 
activity of Lactobacillus and Enterococcus isolated from human feces. Polish 
journal of microbiology / Polskie Towarzystwo Mikrobiologow = The Polish 
Society of Microbiologists 59, 265-269 (2010). 
286. G. Hawksworth, B. S. Drasar, M. J. Hill, Intestinal bacteria and the 
hydrolysis of glycosidic bonds. Journal of medical microbiology 4, 451-459 
(1971). 
287. A. Lidbeck, U. G. Allinger, K. M. Orrhage, L. Ottova, B. Brismar, J.-Å. 
Gustafsson, J. J. Rafter, C. E. Nord, Impact of Lactobacillus acidophilus 
 211 
 
Supplements on the Faecal Microflora and Soluble Faecal Bile Acids in 
Colon Cancer Patients. Microbial Ecology in Health and Disease 4, 81-88 
(1991). 
288. C. B. Cole, R. Fuller, S. M. Carter, Effect of Probiotic Supplements of 
Lactobacillus acidophilus and Bifidobacterium adolescentis 2204 on β-
glueosidase and β-glueuronidase Activity in the Lower Gut of Rats 
Associated with a Human Faecal Flora. Microbial Ecology in Health and 
Disease 2, 223-225 (1989). 
289. B. R. Goldin, S. L. Gorbach, The effect of milk and lactobacillus feeding on 
human intestinal bacterial enzyme activity. The American journal of clinical 
nutrition 39, 756-761 (1984). 
290. M. A. McConnell, G. W. Tannock, A note on lactobacilli and beta-
glucuronidase activity in the intestinal contents of mice. The Journal of 
applied bacteriology 74, 649-651 (1993). 
291. S. M. Huse, Y. Ye, Y. Zhou, A. A. Fodor, A core human microbiome as 
viewed through 16S rRNA sequence clusters. PloS one 7, e34242 (2012). 
292. L. Krych, C. H. Hansen, A. K. Hansen, F. W. van den Berg, D. S. Nielsen, 
Quantitatively different, yet qualitatively alike: a meta-analysis of the mouse 
core gut microbiome with a view towards the human gut microbiome. PloS 
one 8, e62578 (2013). 
293. J. Tap, S. Mondot, F. Levenez, E. Pelletier, C. Caron, J. P. Furet, E. Ugarte, 
R. Munoz-Tamayo, D. L. Paslier, R. Nalin, J. Dore, M. Leclerc, Towards the 
human intestinal microbiota phylogenetic core. Environmental microbiology 
11, 2574-2584 (2009). 
294. M. G. Chapman, A. J. Underwood, Ecological patterns in multivariate 
assemblages: information and interpretation of negative values in ANOSIM 
tests. Marine Ecology Progress Series 180, 257-265 (1999). 
295. B. D. Wallace, H. Wang, K. T. Lane, J. E. Scott, J. Orans, J. S. Koo, M. 
Venkatesh, C. Jobin, L. A. Yeh, S. Mani, M. R. Redinbo, Alleviating cancer 
drug toxicity by inhibiting a bacterial enzyme. Science 330, 831-835 (2010). 
296. J. Nakamura, Y. Kubota, M. Miyaoka, T. Saitoh, F. Mizuno, Y. Benno, 
Comparison of four microbial enzymes in Clostridia and Bacteroides isolated 
from human feces. Microbiology and immunology 46, 487-490 (2002). 
297. D. Beaud, P. Tailliez, J. Anba-Mondoloni, Genetic characterization of the 
beta-glucuronidase enzyme from a human intestinal bacterium, 
Ruminococcus gnavus. Microbiology (Reading, England) 151, 2323-2330 
(2005). 
298. M. van de Guchte, P. Serror, C. Chervaux, T. Smokvina, S. D. Ehrlich, E. 
Maguin, Stress responses in lactic acid bacteria. Antonie van Leeuwenhoek 
82, 187-216 (2002). 
299. F. J. Carr, D. Chill, N. Maida, The lactic acid bacteria: a literature survey. 
Critical reviews in microbiology 28, 281-370 (2002). 
300. R. T. Clarke, Niche in Pasture-Fed Ruminants for the Large Rumen Bacteria 
Oscillospira, Lampropedia, and Quin's and Eadie's Ovals. Applied and 
environmental microbiology 37, 654-657 (1979). 
301. A. Nowak, K. Slizewska, beta-Glucuronidase and beta-glucosidase activity 
and human fecal water genotoxicity in the presence of probiotic lactobacilli 
and the heterocyclic aromatic amine IQ in vitro. Environmental toxicology 
and pharmacology 37, 66-73 (2013). 
302. X. Zhang, Y. Zhao, M. Zhang, X. Pang, J. Xu, C. Kang, M. Li, C. Zhang, Z. 
Zhang, Y. Zhang, X. Li, G. Ning, L. Zhao, Structural changes of gut 
microbiota during berberine-mediated prevention of obesity and insulin 
resistance in high-fat diet-fed rats. PloS one 7, e42529 (2012). 
 212 
 
303. H. L. Greetham, G. R. Gibson, C. Giffard, H. Hippe, B. Merkhoffer, U. 
Steiner, E. Falsen, M. D. Collins, Allobaculum stercoricanis gen. nov., sp. 
nov., isolated from canine feces. Anaerobe 10, 301-307 (2004). 
304. S. H. Duncan, P. Louis, H. J. Flint, Lactate-utilizing bacteria, isolated from 
human feces, that produce butyrate as a major fermentation product. Applied 
and environmental microbiology 70, 5810-5817 (2004). 
305. A. Schwiertz, G. L. Hold, S. H. Duncan, B. Gruhl, M. D. Collins, P. A. 
Lawson, H. J. Flint, M. Blaut, Anaerostipes caccae gen. nov., sp. nov., a new 
saccharolytic, acetate-utilising, butyrate-producing bacterium from human 
faeces. Systematic and applied microbiology 25, 46-51 (2002). 
306. V. Eeckhaut, F. Van Immerseel, F. Pasmans, E. De Brandt, F. Haesebrouck, 
R. Ducatelle, P. Vandamme, Anaerostipes butyraticus sp. nov., an anaerobic, 
butyrate-producing bacterium from Clostridium cluster XIVa isolated from 
broiler chicken caecal content, and emended description of the genus 
Anaerostipes. International Journal of Systematic and Evolutionary 
Microbiology 60, 1108-1112 (2010). 
307. M. Sakamoto, A. Takagaki, K. Matsumoto, Y. Kato, K. Goto, Y. Benno, 
Butyricimonas synergistica gen. nov., sp. nov. and Butyricimonas virosa sp. 
nov., butyric acid-producing bacteria in the family 'Porphyromonadaceae' 
isolated from rat faeces. International journal of systematic and evolutionary 
microbiology 59, 1748-1753 (2009). 
308. L. Wang, C. T. Christophersen, M. J. Sorich, J. P. Gerber, M. T. Angley, M. 
A. Conlon, Increased abundance of Sutterella spp. and Ruminococcus torques 
in feces of children with autism spectrum disorder. Molecular autism 4, 42 
(2013). 
309. T. J. Bussey, T. L. Padain, E. A. Skillings, B. D. Winters, A. J. Morton, L. M. 
Saksida, The touchscreen cognitive testing method for rodents: how to get the 
best out of your rat. Learning & memory 15, 516-523 (2008). 
310. J. S. Andrews, Possible confounding influence of strain, age and gender on 
cognitive performance in rats. Brain research. Cognitive brain research 3, 
251-267 (1996). 
311. F. K. Wong, S. H. Lee, Z. Atcha, A. B. Ong, D. J. Pemberton, W. S. Chen, 
Rasagiline improves learning and memory in young healthy rats. Behavioural 
pharmacology 21, 278-282 (2010). 
312. L. M. Broersen, H. B. Uylings, Visual attention task performance in Wistar 
and Lister hooded rats: response inhibition deficits after medial prefrontal 
cortex lesions. Neuroscience 94, 47-57 (1999). 
313. S. J. Lyst, K. Davis, J. Gigg, R. Hager, Effects of increased spatial 
complexity on behavioural development and task performance in Lister 
Hooded rats. PLoS One 7, e47640 (2012). 
314. B. V. Broberg, R. Dias, B. Y. Glenthoj, C. K. Olsen, Evaluation of a 
neurodevelopmental model of schizophrenia--early postnatal PCP treatment 
in attentional set-shifting. Behavioural brain research 190, 160-163 (2008). 
315. J. J. Werner, D. Zhou, J. G. Caporaso, R. Knight, L. T. Angenent, 
Comparison of Illumina paired-end and single-direction sequencing for 
microbial 16S rRNA gene amplicon surveys. The ISME journal 6, 1273-1276 
(2012). 
316. S. Chakravorty, D. Helb, M. Burday, N. Connell, D. Alland, A detailed 
analysis of 16S ribosomal RNA gene segments for the diagnosis of 
pathogenic bacteria. Journal of microbiological methods 69, 330-339 (2007). 
317. O. Mizrahi-Man, E. R. Davenport, Y. Gilad, Taxonomic classification of 
bacterial 16S rRNA genes using short sequencing reads: evaluation of 
effective study designs. PloS one 8, e53608 (2013). 
318. N. Youssef, C. S. Sheik, L. R. Krumholz, F. Z. Najar, B. A. Roe, M. S. 
Elshahed, Comparison of species richness estimates obtained using nearly 
 213 
 
complete fragments and simulated pyrosequencing-generated fragments in 
16S rRNA gene-based environmental surveys. Applied and environmental 
microbiology 75, 5227-5236 (2009). 
319. Z. Liu, T. Z. DeSantis, G. L. Andersen, R. Knight, Accurate taxonomy 
assignments from 16S rRNA sequences produced by highly parallel 
pyrosequencers. Nucleic acids research 36, e120 (2008). 
320. A. Everard, C. Belzer, L. Geurts, J. P. Ouwerkerk, C. Druart, L. B. Bindels, 
Y. Guiot, M. Derrien, G. G. Muccioli, N. M. Delzenne, W. M. de Vos, P. D. 
Cani, Cross-talk between Akkermansia muciniphila and intestinal epithelium 
controls diet-induced obesity. Proceedings of the National Academy of 
Sciences of the United States of America 110, 9066-9071 (2013). 
321. C. H. Hansen, L. Krych, D. S. Nielsen, F. K. Vogensen, L. H. Hansen, S. J. 
Sorensen, K. Buschard, A. K. Hansen, Early life treatment with vancomycin 
propagates Akkermansia muciniphila and reduces diabetes incidence in the 
NOD mouse. Diabetologia 55, 2285-2294 (2012). 
322. M. Arumugam, J. Raes, E. Pelletier, D. Le Paslier, T. Yamada, D. R. Mende, 
G. R. Fernandes, J. Tap, T. Bruls, J. M. Batto, M. Bertalan, N. Borruel, F. 
Casellas, L. Fernandez, L. Gautier, T. Hansen, M. Hattori, T. Hayashi, M. 
Kleerebezem, K. Kurokawa, M. Leclerc, F. Levenez, C. Manichanh, H. B. 
Nielsen, T. Nielsen, N. Pons, J. Poulain, J. Qin, T. Sicheritz-Ponten, S. Tims, 
D. Torrents, E. Ugarte, E. G. Zoetendal, J. Wang, F. Guarner, O. Pedersen, 
W. M. de Vos, S. Brunak, J. Dore, H. I. T. C. Meta, M. Antolin, F. 
Artiguenave, H. M. Blottiere, M. Almeida, C. Brechot, C. Cara, C. Chervaux, 
A. Cultrone, C. Delorme, G. Denariaz, R. Dervyn, K. U. Foerstner, C. Friss, 
M. van de Guchte, E. Guedon, F. Haimet, W. Huber, J. van Hylckama-Vlieg, 
A. Jamet, C. Juste, G. Kaci, J. Knol, O. Lakhdari, S. Layec, K. Le Roux, E. 
Maguin, A. Merieux, R. Melo Minardi, C. M'Rini, J. Muller, R. Oozeer, J. 
Parkhill, P. Renault, M. Rescigno, N. Sanchez, S. Sunagawa, A. Torrejon, K. 
Turner, G. Vandemeulebrouck, E. Varela, Y. Winogradsky, G. Zeller, J. 
Weissenbach, S. D. Ehrlich, P. Bork, Enterotypes of the human gut 
microbiome. Nature 473, 174-180 (2011). 
323. A. K. Benson, S. A. Kelly, R. Legge, F. Ma, S. J. Low, J. Kim, M. Zhang, P. 
L. Oh, D. Nehrenberg, K. Hua, S. D. Kachman, E. N. Moriyama, J. Walter, 
D. A. Peterson, D. Pomp, Individuality in gut microbiota composition is a 
complex polygenic trait shaped by multiple environmental and host genetic 
factors. Proceedings of the National Academy of Sciences of the United 
States of America 107, 18933-18938 (2010). 
324. A. Spor, O. Koren, R. Ley, Unravelling the effects of the environment and 
host genotype on the gut microbiome. Nature reviews. Microbiology 9, 279-
290 (2011). 
325. K. Lu, R. Mahbub, P. H. Cable, H. Ru, N. M. Parry, W. M. Bodnar, J. S. 
Wishnok, M. Styblo, J. A. Swenberg, J. G. Fox, S. R. Tannenbaum, Gut 
microbiome phenotypes driven by host genetics affect arsenic metabolism. 
Chemical research in toxicology 27, 172-174 (2014). 
326. Y. Ravussin, O. Koren, A. Spor, C. LeDuc, R. Gutman, J. Stombaugh, R. 
Knight, R. E. Ley, R. L. Leibel, Responses of gut microbiota to diet 
composition and weight loss in lean and obese mice. Obesity 20, 738-747 
(2012). 
327. K. P. Scott, S. W. Gratz, P. O. Sheridan, H. J. Flint, S. H. Duncan, The 
influence of diet on the gut microbiota. Pharmacological research : the 
official journal of the Italian Pharmacological Society 69, 52-60 (2013). 
328. M. I. Queipo-Ortuño, L. M. Seoane, M. Murri, M. Pardo, J. M. Gomez-
Zumaquero, F. Cardona, F. Casanueva, F. J. Tinahones, Gut Microbiota 
Composition in Male Rat Models under Different Nutritional Status and 
 214 
 
Physical Activity and Its Association with Serum Leptin and Ghrelin Levels. 
PLoS ONE 8, e65465 (2013). 
329. B. D. Muegge, J. Kuczynski, D. Knights, J. C. Clemente, A. Gonzalez, L. 
Fontana, B. Henrissat, R. Knight, J. I. Gordon, Diet drives convergence in gut 
microbiome functions across mammalian phylogeny and within humans. 
Science 332, 970-974 (2011). 
330. C. Alpert, S. Sczesny, B. Gruhl, M. Blaut, Long-term stability of the human 
gut microbiota in two different rat strains. Current issues in molecular 
biology 10, 17-24 (2008). 
331. S. Y. Han, C. S. Huh, Y. T. Ahn, K. S. Lim, Y. J. Baek, D. H. Kim, 
Hepatoprotective effect of lactic acid bacteria, inhibitors of beta-
glucuronidase production against intestinal microflora. Archives of 
pharmacal research 28, 325-329 (2005). 
332. J. Patocka, D. Jun, K. Kuca, Possible role of hydroxylated metabolites of 
tacrine in drug toxicity and therapy of Alzheimer's disease. Current drug 
metabolism 9, 332-335 (2008). 
333. V. Spaldin, S. Madden, D. A. Adams, R. J. Edwards, D. S. Davies, B. K. 
Park, Determination of human hepatic cytochrome P4501A2 activity in vitro 
use of tacrine as an isoenzyme-specific probe. Drug metabolism and 
disposition: the biological fate of chemicals 23, 929-934 (1995). 
334. R. S. Hsu, G. M. Shutske, E. M. Dileo, S. M. Chesson, A. R. Linville, R. C. 
Allen, Identification of the urinary metabolites of tacrine in the rat. Drug 
metabolism and disposition: the biological fate of chemicals 18, 779-783 
(1990). 
335. I. R. Rowland, A. K. Mallett, C. A. Bearne, M. J. Farthing, Enzyme activities 
of the hindgut microflora of laboratory animals and man. Xenobiotica 16, 
519-523 (1986). 
336. K. Takasuna, T. Hagiwara, M. Hirohashi, M. Kato, M. Nomura, E. Nagai, T. 
Yokoi, T. Kamataki, Involvement of beta-glucuronidase in intestinal 
microflora in the intestinal toxicity of the antitumor camptothecin derivative 
irinotecan hydrochloride (CPT-11) in rats. Cancer research 56, 3752-3757 
(1996). 
337. R. F. Stachlewitz, G. E. Arteel, J. A. Raleigh, H. D. Connor, R. P. Mason, R. 
G. Thurman, Development and characterization of a new model of tacrine-
induced hepatotoxicity: role of the sympathetic nervous system and hypoxia-
reoxygenation. The Journal of pharmacology and experimental therapeutics 
282, 1591-1599 (1997). 
338. H. C. Xing, L. J. Li, K. J. Xu, T. Shen, Y. B. Chen, J. F. Sheng, Y. S. Yu, Y. 
G. Chen, Intestinal microflora in rats with ischemia/reperfusion liver injury. 
Journal of Zhejiang University. Science. B 6, 14-21 (2005). 
339. G. Eichenbaum, C. P. Hsu, V. Subrahmanyam, J. Chen, J. Scicinski, R. A. 
Galemmo, Jr., R. W. Tuman, D. L. Johnson, Oral coadministration of beta-
glucuronidase to increase exposure of extensively glucuronidated drugs that 
undergo enterohepatic recirculation. J Pharm Sci 101, 2545-2556 (2012). 
340. S. Ahmad, M. A. Hughes, K. T. Lane, M. R. Redinbo, L. A. Yeh, J. E. Scott, 
A High Throughput Assay for Discovery of Bacterial beta-Glucuronidase 
Inhibitors. Current chemical genomics 5, 13-20 (2011). 
341. M. Fittkau, W. Voigt, H. J. Holzhausen, H. J. Schmoll, Saccharic acid 1.4-
lactone protects against CPT-11-induced mucosa damage in rats. Journal of 
cancer research and clinical oncology 130, 388-394 (2004). 
342. D. H. Kim, Y. H. Jin, J. B. Park, K. Kobashi, Silymarin and its components 
are inhibitors of beta-glucuronidase. Biological & pharmaceutical bulletin 
17, 443-445 (1994). 
343. M. Narita, E. Nagai, H. Hagiwara, M. Aburada, T. Yokoi, T. Kamataki, 
Inhibition of beta-glucuronidase by natural glucuronides of kampo medicines 
 215 
 
using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate. 
Xenobiotica 23, 5-10 (1993). 
344. G. E. Fox, J. D. Wisotzkey, P. Jurtshuk, Jr., How close is close: 16S rRNA 
sequence identity may not be sufficient to guarantee species identity. 
International journal of systematic bacteriology 42, 166-170 (1992). 
345. J. M. Janda, S. L. Abbott, 16S rRNA gene sequencing for bacterial 
identification in the diagnostic laboratory: pluses, perils, and pitfalls. Journal 
of clinical microbiology 45, 2761-2764 (2007). 
346. J. Rajendhran, P. Gunasekaran, Microbial phylogeny and diversity: Small 
subunit ribosomal RNA sequence analysis and beyond. Microbiological 
Research 166, 99-110 (2011). 
347. K. F. Ilett, L. B. Tee, P. T. Reeves, R. F. Minchin, Metabolism of drugs and 
other xenobiotics in the gut lumen and wall. Pharmacology & therapeutics 
46, 67-93 (1990). 
348. M. R. Dobrinska, Enterohepatic Circulation of Drugs. The Journal of Clinical 
Pharmacology 29, 577-580 (1989). 
349. B. E. Dahlstrom, L. K. Paalzow, Pharmacokinetic interpretation of the 
enterohepatic recirculation and first-pass elimination of morphine in the rat. 
Journal of pharmacokinetics and biopharmaceutics 6, 505-519 (1978). 
350. C. An, T. Kuda, T. Yazaki, H. Takahashi, B. Kimura, FLX pyrosequencing 
analysis of the effects of the brown-algal fermentable polysaccharides 
alginate and laminaran on rat cecal microbiotas. Applied and environmental 







Figure S1 Correlation of plasma ALT and AST at 24 h post-tacrine 







Figure S2 Extracted ion chromatograms of (A) blank plasma, (B) blank plasma 
spiked with 150 ng/mL of tacrine and 1-hydroxytacrine and 10 μL of 200 ng/mL 
Phenacetin (IS) and (C) representative tacrine-dosed LH rat plasma 8 h post-
dosing. 
Baseline separation of the monohydroxylated tacrine metabolites in the plasma of tacrine-
dosed rats were not achievable (Figure S2C) as these positional isomers co-elute closely (143, 
144, 149) and share similar mass fragmentation patterns (147). 2-Hydroxytacrine and 4-
hydroxytacrine were not commercially available to enable the construction of calibration 
curves for metabolite quantitation. As such, semi-quantitation of these three 
































































Figure S3 Linearity of detector response to variation in concentration of (A) 
tacrine and (B) 1-hydroxytacrine in the calibration standards of spiked LH faeces. 
r2 were greater than 0.99 for all standard calibration curves. 




Figure S4 Gel image of mRNA isolated from LH rat livers, conducted using 1.5 
% agarose gel electrophoresis in 1× TAE buffer. Top (left to right): EZ Load 100 
bp Molecular Ruler (50 µg/mL), positive control, isolated RNA after DNase 
digestion from all 12 vehicle-dosed rats. Bottom (left to right): EZ Load 100 bp 
Molecular Ruler (50 µg/mL), negative control (water), isolated RNA after DNase 





Figure S5 Gel image of 4 % agarose gel electrophoresis in 1× TAE buffer to validate 
primers related to tacrine’s disposition and reference genes. (A) From left to right: 
GeneRuler Ultra Low Range DNA Ladder, negative control (water), CYP1A2, 
CYP1A2 NTC, CYP2D1/5, CYP2D1/5 NTC, GST M1, GST M1 NTC, UGT1A, 
UGT1A NTC, UGT2B1, UGT2B1 NTC, β-actin, β-actin NTC, GAPDH, GAPDH 
NTC, MDR3 , MDR3 NTC, BSEP, BSEP NTC, MRP2 and MRP2 NTC. (B) From 
left to right: GeneRuler Ultra Low Range DNA Ladder, negative control (water), 
MRP3, MRP3 NTC, OCT1, OCT1 NTC, AhR, AhR NTC, MDR1A, MDR1A NTC, 
MDR1B, MDR1B NTC, CAR, CAR NTC, OCTN1, OCTN1 NTC, GST T1 and GST 
T1 NTC. (C) From left to right: GeneRuler Ultra Low Range DNA Ladder, negative 
control (water), OCTN2 and OCTN2 NTC.  











Figure S6 Primer validation of Bacteroides-Prevotella-Porphyromonadaceae 
target bacterial group. (A) PCR melt curves revealed two distinct melting 
temperatures corresponding to melt curves of bacterial standards and faecal 
samples. (B) Gel electrophoresis of PCR products. Lanes 2, 3, 4, 5 and 6 
correspond to PCR products of the bacterial standard, post-dose faecal samples 
V10 and T27, spiked sample containing known bacteria and NTC, respectively. 
DNA sequencing of gel bands confirmed bacterial strains belong to Bacteroides-
Prevotella-Porphyromonadaceae target group. Distinct melting temperature 
between the standards and samples may be due to differences in nucleotide length 
and G/C content for segments within the amplified regions. 
Derivative reporter (–Rn) is defined as the ratio of the fluorescence emission intensity of the 
reporter dye to the fluorescence emission intensity of the passive reference dye. Coloured lines 
of (A) represent individual reactions.  
 1   2   3   4   5   6     
Standards 
Samples 




Figure S7 Box-and-whisker plots of pre-dose (–24 to 0 h) bacterial cell counts or 
plasmid copy number per g of faeces of (A) Enterobacteriaceae, (B) 
Lactobacillus, (C) Clostridium coccoides, (D) Clostridium leptum and (E) 
Bacteroides-Prevotella-Porphyromonadaceae in LH rats.  
No statistical differences were observed for each toxicity phenotypes as compared to NOR 
using Kruskal-Wallis test, P>0.05. n=12 for VEH, n=16 for NOR, n=3 for MIL, n=3 for MDR 
and n=4 for EXT. 
A          B 
C          D 




Figure S8 Box-and-whisker plots of post-dose (8–24 h) bacterial cell counts or 
plasmid copy number per g of faeces of (A) Enterobacteriaceae, (B) 
Lactobacillus, (C) Clostridium coccoides, (D) Clostridium leptum and (E) 
Bacteroides-Prevotella-Porphyromonadaceae in LH rats.  
No statistical differences were observed for each toxicity phenotypes as compared to NOR 
using Kruskal-Wallis test, P>0.05. n=12 for VEH, n=16 for NOR, n=3 for MIL, n=3 for MDR 
and n=4 for EXT.  
A          B 
C          D 



















W/EXT 802.900 107.248 1346.268 306.838 7.425 0.141 
W/MDR 839.467 48.070 1690.663 128.719 7.015 0.237 
W/MIL 828.867 164.755 1488.164 509.174 7.321 0.137 
W/NOR 864.500 142.313 1658.537 437.973 7.231 0.270 
X/EXT 993.125 104.996 1872.825 383.440 7.307 0.152 
X/MDR 975.533 93.489 2032.986 196.937 7.288 0.213 
X/MIL 860.600 102.444 1606.816 337.945 7.237 0.266 
X/NOR 1005.633 118.395 2009.436 309.796 7.375 0.146 
Y/EXT 900.675 63.185 1793.452 197.897 6.924 0.165 
Y/MDR 1049.967 38.465 2239.333 171.279 7.381 0.114 
Y/MIL 921.400 35.410 1840.109 114.551 7.196 0.089 
Y/NOR 937.000 151.825 1832.254 410.134 7.144 0.307 
Z/EXT 807.625 146.892 1487.976 433.332 6.995 0.246 
Z/MDR 715.200 19.968 1245.353 75.653 6.990 0.201 
Z/MIL 756.767 98.775 1342.945 338.080 6.747 0.159 
Z/NOR 828.417 172.873 1601.827 505.262 6.991 0.437 
Figure S9 Alpha diversity analysis on microbiota of 83 LH rats based on 
observed species.  
Observed species, Chao1 and Shannon indices were calculated at depth of 10,000 
reads/sample, which is about 80% of the least abundant sample. The analysis can be used as a 
quality check on sufficiency of sequencing depth, as well as to find the difference in species 
richness between groups of samples. In this case, the plateau showed that sequencing was 
sufficient deep to estimate species richness. There was however no qualitative differences 




Figure S10 Number of shared OTUs in the gut microbiome of pre-dose LH rats at 
different definitions of a “core” microbiome. At the most stringent definition of 
having OTUs to be shared across 100% of rats, 189 OTUs were found to be 






Figure S11 Functional metagenomic prediction of the gut microbiome of the 83 
LH rats samples from the 4 time periods (–24 to 0 h, 0–8 h, 8–24 h, 72–96 h) 
using PICRUSt, organised using KEGG annotations. Analysis shows largely 
similar functions between all LH rats. Legend is truncated, and only the first 29 
functions are displayed.  
 






Figure S12 Functional metagenomic prediction of the gut microbiome of the 83 
LH rats samples from the 4 time periods (–24 to 0 h, 0–8 h, 8–24 h, 72–96 h) 
using PICRUSt, organised using COG. Analysis shows largely similar functions 











Figure S13 Taxonomic summaries of gut microbiome from faecal samples from 
LH rat and humans at genus level. The 20 most abundant samples were selected 
from each study, from each study’s respective 16S rRNA fasta file, and 
subsequently recoded into Human1, Human2 and Human3 for ease of reference. 
Taxonomic information are organised in order: Kingdom (k), Phylum (p), Class 
(c), Order (o), Family (f), Genus (g). Legend is truncated, and only the first 29 
taxa are displayed.  




Figure S14 Beta diversity as illustrated using a PCoA of weighted Unifrac 
distance. No clear segregation between responder groups was observed, indicating 
minimal differences between bacterial communities in groups of rats. The degree 
of variation between 10 jackknifed replicates of PCoA is displayed with 






Figure S15 Plasma (A) total bilirubin and (C) direct bilirubin of conventional LH 
rats in Group 1, and (B) total bilirubin and (D) direct bilirubin of β-glucuronidase 
treated rats in Group 2.  
Data represent mean ± SD. For Group 1, n=6 for control, n=10 for non-responders and n=7 for 
responders. For Group 2, n=6 for control, n=4 for non-responders and n=13 for responders. 
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Table S1 Recovery, intra-day precision and accuracy of assay using plasma QC 















Tacrine 3 65.2 ± 11.3 2.8 ± 0.5 17.0 93.6 
150 82.8 ± 13.5 204.8 ± 32.8 16.0 136.5 
350 80.8 ± 14.8 421.5 ± 54.2 12.9 120.4 
1-
hydroxytacrine 
3 78.8 ± 7.2 3.3 ± 0.4 12.9 110.9 
150 86.8 ± 7.9 176.4 ± 23.8 13.5 117.6 
350 85.7 ± 8.4 342.1 ± 29.0 8.5 97.7 
Data for recovery and determined concentration represent mean ± SD.  
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Table S2 Recovery, intra-day precision and accuracy of assay using faecal QC 








Precision (%) Accuracy (%) 
Tacrine 120 3.41±0.172 3.32 100 
500 3.93±0.158 5.17 98.4 
800 4.18±0.247 3.98 98.2 
1-
hydroxytacrine 
240 9.46±0.59 2.22 113 
1000 9.39±6.12 3.89 109 
1600 8.99±0.51 5.67 99.7 
Data for recovery represent mean ± SD.  
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Table S3 Metabolic pathways listed in KEGG database in which 3 or more 
urinary or faecal marker metabolites are found to be associated. 

















C00483 Tyramine Faeces  19.26 
C00183 L-Valine Faeces  13.73 
C00123 L-Leucine Faeces  10.94 
C00407 L-Isoleucine Faeces  10.93 
C00079 L-Phenylalanine Faeces  10.16 
C00645 N-Acetyl-D-mannosamine Faeces  7.71 
C00022 Pyruvate Faeces  4.98 
C00082 L-Tyrosine Faeces  4.73 
C00188 L-Threonine Faeces  4.61 
C00073 L-Methionine Faeces  3.71 
C00047 L-Lysine Faeces  2.97 
C00078 L-Tryptophan Faeces  2.93 
C00025 L-Glutamate Faeces  2.92 
C00187 Cholesterol Faeces  2.38 
C01672 Cadaverine Urine 1.97  
C00417 cis-Aconitate Urine -1.53  
C00198 D-Glucono-1,5-lactone Urine -1.66  
C00122 Fumarate Urine -1.98  
C00811 4-Coumarate Urine -2.12  
C00258 D-Glycerate Urine -2.56  
C00149 (S)-Malate Urine -2.64  
C00026 2-Oxoglutarate Urine -3.44  
C00158 Citrate Urine -4.30  
C00042 Succinate Urine & Faeces -3.17 15.37 
C00099 beta-Alanine Urine & Faeces 1.58 5.60 
C00065 L-Serine Urine & Faeces 1.49 4.94 






C00022 Pyruvate Faeces  4.98 
C00188 L-Threonine Faeces  4.61 
C00041 L-Alanine Faeces  4.31 
C00047 L-Lysine Faeces  2.97 
C00025 L-Glutamate Faeces  2.92 
C00989 4-Hydroxybutanoic acid Faeces  1.43 
C00642 4-Hydroxyphenylacetate Faeces  1.40 
C05852 2-Hydroxyphenylacetate Urine 5.13  
C00086 Urea Urine 1.54  
C00417 cis-Aconitate Urine -1.53  
C00198 D-Glucono-1,5-lactone Urine -1.66  
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C00122 Fumarate Urine -1.98  
C00258 D-Glycerate Urine -2.56  
C00149 (S)-Malate Urine -2.64  
C00026 2-Oxoglutarate Urine -3.44  
C00158 Citrate Urine -4.30  
C00322 2-Oxoadipate Urine -6.43  
C00042 Succinate Urine & Faeces -3.17 15.37 
C00065 L-Serine Urine & Faeces 1.49 4.94 




C00183 L-Valine Faeces  13.73 
C00123 L-Leucine Faeces  10.94 
C00407 L-Isoleucine Faeces  10.93 
C00079 L-Phenylalanine Faeces  10.16 
C00159 D-Mannose Faeces  5.72 
C00188 L-Threonine Faeces  4.61 
C00041 L-Alanine Faeces  4.31 
C00047 L-Lysine Faeces  2.97 
C00025 L-Glutamate Faeces  2.92 
C00392 Mannitol Faeces  2.79 
C00009 Orthophosphate Faeces  2.28 
C05402 Melibiose Faeces  1.99 
C01835 Maltotriose Faeces  0.15 
C00181 D-Xylose Urine 1.62  
C00093 Glycerol 3-phosphate Urine 1.55  
C00086 Urea Urine 1.54  
C00065 L-Serine Urine & Faeces 1.49 4.94 
C00137 myo-Inositol Urine & Faeces 1.68 3.89 
ko01230 
Biosynthesis of 
amino acids (16) 
C00183 L-Valine Faeces  13.73 
C00123 L-Leucine Faeces  10.94 
C00407 L-Isoleucine Faeces  10.93 
C00079 L-Phenylalanine Faeces  10.16 
C00022 Pyruvate Faeces  4.98 
C00082 L-Tyrosine Faeces  4.73 
C00188 L-Threonine Faeces  4.61 
C00041 L-Alanine Faeces  4.31 
C00073 L-Methionine Faeces  3.71 
C00047 L-Lysine Faeces  2.97 
C00078 L-Tryptophan Faeces  2.93 
C00025 L-Glutamate Faeces  2.92 
C00026 2-Oxoglutarate Urine -3.44  
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C00158 Citrate Urine -4.30  
C00322 2-Oxoadipate Urine -6.43  
C00065 L-Serine Urine & Faeces 1.49 4.94 
ko04974  
Protein digestion 
and absorption (15) 
C00483 Tyramine Faeces  19.26 
C00183 L-Valine Faeces  13.73 
C00123 L-Leucine Faeces  10.94 
C00407 L-Isoleucine Faeces  10.93 
C00079 L-Phenylalanine Faeces  10.16 
C00082 L-Tyrosine Faeces  4.73 
C00188 L-Threonine Faeces  4.61 
C00041 L-Alanine Faeces  4.31 
C00073 L-Methionine Faeces  3.71 
C00047 L-Lysine Faeces  2.97 
C00078 L-Tryptophan Faeces  2.93 
C00025 L-Glutamate Faeces  2.92 
C01672 Cadaverine Urine 1.97  
C00099 beta-Alanine Urine & Faeces 1.58 5.60 




C00183 L-Valine Faeces  13.73 
C00123 L-Leucine Faeces  10.94 
C00407 L-Isoleucine Faeces  10.93 
C00079 L-Phenylalanine Faeces  10.16 
C00022 Pyruvate Faeces  4.98 
C00082 L-Tyrosine Faeces  4.73 
C00073 L-Methionine Faeces  3.71 
C00047 L-Lysine Faeces  2.97 
C00078 L-Tryptophan Faeces  2.93 
C00025 L-Glutamate Faeces  2.92 
C00417 cis-Aconitate Urine -1.53  
C00026 2-Oxoglutarate Urine -3.44  
C00158 Citrate Urine -4.30  




C00183 L-Valine Faeces  13.73 
C00123 L-Leucine Faeces  10.94 
C00407 L-Isoleucine Faeces  10.93 
C00079 L-Phenylalanine Faeces  10.16 
C00082 L-Tyrosine Faeces  4.73 
C00188 L-Threonine Faeces  4.61 
C00041 L-Alanine Faeces  4.31 
C00073 L-Methionine Faeces  3.71 
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C00047 L-Lysine Faeces  2.97 
C00078 L-Tryptophan Faeces  2.93 
C00025 L-Glutamate Faeces  2.92 




C00022 Pyruvate Faeces  4.98 
C00041 L-Alanine Faeces  4.31 
C00989 4-Hydroxybutanoic acid Faeces  1.43 
C00198 D-Glucono-1,5-lactone Urine -1.66  
C00122 Fumarate Urine -1.98  
C00258 D-Glycerate Urine -2.56  
C00149 (S)-Malate Urine -2.64  
C00026 2-Oxoglutarate Urine -3.44  
C00158 Citrate Urine -4.30  
C00042 Succinate Urine & Faeces -3.17 15.37 




C00183 L-Valine Faeces  13.73 
C00123 L-Leucine Faeces  10.94 
C00407 L-Isoleucine Faeces  10.93 
C00079 L-Phenylalanine Faeces  10.16 
C00188 L-Threonine Faeces  4.61 
C00041 L-Alanine Faeces  4.31 
C00073 L-Methionine Faeces  3.71 
C00078 L-Tryptophan Faeces  2.93 
C00009 Orthophosphate Faeces  2.28 




C00079 L-Phenylalanine Faeces  10.16 
C00022 Pyruvate Faeces  4.98 
C00082 L-Tyrosine Faeces  4.73 
C05332 Phenethylamine Faeces  4.34 
C00642 4-Hydroxyphenylacetate Faeces  1.40 
C05852 2-Hydroxyphenylacetate Urine 5.13  
C05598 Phenylacetylglycine Urine 2.45  
C00122 Fumarate Urine -1.98  
C00811 4-Coumarate Urine -2.12  





C00022 Pyruvate Faeces  4.98 
C00025 L-Glutamate Faeces  2.92 
C00417 cis-Aconitate Urine -1.53  
C00898 (R,R)-Tartaric acid Urine -2.14  
C00258 D-Glycerate Urine -2.56  
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C00149 (S)-Malate Urine -2.64  
C00026 2-Oxoglutarate Urine -3.44  
C00158 Citrate Urine -4.30  
C00042 Succinate Urine & Faeces -3.17 15.37 





C00022 Pyruvate Faeces  4.98 
C00989 4-Hydroxybutanoic acid Faeces  1.43 
C00417 cis-Aconitate Urine -1.53  
C00122 Fumarate Urine -1.98  
C00149 (S)-Malate Urine -2.64  
C00026 2-Oxoglutarate Urine -3.44  
C00158 Citrate Urine -4.30  




C00483 Tyramine Faeces  19.26 
C00022 Pyruvate Faeces  4.98 
C00082 L-Tyrosine Faeces  4.73 
C06044 4-Hydroxyphenylethanol Faeces  3.21 
C10447 3,4-
Dihydroxyphenylpropanoate 
Faeces  2.44 
C00642 4-Hydroxyphenylacetate Faeces  1.40 
C00122 Fumarate Urine -1.98  




C00022 Pyruvate Faeces  4.98 
C00025 L-Glutamate Faeces  2.92 
C00989 4-Hydroxybutanoic acid Faeces  1.43 
C01089 (R)-3-Hydroxybutanoate Faeces  0.31 
C00122 Fumarate Urine -1.98  
C02630 2-Hydroxyglutarate Urine -3.06  
C00026 2-Oxoglutarate Urine -3.44  




C00183 L-Valine Faeces  13.73 
C00123 L-Leucine Faeces  10.94 
C00407 L-Isoleucine Faeces  10.93 
C00079 L-Phenylalanine Faeces  10.16 
C00082 L-Tyrosine Faeces  4.73 
C00073 L-Methionine Faeces  3.71 
C00078 L-Tryptophan Faeces   2.93 
ko00020  
Citrate cycle (TCA 
cycle) (7) 
C00022 Pyruvate Faeces  4.98 
C00417 cis-Aconitate Urine -1.53  
C00122 Fumarate Urine -1.98  
C00149 (S)-Malate Urine -2.64  
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C00026 2-Oxoglutarate Urine -3.44  
C00158 Citrate Urine -4.30  





C00022 Pyruvate Faeces  4.98 
C00041 L-Alanine Faeces  4.31 
C00025 L-Glutamate Faeces  2.92 
C00122 Fumarate Urine -1.98  
C00026 2-Oxoglutarate Urine -3.44  
C00158 Citrate Urine -4.30  




C00025 L-Glutamate Faeces  2.92 
C00009 Orthophosphate Faeces  2.28 
C00122 Fumarate Urine -1.98  
C00149 (S)-Malate Urine -2.64  
C00158 Citrate Urine -4.30  





C06427 Linolenic acid Faeces  3.52 
C01595 Linoleate Faeces  2.76 
C00712 (9Z)-Octadecenoic acid Faeces  2.45 
C08281 Docosanoic acid Faeces  2.10 
C01530 Octadecanoic acid Faeces  1.93 





C00022 Pyruvate Faeces  4.98 
C00025 L-Glutamate Faeces  2.92 
C00417 cis-Aconitate Urine -1.53  
C01732 Mesaconate Urine -2.81  
C02630 2-Hydroxyglutarate Urine -3.06  





C00431 5-Aminopentanoate Faeces  17.51 
C00022 Pyruvate Faeces  4.98 
C00025 L-Glutamate Faeces  2.92 
C00791 Creatinine Urine 4.53  
C00086 Urea Urine 1.54  
C00122 Fumarate Urine -1.98   
ko00290  
Valine, leucine and 
isoleucine 
biosynthesis (5) 
C00183 L-Valine Faeces  13.73 
C00123 L-Leucine Faeces  10.94 
C00407 L-Isoleucine Faeces  10.93 
C00022 Pyruvate Faeces  4.98 
C00188 L-Threonine Faeces   4.61 
ko01220 C00022 Pyruvate Faeces  4.98 
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C00642 4-Hydroxyphenylacetate Faeces  1.40 
C00122 Fumarate Urine -1.98  
C00811 4-Coumarate Urine -2.12  
C00042 Succinate Urine & Faeces -3.17 15.37 
ko00260  
Glycine, serine and 
threonine 
metabolism (5) 
C00022 Pyruvate Faeces  4.98 
C00188 L-Threonine Faeces  4.61 
C00078 L-Tryptophan Faeces  2.93 
C00258 D-Glycerate Urine -2.56  




C00183 L-Valine Faeces  13.73 
C00407 L-Isoleucine Faeces  10.93 
C00079 L-Phenylalanine Faeces  10.16 
C00082 L-Tyrosine Faeces  4.73 





C00022 Pyruvate Faeces   4.98 
C00474 Ribitol Faeces  1.62 
C00181 D-Xylose Urine 1.62  
C01904 D-Arabitol Urine 1.44  




C00431 5-Aminopentanoate Faeces  17.51 
C00047 L-Lysine Faeces  2.97 
C01672 Cadaverine Urine 1.97  
C00322 2-Oxoadipate Urine -6.43  




C00022 Pyruvate Faeces  4.98 
C00258 D-Glycerate Urine -2.56  
C00149 (S)-Malate Urine -2.64  
C00322 2-Oxoadipate Urine -6.43  
C00065 L-Serine Urine & Faeces 1.49 4.94 
ko00520  
Amino sugar and 
nucleotide sugar 
metabolism (4) 
C00645 N-Acetyl-D-mannosamine Faeces  7.71 
C00159 D-Mannose Faeces  5.72 
C02336 beta-D-Fructose Faeces  5.30 





C00022 Pyruvate Faeces  4.98 
C00041 L-Alanine Faeces  4.31 
C00073 L-Methionine Faeces  3.71 





C00407 L-Isoleucine Faeces  10.93 
C00079 L-Phenylalanine Faeces  10.16 
C00047 L-Lysine Faeces  2.97 
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biosynthesis (4) C01672 Cadaverine Urine 1.97   
ko00280  
Valine, leucine and 
isoleucine 
degradation (4) 
C00183 L-Valine Faeces  13.73 
C00123 L-Leucine Faeces  10.94 
C00407 L-Isoleucine Faeces  10.93 





C00022 Pyruvate Faeces  4.98 
C00041 L-Alanine Faeces  4.31 
C00025 L-Glutamate Faeces  2.92 
C00026 2-Oxoglutarate Urine -3.44   
ko04976  
Bile secretion (4) 
C02528 Chenodeoxycholate Faeces  3.57 
C03990 Lithocholic acid Faeces  2.81 
C00187 Cholesterol Faeces  2.38 




C00022 Pyruvate Faeces  4.98 
C00122 Fumarate Urine -1.98  
C00149 (S)-Malate Urine -2.64  




C00078 L-Tryptophan Faeces  2.93 
C00322 2-Oxoadipate Urine -6.43  
C00954 Indole-3-acetate Urine & Faeces -2.90 1.39 
ko00710  
Carbon fixation in 
photosynthetic 
organisms (3) 
C00022 Pyruvate Faeces  4.98 
C00041 L-Alanine Faeces  4.31 




C00712 (9Z)-Octadecenoic acid Faeces  2.45 
C01530 Octadecanoic acid Faeces  1.93 





C00047 L-Lysine Faeces  2.97 
C00086 Urea Urine 1.54  






C00079 L-Phenylalanine Faeces  10.16 
C00082 L-Tyrosine Faeces  4.73 




C00187 Cholesterol Faeces  2.38 
C00122 Fumarate Urine -1.98  





C00022 Pyruvate Faeces  4.98 
C00153 Nicotinamide Urine 3.08  
C00122 Fumarate Urine -1.98   
ko00940 
Phenylpropanoid 
C00079 L-Phenylalanine Faeces  10.16 
C00082 L-Tyrosine Faeces  4.73 
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C00025 L-Glutamate Faeces  2.92 
C00026 2-Oxoglutarate Urine -3.44  
C00042 Succinate Urine & Faeces -3.17 15.37 
ko02060 
Phosphotransferase 
system (PTS) (3) 
C00159 D-Mannose Faeces  5.72 
C00022 Pyruvate Faeces  4.98 





C00025 L-Glutamate Faeces  2.92 
C00149 (S)-Malate Urine -2.64  




C00159 D-Mannose Faeces  5.72 
C05402 Melibiose Faeces  1.99 




C00047 L-Lysine Faeces  2.97 
C00026 2-Oxoglutarate Urine -3.44  




C00009 Orthophosphate Faeces  2.28 
C00122 Fumarate Urine -1.98  




C00183 L-Valine Faeces  13.73 
C00042 Succinate Urine & Faeces -3.17 15.37 





C00183 L-Valine Faeces  13.73 
C00022 Pyruvate Faeces  4.98 




C00022 Pyruvate Faeces  4.98 
C00198 D-Glucono-1,5-lactone Urine -1.66  





C00022 Pyruvate Faeces  4.98 
C00026 2-Oxoglutarate Urine -3.44  





C00483 Tyramine Faeces  19.26 
C00025 L-Glutamate Faeces  2.92 




Table S4 Sample coding used in MiSeq sequencing experiment.  
Sample 
S/N 










1 -24 to 0 h T1 Non-responder W1 W/NOR 
2 -24 to 0 h T2 Non-responder W2 W/NOR 
3 -24 to 0 h T3 Non-responder W3 W/NOR 
4 -24 to 0 h T4 Non-responder W4 W/NOR 
5 -24 to 0 h T6 Mild responder W6 W/MIL 
6 -24 to 0 h T7 Non-responder W7 W/NOR 
7 -24 to 0 h T8 Extreme responder W8 W/EXT 
8 -24 to 0 h T9 Mild responder W9 W/MIL 
9 -24 to 0 h T10 Extreme responder W10 W/EXT 
10 -24 to 0 h T11 Non-responder W11 W/NOR 
11 -24 to 0 h T12 Extreme responder W12 W/EXT 
12 -24 to 0 h T13 Non-responder W13 W/NOR 
13 -24 to 0 h T14 Extreme responder W14 W/EXT 
14 -24 to 0 h T15 Non-responder W15 W/NOR 
15 -24 to 0 h T16 Non-responder W16 W/NOR 
16 -24 to 0 h T17 Non-responder W17 W/NOR 
17 -24 to 0 h T18 Non-responder W18 W/NOR 
18 -24 to 0 h T19 Non-responder W19 W/NOR 
19 -24 to 0 h T20 Non-responder W20 W/NOR 
20 -24 to 0 h T21 Non-responder W21 W/NOR 
21 -24 to 0 h T22 Moderate responder W22 W/MDR 
22 -24 to 0 h T23 Moderate responder W23 W/MDR 
23 -24 to 0 h T24 Mild responder W24 W/MIL 
24 -24 to 0 h T26 Moderate responder W26 W/MDR 
25 -24 to 0 h T27 Non-responder W27 W/NOR 
26 -24 to 0 h T28 Non-responder W28 W/NOR 
27 0–8 h T1 Non-responder X1 X/NOR 
28 0–8 h T2 Non-responder X2 X/NOR 
29 0–8 h T6 Mild responder X6 X/MIL 
30 0–8 h T8 Extreme responder X8 X/EXT 
31 0–8 h T9 Mild responder X9 X/MIL 
32 0–8 h T10 Extreme responder X10 X/EXT 
33 0–8 h T11 Non-responder X11 X/NOR 
34 0–8 h T12 Extreme responder X12 X/EXT 
35 0–8 h T14 Extreme responder X14 X/EXT 
36 0–8 h T16 Non-responder X16 X/NOR 
37 0–8 h T18 Non-responder X18 X/NOR 
38 0–8 h T22 Moderate responder X22 X/MDR 
39 0–8 h T23 Moderate responder X23 X/MDR 
40 0–8 h T24 Mild responder X24 X/MIL 
41 0–8 h T26 Moderate responder X26 X/MDR 
42 0–8 h T27 Non-responder X27 X/NOR 
43 8–24 h T1 Non-responder Y1 Y/NOR 















45 8–24 h T3 Non-responder Y3 Y/NOR 
46 8–24 h T4 Non-responder Y4 Y/NOR 
47 8–24 h T6 Mild responder Y6 Y/MIL 
48 8–24 h T7 Non-responder Y7 Y/NOR 
49 8–24 h T8 Extreme responder Y8 Y/EXT 
50 8–24 h T9 Mild responder Y9 Y/MIL 
51 8–24 h T10 Extreme responder Y10 Y/EXT 
52 8–24 h T11 Non-responder Y11 Y/NOR 
53 8–24 h T12 Extreme responder Y12 Y/EXT 
54 8–24 h T13 Non-responder Y13 Y/NOR 
55 8–24 h T14 Extreme responder Y14 Y/EXT 
56 8–24 h T15 Non-responder Y15 Y/NOR 
57 8–24 h T16 Non-responder Y16 Y/NOR 
58 8–24 h T17 Non-responder Y17 Y/NOR 
59 8–24 h T18 Non-responder Y18* Y/NOR 
60 8–24 h T19 Non-responder Y19 Y/NOR 
61 8–24 h T20 Non-responder Y20 Y/NOR 
62 8–24 h T21 Non-responder Y21 Y/NOR 
63 8–24 h T22 Moderate responder Y22 Y/MDR 
64 8–24 h T23 Moderate responder Y23 Y/MDR 
65 8–24 h T24 Mild responder Y24 Y/MIL 
66 8–24 h T26 Moderate responder Y26 Y/MDR 
67 8–24 h T27 Non-responder Y27 Y/NOR 
68 8–24 h T28 Non-responder Y28 Y/NOR 
69 72–96 h T1 Non-responder Z1 Z/NOR 
70 72–96 h T2 Non-responder Z2 Z/NOR 
71 72–96 h T6 Mild responder Z6 Z/MIL 
72 72–96 h T8 Extreme responder Z8 Z/EXT 
73 72–96 h T9 Mild responder Z9 Z/MIL 
74 72–96 h T10 Extreme responder Z10 Z/EXT 
75 72–96 h T11 Non-responder Z11 Z/NOR 
76 72–96 h T12 Extreme responder Z12 Z/EXT 
77 72–96 h T14 Extreme responder Z14 Z/EXT 
78 72–96 h T16 Non-responder Z16 Z/NOR 
79 72–96 h T18 Non-responder Z18 Z/NOR 
80 72–96 h T22 Moderate responder Z22 Z/MDR 
81 72–96 h T23 Moderate responder Z23 Z/MDR 
82 72–96 h T24 Mild responder Z24 Z/MIL 
83 72–96 h T26 Moderate responder Z26 Z/MDR 
84 72–96 h T27 Non-responder Z27 Z/NOR 
*Y18 is subsequently omitted after indexing QC revealed unusually low read count.   
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Table S5 Target bacterial species within each target group that are profiled by the 
primers. 
Target bacterial group Target bacterial species 
Clostridium coccoides- 
Eubacterium rectale 
Clostridium coccoides, Cl. proteoclasticum, Cl. 
aminophilum, Cl. symbiosum, Cl. sphenoides, Cl. 
celerecrescens, Cl. aerotolerans,Cl. xylanolyticum, 
Cl. clostridiiforme, Cl. fusiformis, Cl. nexile, Cl. 
oroticum, Cl. populeti, Cl. aminovalericum, Cl. 
indolis, C. herbivorans, Cl. polysaccharolyticum, 
Eubacterium xylanophilum, E. ruminantium, E. 
saburreum, E. fissicatena, E. hadrum, E. rectale, E. 
ramulus, E. contortum, E. eligens, E. hallii, E. 
formicigenerans, E. cellulosolvens, Ruminococcus 
productus†, R. obeum, R. schinkii, R. 
hydrogenotrophicus, R. hansenii, R. torques, R. 
lactaris, R. gnavus, Butyrivibrio fibrisolvens, B. 
crossotus, B. fibrisolvens, Desulfotomaculum 
guttoideum, Roseburia cecicola, Pseudobutyrivibrio 
ruminis, Lachnospira multipara, Lachnospira 
pectinoschiza, Acetitomaculum ruminis, Catonella 
morbi 
Clostridium leptum Clostridium cellulosi, Cl. leptum, Cl. orbiscindens, Cl.  
sporosphaeroides, Cl. viride, Eubacterium desmolans, 
E. siraeum, Faecalibacterium prausnitzii†, 
Ruminococcus albus, R. bromii, R. callidus, R. 
flavefaciens, Clostridium coccoides, Bifidobacterium 
longum, Collinsella aerofaciens, Bacteroides vulgatus 
Enterobacteriaceae Escherichia coli†, Citrobacter freundii, Citrobacter 
koseri, Enterobacter cloacae, Enterobacter 
aerogenes, Enterobacter sakazakii,  Klebsiella 
pneumoniae, Klebsiella oxytoca, Serratia marcescens, 
Proteus mirabilis, Proteus vulgaris, Proteus penneri, 
Hafnia alvei, Edwardsiella tarda, Providencia 
alcalifaciens, Morganella morganii, Salmonella 
choleraesuis, Yersina enterocolitica  
Bacteroides-Prevotella-
Porphyromonadaceae  
Bacteroides fragilis, B. stercoris, B. vulgatus, B. 
eggerthii, B. acidofaciens, B. caccae, B. ovatus, B. 
uniformis, B. thetaiotaomicron, B. distasonis, B. 
merdae, B. forsythus, Prevotella tannerae, P. bryantii, 
P. ruminicola, P. heparinolytica, P. zoogleoformans, 
P. brevis, P. loescheii, P. buccae, P. oralis, P. enoeca, 
P. melaninogenica, P. veroralis, P. intermedia, P. 
albensis, P. nigrescens, P. corporis, P. disiens, P. 
bivia, P. pallens, P. denticola, Porphyromonas 
canoris, P. gingivalis, P. asaccharolytica, P. levii, P. 
cangingivalis, P. endodontalis, P. macacae, P. 
circumdentaria, P. catoniae, P. bennonis, P. gulae, P. 
uenonis, P. cansulci, Dysgonomonas mossii†, D. 
gadei, D. capnocytophagoides 
Lactobacillus  Lactobacillus acidophilus, L. amylovorus, L. 
delbrueckii subsp. bulgaricus, L. delbrueckii subsp. 
delbrueckii†, L. delbrueckii subsp. lactis, L. 
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Target bacterial group Target bacterial species 
amylolyticus, L. acetotolerans, L. crispatus, L. 
amylophilus, L. johnsonii, L. gasseri, L. fermentum, L. 
pontis, L. reuteri, L. mucosae, L. vaginalis, L. panis, 
L. oris, L. pentosus, L. plantarum, L. collinoides, L. 
alimentarius, L. farciminis, L. brevis, L. buchneri, L. 
kefiri, L. fructivorans, L. mali, L. animalis, L. 
murinus, L. ruminis, L. agilis, L. salivarius subsp. 
salicinius, L. aviarius subsp. aviarius, L. sharpeae, L. 
manihotivorans, L. rhamnosus, L. casei subsp. casei, 
L. zeae, L. paracasei subsp. paracasei, L. paracasei 
subsp. tolerans, L. coryniformis subsp. coryniformis, 
L. bifermentans, L. perolens, L. sakei subsp. sakei, L. 
casei subsp. fusiformis, Pediococcus pentosaceus, P. 
parvulus, P. acidilactici, P. dextrinicus, Weissella 
halotolerans, W. confusus, W. Paramesenteroides, W. 
hellenica, W. viridescens, W. kandleri, W. minor, 
Leuconostoc Lactis 
 
Erysipelotrichaceae Allobaculum sterocoricanis, Turicibacter sanguinis†, 
Eubacterium cylindroides, Streptococcus 
pleomorphus, Caldilinea aerophilia 
† Bacterial reference strain used as positive control and standards in qPCR assay.   
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Table S6 qPCR cycling conditions of target bacterial groups. 









95 5 min 1 
95 15 sec 30 
55* 20 sec 
72 45 sec 
72 5 min 1 
Clostridium leptum  
(239 bp) 
95 5 min 1 
94 20 sec 40 
50* 30 sec 
72 50 sec 
94 15 sec 1 
Enterobacteriaceae  
(428 bp) 
95 5 min 1 
94 20 sec 40 
60* 30 sec 
72 50 sec 




95 10 min 1 
95 30 sec 40 
68* 1 min 
72 35 sec 
72 7 min 1 
Lactobacillus  
(341 bp) 
95 5 min 1 
95 30 sec 30 
58* 30 sec 
72 35 sec 
72 7 min 1 
Erysipelotrichaceae†  
(450 bp) 
95 5 min 1 
95 30 sec 35 
61* 30 sec 
72 30 sec 
72 5 min 1 
* Annealing temperature of primers.  
† 16S-rDNA primers originally designed to target only Turicibacter sanguinis showed 
positive qPCR results for the bacterial standards but was below the limit of detection for 
faecal samples. As such, primer design was broadened to profile the Erysipelotrichaceae 
family as a target bacterial group by including two additional species within the family, 
Allobaculum stercorcanis and Eubacterium cylindroides. The target bacterial group still fell 
below the limit of detection in the faecal samples despite the reported abundance of 
Allobaculum stercoricanis in the rat gut microbiome (350). As a result, further analysis of the 





Table S7 List of human 16S rRNA sequencing samples used in the study. The 20 
most abundant samples were selected from each study, from each study’s 
respective 16S rRNA fasta file, and subsequently recoded into Human1, Human2 
and Human3 for ease of reference. 
Seq ID Sample ID used 
in each respective 
studies 
Sample coding 
used in this 
study 
Region of 16S 
rRNA 
amplified 
TS2 F1T2Le1 Human1* V2 
TS5 F2T2Le1 Human1 V2 
TS7 F3T1Le1 Human1 V2 
TS8 F3T2Le1 Human1 V2 
TS9 F3MOv1 Human1 V2 
TS14 F5T2Le1 Human1 V2 
TS15 F5MOv1 Human1 V2 
TS19 F7T1Ob1 Human1 V2 
TS20 F7T2Ob1 Human1 V2 
TS21 F7MOb1 Human1 V2 
TS25 F9T1Le1 Human1 V2 
TS26 F9T2Le1 Human1 V2 
TS27 F9MOb1 Human1 V2 
TS31 F11T1Le1 Human1 V2 
TS32 F11T2Le1 Human1 V2 
TS33 F11MOv1 Human1 V2 
TS49 F15T1Ob1 Human1 V2 
TS50 F15T2Ob1 Human1 V2 
TS51 F15MOb1 Human1 V2 
TS149 F43T2Ob1 Human1 V2 
h68B.4.418611 Same as Seq ID Human2** V4 
h47B.1.418571 Same as Seq ID Human2 V4 
h35A.3.418524 Same as Seq ID Human2 V4 
h305C.2.418553 Same as Seq ID Human2 V4 
h301A.1.418425 Same as Seq ID Human2 V4 
h186B.1.418751 Same as Seq ID Human2 V4 
USygt44.T1.418626 Same as Seq ID Human2 V4 
USygt21.F.418579 Same as Seq ID Human2 V4 
USygt2.M.418457 Same as Seq ID Human2 V4 
USygt12.F.418502 Same as Seq ID Human2 V4 
USinfTw1.2.418491 Same as Seq ID Human2 V4 
TS5.418546 Same as Seq ID Human2 V4 
AmzC9adltM.418480 Same as Seq ID Human2 V4 
AmzC6chldM2.418719 Same as Seq ID Human2 V4 
AmzC30adltF.418737 Same as Seq ID Human2 V4 
AmzC2chldM1.418776 Same as Seq ID Human2 V4 
AmzC28chldM.418506 Same as Seq ID Human2 V4 
AmzC22chldM.418704 Same as Seq ID Human2 V4 
Amz6eldF.418597 Same as Seq ID Human2 V4 
AmzC3adltM.418849 Same as Seq ID Human2 V4 
SRS011410.SRX020666 Same as Seq ID Human3*** V3–5 
SRS014369.SRX020558 Same as Seq ID Human3 V3–5 
SRS014287.SRX020551 Same as Seq ID Human3 V3–5 
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Seq ID Sample ID used 
in each respective 
studies 
Sample coding 
used in this 
study 
Region of 16S 
rRNA 
amplified 
SRS014885.SRX020558 Same as Seq ID Human3 V3–5 
SRS015281.SRX020558 Same as Seq ID Human3 V3–5 
SRS015518.SRX020573 Same as Seq ID Human3 V3–5 
SRS015599.SRX020573 Same as Seq ID Human3 V3–5 
SRS015663.SRX020573 Same as Seq ID Human3 V3–5 
SRS015815.SRX020562 Same as Seq ID Human3 V3–5 
SRS016152.SRX020573 Same as Seq ID Human3 V3–5 
SRS016335.SRX020522 Same as Seq ID Human3 V3–5 
SRS043804.SRX020531 Same as Seq ID Human3 V3–5 
SRS055482.SRX020514 Same as Seq ID Human3 V3–5 
SRS046313.SRX020514 Same as Seq ID Human3 V3–5 
SRS045414.SRX020518 Same as Seq ID Human3 V3–5 
SRS052697.SRX020514 Same as Seq ID Human3 V3–5 
SRS046382.SRX020563 Same as Seq ID Human3 V3–5 
SRS054590.SRX020514 Same as Seq ID Human3 V3–5 
SRS042703.SRX020518 Same as Seq ID Human3 V3–5 
SRS065725.SRX020556 Same as Seq ID Human3 V3–5 
 
* Human1 from reference (20). Data available from: 
http://gordonlab.wustl.edu/NatureTwins_2008/TurnbaughNature_11_30_08.html  
** Human2 from reference (54). Data available from: 
http://metagenomics.anl.gov/metagenomics.cgi?page=MetagenomeProject&project=401  




Supplementary Method 1 Bioinformatics data processing with QIIME 1.7.0 
1. Introduction 
This protocol describes QIIME 1.7.0 (Quantitative Insights Into 
Microbial Ecology) for microbiome community profiling using the 
16S data retrieved from MiSeq benchtop sequencer. The process 
includes the merge of paired end reads, OTU picking, taxonomic 
assignment, construction of phylogenetic trees from representative 
sequences of OTUs, as well as downstream statistical analysis, 
visualization, and production of publication-quality graphics. 
2. Requirement 
a. Data requirement 
i. Paired end reads from MiSeq (e.g. R1.fastq.gz, R2.fastq.gz) 
(https://basespace.illumina.com/run/3671684/Tacrine-rat-
fecal-microbiome) 
ii. Greengenes (Aug 13) reference database 
(ftp://greengenes.microbio.me/greengenes_release/gg_13_5/g
g_13_8_otus.tar.gz) 
iii. User-created mapping file (e.g. map.txt) that contain sample 
category information and description. Information on creating 
map file can be found at 
http://qiime.org/documentation/file_formats.html#metadata-
mapping-files 
b. Software requirement 
i. FLASh 1.2.7 (http://ccb.jhu.edu/software/FLASH/) 
ii. Qiime 1.7.0 (http://qiime.org/) 
iii. Virtualbox if using Windows 
(http://www.virtualbox.org/wiki/Downloads) 
3. Proceduces  
a. FLASh to merge paired end reads 
i. Copy executable file (.exe) from FLASh to folder containing 
paired end reads for each sample 
ii. Open cmd.exe on Windows by searching “cmd.exe” from 
Windows Start button. 
iii. Change directory to folder containing paired ends reads 
iv. Type  
flash R1.fastq.gz R2.fastq.gz -o W1 -d merge/ 
 
where 
R1.fastq.gz and R2.fastq.gz are the forward and 
reverse reads 
W1 is the name of the sample 
merge/ is the name of the output directory 
 
v. To concatenate multiple scripts together to process one sample 
after another, use “&” to chain multiple scripts together. 
b. Quality filter 
i. Start Oracle Virtualbox, start Qiime 1.7.0 
ii. Open terminal on Ubuntu by clicking the black icon of the left 
iii. Change directory to folder containing merged reads 
iv. The following step make use of the quality filtering 
component of “split_libraies_fastq.py” script, then renaming 
the output file “seqs.fna” to “sample_nameseqs.fna”. Type 
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split_libraries_fastq.py -i W1.extendedFrags.fastq --
sample_id W1 -o q30/ -m map.txt -q30 --barcode_type 
'not-barcoded' && mv q30/seqs.fna q30/W1seqs.fna 
 
where 
W1.extendedFrags.fastq is the merged read 
W1 is the sample id 
q30/ is the output folder 
map.txt is the mapping file 
-q30 is the quality score (30 in this case) 
--barcode_type is set as 'not-barcoded' 
mv renames seqs.fna to W1seqs.fna 
v. To concatenate multiple scripts together to process one sample 
after another, use “&&” to chain multiple scripts together. 
c. Concantenate all sample sequences to one .fna file 
i. Open cmd.exe on Windows by searching “cmd.exe” from 
Windows Start button. 
ii. This step combines all the previous .fna files into one seqs.fna. 
Type 
COPY W1seqs.fna+W2seqs.fna+ …Z27seqs.fna 
seqs.fna 
d. Filter chimeric sequences away from seqs.fna 
i. Open terminal on Ubuntu by clicking the black icon of the left 
ii. Change directory to folder containing seqs.fna 
iii. Type 




2. filter_fasta.py -f seqs.fna -o 
seqs_chimeras_filtered.fna -s 
usearch_checked_chimeras/chimeras.txt -n 
e. Pick open-reference OTU from chimera-filtered seqs.fna 
i. Open terminal on Ubuntu by clicking the black icon of the left 
ii. Change directory to folder containing 
seqs_chimeras_filtered.fna 
iii. Set variables by typing 










iv. Execute open-reference OTU pick by typing 
1. pick_open_reference_otus.py -i $PWD/seqs_ 
chimeras_filtered.fna -r $reference_seqs -o 




f. Check biom file 
i. Open terminal on Ubuntu by clicking the black icon of the left 
ii. Change directory to folder orq30/ 
iii. Type 
1. print_biom_table_summary.py -i 
otu_table_mc2_w_tax_no_pynast_failures.biom 
iv. Take note of number of reads from the sample with the least 
number of reads 
v. This step filters any unwanted samples from the biom table 
(e.g. outlier data), if any. Type 




vi. This step sorts samples in biom according to a list of sample 
in desired order. The list.txt should contain names of samples, 
with each name in each row. Type 
1. sort_otu_table.py -i 
otu_table_mc2_w_tax_no_pynast_failures.biom -o 
otu_table_sorted.biom -l list_ordered.txt 
g. Draw taxonomy summary from OTU table 
i. Open terminal on Ubuntu by clicking the black icon of the left 
ii. Change directory to folder orq30/ 
iii. Type 
1. summarize_taxa_through_plots.py -i 
otu_table_sorted.biom -o taxasummary -m map.txt 
iv. Resultant bar and area charts can be open in any web browser. 
h. Perform alpha rarefaction to find alpha diversity 
i. Open terminal on Ubuntu by clicking the black icon of the left 
ii. Change directory to folder orq30/ 
iii. Type 
1. echo "alpha_diversity:metrics 
shannon,PD_whole_tree,chao1,observed_species" > 
alpha_params.txt 
2. alpha_rarefaction.py -i otu_table_sorted.biom -m 
map.txt -o alpha/ -p alpha_params.txt -t rep_set.tre -e 
10000 
iv. The value after -e should be set at ~80% of the least number 
of reads 
v. Resultant plots can be open in any web browser. 
i. Perform beta rarefaction to find beta diversity 
i. Open terminal on Ubuntu by clicking the black icon of the left 
ii. Change directory to folder orq30/ 
iii. Type 
1. beta_diversity_through_plots.py -i otu_table.biom -m 
map.txt -o beta/ -t rep_set.tre -e 10000 
iv. The value after -e should be set at ~80% of the least number 
of reads, and should be consistent as used in alpha rarefaction. 
v. Once the workflow is complete, use emperor to create PCoA 
plots viewable on Google Chrome. Type 
1. make_emperor.py -i unweighted_unifrac_pc.txt -m 
map.txt -o unweighted_unifrac_pc 
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2. make_emperor.py -i weighted_unifrac_pc.txt -m 
map.txt -o weighted_unifrac_pc 
3. make_emperor.py -i unweighted_unifrac_dm.txt -m 
map.txt -o unweighted_unifrac_dm 
4. make_emperor.py -i weighted_unifrac_dm.txt -m 
map.txt -o weighted_unifrac_dm 
vi. View PCoA plots on Google chrome (not supported on other 
web browser) 
vii. For jackknifed beta diversity, repeat analysis by typing 
1. jackknifed_beta_diversity.py -i otu_table.biom -o 
beta_jack -e 10000 -m map.txt -t rep_set.tre 
j. Perform statistical test (within QIIME) 
i. Generate an OTU table for each cluster of groups for 
ANOSIM 
1. filter_samples_from_otu_table.py -i otu_table.biom -o 
otu_table_A.biom --sample_id_fp 
samples_to_keep.txt 
ii. Perform beta rerafaction to find beta diversity, to generate 
unifrac_dm.txt for ANOSIM 
1. beta_diversity_through_plots.py -i otu_table_A.biom -
m map.txt -o beta/ -t rep_set.tre -e 10000 
iii. To compare one category from another using ANOSIM 
1. compare_categories.py --method anosim -i 
unweighted_unifrac_dm.txt -m map.txt -c Treatment -
o anosim_out -n 999 
k. Perform statistical test (outside QIIME) 
i. Output files from the result of taxonomy summary can be 
opened in Excel/SPSS for further statistical analysis, e.g. 
otu_table_L2.txt, otu_table_L6.txt, etc. 
Taxonomic information are organised in order: Kingdom (L1), 
Phylum (L2), Class (L3), Order (L4), Family (L5), Genus 
(L6), Species (L7). L1 and L7 are not generated by default. 
l. Perform PICRUSt prediction 
i. Upload otu_table.biom onto Galaxy online under “Get Data”, 
“Upload file” on the left panel 
http://huttenhower.sph.harvard.edu/galaxy/root?tool_id=PICR
USt_normalize 
1. Select “Normalize By Copy Number” on the left 
panel, choosing Greengenes version used in closed-
reference OTU pick 
2. Select “Predict Metagenome” on the left panel, 
choosing desired functional predictions (e.g. KEGG, 
COG) 
3. Select “Categorize by function” on the left panel, 
choosing desired hierarchy level (e.g. 1–3 for KEGG, 
1–2 for COG ) 
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ii. Download output .picrustc file from right panel, rename as 
output.biom 
iii. Draw functional data summary via plots 
1. Create parameter file by copying the lines below to 
paraL3.txt 
a. summarize_taxa:md_identifier    
"KEGG_Pathways" 
summarize_taxa:absolute_abundance   True 
summarize_taxa:level    3 
2. summarize_taxa_through_plots.py -i output.biom -p 
paraL3.txt -o KEGG3 
where output.biom is the otu table 
   paraL3.txt is a parameter file 
   KEGG3 is the output folder 
m. Perform Rat vs Human comparison 
i. Merge or filter desired samples from human studies 
1. add_qiime_labels.py -i fasta_dir -m map.txt -c Name -
n 1000000 
2. filter_fasta.py -f obslean.fna -o human1.fna --
sample_id_fp map.txt 
ii. Set variable 










iii. Perform closed-reference OTU pick 
1. pick_closed_reference_otus.py -i $PWD/human1.fna -
r $reference_seqs -o $PWD/human1/ -p 
$PWD/usearch_para.txt -t $reference_tax 
iv. Repeat for other studies 
v. Merge resultant OTU tables together 
1. merge_otu_tables.py -i 
rat.biom,human1.biom,human2.biom,human3.biom -o 
combine.biom 
vi. Draw taxonomy summary from OTU table 
1. summarize_taxa_through_plots.py -i combine.biom -o 
taxasummary -m map.txt 
 
